drug disease epistemic_status gap_score max_jaccard gene_link similar_drug emergence_score disease_trend drug_availability years_to_validate urgency_score priority_tier validation_method loop_suggestion alcaftadine parkinsons_disease GAP_HIGH 0.365 1.0 cyproheptadine 0.8 RAPID_RISE 0.85 3 0.17904 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alcaftadine→?; validate in parkinsons_disease cell model. Expected: similar to cyproheptadine (Jaccard=1.00) mephentermine hypertension GAP_HIGH 0.3635 1.0 selegiline 0.8 RAPID_RISE 0.85 3 0.1783 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mephentermine→?; validate in hypertension cell model. Expected: similar to selegiline (Jaccard=1.00) loratadine alzheimers_disease GAP_HIGH 0.3566 1.0 alcaftadine 0.8 RAPID_RISE 0.85 3 0.17492 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay loratadine→?; validate in alzheimers_disease cell model. Expected: similar to alcaftadine (Jaccard=1.00) loratadine parkinsons_disease GAP_HIGH 0.3566 1.0 cyproheptadine 0.8 RAPID_RISE 0.85 3 0.17492 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay loratadine→?; validate in parkinsons_disease cell model. Expected: similar to cyproheptadine (Jaccard=1.00) polythiazide parkinsons_disease GAP_HIGH 0.3364 0.7272727272727273 quinethazone 0.8 RAPID_RISE 0.85 3 0.16501 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay polythiazide→?; validate in parkinsons_disease cell model. Expected: similar to quinethazone (Jaccard=0.73) nicardipine hypertension GAP_HIGH 0.3327 1.0 nilvadipine 0.8 RAPID_RISE 0.85 3 0.16319 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nicardipine→?; validate in hypertension cell model. Expected: similar to nilvadipine (Jaccard=1.00) emtricitabine thyroid_cancer GAP_HIGH 0.3185 0.6666666666666666 pentostatin 0.8 RAPID_RISE 0.85 3 0.15623 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay emtricitabine→?; validate in thyroid_cancer cell model. Expected: similar to pentostatin (Jaccard=0.67) cyproheptadine hypertension GAP_HIGH 0.3108 1.0 alcaftadine 0.8 RAPID_RISE 0.85 3 0.15245 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyproheptadine→?; validate in hypertension cell model. Expected: similar to alcaftadine (Jaccard=1.00) methyclothiazide endogenous_depression GAP_HIGH 0.3099 0.7777777777777778 quinethazone 0.8 RAPID_RISE 0.85 3 0.15201 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methyclothiazide→?; validate in endogenous_depression cell model. Expected: similar to quinethazone (Jaccard=0.78) amlodipine hypertension GAP_HIGH 0.3048 1.0 nilvadipine 0.8 RAPID_RISE 0.85 3 0.14951 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amlodipine→?; validate in hypertension cell model. Expected: similar to nilvadipine (Jaccard=1.00) tolazoline obesity GAP_HIGH 0.2806 0.8 phenformin 0.8 RAPID_RISE 0.85 3 0.13764 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolazoline→?; validate in obesity cell model. Expected: similar to phenformin (Jaccard=0.80) selegiline endogenous_depression GAP_HIGH 0.2804 1.0 mephentermine 0.8 RAPID_RISE 0.85 3 0.13754 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay selegiline→?; validate in endogenous_depression cell model. Expected: similar to mephentermine (Jaccard=1.00) tolazoline type_2_diabetes_mellitus GAP_HIGH 0.28 0.8 phenformin 0.8 RAPID_RISE 0.85 3 0.13734 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolazoline→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to phenformin (Jaccard=0.80) tolazamide type_2_diabetes_mellitus GAP_HIGH 0.2779 0.7 gliquidone 0.8 RAPID_RISE 0.85 3 0.13631 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolazamide→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to gliquidone (Jaccard=0.70) trifluridine melanoma GAP_HIGH 0.2772 0.6 telbivudine 0.8 RAPID_RISE 0.85 3 0.13597 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trifluridine→?; validate in melanoma cell model. Expected: similar to telbivudine (Jaccard=0.60) alcaftadine amyotrophic_lateral_sclerosis GAP_HIGH 0.3649 1.0 cyproheptadine 0.6 RISING 0.85 3 0.13424 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alcaftadine→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to cyproheptadine (Jaccard=1.00) eplerenone melanoma GAP_HIGH 0.2734 0.8571428571428571 prednicarbate 0.8 RAPID_RISE 0.85 3 0.13411 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay eplerenone→?; validate in melanoma cell model. Expected: similar to prednicarbate (Jaccard=0.86) alcaftadine colon_cancer GAP_HIGH 0.3644 1.0 cyproheptadine 0.6 RISING 0.85 3 0.13406 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alcaftadine→?; validate in colon_cancer cell model. Expected: similar to cyproheptadine (Jaccard=1.00) mephentermine amyotrophic_lateral_sclerosis GAP_HIGH 0.3641 1.0 selegiline 0.6 RISING 0.85 3 0.13395 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mephentermine→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to selegiline (Jaccard=1.00) glipizide type_2_diabetes_mellitus GAP_HIGH 0.2726 0.7777777777777778 gliquidone 0.8 RAPID_RISE 0.85 3 0.13371 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glipizide→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to gliquidone (Jaccard=0.78) mephentermine multiple_sclerosis GAP_HIGH 0.3632 1.0 selegiline 0.6 RISING 0.85 3 0.13362 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mephentermine→?; validate in multiple_sclerosis cell model. Expected: similar to selegiline (Jaccard=1.00) pyrimethamine obesity GAP_HIGH 0.271 0.6 triamterene 0.8 RAPID_RISE 0.85 3 0.13293 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pyrimethamine→?; validate in obesity cell model. Expected: similar to triamterene (Jaccard=0.60) pyrimethamine type_2_diabetes_mellitus GAP_HIGH 0.2705 0.6 triamterene 0.8 RAPID_RISE 0.85 3 0.13268 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pyrimethamine→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to triamterene (Jaccard=0.60) ritodrine systemic_lupus_erythematosus GAP_HIGH 0.3599 1.0 arformoterol 0.6 RISING 0.85 3 0.1324 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ritodrine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to arformoterol (Jaccard=1.00) ritodrine skin_cancer GAP_HIGH 0.3597 1.0 arformoterol 0.6 RISING 0.85 3 0.13233 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ritodrine→?; validate in skin_cancer cell model. Expected: similar to arformoterol (Jaccard=1.00) labetalol hypertension GAP_HIGH 0.3821 1.0 solifenacin 0.8 RAPID_RISE 0.6 3 0.1323 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay labetalol→?; validate in hypertension cell model. Expected: similar to solifenacin (Jaccard=1.00) loratadine amyotrophic_lateral_sclerosis GAP_HIGH 0.3565 1.0 cyproheptadine 0.6 RISING 0.85 3 0.13115 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay loratadine→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to cyproheptadine (Jaccard=1.00) tenofovir thyroid_cancer GAP_HIGH 0.2647 0.6 cladribine 0.8 RAPID_RISE 0.85 3 0.12984 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tenofovir→?; validate in thyroid_cancer cell model. Expected: similar to cladribine (Jaccard=0.60) abacavir melanoma GAP_HIGH 0.262 0.6 entecavir 0.8 RAPID_RISE 0.85 3 0.12852 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay abacavir→?; validate in melanoma cell model. Expected: similar to entecavir (Jaccard=0.60) remifentanil obesity GAP_HIGH 0.3702 1.0 milnacipran 0.8 RAPID_RISE 0.6 3 0.12818 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay remifentanil→?; validate in obesity cell model. Expected: similar to milnacipran (Jaccard=1.00) l-cystine hypertension GAP_HIGH 0.26 0.475 l-methionine 0.8 RAPID_RISE 0.85 3 0.12753 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-cystine→?; validate in hypertension cell model. Expected: similar to l-methionine (Jaccard=0.47) carboprost_tromethamine thyroid_cancer GAP_HIGH 0.2576 0.5 travoprost 0.8 RAPID_RISE 0.85 3 0.12636 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carboprost_tromethamine→?; validate in thyroid_cancer cell model. Expected: similar to travoprost (Jaccard=0.50) eprosartan ulcerative_colitis GAP_HIGH 0.3603 1.0 telmisartan 0.8 RAPID_RISE 0.6 3 0.12475 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay eprosartan→?; validate in ulcerative_colitis cell model. Expected: similar to telmisartan (Jaccard=1.00) polythiazide salivary_gland_cancer GAP_HIGH 0.3368 0.7272727272727273 quinethazone 0.6 RISING 0.85 3 0.1239 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay polythiazide→?; validate in salivary_gland_cancer cell model. Expected: similar to quinethazone (Jaccard=0.73) telbivudine pharynx_cancer GAP_HIGH 0.3364 0.6 pentostatin 0.6 RISING 0.85 3 0.12376 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay telbivudine→?; validate in pharynx_cancer cell model. Expected: similar to pentostatin (Jaccard=0.60) polythiazide amyotrophic_lateral_sclerosis GAP_HIGH 0.3363 0.7272727272727273 quinethazone 0.6 RISING 0.85 3 0.12372 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay polythiazide→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to quinethazone (Jaccard=0.73) aminoglutethimide obesity GAP_HIGH 0.2519 0.6 clofibrate 0.8 RAPID_RISE 0.85 3 0.12356 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminoglutethimide→?; validate in obesity cell model. Expected: similar to clofibrate (Jaccard=0.60) telbivudine salivary_gland_cancer GAP_HIGH 0.3358 0.6 pentostatin 0.6 RISING 0.85 3 0.12354 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay telbivudine→?; validate in salivary_gland_cancer cell model. Expected: similar to pentostatin (Jaccard=0.60) glimepiride kidney_cancer GAP_HIGH 0.3355 0.7777777777777778 tolazamide 0.6 RISING 0.85 3 0.12343 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glimepiride→?; validate in kidney_cancer cell model. Expected: similar to tolazamide (Jaccard=0.78) telbivudine ocular_cancer GAP_HIGH 0.3355 0.6 pentostatin 0.6 RISING 0.85 3 0.12343 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay telbivudine→?; validate in ocular_cancer cell model. Expected: similar to pentostatin (Jaccard=0.60) dopamine thyroid_cancer GAP_HIGH 0.2515 0.75 dipivefrin 0.8 RAPID_RISE 0.85 3 0.12336 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dopamine→?; validate in thyroid_cancer cell model. Expected: similar to dipivefrin (Jaccard=0.75) azacitidine thyroid_cancer GAP_HIGH 0.2511 0.6666666666666666 clofarabine 0.8 RAPID_RISE 0.85 3 0.12317 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay azacitidine→?; validate in thyroid_cancer cell model. Expected: similar to clofarabine (Jaccard=0.67) mephentermine metabolic_syndrome_x GAP_HIGH 0.3628 1.0 selegiline 0.55 STABLE 0.85 3 0.12235 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mephentermine→?; validate in metabolic_syndrome_x cell model. Expected: similar to selegiline (Jaccard=1.00) ephedrine hypertension GAP_HIGH 0.2484 0.75 tropicamide 0.8 RAPID_RISE 0.85 3 0.12184 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ephedrine→?; validate in hypertension cell model. Expected: similar to tropicamide (Jaccard=0.75) glimepiride pancreatic_cancer GAP_HIGH 0.3276 0.7777777777777778 tolazamide 0.6 RISING 0.85 3 0.12052 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glimepiride→?; validate in pancreatic_cancer cell model. Expected: similar to tolazamide (Jaccard=0.78) glimepiride multiple_sclerosis GAP_HIGH 0.3274 0.7777777777777778 tolazamide 0.6 RISING 0.85 3 0.12045 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glimepiride→?; validate in multiple_sclerosis cell model. Expected: similar to tolazamide (Jaccard=0.78) aminophenazone alzheimers_disease GAP_HIGH 0.2439 0.5 ezetimibe 0.8 RAPID_RISE 0.85 3 0.11964 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminophenazone→?; validate in alzheimers_disease cell model. Expected: similar to ezetimibe (Jaccard=0.50) aminophenazone parkinsons_disease GAP_HIGH 0.2439 0.5 ezetimibe 0.8 RAPID_RISE 0.85 3 0.11964 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminophenazone→?; validate in parkinsons_disease cell model. Expected: similar to ezetimibe (Jaccard=0.50) amodiaquine kidney_cancer GAP_HIGH 0.325 1.0 quinacrine 0.6 RISING 0.85 3 0.11956 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amodiaquine→?; validate in kidney_cancer cell model. Expected: similar to quinacrine (Jaccard=1.00) emtricitabine pharynx_cancer GAP_HIGH 0.3188 0.6666666666666666 pentostatin 0.6 RISING 0.85 3 0.11728 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay emtricitabine→?; validate in pharynx_cancer cell model. Expected: similar to pentostatin (Jaccard=0.67) emtricitabine salivary_gland_cancer GAP_HIGH 0.3181 0.6666666666666666 pentostatin 0.6 RISING 0.85 3 0.11702 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay emtricitabine→?; validate in salivary_gland_cancer cell model. Expected: similar to pentostatin (Jaccard=0.67) emtricitabine lung_cancer GAP_HIGH 0.3179 0.6666666666666666 pentostatin 0.6 RISING 0.85 3 0.11695 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay emtricitabine→?; validate in lung_cancer cell model. Expected: similar to pentostatin (Jaccard=0.67) oxyphenonium type_1_diabetes_mellitus GAP_HIGH 0.3179 0.6666666666666666 methylphenidate 0.6 RISING 0.85 3 0.11695 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxyphenonium→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to methylphenidate (Jaccard=0.67) amodiaquine pancreatic_cancer GAP_HIGH 0.3171 1.0 quinacrine 0.6 RISING 0.85 3 0.11666 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amodiaquine→?; validate in pancreatic_cancer cell model. Expected: similar to quinacrine (Jaccard=1.00) lubiprostone salivary_gland_cancer GAP_HIGH 0.3171 0.6666666666666666 carboprost_tromethamine 0.6 RISING 0.85 3 0.11666 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lubiprostone→?; validate in salivary_gland_cancer cell model. Expected: similar to carboprost_tromethamine (Jaccard=0.67) quazepam alzheimers_disease GAP_HIGH 0.3367 0.8333333333333334 cinolazepam 0.8 RAPID_RISE 0.6 3 0.11658 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quazepam→?; validate in alzheimers_disease cell model. Expected: similar to cinolazepam (Jaccard=0.83) lubiprostone skin_cancer GAP_HIGH 0.3153 0.6666666666666666 carboprost_tromethamine 0.6 RISING 0.85 3 0.11599 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lubiprostone→?; validate in skin_cancer cell model. Expected: similar to carboprost_tromethamine (Jaccard=0.67) nisoldipine hypertension GAP_HIGH 0.2363 0.6666666666666666 nimodipine 0.8 RAPID_RISE 0.85 3 0.11591 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nisoldipine→?; validate in hypertension cell model. Expected: similar to nimodipine (Jaccard=0.67) methyclothiazide amyotrophic_lateral_sclerosis GAP_HIGH 0.3107 0.7777777777777778 quinethazone 0.6 RISING 0.85 3 0.1143 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methyclothiazide→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to quinethazone (Jaccard=0.78) agomelatine parkinsons_disease GAP_HIGH 0.2314 0.6363636363636364 tolmetin 0.8 RAPID_RISE 0.85 3 0.11351 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay agomelatine→?; validate in parkinsons_disease cell model. Expected: similar to tolmetin (Jaccard=0.64) primidone alzheimers_disease GAP_HIGH 0.2293 0.5 ezetimibe 0.8 RAPID_RISE 0.85 3 0.11248 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay primidone→?; validate in alzheimers_disease cell model. Expected: similar to ezetimibe (Jaccard=0.50) gliquidone kidney_cancer GAP_HIGH 0.3044 0.7 tolazamide 0.6 RISING 0.85 3 0.11198 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay gliquidone→?; validate in kidney_cancer cell model. Expected: similar to tolazamide (Jaccard=0.70) acetylcysteine hypertension GAP_HIGH 0.2266 0.4444444444444444 calcium_acetate 0.8 RAPID_RISE 0.85 3 0.11115 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acetylcysteine→?; validate in hypertension cell model. Expected: similar to calcium_acetate (Jaccard=0.44) methamphetamine obesity GAP_HIGH 0.2246 0.8 dextroamphetamine 0.8 RAPID_RISE 0.85 3 0.11017 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methamphetamine→?; validate in obesity cell model. Expected: similar to dextroamphetamine (Jaccard=0.80) gliquidone pancreatic_cancer GAP_HIGH 0.2965 0.7 tolazamide 0.6 RISING 0.85 3 0.10908 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay gliquidone→?; validate in pancreatic_cancer cell model. Expected: similar to tolazamide (Jaccard=0.70) gliquidone multiple_sclerosis GAP_HIGH 0.2964 0.7 tolazamide 0.6 RISING 0.85 3 0.10904 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay gliquidone→?; validate in multiple_sclerosis cell model. Expected: similar to tolazamide (Jaccard=0.70) orciprenaline thyroid_cancer GAP_HIGH 0.2212 0.6 dipivefrin 0.8 RAPID_RISE 0.85 3 0.1085 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay orciprenaline→?; validate in thyroid_cancer cell model. Expected: similar to dipivefrin (Jaccard=0.60) methylprednisolone brain_cancer GAP_HIGH 0.2945 1.0 fluorometholone 0.6 RISING 0.85 3 0.10834 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methylprednisolone→?; validate in brain_cancer cell model. Expected: similar to fluorometholone (Jaccard=1.00) metolazone amyotrophic_lateral_sclerosis GAP_HIGH 0.2944 0.6666666666666666 gabapentin 0.6 RISING 0.85 3 0.10831 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay metolazone→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to gabapentin (Jaccard=0.67) valsartan type_2_diabetes_mellitus GAP_HIGH 0.3124 1.0 olmesartan 0.8 RAPID_RISE 0.6 3 0.10817 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay valsartan→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to olmesartan (Jaccard=1.00) benzthiazide salivary_gland_cancer GAP_HIGH 0.2915 0.625 methyclothiazide 0.6 RISING 0.85 3 0.10724 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzthiazide→?; validate in salivary_gland_cancer cell model. Expected: similar to methyclothiazide (Jaccard=0.62) benzthiazide ocular_cancer GAP_HIGH 0.2912 0.625 methyclothiazide 0.6 RISING 0.85 3 0.10713 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzthiazide→?; validate in ocular_cancer cell model. Expected: similar to methyclothiazide (Jaccard=0.62) methylprednisolone hematologic_cancer GAP_HIGH 0.289 1.0 fluorometholone 0.6 RISING 0.85 3 0.10632 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methylprednisolone→?; validate in hematologic_cancer cell model. Expected: similar to fluorometholone (Jaccard=1.00) tafluprost thyroid_cancer GAP_HIGH 0.3062 1.0 latanoprost 0.8 RAPID_RISE 0.6 3 0.10602 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tafluprost→?; validate in thyroid_cancer cell model. Expected: similar to latanoprost (Jaccard=1.00) pralatrexate larynx_cancer GAP_HIGH 0.2861 0.7142857142857143 methotrexate 0.6 RISING 0.85 3 0.10525 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pralatrexate→?; validate in larynx_cancer cell model. Expected: similar to methotrexate (Jaccard=0.71) clodronate penile_cancer GAP_HIGH 0.286 1.0 etidronic_acid 0.6 RISING 0.85 3 0.10522 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clodronate→?; validate in penile_cancer cell model. Expected: similar to etidronic_acid (Jaccard=1.00) hydrochlorothiazide hypertension GAP_HIGH 0.2138 0.45454545454545453 polythiazide 0.8 RAPID_RISE 0.85 3 0.10487 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay hydrochlorothiazide→?; validate in hypertension cell model. Expected: similar to polythiazide (Jaccard=0.45) gliclazide type_2_diabetes_mellitus GAP_HIGH 0.2125 0.6666666666666666 gliquidone 0.8 RAPID_RISE 0.85 3 0.10423 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay gliclazide→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to gliquidone (Jaccard=0.67) pralatrexate brain_cancer GAP_HIGH 0.2827 0.7142857142857143 methotrexate 0.6 RISING 0.85 3 0.104 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pralatrexate→?; validate in brain_cancer cell model. Expected: similar to methotrexate (Jaccard=0.71) pralatrexate head_and_neck_cancer GAP_HIGH 0.2819 0.7142857142857143 methotrexate 0.6 RISING 0.85 3 0.10371 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pralatrexate→?; validate in head_and_neck_cancer cell model. Expected: similar to methotrexate (Jaccard=0.71) trifluridine lymphatic_system_cancer GAP_HIGH 0.2815 0.5714285714285714 gemcitabine 0.6 RISING 0.85 3 0.10356 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trifluridine→?; validate in lymphatic_system_cancer cell model. Expected: similar to gemcitabine (Jaccard=0.57) adenine thyroid_cancer GAP_HIGH 0.2109 0.5 tioguanine 0.8 RAPID_RISE 0.85 3 0.10345 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay adenine→?; validate in thyroid_cancer cell model. Expected: similar to tioguanine (Jaccard=0.50) eplerenone head_and_neck_cancer GAP_HIGH 0.2789 0.8571428571428571 prednicarbate 0.6 RISING 0.85 3 0.1026 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay eplerenone→?; validate in head_and_neck_cancer cell model. Expected: similar to prednicarbate (Jaccard=0.86) trifluridine mediastinal_cancer GAP_HIGH 0.2783 0.6 telbivudine 0.6 RISING 0.85 3 0.10238 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trifluridine→?; validate in mediastinal_cancer cell model. Expected: similar to telbivudine (Jaccard=0.60) trifluridine thymus_cancer GAP_HIGH 0.2781 0.6 telbivudine 0.6 RISING 0.85 3 0.10231 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trifluridine→?; validate in thymus_cancer cell model. Expected: similar to telbivudine (Jaccard=0.60) floxuridine melanoma GAP_HIGH 0.2078 0.5714285714285714 entecavir 0.8 RAPID_RISE 0.85 3 0.10193 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay floxuridine→?; validate in melanoma cell model. Expected: similar to entecavir (Jaccard=0.57) floxuridine thyroid_cancer GAP_HIGH 0.2069 0.5714285714285714 entecavir 0.8 RAPID_RISE 0.85 3 0.10149 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay floxuridine→?; validate in thyroid_cancer cell model. Expected: similar to entecavir (Jaccard=0.57) alcaftadine creutzfeldt-jakob_disease GAP_HIGH 0.3663 1.0 cyproheptadine 0.45 STABLE 0.85 3 0.10107 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alcaftadine→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to cyproheptadine (Jaccard=1.00) eplerenone mediastinal_cancer GAP_HIGH 0.2745 0.8571428571428571 prednicarbate 0.6 RISING 0.85 3 0.10099 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay eplerenone→?; validate in mediastinal_cancer cell model. Expected: similar to prednicarbate (Jaccard=0.86) eplerenone thymus_cancer GAP_HIGH 0.2743 0.8571428571428571 prednicarbate 0.6 RISING 0.85 3 0.10091 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay eplerenone→?; validate in thymus_cancer cell model. Expected: similar to prednicarbate (Jaccard=0.86) mephentermine creutzfeldt-jakob_disease GAP_HIGH 0.3655 1.0 selegiline 0.45 STABLE 0.85 3 0.10085 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mephentermine→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to selegiline (Jaccard=1.00) clofarabine hematologic_cancer GAP_HIGH 0.274 0.7777777777777778 regadenoson 0.6 RISING 0.85 3 0.1008 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clofarabine→?; validate in hematologic_cancer cell model. Expected: similar to regadenoson (Jaccard=0.78) regadenoson thyroid_cancer GAP_HIGH 0.291 0.7777777777777778 clofarabine 0.8 RAPID_RISE 0.6 3 0.10076 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay regadenoson→?; validate in thyroid_cancer cell model. Expected: similar to clofarabine (Jaccard=0.78) nelarabine hematologic_cancer GAP_HIGH 0.2735 0.5 emtricitabine 0.6 RISING 0.85 3 0.10062 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nelarabine→?; validate in hematologic_cancer cell model. Expected: similar to emtricitabine (Jaccard=0.50) clotiazepam parkinsons_disease GAP_HIGH 0.2904 0.8333333333333334 cinolazepam 0.8 RAPID_RISE 0.6 3 0.10055 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clotiazepam→?; validate in parkinsons_disease cell model. Expected: similar to cinolazepam (Jaccard=0.83) flutamide prostate_cancer GAP_HIGH 0.2732 0.6666666666666666 enzalutamide 0.6 RISING 0.85 3 0.10051 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flutamide→?; validate in prostate_cancer cell model. Expected: similar to enzalutamide (Jaccard=0.67) isoetarine alzheimers_disease GAP_HIGH 0.2043 0.5714285714285714 salbutamol 0.8 RAPID_RISE 0.85 3 0.10021 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isoetarine→?; validate in alzheimers_disease cell model. Expected: similar to salbutamol (Jaccard=0.57) isoetarine parkinsons_disease GAP_HIGH 0.2043 0.5714285714285714 salbutamol 0.8 RAPID_RISE 0.85 3 0.10021 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isoetarine→?; validate in parkinsons_disease cell model. Expected: similar to salbutamol (Jaccard=0.57) pirenzepine type_2_diabetes_mellitus GAP_HIGH 0.2042 0.7857142857142857 zuclopenthixol 0.8 RAPID_RISE 0.85 3 0.10016 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pirenzepine→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to zuclopenthixol (Jaccard=0.79) dronedarone melanoma GAP_HIGH 0.2041 0.4166666666666667 proparacaine 0.8 RAPID_RISE 0.85 3 0.10011 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dronedarone→?; validate in melanoma cell model. Expected: similar to proparacaine (Jaccard=0.42) isoetarine hypertension GAP_HIGH 0.2036 0.5714285714285714 salbutamol 0.8 RAPID_RISE 0.85 3 0.09987 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isoetarine→?; validate in hypertension cell model. Expected: similar to salbutamol (Jaccard=0.57) cytarabine lymphatic_system_cancer GAP_HIGH 0.2714 0.6 nelarabine 0.6 RISING 0.85 3 0.09984 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cytarabine→?; validate in lymphatic_system_cancer cell model. Expected: similar to nelarabine (Jaccard=0.60) quinapril hypertension GAP_HIGH 0.2877 0.75 cilazapril 0.8 RAPID_RISE 0.6 3 0.09962 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinapril→?; validate in hypertension cell model. Expected: similar to cilazapril (Jaccard=0.75) zolmitriptan ulcerative_colitis GAP_HIGH 0.2874 0.8181818181818182 midodrine 0.8 RAPID_RISE 0.6 3 0.09951 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zolmitriptan→?; validate in ulcerative_colitis cell model. Expected: similar to midodrine (Jaccard=0.82) tioguanine hematologic_cancer GAP_HIGH 0.27 0.5 adenine 0.6 RISING 0.85 3 0.09933 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tioguanine→?; validate in hematologic_cancer cell model. Expected: similar to adenine (Jaccard=0.50) sulfanilamide obesity GAP_HIGH 0.2015 0.6 clofibrate 0.8 RAPID_RISE 0.85 3 0.09884 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfanilamide→?; validate in obesity cell model. Expected: similar to clofibrate (Jaccard=0.60) loratadine creutzfeldt-jakob_disease GAP_HIGH 0.3579 1.0 cyproheptadine 0.45 STABLE 0.85 3 0.09875 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay loratadine→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to cyproheptadine (Jaccard=1.00) sodium_lauryl_sulfate alzheimers_disease GAP_HIGH 0.2011 0.3333333333333333 tetrabenazine 0.8 RAPID_RISE 0.85 3 0.09864 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sodium_lauryl_sulfate→?; validate in alzheimers_disease cell model. Expected: similar to tetrabenazine (Jaccard=0.33) sodium_lauryl_sulfate parkinsons_disease GAP_HIGH 0.2011 0.3333333333333333 tetrabenazine 0.8 RAPID_RISE 0.85 3 0.09864 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sodium_lauryl_sulfate→?; validate in parkinsons_disease cell model. Expected: similar to tetrabenazine (Jaccard=0.33) glipizide kidney_cancer GAP_HIGH 0.2652 0.7 tolazamide 0.6 RISING 0.85 3 0.09756 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glipizide→?; validate in kidney_cancer cell model. Expected: similar to tolazamide (Jaccard=0.70) benzatropine alzheimers_disease GAP_HIGH 0.1988 0.625 bepridil 0.8 RAPID_RISE 0.85 3 0.09751 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzatropine→?; validate in alzheimers_disease cell model. Expected: similar to bepridil (Jaccard=0.62) benzatropine parkinsons_disease GAP_HIGH 0.1988 0.625 bepridil 0.8 RAPID_RISE 0.85 3 0.09751 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzatropine→?; validate in parkinsons_disease cell model. Expected: similar to bepridil (Jaccard=0.62) tenofovir pharynx_cancer GAP_HIGH 0.2649 0.6 cladribine 0.6 RISING 0.85 3 0.09745 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tenofovir→?; validate in pharynx_cancer cell model. Expected: similar to cladribine (Jaccard=0.60) tenofovir salivary_gland_cancer GAP_HIGH 0.2643 0.6 cladribine 0.6 RISING 0.85 3 0.09723 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tenofovir→?; validate in salivary_gland_cancer cell model. Expected: similar to cladribine (Jaccard=0.60) tenofovir ocular_cancer GAP_HIGH 0.264 0.6 cladribine 0.6 RISING 0.85 3 0.09712 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tenofovir→?; validate in ocular_cancer cell model. Expected: similar to cladribine (Jaccard=0.60) abacavir mediastinal_cancer GAP_HIGH 0.2631 0.6 entecavir 0.6 RISING 0.85 3 0.09679 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay abacavir→?; validate in mediastinal_cancer cell model. Expected: similar to entecavir (Jaccard=0.60) abacavir thymus_cancer GAP_HIGH 0.263 0.6 entecavir 0.6 RISING 0.85 3 0.09675 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay abacavir→?; validate in thymus_cancer cell model. Expected: similar to entecavir (Jaccard=0.60) buclizine duodenum_cancer GAP_HIGH 0.2601 1.0 meclizine 0.6 RISING 0.85 3 0.09569 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay buclizine→?; validate in duodenum_cancer cell model. Expected: similar to meclizine (Jaccard=1.00) buclizine gallbladder_cancer GAP_HIGH 0.2601 1.0 meclizine 0.6 RISING 0.85 3 0.09569 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay buclizine→?; validate in gallbladder_cancer cell model. Expected: similar to meclizine (Jaccard=1.00) pirbuterol alzheimers_disease GAP_HIGH 0.2758 0.8 salbutamol 0.8 RAPID_RISE 0.6 3 0.09549 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pirbuterol→?; validate in alzheimers_disease cell model. Expected: similar to salbutamol (Jaccard=0.80) pirbuterol parkinsons_disease GAP_HIGH 0.2758 0.8 salbutamol 0.8 RAPID_RISE 0.6 3 0.09549 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pirbuterol→?; validate in parkinsons_disease cell model. Expected: similar to salbutamol (Jaccard=0.80) sulpiride systemic_lupus_erythematosus GAP_HIGH 0.2592 0.75 zafirlukast 0.6 RISING 0.85 3 0.09536 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulpiride→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to zafirlukast (Jaccard=0.75) ramipril type_2_diabetes_mellitus GAP_HIGH 0.275 1.0 trandolapril 0.8 RAPID_RISE 0.6 3 0.09522 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ramipril→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to trandolapril (Jaccard=1.00) buclizine lung_cancer GAP_HIGH 0.2586 1.0 meclizine 0.6 RISING 0.85 3 0.09514 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay buclizine→?; validate in lung_cancer cell model. Expected: similar to meclizine (Jaccard=1.00) adenosine kidney_cancer GAP_HIGH 0.2584 0.6153846153846154 lamivudine 0.6 RISING 0.85 3 0.09506 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay adenosine→?; validate in kidney_cancer cell model. Expected: similar to lamivudine (Jaccard=0.62) carboprost_tromethamine pharynx_cancer GAP_HIGH 0.2578 0.5 travoprost 0.6 RISING 0.85 3 0.09484 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carboprost_tromethamine→?; validate in pharynx_cancer cell model. Expected: similar to travoprost (Jaccard=0.50) polythiazide chronic_kidney_failure GAP_HIGH 0.3431 0.7272727272727273 quinethazone 0.45 STABLE 0.85 3 0.09467 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay polythiazide→?; validate in chronic_kidney_failure cell model. Expected: similar to quinethazone (Jaccard=0.73) glipizide pancreatic_cancer GAP_HIGH 0.2573 0.7 tolazamide 0.6 RISING 0.85 3 0.09466 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glipizide→?; validate in pancreatic_cancer cell model. Expected: similar to tolazamide (Jaccard=0.70) glipizide multiple_sclerosis GAP_HIGH 0.2572 0.7 tolazamide 0.6 RISING 0.85 3 0.09462 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glipizide→?; validate in multiple_sclerosis cell model. Expected: similar to tolazamide (Jaccard=0.70) tolazoline polycystic_ovary_syndrome GAP_HIGH 0.28 0.8 phenformin 0.55 STABLE 0.85 3 0.09442 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolazoline→?; validate in polycystic_ovary_syndrome cell model. Expected: similar to phenformin (Jaccard=0.80) carboprost_tromethamine uterine_cancer GAP_HIGH 0.2559 0.5 travoprost 0.6 RISING 0.85 3 0.09414 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carboprost_tromethamine→?; validate in uterine_cancer cell model. Expected: similar to travoprost (Jaccard=0.50) adenosine penile_cancer GAP_HIGH 0.2557 0.6153846153846154 lamivudine 0.6 RISING 0.85 3 0.09407 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay adenosine→?; validate in penile_cancer cell model. Expected: similar to lamivudine (Jaccard=0.62) carboprost_tromethamine testicular_cancer GAP_HIGH 0.2553 0.5 travoprost 0.6 RISING 0.85 3 0.09392 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carboprost_tromethamine→?; validate in testicular_cancer cell model. Expected: similar to travoprost (Jaccard=0.50) carboprost_tromethamine vaginal_cancer GAP_HIGH 0.2553 0.5 travoprost 0.6 RISING 0.85 3 0.09392 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carboprost_tromethamine→?; validate in vaginal_cancer cell model. Expected: similar to travoprost (Jaccard=0.50) orphenadrine alzheimers_disease GAP_HIGH 0.1909 0.6 disopyramide 0.8 RAPID_RISE 0.85 3 0.09364 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay orphenadrine→?; validate in alzheimers_disease cell model. Expected: similar to disopyramide (Jaccard=0.60) orphenadrine parkinsons_disease GAP_HIGH 0.1908 0.6 disopyramide 0.8 RAPID_RISE 0.85 3 0.09359 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay orphenadrine→?; validate in parkinsons_disease cell model. Expected: similar to disopyramide (Jaccard=0.60) phenylephrine hypertension GAP_HIGH 0.1908 0.5 salbutamol 0.8 RAPID_RISE 0.85 3 0.09359 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenylephrine→?; validate in hypertension cell model. Expected: similar to salbutamol (Jaccard=0.50) phenindione duodenum_cancer GAP_HIGH 0.2541 0.7692307692307693 clozapine 0.6 RISING 0.85 3 0.09348 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenindione→?; validate in duodenum_cancer cell model. Expected: similar to clozapine (Jaccard=0.77) phenindione gallbladder_cancer GAP_HIGH 0.2541 0.7692307692307693 clozapine 0.6 RISING 0.85 3 0.09348 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenindione→?; validate in gallbladder_cancer cell model. Expected: similar to clozapine (Jaccard=0.77) cyproterone_acetate head_and_neck_cancer GAP_HIGH 0.2541 0.7142857142857143 prednicarbate 0.6 RISING 0.85 3 0.09348 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyproterone_acetate→?; validate in head_and_neck_cancer cell model. Expected: similar to prednicarbate (Jaccard=0.71) l-arginine larynx_cancer GAP_HIGH 0.2533 0.6363636363636364 doxorubicin 0.6 RISING 0.85 3 0.09319 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-arginine→?; validate in larynx_cancer cell model. Expected: similar to doxorubicin (Jaccard=0.64) phenylephrine obesity GAP_HIGH 0.1898 0.5 salbutamol 0.8 RAPID_RISE 0.85 3 0.0931 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenylephrine→?; validate in obesity cell model. Expected: similar to salbutamol (Jaccard=0.50) amphetamine thyroid_cancer GAP_HIGH 0.1898 0.4 vorinostat 0.8 RAPID_RISE 0.85 3 0.0931 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amphetamine→?; validate in thyroid_cancer cell model. Expected: similar to vorinostat (Jaccard=0.40) phenindione lung_cancer GAP_HIGH 0.2526 0.7692307692307693 clozapine 0.6 RISING 0.85 3 0.09293 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenindione→?; validate in lung_cancer cell model. Expected: similar to clozapine (Jaccard=0.77) phenindione rectum_cancer GAP_HIGH 0.2526 0.7692307692307693 clozapine 0.6 RISING 0.85 3 0.09293 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenindione→?; validate in rectum_cancer cell model. Expected: similar to clozapine (Jaccard=0.77) chlorpropamide type_2_diabetes_mellitus GAP_HIGH 0.1892 0.5 gliquidone 0.8 RAPID_RISE 0.85 3 0.09281 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorpropamide→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to gliquidone (Jaccard=0.50) cyproterone_acetate germ_cell_cancer GAP_HIGH 0.252 0.7142857142857143 prednicarbate 0.6 RISING 0.85 3 0.09271 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyproterone_acetate→?; validate in germ_cell_cancer cell model. Expected: similar to prednicarbate (Jaccard=0.71) dopamine pharynx_cancer GAP_HIGH 0.2518 0.75 dipivefrin 0.6 RISING 0.85 3 0.09263 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dopamine→?; validate in pharynx_cancer cell model. Expected: similar to dipivefrin (Jaccard=0.75) telbivudine peripheral_nervous_system_neoplasm GAP_HIGH 0.3352 0.6 pentostatin 0.45 STABLE 0.85 3 0.09249 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay telbivudine→?; validate in peripheral_nervous_system_neoplasm cell model. Expected: similar to pentostatin (Jaccard=0.60) lubiprostone pharynx_cancer GAP_HIGH 0.2514 0.4444444444444444 travoprost 0.6 RISING 0.85 3 0.09249 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lubiprostone→?; validate in pharynx_cancer cell model. Expected: similar to travoprost (Jaccard=0.44) l-arginine esophageal_cancer GAP_HIGH 0.2512 0.6363636363636364 doxorubicin 0.6 RISING 0.85 3 0.09241 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-arginine→?; validate in esophageal_cancer cell model. Expected: similar to doxorubicin (Jaccard=0.64) prazepam parkinsons_disease GAP_HIGH 0.2662 0.7 estazolam 0.8 RAPID_RISE 0.6 3 0.09217 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prazepam→?; validate in parkinsons_disease cell model. Expected: similar to estazolam (Jaccard=0.70) mepenzolate stomach_cancer GAP_HIGH 0.2501 0.6666666666666666 bepridil 0.6 RISING 0.85 3 0.09201 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mepenzolate→?; validate in stomach_cancer cell model. Expected: similar to bepridil (Jaccard=0.67) l-arginine brain_cancer GAP_HIGH 0.2499 0.6363636363636364 doxorubicin 0.6 RISING 0.85 3 0.09194 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-arginine→?; validate in brain_cancer cell model. Expected: similar to doxorubicin (Jaccard=0.64) dopamine uterine_cancer GAP_HIGH 0.2498 0.75 dipivefrin 0.6 RISING 0.85 3 0.0919 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dopamine→?; validate in uterine_cancer cell model. Expected: similar to dipivefrin (Jaccard=0.75) azacitidine stomach_cancer GAP_HIGH 0.2497 0.6666666666666666 clofarabine 0.6 RISING 0.85 3 0.09186 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay azacitidine→?; validate in stomach_cancer cell model. Expected: similar to clofarabine (Jaccard=0.67) dopamine vaginal_cancer GAP_HIGH 0.2493 0.75 dipivefrin 0.6 RISING 0.85 3 0.09171 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dopamine→?; validate in vaginal_cancer cell model. Expected: similar to dipivefrin (Jaccard=0.75) dopamine vulva_cancer GAP_HIGH 0.2493 0.75 dipivefrin 0.6 RISING 0.85 3 0.09171 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dopamine→?; validate in vulva_cancer cell model. Expected: similar to dipivefrin (Jaccard=0.75) l-arginine head_and_neck_cancer GAP_HIGH 0.2491 0.6363636363636364 doxorubicin 0.6 RISING 0.85 3 0.09164 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-arginine→?; validate in head_and_neck_cancer cell model. Expected: similar to doxorubicin (Jaccard=0.64) azacitidine skin_cancer GAP_HIGH 0.249 0.6666666666666666 clofarabine 0.6 RISING 0.85 3 0.0916 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay azacitidine→?; validate in skin_cancer cell model. Expected: similar to clofarabine (Jaccard=0.67) codeine alcohol_dependence GAP_HIGH 0.3319 0.9285714285714286 ethylmorphine 0.45 STABLE 0.85 3 0.09158 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay codeine→?; validate in alcohol_dependence cell model. Expected: similar to ethylmorphine (Jaccard=0.93) pyrimethamine metabolic_syndrome_x GAP_HIGH 0.2714 0.6 triamterene 0.55 STABLE 0.85 3 0.09152 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pyrimethamine→?; validate in metabolic_syndrome_x cell model. Expected: similar to triamterene (Jaccard=0.60) pirbuterol thyroid_cancer GAP_HIGH 0.2642 0.75 dipivefrin 0.8 RAPID_RISE 0.6 3 0.09148 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pirbuterol→?; validate in thyroid_cancer cell model. Expected: similar to dipivefrin (Jaccard=0.75) nicardipine systemic_scleroderma GAP_HIGH 0.3315 1.0 amlodipine 0.45 STABLE 0.85 3 0.09147 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nicardipine→?; validate in systemic_scleroderma cell model. Expected: similar to amlodipine (Jaccard=1.00) glimepiride gout GAP_HIGH 0.3311 0.7777777777777778 tolazamide 0.45 STABLE 0.85 3 0.09136 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glimepiride→?; validate in gout cell model. Expected: similar to tolazamide (Jaccard=0.78) phenoxybenzamine parkinsons_disease GAP_HIGH 0.1862 0.5833333333333334 benzphetamine 0.8 RAPID_RISE 0.85 3 0.09133 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenoxybenzamine→?; validate in parkinsons_disease cell model. Expected: similar to benzphetamine (Jaccard=0.58) terbutaline thyroid_cancer GAP_HIGH 0.186 0.5 dipivefrin 0.8 RAPID_RISE 0.85 3 0.09124 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay terbutaline→?; validate in thyroid_cancer cell model. Expected: similar to dipivefrin (Jaccard=0.50) pyrimethamine polycystic_ovary_syndrome GAP_HIGH 0.2705 0.6 triamterene 0.55 STABLE 0.85 3 0.09122 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pyrimethamine→?; validate in polycystic_ovary_syndrome cell model. Expected: similar to triamterene (Jaccard=0.60) esmolol larynx_cancer GAP_HIGH 0.3498 1.0 procarbazine 0.6 RISING 0.6 3 0.09084 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay esmolol→?; validate in larynx_cancer cell model. Expected: similar to procarbazine (Jaccard=1.00) vidarabine thyroid_cancer GAP_HIGH 0.1842 0.4782608695652174 clofarabine 0.8 RAPID_RISE 0.85 3 0.09035 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vidarabine→?; validate in thyroid_cancer cell model. Expected: similar to clofarabine (Jaccard=0.48) vidarabine melanoma GAP_HIGH 0.1841 0.47368421052631576 entecavir 0.8 RAPID_RISE 0.85 3 0.0903 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vidarabine→?; validate in melanoma cell model. Expected: similar to entecavir (Jaccard=0.47) glisoxepide kidney_cancer GAP_HIGH 0.2454 0.5 tolazamide 0.6 RISING 0.85 3 0.09028 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glisoxepide→?; validate in kidney_cancer cell model. Expected: similar to tolazamide (Jaccard=0.50) nilvadipine systemic_scleroderma GAP_HIGH 0.327 1.0 amlodipine 0.45 STABLE 0.85 3 0.09022 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nilvadipine→?; validate in systemic_scleroderma cell model. Expected: similar to amlodipine (Jaccard=1.00) glimepiride osteoarthritis GAP_HIGH 0.3269 0.7777777777777778 tolazamide 0.45 STABLE 0.85 3 0.0902 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glimepiride→?; validate in osteoarthritis cell model. Expected: similar to tolazamide (Jaccard=0.78) flavin_adenine_dinucleotide thyroid_cancer GAP_HIGH 0.1838 0.4 nelarabine 0.8 RAPID_RISE 0.85 3 0.09016 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flavin_adenine_dinucleotide→?; validate in thyroid_cancer cell model. Expected: similar to nelarabine (Jaccard=0.40) esmolol head_and_neck_cancer GAP_HIGH 0.3456 1.0 procarbazine 0.6 RISING 0.6 3 0.08975 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay esmolol→?; validate in head_and_neck_cancer cell model. Expected: similar to procarbazine (Jaccard=1.00) aminophenazone amyotrophic_lateral_sclerosis GAP_HIGH 0.2438 0.5 ezetimibe 0.6 RISING 0.85 3 0.08969 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminophenazone→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to ezetimibe (Jaccard=0.50) arbutamine alzheimers_disease GAP_HIGH 0.1822 0.5333333333333333 masoprocol 0.8 RAPID_RISE 0.85 3 0.08937 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay arbutamine→?; validate in alzheimers_disease cell model. Expected: similar to masoprocol (Jaccard=0.53) proparacaine prostate_cancer GAP_HIGH 0.2429 0.6875 oxybuprocaine 0.6 RISING 0.85 3 0.08936 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay proparacaine→?; validate in prostate_cancer cell model. Expected: similar to oxybuprocaine (Jaccard=0.69) alcaftadine ovarian_cancer GAP_HIGH 0.3641 1.0 cyproheptadine 0.4 STABLE 0.85 3 0.0893 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alcaftadine→?; validate in ovarian_cancer cell model. Expected: similar to cyproheptadine (Jaccard=1.00) tropicamide idiopathic_pulmonary_fibrosis GAP_HIGH 0.3234 0.75 ephedrine 0.45 STABLE 0.85 3 0.08923 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tropicamide→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to ephedrine (Jaccard=0.75) spirapril alzheimers_disease GAP_HIGH 0.2575 0.6 moexipril 0.8 RAPID_RISE 0.6 3 0.08916 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay spirapril→?; validate in alzheimers_disease cell model. Expected: similar to moexipril (Jaccard=0.60) spirapril parkinsons_disease GAP_HIGH 0.2575 0.6 moexipril 0.8 RAPID_RISE 0.6 3 0.08916 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay spirapril→?; validate in parkinsons_disease cell model. Expected: similar to moexipril (Jaccard=0.60) tropicamide narcolepsy GAP_HIGH 0.3229 0.75 ephedrine 0.45 STABLE 0.85 3 0.08909 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tropicamide→?; validate in narcolepsy cell model. Expected: similar to ephedrine (Jaccard=0.75) paclitaxel larynx_cancer GAP_HIGH 0.2058 0.6 docetaxel 0.6 RISING 1.0 3 0.08907 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay paclitaxel→?; validate in larynx_cancer cell model. Expected: similar to docetaxel (Jaccard=0.60) l-citrulline parkinsons_disease GAP_HIGH 0.1808 0.5058823529411764 l-glutamine 0.8 RAPID_RISE 0.85 3 0.08869 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-citrulline→?; validate in parkinsons_disease cell model. Expected: similar to l-glutamine (Jaccard=0.51) tropicamide chronic_obstructive_pulmonary_disease GAP_HIGH 0.3211 0.75 ephedrine 0.45 STABLE 0.85 3 0.0886 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tropicamide→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to ephedrine (Jaccard=0.75) benazepril hypertension GAP_HIGH 0.2559 0.6666666666666666 rescinnamine 0.8 RAPID_RISE 0.6 3 0.0886 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benazepril→?; validate in hypertension cell model. Expected: similar to rescinnamine (Jaccard=0.67) rimexolone obesity GAP_HIGH 0.1804 0.625 amcinonide 0.8 RAPID_RISE 0.85 3 0.08849 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay rimexolone→?; validate in obesity cell model. Expected: similar to amcinonide (Jaccard=0.62) methadyl_acetate esophageal_cancer GAP_HIGH 0.2398 0.75 tamoxifen 0.6 RISING 0.85 3 0.08822 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methadyl_acetate→?; validate in esophageal_cancer cell model. Expected: similar to tamoxifen (Jaccard=0.75) tropicamide psoriasis GAP_HIGH 0.3195 0.75 ephedrine 0.45 STABLE 0.85 3 0.08815 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tropicamide→?; validate in psoriasis cell model. Expected: similar to ephedrine (Jaccard=0.75) ritodrine rheumatoid_arthritis GAP_HIGH 0.3585 1.0 arformoterol 0.4 STABLE 0.85 3 0.08793 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ritodrine→?; validate in rheumatoid_arthritis cell model. Expected: similar to arformoterol (Jaccard=1.00) amitriptyline endogenous_depression GAP_HIGH 0.1791 0.75 doxepin 0.8 RAPID_RISE 0.85 3 0.08785 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amitriptyline→?; validate in endogenous_depression cell model. Expected: similar to doxepin (Jaccard=0.75) tropicamide vitiligo GAP_HIGH 0.318 0.75 ephedrine 0.45 STABLE 0.85 3 0.08774 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tropicamide→?; validate in vitiligo cell model. Expected: similar to ephedrine (Jaccard=0.75) milnacipran breast_cancer GAP_HIGH 0.3375 1.0 remifentanil 0.6 RISING 0.6 3 0.08764 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay milnacipran→?; validate in breast_cancer cell model. Expected: similar to remifentanil (Jaccard=1.00) loratadine epilepsy_syndrome GAP_HIGH 0.3573 1.0 alcaftadine 0.4 STABLE 0.85 3 0.08763 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay loratadine→?; validate in epilepsy_syndrome cell model. Expected: similar to alcaftadine (Jaccard=1.00) quazepam amyotrophic_lateral_sclerosis GAP_HIGH 0.3366 0.8333333333333334 cinolazepam 0.6 RISING 0.6 3 0.08741 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quazepam→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to cinolazepam (Jaccard=0.83) pentostatin lymphatic_system_cancer GAP_HIGH 0.3364 0.6666666666666666 emtricitabine 0.6 RISING 0.6 3 0.08736 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pentostatin→?; validate in lymphatic_system_cancer cell model. Expected: similar to emtricitabine (Jaccard=0.67) lubiprostone peripheral_nervous_system_neoplasm GAP_HIGH 0.3165 0.6666666666666666 carboprost_tromethamine 0.45 STABLE 0.85 3 0.08733 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lubiprostone→?; validate in peripheral_nervous_system_neoplasm cell model. Expected: similar to carboprost_tromethamine (Jaccard=0.67) paclitaxel kidney_cancer GAP_HIGH 0.2015 0.6 docetaxel 0.6 RISING 1.0 3 0.08721 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay paclitaxel→?; validate in kidney_cancer cell model. Expected: similar to docetaxel (Jaccard=0.60) arformoterol asthma GAP_HIGH 0.3358 1.0 ritodrine 0.6 RISING 0.6 3 0.0872 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay arformoterol→?; validate in asthma cell model. Expected: similar to ritodrine (Jaccard=1.00) oxyphenonium celiac_disease GAP_HIGH 0.316 0.6666666666666666 methylphenidate 0.45 STABLE 0.85 3 0.08719 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxyphenonium→?; validate in celiac_disease cell model. Expected: similar to methylphenidate (Jaccard=0.67) lubiprostone sarcoma GAP_HIGH 0.3157 0.6666666666666666 carboprost_tromethamine 0.45 STABLE 0.85 3 0.08711 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lubiprostone→?; validate in sarcoma cell model. Expected: similar to carboprost_tromethamine (Jaccard=0.67) isradipine hypertension GAP_HIGH 0.1774 0.3333333333333333 nimodipine 0.8 RAPID_RISE 0.85 3 0.08702 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isradipine→?; validate in hypertension cell model. Expected: similar to nimodipine (Jaccard=0.33) methadyl_acetate germ_cell_cancer GAP_HIGH 0.2355 0.75 tamoxifen 0.6 RISING 0.85 3 0.08664 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methadyl_acetate→?; validate in germ_cell_cancer cell model. Expected: similar to tamoxifen (Jaccard=0.75) penicillamine hematologic_cancer GAP_HIGH 0.2355 0.4 l-histidine 0.6 RISING 0.85 3 0.08664 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay penicillamine→?; validate in hematologic_cancer cell model. Expected: similar to l-histidine (Jaccard=0.40) methotrexate muscle_cancer GAP_HIGH 0.2001 0.7142857142857143 pralatrexate 0.6 RISING 1.0 3 0.0866 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methotrexate→?; validate in muscle_cancer cell model. Expected: similar to pralatrexate (Jaccard=0.71) methotrexate lung_cancer GAP_HIGH 0.2 0.7142857142857143 pralatrexate 0.6 RISING 1.0 3 0.08656 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methotrexate→?; validate in lung_cancer cell model. Expected: similar to pralatrexate (Jaccard=0.71) methotrexate urinary_bladder_cancer GAP_HIGH 0.1996 0.7142857142857143 pralatrexate 0.6 RISING 1.0 3 0.08639 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methotrexate→?; validate in urinary_bladder_cancer cell model. Expected: similar to pralatrexate (Jaccard=0.71) oxyphenonium crohns_disease GAP_HIGH 0.3126 0.6666666666666666 methylphenidate 0.45 STABLE 0.85 3 0.08625 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxyphenonium→?; validate in crohns_disease cell model. Expected: similar to methylphenidate (Jaccard=0.67) oxyphenonium idiopathic_pulmonary_fibrosis GAP_HIGH 0.3122 0.6666666666666666 methylphenidate 0.45 STABLE 0.85 3 0.08614 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxyphenonium→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to methylphenidate (Jaccard=0.67) oxyphenonium primary_biliary_cirrhosis GAP_HIGH 0.312 0.6666666666666666 methylphenidate 0.45 STABLE 0.85 3 0.08609 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxyphenonium→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to methylphenidate (Jaccard=0.67) cyproheptadine nicotine_dependence GAP_HIGH 0.3114 1.0 alcaftadine 0.45 STABLE 0.85 3 0.08592 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyproheptadine→?; validate in nicotine_dependence cell model. Expected: similar to alcaftadine (Jaccard=1.00) clozapine systemic_lupus_erythematosus GAP_HIGH 0.1985 0.7692307692307693 phenindione 0.6 RISING 1.0 3 0.08591 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clozapine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to phenindione (Jaccard=0.77) methadyl_acetate mediastinal_cancer GAP_HIGH 0.2332 0.75 tamoxifen 0.6 RISING 0.85 3 0.08579 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methadyl_acetate→?; validate in mediastinal_cancer cell model. Expected: similar to tamoxifen (Jaccard=0.75) methotrexate testicular_cancer GAP_HIGH 0.1982 0.7142857142857143 pralatrexate 0.6 RISING 1.0 3 0.08578 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methotrexate→?; validate in testicular_cancer cell model. Expected: similar to pralatrexate (Jaccard=0.71) cyproheptadine allergic_rhinitis GAP_HIGH 0.3108 1.0 alcaftadine 0.45 STABLE 0.85 3 0.08575 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyproheptadine→?; validate in allergic_rhinitis cell model. Expected: similar to alcaftadine (Jaccard=1.00) methyclothiazide conduct_disorder GAP_HIGH 0.3101 0.7777777777777778 quinethazone 0.45 STABLE 0.85 3 0.08556 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methyclothiazide→?; validate in conduct_disorder cell model. Expected: similar to quinethazone (Jaccard=0.78) methyclothiazide migraine GAP_HIGH 0.3098 0.7777777777777778 quinethazone 0.45 STABLE 0.85 3 0.08548 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methyclothiazide→?; validate in migraine cell model. Expected: similar to quinethazone (Jaccard=0.78) aminophenazone gilles_de_la_tourette_syndrome GAP_HIGH 0.2527 0.5 ezetimibe 0.55 STABLE 0.85 3 0.08522 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminophenazone→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to ezetimibe (Jaccard=0.50) olmesartan ulcerative_colitis GAP_HIGH 0.2461 0.5714285714285714 telmisartan 0.8 RAPID_RISE 0.6 3 0.08521 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay olmesartan→?; validate in ulcerative_colitis cell model. Expected: similar to telmisartan (Jaccard=0.57) procarbazine esophageal_cancer GAP_HIGH 0.2314 0.6363636363636364 melphalan 0.6 RISING 0.85 3 0.08513 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay procarbazine→?; validate in esophageal_cancer cell model. Expected: similar to melphalan (Jaccard=0.64) orlistat obesity GAP_HIGH 0.2458 0.42857142857142855 sodium_tetradecyl_sulfate 0.8 RAPID_RISE 0.6 3 0.08511 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay orlistat→?; validate in obesity cell model. Expected: similar to sodium_tetradecyl_sulfate (Jaccard=0.43) agomelatine amyotrophic_lateral_sclerosis GAP_HIGH 0.2313 0.6363636363636364 tolmetin 0.6 RISING 0.85 3 0.08509 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay agomelatine→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to tolmetin (Jaccard=0.64) aminoglutethimide metabolic_syndrome_x GAP_HIGH 0.2523 0.6 clofibrate 0.55 STABLE 0.85 3 0.08508 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminoglutethimide→?; validate in metabolic_syndrome_x cell model. Expected: similar to clofibrate (Jaccard=0.60) codeine pancreatitis GAP_HIGH 0.3079 0.9285714285714286 ethylmorphine 0.45 STABLE 0.85 3 0.08495 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay codeine→?; validate in pancreatitis cell model. Expected: similar to ethylmorphine (Jaccard=0.93) orlistat type_2_diabetes_mellitus GAP_HIGH 0.2452 0.42857142857142855 sodium_tetradecyl_sulfate 0.8 RAPID_RISE 0.6 3 0.0849 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay orlistat→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to sodium_tetradecyl_sulfate (Jaccard=0.43) codeine nicotine_dependence GAP_HIGH 0.3074 0.9285714285714286 ethylmorphine 0.45 STABLE 0.85 3 0.08482 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay codeine→?; validate in nicotine_dependence cell model. Expected: similar to ethylmorphine (Jaccard=0.93) glutethimide asthma GAP_HIGH 0.2305 0.6 ethotoin 0.6 RISING 0.85 3 0.0848 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glutethimide→?; validate in asthma cell model. Expected: similar to ethotoin (Jaccard=0.60) codeine conduct_disorder GAP_HIGH 0.3069 0.9285714285714286 ethylmorphine 0.45 STABLE 0.85 3 0.08468 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay codeine→?; validate in conduct_disorder cell model. Expected: similar to ethylmorphine (Jaccard=0.93) codeine panic_disorder GAP_HIGH 0.3069 0.9285714285714286 ethylmorphine 0.45 STABLE 0.85 3 0.08468 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay codeine→?; validate in panic_disorder cell model. Expected: similar to ethylmorphine (Jaccard=0.93) carbidopa parkinsons_disease GAP_HIGH 0.2445 0.9375 methyldopa 0.8 RAPID_RISE 0.6 3 0.08466 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carbidopa→?; validate in parkinsons_disease cell model. Expected: similar to methyldopa (Jaccard=0.94) primidone amyotrophic_lateral_sclerosis GAP_HIGH 0.2292 0.5 ezetimibe 0.6 RISING 0.85 3 0.08432 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay primidone→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to ezetimibe (Jaccard=0.50) pentostatin hematologic_cancer GAP_HIGH 0.3241 0.6666666666666666 emtricitabine 0.6 RISING 0.6 3 0.08416 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pentostatin→?; validate in hematologic_cancer cell model. Expected: similar to emtricitabine (Jaccard=0.67) procaine obesity GAP_HIGH 0.1711 0.5789473684210527 chloroprocaine 0.8 RAPID_RISE 0.85 3 0.08393 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay procaine→?; validate in obesity cell model. Expected: similar to chloroprocaine (Jaccard=0.58) phentermine obesity GAP_HIGH 0.171 0.5454545454545454 dextroamphetamine 0.8 RAPID_RISE 0.85 3 0.08388 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phentermine→?; validate in obesity cell model. Expected: similar to dextroamphetamine (Jaccard=0.55) doxylamine skin_cancer GAP_HIGH 0.2263 0.6666666666666666 orphenadrine 0.6 RISING 0.85 3 0.08325 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxylamine→?; validate in skin_cancer cell model. Expected: similar to orphenadrine (Jaccard=0.67) cilazapril alzheimers_disease GAP_HIGH 0.2404 0.6 moexipril 0.8 RAPID_RISE 0.6 3 0.08324 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cilazapril→?; validate in alzheimers_disease cell model. Expected: similar to moexipril (Jaccard=0.60) cilazapril parkinsons_disease GAP_HIGH 0.2404 0.6 moexipril 0.8 RAPID_RISE 0.6 3 0.08324 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cilazapril→?; validate in parkinsons_disease cell model. Expected: similar to moexipril (Jaccard=0.60) aceprometazine ankylosing_spondylitis GAP_HIGH 0.3016 1.0 propiomazine 0.45 STABLE 0.85 3 0.08322 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aceprometazine→?; validate in ankylosing_spondylitis cell model. Expected: similar to propiomazine (Jaccard=1.00) acetylcysteine systemic_lupus_erythematosus GAP_HIGH 0.2261 0.4444444444444444 calcium_acetate 0.6 RISING 0.85 3 0.08318 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acetylcysteine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to calcium_acetate (Jaccard=0.44) cladribine hematologic_cancer GAP_HIGH 0.2258 0.6 tenofovir 0.6 RISING 0.85 3 0.08307 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cladribine→?; validate in hematologic_cancer cell model. Expected: similar to tenofovir (Jaccard=0.60) gliquidone gout GAP_HIGH 0.3001 0.7 tolazamide 0.45 STABLE 0.85 3 0.0828 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay gliquidone→?; validate in gout cell model. Expected: similar to tolazamide (Jaccard=0.70) aceprometazine osteoporosis GAP_HIGH 0.2998 1.0 propiomazine 0.45 STABLE 0.85 3 0.08272 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aceprometazine→?; validate in osteoporosis cell model. Expected: similar to propiomazine (Jaccard=1.00) aceprometazine psoriasis GAP_HIGH 0.2998 1.0 propiomazine 0.45 STABLE 0.85 3 0.08272 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aceprometazine→?; validate in psoriasis cell model. Expected: similar to propiomazine (Jaccard=1.00) polythiazide epilepsy_syndrome GAP_HIGH 0.337 0.7272727272727273 quinethazone 0.4 STABLE 0.85 3 0.08265 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay polythiazide→?; validate in epilepsy_syndrome cell model. Expected: similar to quinethazone (Jaccard=0.73) benzthiazide glaucoma GAP_HIGH 0.2994 0.625 methyclothiazide 0.45 STABLE 0.85 3 0.08261 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzthiazide→?; validate in glaucoma cell model. Expected: similar to methyclothiazide (Jaccard=0.62) difenoxin prostate_cancer GAP_HIGH 0.2245 0.6153846153846154 clotrimazole 0.6 RISING 0.85 3 0.08259 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay difenoxin→?; validate in prostate_cancer cell model. Expected: similar to clotrimazole (Jaccard=0.62) milnacipran gilles_de_la_tourette_syndrome GAP_HIGH 0.3469 1.0 remifentanil 0.55 STABLE 0.6 3 0.08258 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay milnacipran→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to remifentanil (Jaccard=1.00) difenoxin mediastinal_cancer GAP_HIGH 0.2243 0.6153846153846154 clotrimazole 0.6 RISING 0.85 3 0.08252 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay difenoxin→?; validate in mediastinal_cancer cell model. Expected: similar to clotrimazole (Jaccard=0.62) benzthiazide nephrolithiasis GAP_HIGH 0.2981 0.625 methyclothiazide 0.45 STABLE 0.85 3 0.08225 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzthiazide→?; validate in nephrolithiasis cell model. Expected: similar to methyclothiazide (Jaccard=0.62) benzthiazide refractive_error GAP_HIGH 0.2981 0.625 methyclothiazide 0.45 STABLE 0.85 3 0.08225 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzthiazide→?; validate in refractive_error cell model. Expected: similar to methyclothiazide (Jaccard=0.62) gliquidone osteoarthritis GAP_HIGH 0.2959 0.7 tolazamide 0.45 STABLE 0.85 3 0.08164 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay gliquidone→?; validate in osteoarthritis cell model. Expected: similar to tolazamide (Jaccard=0.70) quinacrine duodenum_cancer GAP_HIGH 0.2215 0.6086956521739131 chlorprothixene 0.6 RISING 0.85 3 0.08149 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinacrine→?; validate in duodenum_cancer cell model. Expected: similar to chlorprothixene (Jaccard=0.61) orciprenaline pharynx_cancer GAP_HIGH 0.2214 0.6 dipivefrin 0.6 RISING 0.85 3 0.08145 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay orciprenaline→?; validate in pharynx_cancer cell model. Expected: similar to dipivefrin (Jaccard=0.60) metolazone nicotine_dependence GAP_HIGH 0.2945 0.6666666666666666 gabapentin 0.45 STABLE 0.85 3 0.08126 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay metolazone→?; validate in nicotine_dependence cell model. Expected: similar to gabapentin (Jaccard=0.67) sulfadiazine vaginal_cancer GAP_HIGH 0.2207 0.65 sulfapyridine 0.6 RISING 0.85 3 0.08119 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfadiazine→?; validate in vaginal_cancer cell model. Expected: similar to sulfapyridine (Jaccard=0.65) sulfadiazine vulva_cancer GAP_HIGH 0.2207 0.65 sulfapyridine 0.6 RISING 0.85 3 0.08119 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfadiazine→?; validate in vulva_cancer cell model. Expected: similar to sulfapyridine (Jaccard=0.65) sulfadiazine vascular_cancer GAP_HIGH 0.2206 0.65 sulfapyridine 0.6 RISING 0.85 3 0.08116 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfadiazine→?; validate in vascular_cancer cell model. Expected: similar to sulfapyridine (Jaccard=0.65) nandrolone_phenpropionate brain_cancer GAP_HIGH 0.2206 0.5714285714285714 cyproterone_acetate 0.6 RISING 0.85 3 0.08116 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nandrolone_phenpropionate→?; validate in brain_cancer cell model. Expected: similar to cyproterone_acetate (Jaccard=0.57) clenbuterol salivary_gland_cancer GAP_HIGH 0.312 1.0 epinephrine 0.6 RISING 0.6 3 0.08102 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clenbuterol→?; validate in salivary_gland_cancer cell model. Expected: similar to epinephrine (Jaccard=1.00) clenbuterol ocular_cancer GAP_HIGH 0.3117 1.0 epinephrine 0.6 RISING 0.6 3 0.08094 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clenbuterol→?; validate in ocular_cancer cell model. Expected: similar to epinephrine (Jaccard=1.00) orciprenaline asthma GAP_HIGH 0.2198 0.6 dipivefrin 0.6 RISING 0.85 3 0.08086 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay orciprenaline→?; validate in asthma cell model. Expected: similar to dipivefrin (Jaccard=0.60) metolazone systemic_scleroderma GAP_HIGH 0.2927 0.6666666666666666 gabapentin 0.45 STABLE 0.85 3 0.08076 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay metolazone→?; validate in systemic_scleroderma cell model. Expected: similar to gabapentin (Jaccard=0.67) orciprenaline uterine_cancer GAP_HIGH 0.2195 0.6 dipivefrin 0.6 RISING 0.85 3 0.08075 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay orciprenaline→?; validate in uterine_cancer cell model. Expected: similar to dipivefrin (Jaccard=0.60) mesalazine hypertension GAP_HIGH 0.1645 0.6666666666666666 isoprenaline 0.8 RAPID_RISE 0.85 3 0.08069 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mesalazine→?; validate in hypertension cell model. Expected: similar to isoprenaline (Jaccard=0.67) l-cysteine hematologic_cancer GAP_HIGH 0.219 0.6229508196721312 l-serine 0.6 RISING 0.85 3 0.08057 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-cysteine→?; validate in hematologic_cancer cell model. Expected: similar to l-serine (Jaccard=0.62) phenylpropanolamine obesity GAP_HIGH 0.1642 0.55 bethanidine 0.8 RAPID_RISE 0.85 3 0.08054 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenylpropanolamine→?; validate in obesity cell model. Expected: similar to bethanidine (Jaccard=0.55) orciprenaline testicular_cancer GAP_HIGH 0.2189 0.6 dipivefrin 0.6 RISING 0.85 3 0.08053 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay orciprenaline→?; validate in testicular_cancer cell model. Expected: similar to dipivefrin (Jaccard=0.60) primidone gilles_de_la_tourette_syndrome GAP_HIGH 0.238 0.5 ezetimibe 0.55 STABLE 0.85 3 0.08026 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay primidone→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to ezetimibe (Jaccard=0.50) mesalazine obesity GAP_HIGH 0.1635 0.6666666666666666 isoprenaline 0.8 RAPID_RISE 0.85 3 0.0802 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mesalazine→?; validate in obesity cell model. Expected: similar to isoprenaline (Jaccard=0.67) nilvadipine rheumatoid_arthritis GAP_HIGH 0.3264 1.0 amlodipine 0.4 STABLE 0.85 3 0.08005 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nilvadipine→?; validate in rheumatoid_arthritis cell model. Expected: similar to amlodipine (Jaccard=1.00) l-cysteine pharynx_cancer GAP_HIGH 0.2175 0.6229508196721312 l-serine 0.6 RISING 0.85 3 0.08002 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-cysteine→?; validate in pharynx_cancer cell model. Expected: similar to l-serine (Jaccard=0.62) phenmetrazine kidney_cancer GAP_HIGH 0.2174 0.5555555555555556 clofibrate 0.6 RISING 0.85 3 0.07998 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenmetrazine→?; validate in kidney_cancer cell model. Expected: similar to clofibrate (Jaccard=0.56) l-cysteine salivary_gland_cancer GAP_HIGH 0.2168 0.6229508196721312 l-serine 0.6 RISING 0.85 3 0.07976 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-cysteine→?; validate in salivary_gland_cancer cell model. Expected: similar to l-serine (Jaccard=0.62) sodium_lauryl_sulfate polycystic_ovary_syndrome GAP_HIGH 0.2365 0.5 orlistat 0.55 STABLE 0.85 3 0.07975 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sodium_lauryl_sulfate→?; validate in polycystic_ovary_syndrome cell model. Expected: similar to orlistat (Jaccard=0.50) tolazamide systemic_lupus_erythematosus GAP_HIGH 0.2166 0.4666666666666667 chlorpropamide 0.6 RISING 0.85 3 0.07968 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolazamide→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to chlorpropamide (Jaccard=0.47) clodronate malignant_glioma GAP_HIGH 0.2887 1.0 etidronic_acid 0.45 STABLE 0.85 3 0.07966 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clodronate→?; validate in malignant_glioma cell model. Expected: similar to etidronic_acid (Jaccard=1.00) tafluprost pharynx_cancer GAP_HIGH 0.3065 1.0 latanoprost 0.6 RISING 0.6 3 0.07959 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tafluprost→?; validate in pharynx_cancer cell model. Expected: similar to latanoprost (Jaccard=1.00) deferasirox thyroid_cancer GAP_HIGH 0.2295 0.5 linaclotide 0.8 RAPID_RISE 0.6 3 0.07946 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay deferasirox→?; validate in thyroid_cancer cell model. Expected: similar to linaclotide (Jaccard=0.50) antazoline stomach_cancer GAP_HIGH 0.2156 0.6666666666666666 bepridil 0.6 RISING 0.85 3 0.07932 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay antazoline→?; validate in stomach_cancer cell model. Expected: similar to bepridil (Jaccard=0.67) dextrothyroxine larynx_cancer GAP_HIGH 0.2152 0.25 methimazole 0.6 RISING 0.85 3 0.07917 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dextrothyroxine→?; validate in larynx_cancer cell model. Expected: similar to methimazole (Jaccard=0.25) nandrolone_phenpropionate hematologic_cancer GAP_HIGH 0.2151 0.5714285714285714 cyproterone_acetate 0.6 RISING 0.85 3 0.07913 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nandrolone_phenpropionate→?; validate in hematologic_cancer cell model. Expected: similar to cyproterone_acetate (Jaccard=0.57) ponatinib thyroid_cancer GAP_HIGH 0.1613 0.39473684210526316 imatinib 0.8 RAPID_RISE 0.85 3 0.07912 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ponatinib→?; validate in thyroid_cancer cell model. Expected: similar to imatinib (Jaccard=0.39) methyldopa hypertension GAP_HIGH 0.2284 0.9375 carbidopa 0.8 RAPID_RISE 0.6 3 0.07908 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methyldopa→?; validate in hypertension cell model. Expected: similar to carbidopa (Jaccard=0.94) tafluprost uterine_cancer GAP_HIGH 0.3045 1.0 latanoprost 0.6 RISING 0.6 3 0.07907 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tafluprost→?; validate in uterine_cancer cell model. Expected: similar to latanoprost (Jaccard=1.00) phenmetrazine penile_cancer GAP_HIGH 0.2148 0.5555555555555556 probenecid 0.6 RISING 0.85 3 0.07902 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenmetrazine→?; validate in penile_cancer cell model. Expected: similar to probenecid (Jaccard=0.56) bepotastine epilepsy_syndrome GAP_HIGH 0.3221 1.0 droperidol 0.4 STABLE 0.85 3 0.079 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bepotastine→?; validate in epilepsy_syndrome cell model. Expected: similar to droperidol (Jaccard=1.00) quinapril alzheimers_disease GAP_HIGH 0.2281 0.5 moexipril 0.8 RAPID_RISE 0.6 3 0.07898 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinapril→?; validate in alzheimers_disease cell model. Expected: similar to moexipril (Jaccard=0.50) quinapril parkinsons_disease GAP_HIGH 0.2281 0.5 moexipril 0.8 RAPID_RISE 0.6 3 0.07898 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinapril→?; validate in parkinsons_disease cell model. Expected: similar to moexipril (Jaccard=0.50) mefenamic_acid thyroid_cancer GAP_HIGH 0.161 0.5384615384615384 clonidine 0.8 RAPID_RISE 0.85 3 0.07897 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mefenamic_acid→?; validate in thyroid_cancer cell model. Expected: similar to clonidine (Jaccard=0.54) tafluprost testicular_cancer GAP_HIGH 0.3039 1.0 latanoprost 0.6 RISING 0.6 3 0.07892 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tafluprost→?; validate in testicular_cancer cell model. Expected: similar to latanoprost (Jaccard=1.00) tafluprost vaginal_cancer GAP_HIGH 0.3039 1.0 latanoprost 0.6 RISING 0.6 3 0.07892 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tafluprost→?; validate in vaginal_cancer cell model. Expected: similar to latanoprost (Jaccard=1.00) acetic_acid larynx_cancer GAP_HIGH 0.2143 0.25 hydroxyurea 0.6 RISING 0.85 3 0.07884 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acetic_acid→?; validate in larynx_cancer cell model. Expected: similar to hydroxyurea (Jaccard=0.25) lisinopril dilated_cardiomyopathy GAP_HIGH 0.2428 0.7777777777777778 trandolapril 0.45 STABLE 1.0 3 0.07881 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lisinopril→?; validate in dilated_cardiomyopathy cell model. Expected: similar to trandolapril (Jaccard=0.78) sulfamethizole melanoma GAP_HIGH 0.1605 0.4 sulfapyridine 0.8 RAPID_RISE 0.85 3 0.07873 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfamethizole→?; validate in melanoma cell model. Expected: similar to sulfapyridine (Jaccard=0.40) propericiazine hematologic_cancer GAP_HIGH 0.2137 0.8333333333333334 thioproperazine 0.6 RISING 0.85 3 0.07862 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propericiazine→?; validate in hematologic_cancer cell model. Expected: similar to thioproperazine (Jaccard=0.83) antipyrine asthma GAP_HIGH 0.2134 0.6818181818181818 ethotoin 0.6 RISING 0.85 3 0.07851 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay antipyrine→?; validate in asthma cell model. Expected: similar to ethotoin (Jaccard=0.68) prednisolone hematologic_cancer GAP_HIGH 0.213 0.75 loteprednol 0.6 RISING 0.85 3 0.07836 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prednisolone→?; validate in hematologic_cancer cell model. Expected: similar to loteprednol (Jaccard=0.75) anileridine type_2_diabetes_mellitus GAP_HIGH 0.1596 0.4166666666666667 milnacipran 0.8 RAPID_RISE 0.85 3 0.07829 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay anileridine→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to milnacipran (Jaccard=0.42) moexipril hypertension GAP_HIGH 0.226 0.6 cilazapril 0.8 RAPID_RISE 0.6 3 0.07825 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay moexipril→?; validate in hypertension cell model. Expected: similar to cilazapril (Jaccard=0.60) disopyramide celiac_disease GAP_HIGH 0.2834 0.75 mepenzolate 0.45 STABLE 0.85 3 0.07819 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay disopyramide→?; validate in celiac_disease cell model. Expected: similar to mepenzolate (Jaccard=0.75) mepyramine systemic_lupus_erythematosus GAP_HIGH 0.2122 0.625 tripelennamine 0.6 RISING 0.85 3 0.07807 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mepyramine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to tripelennamine (Jaccard=0.62) pralatrexate malignant_glioma GAP_HIGH 0.2819 0.7142857142857143 methotrexate 0.45 STABLE 0.85 3 0.07778 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pralatrexate→?; validate in malignant_glioma cell model. Expected: similar to methotrexate (Jaccard=0.71) ranolazine restless_legs_syndrome GAP_HIGH 0.2306 0.5714285714285714 methocarbamol 0.55 STABLE 0.85 3 0.07777 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ranolazine→?; validate in restless_legs_syndrome cell model. Expected: similar to methocarbamol (Jaccard=0.57) nitisinone duodenum_cancer GAP_HIGH 0.2113 0.25 finasteride 0.6 RISING 0.85 3 0.07773 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nitisinone→?; validate in duodenum_cancer cell model. Expected: similar to finasteride (Jaccard=0.25) nitisinone gallbladder_cancer GAP_HIGH 0.2113 0.25 finasteride 0.6 RISING 0.85 3 0.07773 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nitisinone→?; validate in gallbladder_cancer cell model. Expected: similar to finasteride (Jaccard=0.25) levomilnacipran breast_cancer GAP_HIGH 0.299 1.0 remifentanil 0.6 RISING 0.6 3 0.07765 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levomilnacipran→?; validate in breast_cancer cell model. Expected: similar to remifentanil (Jaccard=1.00) dextrothyroxine head_and_neck_cancer GAP_HIGH 0.211 0.25 methimazole 0.6 RISING 0.85 3 0.07762 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dextrothyroxine→?; validate in head_and_neck_cancer cell model. Expected: similar to methimazole (Jaccard=0.25) tolazoline osteoarthritis GAP_HIGH 0.2808 0.8 phenformin 0.45 STABLE 0.85 3 0.07748 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolazoline→?; validate in osteoarthritis cell model. Expected: similar to phenformin (Jaccard=0.80) tolazoline systemic_scleroderma GAP_HIGH 0.2804 0.8 phenformin 0.45 STABLE 0.85 3 0.07737 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolazoline→?; validate in systemic_scleroderma cell model. Expected: similar to phenformin (Jaccard=0.80) solifenacin acquired_immunodeficiency_syndrome GAP_HIGH 0.3248 0.6 alvimopan 0.55 STABLE 0.6 3 0.07732 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay solifenacin→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to alvimopan (Jaccard=0.60) disopyramide crohns_disease GAP_HIGH 0.2799 0.75 mepenzolate 0.45 STABLE 0.85 3 0.07723 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay disopyramide→?; validate in crohns_disease cell model. Expected: similar to mepenzolate (Jaccard=0.75) trifluridine malignant_mesothelioma GAP_HIGH 0.2797 0.6 telbivudine 0.45 STABLE 0.85 3 0.07717 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trifluridine→?; validate in malignant_mesothelioma cell model. Expected: similar to telbivudine (Jaccard=0.60) nitisinone lung_cancer GAP_HIGH 0.2097 0.25 finasteride 0.6 RISING 0.85 3 0.07715 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nitisinone→?; validate in lung_cancer cell model. Expected: similar to finasteride (Jaccard=0.25) nitisinone rectum_cancer GAP_HIGH 0.2097 0.25 finasteride 0.6 RISING 0.85 3 0.07715 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nitisinone→?; validate in rectum_cancer cell model. Expected: similar to finasteride (Jaccard=0.25) dronedarone kidney_cancer GAP_HIGH 0.2095 0.4166666666666667 proparacaine 0.6 RISING 0.85 3 0.07707 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dronedarone→?; validate in kidney_cancer cell model. Expected: similar to proparacaine (Jaccard=0.42) phenobarbital alzheimers_disease GAP_HIGH 0.2221 0.5384615384615384 ketazolam 0.8 RAPID_RISE 0.6 3 0.0769 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenobarbital→?; validate in alzheimers_disease cell model. Expected: similar to ketazolam (Jaccard=0.54) chlordiazepoxide ulcerative_colitis GAP_HIGH 0.1567 0.5555555555555556 diazepam 0.8 RAPID_RISE 0.85 3 0.07686 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlordiazepoxide→?; validate in ulcerative_colitis cell model. Expected: similar to diazepam (Jaccard=0.56) floxuridine mediastinal_cancer GAP_HIGH 0.2089 0.5714285714285714 entecavir 0.6 RISING 0.85 3 0.07685 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay floxuridine→?; validate in mediastinal_cancer cell model. Expected: similar to entecavir (Jaccard=0.57) norepinephrine systemic_lupus_erythematosus GAP_HIGH 0.2089 0.5714285714285714 isoetarine 0.6 RISING 0.85 3 0.07685 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay norepinephrine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to isoetarine (Jaccard=0.57) droperidol colon_cancer GAP_HIGH 0.2959 1.0 bepotastine 0.6 RISING 0.6 3 0.07684 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay droperidol→?; validate in colon_cancer cell model. Expected: similar to bepotastine (Jaccard=1.00) floxuridine thymus_cancer GAP_HIGH 0.2088 0.5714285714285714 entecavir 0.6 RISING 0.85 3 0.07681 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay floxuridine→?; validate in thymus_cancer cell model. Expected: similar to entecavir (Jaccard=0.57) adenine skin_cancer GAP_HIGH 0.2088 0.5 tioguanine 0.6 RISING 0.85 3 0.07681 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay adenine→?; validate in skin_cancer cell model. Expected: similar to tioguanine (Jaccard=0.50) methotrexate stomach_cancer GAP_HIGH 0.1772 0.6 pemetrexed 0.6 RISING 1.0 3 0.07669 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methotrexate→?; validate in stomach_cancer cell model. Expected: similar to pemetrexed (Jaccard=0.60) disopyramide sclerosing_cholangitis GAP_HIGH 0.2779 0.75 mepenzolate 0.45 STABLE 0.85 3 0.07668 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay disopyramide→?; validate in sclerosing_cholangitis cell model. Expected: similar to mepenzolate (Jaccard=0.75) disopyramide creutzfeldt-jakob_disease GAP_HIGH 0.2778 0.75 mepenzolate 0.45 STABLE 0.85 3 0.07665 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay disopyramide→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to mepenzolate (Jaccard=0.75) aciclovir skin_cancer GAP_HIGH 0.2083 0.3333333333333333 cyclosporine 0.6 RISING 0.85 3 0.07663 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aciclovir→?; validate in skin_cancer cell model. Expected: similar to cyclosporine (Jaccard=0.33) dextrothyroxine penile_cancer GAP_HIGH 0.2083 0.25 methimazole 0.6 RISING 0.85 3 0.07663 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dextrothyroxine→?; validate in penile_cancer cell model. Expected: similar to methimazole (Jaccard=0.25) tamoxifen breast_cancer GAP_HIGH 0.177 0.75 methadyl_acetate 0.6 RISING 1.0 3 0.07661 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tamoxifen→?; validate in breast_cancer cell model. Expected: similar to methadyl_acetate (Jaccard=0.75) dapsone systemic_lupus_erythematosus GAP_HIGH 0.2082 0.625 sulfamethizole 0.6 RISING 0.85 3 0.07659 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dapsone→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to sulfamethizole (Jaccard=0.62) l-methionine hematologic_cancer GAP_HIGH 0.2082 0.5967741935483871 l-serine 0.6 RISING 0.85 3 0.07659 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-methionine→?; validate in hematologic_cancer cell model. Expected: similar to l-serine (Jaccard=0.60) aciclovir vaginal_cancer GAP_HIGH 0.2082 0.3333333333333333 cyclosporine 0.6 RISING 0.85 3 0.07659 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aciclovir→?; validate in vaginal_cancer cell model. Expected: similar to cyclosporine (Jaccard=0.33) aciclovir vulva_cancer GAP_HIGH 0.2082 0.3333333333333333 cyclosporine 0.6 RISING 0.85 3 0.07659 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aciclovir→?; validate in vulva_cancer cell model. Expected: similar to cyclosporine (Jaccard=0.33) cyproheptadine epilepsy_syndrome GAP_HIGH 0.3122 1.0 alcaftadine 0.4 STABLE 0.85 3 0.07657 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyproheptadine→?; validate in epilepsy_syndrome cell model. Expected: similar to alcaftadine (Jaccard=1.00) disopyramide ankylosing_spondylitis GAP_HIGH 0.2774 0.75 mepenzolate 0.45 STABLE 0.85 3 0.07654 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay disopyramide→?; validate in ankylosing_spondylitis cell model. Expected: similar to mepenzolate (Jaccard=0.75) dapsone skin_cancer GAP_HIGH 0.208 0.625 sulfamethizole 0.6 RISING 0.85 3 0.07652 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dapsone→?; validate in skin_cancer cell model. Expected: similar to sulfamethizole (Jaccard=0.62) acetic_acid germ_cell_cancer GAP_HIGH 0.208 0.25 hydroxyurea 0.6 RISING 0.85 3 0.07652 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acetic_acid→?; validate in germ_cell_cancer cell model. Expected: similar to hydroxyurea (Jaccard=0.25) dapsone vulva_cancer GAP_HIGH 0.2079 0.625 sulfamethizole 0.6 RISING 0.85 3 0.07648 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dapsone→?; validate in vulva_cancer cell model. Expected: similar to sulfamethizole (Jaccard=0.62) glucosamine thyroid_cancer GAP_HIGH 0.1559 0.46153846153846156 clofarabine 0.8 RAPID_RISE 0.85 3 0.07647 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glucosamine→?; validate in thyroid_cancer cell model. Expected: similar to clofarabine (Jaccard=0.46) methyclothiazide vulva_cancer GAP_HIGH 0.2078 0.4444444444444444 hydrochlorothiazide 0.6 RISING 0.85 3 0.07645 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methyclothiazide→?; validate in vulva_cancer cell model. Expected: similar to hydrochlorothiazide (Jaccard=0.44) chlorthalidone duodenum_cancer GAP_HIGH 0.2076 0.5 clozapine 0.6 RISING 0.85 3 0.07637 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorthalidone→?; validate in duodenum_cancer cell model. Expected: similar to clozapine (Jaccard=0.50) chlorthalidone gallbladder_cancer GAP_HIGH 0.2076 0.5 clozapine 0.6 RISING 0.85 3 0.07637 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorthalidone→?; validate in gallbladder_cancer cell model. Expected: similar to clozapine (Jaccard=0.50) acetic_acid penile_cancer GAP_HIGH 0.2074 0.25 hydroxyurea 0.6 RISING 0.85 3 0.0763 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acetic_acid→?; validate in penile_cancer cell model. Expected: similar to hydroxyurea (Jaccard=0.25) nilotinib penile_cancer GAP_HIGH 0.2073 0.5714285714285714 sunitinib 0.6 RISING 0.85 3 0.07626 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nilotinib→?; validate in penile_cancer cell model. Expected: similar to sunitinib (Jaccard=0.57) cyproheptadine schizophrenia GAP_HIGH 0.3109 1.0 alcaftadine 0.4 STABLE 0.85 3 0.07625 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyproheptadine→?; validate in schizophrenia cell model. Expected: similar to alcaftadine (Jaccard=1.00) acetylcysteine metabolic_syndrome_x GAP_HIGH 0.226 0.4444444444444444 calcium_acetate 0.55 STABLE 0.85 3 0.07621 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acetylcysteine→?; validate in metabolic_syndrome_x cell model. Expected: similar to calcium_acetate (Jaccard=0.44) dronedarone penile_cancer GAP_HIGH 0.2069 0.4166666666666667 proparacaine 0.6 RISING 0.85 3 0.07612 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dronedarone→?; validate in penile_cancer cell model. Expected: similar to proparacaine (Jaccard=0.42) dasatinib penile_cancer GAP_HIGH 0.2068 0.5833333333333334 crizotinib 0.6 RISING 0.85 3 0.07608 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dasatinib→?; validate in penile_cancer cell model. Expected: similar to crizotinib (Jaccard=0.58) amiloride larynx_cancer GAP_HIGH 0.2068 0.3333333333333333 vincristine 0.6 RISING 0.85 3 0.07608 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amiloride→?; validate in larynx_cancer cell model. Expected: similar to vincristine (Jaccard=0.33) calcidiol vaginal_cancer GAP_HIGH 0.2929 0.8 calcipotriol 0.6 RISING 0.6 3 0.07606 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay calcidiol→?; validate in vaginal_cancer cell model. Expected: similar to calcipotriol (Jaccard=0.80) l-methionine pharynx_cancer GAP_HIGH 0.2067 0.5967741935483871 l-serine 0.6 RISING 0.85 3 0.07604 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-methionine→?; validate in pharynx_cancer cell model. Expected: similar to l-serine (Jaccard=0.60) ziprasidone multiple_sclerosis GAP_HIGH 0.2064 0.6 olanzapine 0.6 RISING 0.85 3 0.07593 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ziprasidone→?; validate in multiple_sclerosis cell model. Expected: similar to olanzapine (Jaccard=0.60) prednicarbate kidney_cancer GAP_HIGH 0.2062 0.5454545454545454 medrysone 0.6 RISING 0.85 3 0.07586 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prednicarbate→?; validate in kidney_cancer cell model. Expected: similar to medrysone (Jaccard=0.55) l-methionine salivary_gland_cancer GAP_HIGH 0.2061 0.5967741935483871 l-serine 0.6 RISING 0.85 3 0.07582 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-methionine→?; validate in salivary_gland_cancer cell model. Expected: similar to l-serine (Jaccard=0.60) eplerenone idiopathic_pulmonary_fibrosis GAP_HIGH 0.2747 0.8571428571428571 prednicarbate 0.45 STABLE 0.85 3 0.07579 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay eplerenone→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to prednicarbate (Jaccard=0.86) chlorthalidone lung_cancer GAP_HIGH 0.206 0.5 clozapine 0.6 RISING 0.85 3 0.07578 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorthalidone→?; validate in lung_cancer cell model. Expected: similar to clozapine (Jaccard=0.50) nilotinib prostate_cancer GAP_HIGH 0.2058 0.5714285714285714 sunitinib 0.6 RISING 0.85 3 0.07571 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nilotinib→?; validate in prostate_cancer cell model. Expected: similar to sunitinib (Jaccard=0.57) perphenazine prostate_cancer GAP_HIGH 0.2057 0.8181818181818182 propericiazine 0.6 RISING 0.85 3 0.07567 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay perphenazine→?; validate in prostate_cancer cell model. Expected: similar to propericiazine (Jaccard=0.82) paricalcitol vaginal_cancer GAP_HIGH 0.2913 0.8333333333333334 calcipotriol 0.6 RISING 0.6 3 0.07565 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay paricalcitol→?; validate in vaginal_cancer cell model. Expected: similar to calcipotriol (Jaccard=0.83) dasatinib prostate_cancer GAP_HIGH 0.2053 0.5833333333333334 crizotinib 0.6 RISING 0.85 3 0.07553 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dasatinib→?; validate in prostate_cancer cell model. Expected: similar to crizotinib (Jaccard=0.58) dasatinib mediastinal_cancer GAP_HIGH 0.2051 0.5833333333333334 crizotinib 0.6 RISING 0.85 3 0.07545 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dasatinib→?; validate in mediastinal_cancer cell model. Expected: similar to crizotinib (Jaccard=0.58) clotiazepam amyotrophic_lateral_sclerosis GAP_HIGH 0.2903 0.8333333333333334 cinolazepam 0.6 RISING 0.6 3 0.07539 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clotiazepam→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to cinolazepam (Jaccard=0.83) mepenzolate osteoporosis GAP_HIGH 0.2732 0.75 disopyramide 0.45 STABLE 0.85 3 0.07538 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mepenzolate→?; validate in osteoporosis cell model. Expected: similar to disopyramide (Jaccard=0.75) amiloride esophageal_cancer GAP_HIGH 0.2047 0.3333333333333333 vincristine 0.6 RISING 0.85 3 0.07531 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amiloride→?; validate in esophageal_cancer cell model. Expected: similar to vincristine (Jaccard=0.33) solifenacin rheumatoid_arthritis GAP_HIGH 0.4347 1.0 labetalol 0.4 STABLE 0.6 3 0.07526 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay solifenacin→?; validate in rheumatoid_arthritis cell model. Expected: similar to labetalol (Jaccard=1.00) dihomo-gamma-linolenic_acid salivary_gland_cancer GAP_HIGH 0.2045 0.46153846153846156 carboprost_tromethamine 0.6 RISING 0.85 3 0.07523 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dihomo-gamma-linolenic_acid→?; validate in salivary_gland_cancer cell model. Expected: similar to carboprost_tromethamine (Jaccard=0.46) regadenoson stomach_cancer GAP_HIGH 0.2896 0.7777777777777778 clofarabine 0.6 RISING 0.6 3 0.0752 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay regadenoson→?; validate in stomach_cancer cell model. Expected: similar to clofarabine (Jaccard=0.78) fenbufen alzheimers_disease GAP_HIGH 0.2172 0.6666666666666666 phenindione 0.8 RAPID_RISE 0.6 3 0.0752 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fenbufen→?; validate in alzheimers_disease cell model. Expected: similar to phenindione (Jaccard=0.67) teniposide hematologic_cancer GAP_HIGH 0.2044 0.5714285714285714 podofilox 0.6 RISING 0.85 3 0.0752 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay teniposide→?; validate in hematologic_cancer cell model. Expected: similar to podofilox (Jaccard=0.57) regadenoson skin_cancer GAP_HIGH 0.2889 0.7777777777777778 clofarabine 0.6 RISING 0.6 3 0.07502 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay regadenoson→?; validate in skin_cancer cell model. Expected: similar to clofarabine (Jaccard=0.78) isoetarine asthma GAP_HIGH 0.2037 0.5714285714285714 norepinephrine 0.6 RISING 0.85 3 0.07494 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isoetarine→?; validate in asthma cell model. Expected: similar to norepinephrine (Jaccard=0.57) sulfaphenazole vaginal_cancer GAP_HIGH 0.2037 0.5714285714285714 vismodegib 0.6 RISING 0.85 3 0.07494 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfaphenazole→?; validate in vaginal_cancer cell model. Expected: similar to vismodegib (Jaccard=0.57) sulfaphenazole vulva_cancer GAP_HIGH 0.2037 0.5714285714285714 vismodegib 0.6 RISING 0.85 3 0.07494 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfaphenazole→?; validate in vulva_cancer cell model. Expected: similar to vismodegib (Jaccard=0.57) sulfaphenazole vascular_cancer GAP_HIGH 0.2036 0.5714285714285714 vismodegib 0.6 RISING 0.85 3 0.0749 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfaphenazole→?; validate in vascular_cancer cell model. Expected: similar to vismodegib (Jaccard=0.57) prednisone prostate_cancer GAP_HIGH 0.2034 0.8235294117647058 testolactone 0.6 RISING 0.85 3 0.07483 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prednisone→?; validate in prostate_cancer cell model. Expected: similar to testolactone (Jaccard=0.82) fluspirilene colon_cancer GAP_HIGH 0.2881 1.0 bepotastine 0.6 RISING 0.6 3 0.07482 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluspirilene→?; validate in colon_cancer cell model. Expected: similar to bepotastine (Jaccard=1.00) solifenacin gilles_de_la_tourette_syndrome GAP_HIGH 0.3141 0.6 alvimopan 0.55 STABLE 0.6 3 0.07477 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay solifenacin→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to alvimopan (Jaccard=0.60) calcium_acetate idiopathic_pulmonary_fibrosis GAP_HIGH 0.2707 0.4444444444444444 acetylcysteine 0.45 STABLE 0.85 3 0.07469 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay calcium_acetate→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to acetylcysteine (Jaccard=0.44) menadione thyroid_cancer GAP_HIGH 0.1522 0.42857142857142855 lenalidomide 0.8 RAPID_RISE 0.85 3 0.07466 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay menadione→?; validate in thyroid_cancer cell model. Expected: similar to lenalidomide (Jaccard=0.43) prednisone hematologic_cancer GAP_HIGH 0.2029 0.8235294117647058 testolactone 0.6 RISING 0.85 3 0.07464 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prednisone→?; validate in hematologic_cancer cell model. Expected: similar to testolactone (Jaccard=0.82) vandetanib thyroid_cancer GAP_HIGH 0.1521 0.6060606060606061 gefitinib 0.8 RAPID_RISE 0.85 3 0.07461 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vandetanib→?; validate in thyroid_cancer cell model. Expected: similar to gefitinib (Jaccard=0.61) dihomo-gamma-linolenic_acid skin_cancer GAP_HIGH 0.2027 0.46153846153846156 carboprost_tromethamine 0.6 RISING 0.85 3 0.07457 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dihomo-gamma-linolenic_acid→?; validate in skin_cancer cell model. Expected: similar to carboprost_tromethamine (Jaccard=0.46) amiloride head_and_neck_cancer GAP_HIGH 0.2026 0.3333333333333333 vincristine 0.6 RISING 0.85 3 0.07453 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amiloride→?; validate in head_and_neck_cancer cell model. Expected: similar to vincristine (Jaccard=0.33) cytarabine mediastinal_cancer GAP_HIGH 0.2025 0.4 telbivudine 0.6 RISING 0.85 3 0.0745 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cytarabine→?; validate in mediastinal_cancer cell model. Expected: similar to telbivudine (Jaccard=0.40) terbutaline polycystic_ovary_syndrome GAP_HIGH 0.2205 0.6666666666666666 pirbuterol 0.55 STABLE 0.85 3 0.07436 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay terbutaline→?; validate in polycystic_ovary_syndrome cell model. Expected: similar to pirbuterol (Jaccard=0.67) teniposide lung_cancer GAP_HIGH 0.202 0.5714285714285714 podofilox 0.6 RISING 0.85 3 0.07431 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay teniposide→?; validate in lung_cancer cell model. Expected: similar to podofilox (Jaccard=0.57) quinethazone vulva_cancer GAP_HIGH 0.2019 0.4444444444444444 hydrochlorothiazide 0.6 RISING 0.85 3 0.07428 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinethazone→?; validate in vulva_cancer cell model. Expected: similar to hydrochlorothiazide (Jaccard=0.44) ramipril type_1_diabetes_mellitus GAP_HIGH 0.2859 1.0 trandolapril 0.6 RISING 0.6 3 0.07424 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ramipril→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to trandolapril (Jaccard=1.00) perphenazine systemic_lupus_erythematosus GAP_HIGH 0.2015 0.8181818181818182 propericiazine 0.6 RISING 0.85 3 0.07413 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay perphenazine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to propericiazine (Jaccard=0.82) aminoglutethimide atherosclerosis GAP_HIGH 0.2685 0.6 clofibrate 0.45 STABLE 0.85 3 0.07408 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminoglutethimide→?; validate in atherosclerosis cell model. Expected: similar to clofibrate (Jaccard=0.60) dextrothyroxine hypothyroidism GAP_HIGH 0.2685 0.25 methimazole 0.45 STABLE 0.85 3 0.07408 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dextrothyroxine→?; validate in hypothyroidism cell model. Expected: similar to methimazole (Jaccard=0.25) pipotiazine hematologic_cancer GAP_HIGH 0.2009 0.9166666666666666 thioproperazine 0.6 RISING 0.85 3 0.07391 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pipotiazine→?; validate in hematologic_cancer cell model. Expected: similar to thioproperazine (Jaccard=0.92) calcium_acetate attention_deficit_hyperactivity_disorder GAP_HIGH 0.2674 0.4444444444444444 acetylcysteine 0.45 STABLE 0.85 3 0.07378 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay calcium_acetate→?; validate in attention_deficit_hyperactivity_disorder cell model. Expected: similar to acetylcysteine (Jaccard=0.44) diphenhydramine parkinsons_disease GAP_HIGH 0.1504 0.6296296296296297 naftifine 0.8 RAPID_RISE 0.85 3 0.07377 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphenhydramine→?; validate in parkinsons_disease cell model. Expected: similar to naftifine (Jaccard=0.63) butabarbital duodenum_cancer GAP_HIGH 0.283 0.7333333333333333 clobazam 0.6 RISING 0.6 3 0.07349 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay butabarbital→?; validate in duodenum_cancer cell model. Expected: similar to clobazam (Jaccard=0.73) butabarbital gallbladder_cancer GAP_HIGH 0.283 0.7333333333333333 clobazam 0.6 RISING 0.6 3 0.07349 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay butabarbital→?; validate in gallbladder_cancer cell model. Expected: similar to clobazam (Jaccard=0.73) levomilnacipran gilles_de_la_tourette_syndrome GAP_HIGH 0.3084 1.0 remifentanil 0.55 STABLE 0.6 3 0.07341 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levomilnacipran→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to remifentanil (Jaccard=1.00) cyclopentolate gilles_de_la_tourette_syndrome GAP_HIGH 0.2175 0.7142857142857143 remifentanil 0.55 STABLE 0.85 3 0.07335 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyclopentolate→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to remifentanil (Jaccard=0.71) calcium_acetate systemic_scleroderma GAP_HIGH 0.2658 0.4444444444444444 acetylcysteine 0.45 STABLE 0.85 3 0.07334 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay calcium_acetate→?; validate in systemic_scleroderma cell model. Expected: similar to acetylcysteine (Jaccard=0.44) aceprometazine rheumatoid_arthritis GAP_HIGH 0.2982 1.0 propiomazine 0.4 STABLE 0.85 3 0.07314 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aceprometazine→?; validate in rheumatoid_arthritis cell model. Expected: similar to propiomazine (Jaccard=1.00) butabarbital lung_cancer GAP_HIGH 0.2814 0.7333333333333333 clobazam 0.6 RISING 0.6 3 0.07308 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay butabarbital→?; validate in lung_cancer cell model. Expected: similar to clobazam (Jaccard=0.73) butabarbital rectum_cancer GAP_HIGH 0.2814 0.7333333333333333 clobazam 0.6 RISING 0.6 3 0.07308 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay butabarbital→?; validate in rectum_cancer cell model. Expected: similar to clobazam (Jaccard=0.73) remifentanil narcolepsy GAP_HIGH 0.3744 1.0 milnacipran 0.45 STABLE 0.6 3 0.07292 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay remifentanil→?; validate in narcolepsy cell model. Expected: similar to milnacipran (Jaccard=1.00) salbutamol thyroid_cancer GAP_HIGH 0.2105 0.6 dipivefrin 0.8 RAPID_RISE 0.6 3 0.07288 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay salbutamol→?; validate in thyroid_cancer cell model. Expected: similar to dipivefrin (Jaccard=0.60) buclizine azoospermia GAP_HIGH 0.264 1.0 meclizine 0.45 STABLE 0.85 3 0.07284 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay buclizine→?; validate in azoospermia cell model. Expected: similar to meclizine (Jaccard=1.00) acetophenazine hematologic_cancer GAP_HIGH 0.1979 0.6666666666666666 nefazodone 0.6 RISING 0.85 3 0.0728 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acetophenazine→?; validate in hematologic_cancer cell model. Expected: similar to nefazodone (Jaccard=0.67) sulpiride idiopathic_pulmonary_fibrosis GAP_HIGH 0.2634 0.75 zafirlukast 0.45 STABLE 0.85 3 0.07268 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulpiride→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to zafirlukast (Jaccard=0.75) clofibrate leprosy GAP_HIGH 0.2634 0.5555555555555556 phenmetrazine 0.45 STABLE 0.85 3 0.07268 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clofibrate→?; validate in leprosy cell model. Expected: similar to phenmetrazine (Jaccard=0.56) l-cystine narcolepsy GAP_HIGH 0.2632 0.475 l-methionine 0.45 STABLE 0.85 3 0.07262 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-cystine→?; validate in narcolepsy cell model. Expected: similar to l-methionine (Jaccard=0.47) l-asparagine hematologic_cancer GAP_HIGH 0.1974 0.36666666666666664 l-serine 0.6 RISING 0.85 3 0.07262 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-asparagine→?; validate in hematologic_cancer cell model. Expected: similar to l-serine (Jaccard=0.37) pipotiazine systemic_lupus_erythematosus GAP_HIGH 0.1971 0.9166666666666666 thioproperazine 0.6 RISING 0.85 3 0.07251 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pipotiazine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to thioproperazine (Jaccard=0.92) medroxyprogesterone_acetate breast_cancer GAP_HIGH 0.1971 0.6 etonogestrel 0.6 RISING 0.85 3 0.07251 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay medroxyprogesterone_acetate→?; validate in breast_cancer cell model. Expected: similar to etonogestrel (Jaccard=0.60) medroxyprogesterone_acetate uterine_cancer GAP_HIGH 0.1968 0.6 etonogestrel 0.6 RISING 0.85 3 0.0724 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay medroxyprogesterone_acetate→?; validate in uterine_cancer cell model. Expected: similar to etonogestrel (Jaccard=0.60) remifentanil panic_disorder GAP_HIGH 0.3713 1.0 milnacipran 0.45 STABLE 0.6 3 0.07232 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay remifentanil→?; validate in panic_disorder cell model. Expected: similar to milnacipran (Jaccard=1.00) l-asparagine pharynx_cancer GAP_HIGH 0.1959 0.36666666666666664 l-serine 0.6 RISING 0.85 3 0.07207 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-asparagine→?; validate in pharynx_cancer cell model. Expected: similar to l-serine (Jaccard=0.37) tauroursodeoxycholic_acid prostate_cancer GAP_HIGH 0.1959 0.23529411764705882 drostanolone 0.6 RISING 0.85 3 0.07207 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tauroursodeoxycholic_acid→?; validate in prostate_cancer cell model. Expected: similar to drostanolone (Jaccard=0.24) remifentanil systemic_scleroderma GAP_HIGH 0.37 1.0 milnacipran 0.45 STABLE 0.6 3 0.07206 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay remifentanil→?; validate in systemic_scleroderma cell model. Expected: similar to milnacipran (Jaccard=1.00) sulpiride chronic_obstructive_pulmonary_disease GAP_HIGH 0.2611 0.75 zafirlukast 0.45 STABLE 0.85 3 0.07204 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulpiride→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to zafirlukast (Jaccard=0.75) buclizine narcolepsy GAP_HIGH 0.261 1.0 meclizine 0.45 STABLE 0.85 3 0.07201 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay buclizine→?; validate in narcolepsy cell model. Expected: similar to meclizine (Jaccard=1.00) acetophenazine muscle_cancer GAP_HIGH 0.1957 0.6666666666666666 nefazodone 0.6 RISING 0.85 3 0.072 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acetophenazine→?; validate in muscle_cancer cell model. Expected: similar to nefazodone (Jaccard=0.67) glipizide gout GAP_HIGH 0.2609 0.7 tolazamide 0.45 STABLE 0.85 3 0.07199 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glipizide→?; validate in gout cell model. Expected: similar to tolazamide (Jaccard=0.70) l-cystine autistic_disorder GAP_HIGH 0.2606 0.475 l-methionine 0.45 STABLE 0.85 3 0.0719 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-cystine→?; validate in autistic_disorder cell model. Expected: similar to l-methionine (Jaccard=0.47) l-cystine nicotine_dependence GAP_HIGH 0.2606 0.475 l-methionine 0.45 STABLE 0.85 3 0.0719 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-cystine→?; validate in nicotine_dependence cell model. Expected: similar to l-methionine (Jaccard=0.47) l-asparagine salivary_gland_cancer GAP_HIGH 0.1953 0.36666666666666664 l-serine 0.6 RISING 0.85 3 0.07185 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-asparagine→?; validate in salivary_gland_cancer cell model. Expected: similar to l-serine (Jaccard=0.37) l-cystine conduct_disorder GAP_HIGH 0.2601 0.475 l-methionine 0.45 STABLE 0.85 3 0.07177 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-cystine→?; validate in conduct_disorder cell model. Expected: similar to l-methionine (Jaccard=0.47) nateglinide type_2_diabetes_mellitus GAP_HIGH 0.1462 0.5555555555555556 phenelzine 0.8 RAPID_RISE 0.85 3 0.07171 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nateglinide→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to phenelzine (Jaccard=0.56) sulpiride atopic_dermatitis GAP_HIGH 0.2597 0.75 zafirlukast 0.45 STABLE 0.85 3 0.07166 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulpiride→?; validate in atopic_dermatitis cell model. Expected: similar to zafirlukast (Jaccard=0.75) sulpiride psoriasis GAP_HIGH 0.2595 0.75 zafirlukast 0.45 STABLE 0.85 3 0.0716 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulpiride→?; validate in psoriasis cell model. Expected: similar to zafirlukast (Jaccard=0.75) lapatinib larynx_cancer GAP_HIGH 0.1946 0.5 docetaxel 0.6 RISING 0.85 3 0.07159 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lapatinib→?; validate in larynx_cancer cell model. Expected: similar to docetaxel (Jaccard=0.50) tauroursodeoxycholic_acid duodenum_cancer GAP_HIGH 0.1945 0.23529411764705882 drostanolone 0.6 RISING 0.85 3 0.07155 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tauroursodeoxycholic_acid→?; validate in duodenum_cancer cell model. Expected: similar to drostanolone (Jaccard=0.24) tauroursodeoxycholic_acid gallbladder_cancer GAP_HIGH 0.1945 0.23529411764705882 drostanolone 0.6 RISING 0.85 3 0.07155 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tauroursodeoxycholic_acid→?; validate in gallbladder_cancer cell model. Expected: similar to drostanolone (Jaccard=0.24) nabumetone osteoarthritis GAP_HIGH 0.2593 0.8888888888888888 midodrine 0.45 STABLE 0.85 3 0.07154 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nabumetone→?; validate in osteoarthritis cell model. Expected: similar to midodrine (Jaccard=0.89) atenolol larynx_cancer GAP_HIGH 0.2748 0.875 procarbazine 0.6 RISING 0.6 3 0.07136 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay atenolol→?; validate in larynx_cancer cell model. Expected: similar to procarbazine (Jaccard=0.88) perphenazine gilles_de_la_tourette_syndrome GAP_HIGH 0.2115 0.8181818181818182 propericiazine 0.55 STABLE 0.85 3 0.07132 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay perphenazine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to propericiazine (Jaccard=0.82) gemcitabine lung_cancer GAP_HIGH 0.1938 0.5714285714285714 trifluridine 0.6 RISING 0.85 3 0.0713 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay gemcitabine→?; validate in lung_cancer cell model. Expected: similar to trifluridine (Jaccard=0.57) isoprenaline esophageal_cancer GAP_HIGH 0.1937 0.6666666666666666 mesalazine 0.6 RISING 0.85 3 0.07126 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isoprenaline→?; validate in esophageal_cancer cell model. Expected: similar to mesalazine (Jaccard=0.67) quinestrol brain_cancer GAP_HIGH 0.2742 0.6923076923076923 mestranol 0.6 RISING 0.6 3 0.07121 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinestrol→?; validate in brain_cancer cell model. Expected: similar to mestranol (Jaccard=0.69) estropipate brain_cancer GAP_HIGH 0.1934 0.375 estrone 0.6 RISING 0.85 3 0.07115 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estropipate→?; validate in brain_cancer cell model. Expected: similar to estrone (Jaccard=0.38) ritodrine hematologic_cancer GAP_HIGH 0.1932 0.4 arbutamine 0.6 RISING 0.85 3 0.07108 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ritodrine→?; validate in hematologic_cancer cell model. Expected: similar to arbutamine (Jaccard=0.40) isoprenaline type_1_diabetes_mellitus GAP_HIGH 0.193 0.6666666666666666 mesalazine 0.6 RISING 0.85 3 0.071 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isoprenaline→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to mesalazine (Jaccard=0.67) tauroursodeoxycholic_acid lung_cancer GAP_HIGH 0.193 0.23529411764705882 drostanolone 0.6 RISING 0.85 3 0.071 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tauroursodeoxycholic_acid→?; validate in lung_cancer cell model. Expected: similar to drostanolone (Jaccard=0.24) methylphenobarbital alzheimers_disease GAP_HIGH 0.205 0.45454545454545453 milnacipran 0.8 RAPID_RISE 0.6 3 0.07098 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methylphenobarbital→?; validate in alzheimers_disease cell model. Expected: similar to milnacipran (Jaccard=0.45) gemcitabine pancreatic_cancer GAP_HIGH 0.1928 0.5714285714285714 trifluridine 0.6 RISING 0.85 3 0.07093 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay gemcitabine→?; validate in pancreatic_cancer cell model. Expected: similar to trifluridine (Jaccard=0.57) pemetrexed larynx_cancer GAP_HIGH 0.273 0.6666666666666666 capecitabine 0.6 RISING 0.6 3 0.07089 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pemetrexed→?; validate in larynx_cancer cell model. Expected: similar to capecitabine (Jaccard=0.67) lisinopril sarcoma GAP_HIGH 0.2184 0.7777777777777778 trandolapril 0.45 STABLE 1.0 3 0.07089 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lisinopril→?; validate in sarcoma cell model. Expected: similar to trandolapril (Jaccard=0.78) megestrol_acetate breast_cancer GAP_HIGH 0.1925 0.6666666666666666 ethynodiol 0.6 RISING 0.85 3 0.07082 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay megestrol_acetate→?; validate in breast_cancer cell model. Expected: similar to ethynodiol (Jaccard=0.67) imipramine duodenum_cancer GAP_HIGH 0.1925 0.5714285714285714 desipramine 0.6 RISING 0.85 3 0.07082 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay imipramine→?; validate in duodenum_cancer cell model. Expected: similar to desipramine (Jaccard=0.57) imipramine gallbladder_cancer GAP_HIGH 0.1925 0.5714285714285714 desipramine 0.6 RISING 0.85 3 0.07082 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay imipramine→?; validate in gallbladder_cancer cell model. Expected: similar to desipramine (Jaccard=0.57) sulfadiazine leprosy GAP_HIGH 0.2566 0.65 sulfapyridine 0.45 STABLE 0.85 3 0.0708 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfadiazine→?; validate in leprosy cell model. Expected: similar to sulfapyridine (Jaccard=0.65) milnacipran type_1_diabetes_mellitus GAP_HIGH 0.2725 0.7142857142857143 cyclopentolate 0.6 RISING 0.6 3 0.07076 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay milnacipran→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to cyclopentolate (Jaccard=0.71) megestrol_acetate head_and_neck_cancer GAP_HIGH 0.1921 0.625 prednicarbate 0.6 RISING 0.85 3 0.07067 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay megestrol_acetate→?; validate in head_and_neck_cancer cell model. Expected: similar to prednicarbate (Jaccard=0.62) tranylcypromine kidney_cancer GAP_HIGH 0.1921 0.5555555555555556 clofibrate 0.6 RISING 0.85 3 0.07067 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tranylcypromine→?; validate in kidney_cancer cell model. Expected: similar to clofibrate (Jaccard=0.56) lisinopril systemic_scleroderma GAP_HIGH 0.2176 0.7777777777777778 trandolapril 0.45 STABLE 1.0 3 0.07063 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lisinopril→?; validate in systemic_scleroderma cell model. Expected: similar to trandolapril (Jaccard=0.78) desogestrel germ_cell_cancer GAP_HIGH 0.2719 0.8 norethindrone 0.6 RISING 0.6 3 0.07061 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay desogestrel→?; validate in germ_cell_cancer cell model. Expected: similar to norethindrone (Jaccard=0.80) ribavirin thyroid_cancer GAP_HIGH 0.2033 0.47619047619047616 clofarabine 0.8 RAPID_RISE 0.6 3 0.07039 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ribavirin→?; validate in thyroid_cancer cell model. Expected: similar to clofarabine (Jaccard=0.48) pemetrexed esophageal_cancer GAP_HIGH 0.2709 0.6666666666666666 fluorouracil 0.6 RISING 0.6 3 0.07035 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pemetrexed→?; validate in esophageal_cancer cell model. Expected: similar to fluorouracil (Jaccard=0.67) sorafenib thyroid_cancer GAP_HIGH 0.1433 0.42105263157894735 pazopanib 0.8 RAPID_RISE 0.85 3 0.07029 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sorafenib→?; validate in thyroid_cancer cell model. Expected: similar to pazopanib (Jaccard=0.42) atenolol head_and_neck_cancer GAP_HIGH 0.2706 0.875 procarbazine 0.6 RISING 0.6 3 0.07027 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay atenolol→?; validate in head_and_neck_cancer cell model. Expected: similar to procarbazine (Jaccard=0.88) tolterodine prostate_cancer GAP_HIGH 0.191 0.5714285714285714 reboxetine 0.6 RISING 0.85 3 0.07027 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolterodine→?; validate in prostate_cancer cell model. Expected: similar to reboxetine (Jaccard=0.57) fluorometholone kidney_cancer GAP_HIGH 0.191 0.5 medrysone 0.6 RISING 0.85 3 0.07027 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluorometholone→?; validate in kidney_cancer cell model. Expected: similar to medrysone (Jaccard=0.50) tolterodine mediastinal_cancer GAP_HIGH 0.1908 0.5714285714285714 reboxetine 0.6 RISING 0.85 3 0.07019 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolterodine→?; validate in mediastinal_cancer cell model. Expected: similar to reboxetine (Jaccard=0.57) atropine parkinsons_disease GAP_HIGH 0.1431 0.3333333333333333 homatropine_methylbromide 0.8 RAPID_RISE 0.85 3 0.07019 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay atropine→?; validate in parkinsons_disease cell model. Expected: similar to homatropine_methylbromide (Jaccard=0.33) eprosartan psoriasis GAP_HIGH 0.3603 1.0 telmisartan 0.45 STABLE 0.6 3 0.07017 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay eprosartan→?; validate in psoriasis cell model. Expected: similar to telmisartan (Jaccard=1.00) tolterodine thymus_cancer GAP_HIGH 0.1907 0.5714285714285714 reboxetine 0.6 RISING 0.85 3 0.07016 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolterodine→?; validate in thymus_cancer cell model. Expected: similar to reboxetine (Jaccard=0.57) cyproterone_acetate malignant_glioma GAP_HIGH 0.2541 0.7142857142857143 prednicarbate 0.45 STABLE 0.85 3 0.07011 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyproterone_acetate→?; validate in malignant_glioma cell model. Expected: similar to prednicarbate (Jaccard=0.71) lapatinib kidney_cancer GAP_HIGH 0.1903 0.5 docetaxel 0.6 RISING 0.85 3 0.07001 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lapatinib→?; validate in kidney_cancer cell model. Expected: similar to docetaxel (Jaccard=0.50) phenylephrine systemic_lupus_erythematosus GAP_HIGH 0.1903 0.5 salbutamol 0.6 RISING 0.85 3 0.07001 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenylephrine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to salbutamol (Jaccard=0.50) phenindione creutzfeldt-jakob_disease GAP_HIGH 0.2537 0.7692307692307693 clozapine 0.45 STABLE 0.85 3 0.07 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenindione→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to clozapine (Jaccard=0.77) clofibrate malaria GAP_HIGH 0.2536 0.6 sulfanilamide 0.45 STABLE 0.85 3 0.06997 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clofibrate→?; validate in malaria cell model. Expected: similar to sulfanilamide (Jaccard=0.60) amphetamine pharynx_cancer GAP_HIGH 0.19 0.4 vorinostat 0.6 RISING 0.85 3 0.0699 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amphetamine→?; validate in pharynx_cancer cell model. Expected: similar to vorinostat (Jaccard=0.40) aminoglutethimide leprosy GAP_HIGH 0.2533 0.45454545454545453 phenmetrazine 0.45 STABLE 0.85 3 0.06989 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminoglutethimide→?; validate in leprosy cell model. Expected: similar to phenmetrazine (Jaccard=0.45) pemetrexed head_and_neck_cancer GAP_HIGH 0.2688 0.6666666666666666 capecitabine 0.6 RISING 0.6 3 0.0698 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pemetrexed→?; validate in head_and_neck_cancer cell model. Expected: similar to capecitabine (Jaccard=0.67) quinestrol hematologic_cancer GAP_HIGH 0.2687 0.6923076923076923 mestranol 0.6 RISING 0.6 3 0.06978 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinestrol→?; validate in hematologic_cancer cell model. Expected: similar to mestranol (Jaccard=0.69) isoprenaline germ_cell_cancer GAP_HIGH 0.1895 0.6666666666666666 mesalazine 0.6 RISING 0.85 3 0.06971 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isoprenaline→?; validate in germ_cell_cancer cell model. Expected: similar to mesalazine (Jaccard=0.67) atenolol germ_cell_cancer GAP_HIGH 0.2684 0.875 procarbazine 0.6 RISING 0.6 3 0.0697 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay atenolol→?; validate in germ_cell_cancer cell model. Expected: similar to procarbazine (Jaccard=0.88) tranylcypromine penile_cancer GAP_HIGH 0.1894 0.5555555555555556 probenecid 0.6 RISING 0.85 3 0.06968 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tranylcypromine→?; validate in penile_cancer cell model. Expected: similar to probenecid (Jaccard=0.56) amphetamine salivary_gland_cancer GAP_HIGH 0.1894 0.4 vorinostat 0.6 RISING 0.85 3 0.06968 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amphetamine→?; validate in salivary_gland_cancer cell model. Expected: similar to vorinostat (Jaccard=0.40) amphetamine muscle_cancer GAP_HIGH 0.1893 0.4 vorinostat 0.6 RISING 0.85 3 0.06964 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amphetamine→?; validate in muscle_cancer cell model. Expected: similar to vorinostat (Jaccard=0.40) quinestrol duodenum_cancer GAP_HIGH 0.2678 0.6923076923076923 mestranol 0.6 RISING 0.6 3 0.06954 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinestrol→?; validate in duodenum_cancer cell model. Expected: similar to mestranol (Jaccard=0.69) quinestrol gallbladder_cancer GAP_HIGH 0.2678 0.6923076923076923 mestranol 0.6 RISING 0.6 3 0.06954 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinestrol→?; validate in gallbladder_cancer cell model. Expected: similar to mestranol (Jaccard=0.69) labetalol acquired_immunodeficiency_syndrome GAP_HIGH 0.2921 0.6 alvimopan 0.55 STABLE 0.6 3 0.06953 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay labetalol→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to alvimopan (Jaccard=0.60) mepenzolate chronic_obstructive_pulmonary_disease GAP_HIGH 0.2515 0.6666666666666666 bepridil 0.45 STABLE 0.85 3 0.06939 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mepenzolate→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to bepridil (Jaccard=0.67) epoprostenol thyroid_cancer GAP_HIGH 0.2001 0.3333333333333333 travoprost 0.8 RAPID_RISE 0.6 3 0.06928 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay epoprostenol→?; validate in thyroid_cancer cell model. Expected: similar to travoprost (Jaccard=0.33) pirenzepine metabolic_syndrome_x GAP_HIGH 0.2051 0.7857142857142857 zuclopenthixol 0.55 STABLE 0.85 3 0.06917 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pirenzepine→?; validate in metabolic_syndrome_x cell model. Expected: similar to zuclopenthixol (Jaccard=0.79) dobutamine salivary_gland_cancer GAP_HIGH 0.188 0.5 isoetarine 0.6 RISING 0.85 3 0.06916 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dobutamine→?; validate in salivary_gland_cancer cell model. Expected: similar to isoetarine (Jaccard=0.50) prazepam amyotrophic_lateral_sclerosis GAP_HIGH 0.2661 0.7 estazolam 0.6 RISING 0.6 3 0.0691 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prazepam→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to estazolam (Jaccard=0.70) metoclopramide prostate_cancer GAP_HIGH 0.1878 0.7936507936507936 procainamide 0.6 RISING 0.85 3 0.06909 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay metoclopramide→?; validate in prostate_cancer cell model. Expected: similar to procainamide (Jaccard=0.79) megestrol_acetate mediastinal_cancer GAP_HIGH 0.1877 0.625 prednicarbate 0.6 RISING 0.85 3 0.06905 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay megestrol_acetate→?; validate in mediastinal_cancer cell model. Expected: similar to prednicarbate (Jaccard=0.62) lapatinib penile_cancer GAP_HIGH 0.1877 0.5 docetaxel 0.6 RISING 0.85 3 0.06905 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lapatinib→?; validate in penile_cancer cell model. Expected: similar to docetaxel (Jaccard=0.50) megestrol_acetate thymus_cancer GAP_HIGH 0.1876 0.625 prednicarbate 0.6 RISING 0.85 3 0.06902 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay megestrol_acetate→?; validate in thymus_cancer cell model. Expected: similar to prednicarbate (Jaccard=0.62) methyltestosterone brain_cancer GAP_HIGH 0.1875 0.5454545454545454 cortisone_acetate 0.6 RISING 0.85 3 0.06898 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methyltestosterone→?; validate in brain_cancer cell model. Expected: similar to cortisone_acetate (Jaccard=0.55) l-arginine intracranial_aneurysm GAP_HIGH 0.2499 0.6363636363636364 doxorubicin 0.45 STABLE 0.85 3 0.06895 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-arginine→?; validate in intracranial_aneurysm cell model. Expected: similar to doxorubicin (Jaccard=0.64) acetophenazine gilles_de_la_tourette_syndrome GAP_HIGH 0.2042 0.6666666666666666 nefazodone 0.55 STABLE 0.85 3 0.06886 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acetophenazine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to nefazodone (Jaccard=0.67) doxycycline malaria GAP_HIGH 0.2495 0.4666666666666667 tetracycline 0.45 STABLE 0.85 3 0.06884 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxycycline→?; validate in malaria cell model. Expected: similar to tetracycline (Jaccard=0.47) alpha-linolenic_acid polycystic_ovary_syndrome GAP_HIGH 0.2037 0.3 orlistat 0.55 STABLE 0.85 3 0.06869 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alpha-linolenic_acid→?; validate in polycystic_ovary_syndrome cell model. Expected: similar to orlistat (Jaccard=0.30) methyltestosterone head_and_neck_cancer GAP_HIGH 0.1867 0.5454545454545454 cortisone_acetate 0.6 RISING 0.85 3 0.06868 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methyltestosterone→?; validate in head_and_neck_cancer cell model. Expected: similar to cortisone_acetate (Jaccard=0.55) pirbuterol pharynx_cancer GAP_HIGH 0.2644 0.75 dipivefrin 0.6 RISING 0.6 3 0.06866 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pirbuterol→?; validate in pharynx_cancer cell model. Expected: similar to dipivefrin (Jaccard=0.75) tretinoin stomach_cancer GAP_HIGH 0.2641 0.7777777777777778 alitretinoin 0.6 RISING 0.6 3 0.06858 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tretinoin→?; validate in stomach_cancer cell model. Expected: similar to alitretinoin (Jaccard=0.78) dobutamine systemic_lupus_erythematosus GAP_HIGH 0.1864 0.5 isoetarine 0.6 RISING 0.85 3 0.06857 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dobutamine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to isoetarine (Jaccard=0.50) ephedrine allergic_rhinitis GAP_HIGH 0.2484 0.75 tropicamide 0.45 STABLE 0.85 3 0.06854 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ephedrine→?; validate in allergic_rhinitis cell model. Expected: similar to tropicamide (Jaccard=0.75) dobutamine skin_cancer GAP_HIGH 0.1862 0.5 isoetarine 0.6 RISING 0.85 3 0.0685 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dobutamine→?; validate in skin_cancer cell model. Expected: similar to isoetarine (Jaccard=0.50) terbutaline pharynx_cancer GAP_HIGH 0.1862 0.5 dipivefrin 0.6 RISING 0.85 3 0.0685 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay terbutaline→?; validate in pharynx_cancer cell model. Expected: similar to dipivefrin (Jaccard=0.50) ephedrine osteoporosis GAP_HIGH 0.2482 0.75 tropicamide 0.45 STABLE 0.85 3 0.06848 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ephedrine→?; validate in osteoporosis cell model. Expected: similar to tropicamide (Jaccard=0.75) isoetarine metabolic_syndrome_x GAP_HIGH 0.203 0.5714285714285714 salbutamol 0.55 STABLE 0.85 3 0.06846 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isoetarine→?; validate in metabolic_syndrome_x cell model. Expected: similar to salbutamol (Jaccard=0.57) phenoxybenzamine amyotrophic_lateral_sclerosis GAP_HIGH 0.1861 0.5833333333333334 benzphetamine 0.6 RISING 0.85 3 0.06846 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenoxybenzamine→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to benzphetamine (Jaccard=0.58) ephedrine migraine GAP_HIGH 0.2481 0.75 tropicamide 0.45 STABLE 0.85 3 0.06845 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ephedrine→?; validate in migraine cell model. Expected: similar to tropicamide (Jaccard=0.75) amoxapine duodenum_cancer GAP_HIGH 0.1858 0.64 loxapine 0.6 RISING 0.85 3 0.06835 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amoxapine→?; validate in duodenum_cancer cell model. Expected: similar to loxapine (Jaccard=0.64) amoxapine gallbladder_cancer GAP_HIGH 0.1858 0.64 loxapine 0.6 RISING 0.85 3 0.06835 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amoxapine→?; validate in gallbladder_cancer cell model. Expected: similar to loxapine (Jaccard=0.64) ephedrine osteoarthritis GAP_HIGH 0.2477 0.75 tropicamide 0.45 STABLE 0.85 3 0.06834 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ephedrine→?; validate in osteoarthritis cell model. Expected: similar to tropicamide (Jaccard=0.75) primidone barretts_esophagus GAP_HIGH 0.2476 0.2 pantoprazole 0.45 STABLE 0.85 3 0.06832 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay primidone→?; validate in barretts_esophagus cell model. Expected: similar to pantoprazole (Jaccard=0.20) pirbuterol asthma GAP_HIGH 0.2628 0.75 dipivefrin 0.6 RISING 0.6 3 0.06825 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pirbuterol→?; validate in asthma cell model. Expected: similar to dipivefrin (Jaccard=0.75) alpha-linolenic_acid ocular_cancer GAP_HIGH 0.1853 0.2222222222222222 dihomo-gamma-linolenic_acid 0.6 RISING 0.85 3 0.06817 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alpha-linolenic_acid→?; validate in ocular_cancer cell model. Expected: similar to dihomo-gamma-linolenic_acid (Jaccard=0.22) vidarabine mediastinal_cancer GAP_HIGH 0.1852 0.47368421052631576 entecavir 0.6 RISING 0.85 3 0.06813 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vidarabine→?; validate in mediastinal_cancer cell model. Expected: similar to entecavir (Jaccard=0.47) dihydrotachysterol vaginal_cancer GAP_HIGH 0.2623 0.7142857142857143 calcipotriol 0.6 RISING 0.6 3 0.06812 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dihydrotachysterol→?; validate in vaginal_cancer cell model. Expected: similar to calcipotriol (Jaccard=0.71) vidarabine thymus_cancer GAP_HIGH 0.1851 0.47368421052631576 entecavir 0.6 RISING 0.85 3 0.0681 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vidarabine→?; validate in thymus_cancer cell model. Expected: similar to entecavir (Jaccard=0.47) sulfanilamide metabolic_syndrome_x GAP_HIGH 0.2019 0.6 clofibrate 0.55 STABLE 0.85 3 0.06809 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfanilamide→?; validate in metabolic_syndrome_x cell model. Expected: similar to clofibrate (Jaccard=0.60) estradiol_valeratedienogest prostate_cancer GAP_HIGH 0.2618 0.8333333333333334 levorphanol 0.6 RISING 0.6 3 0.06799 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estradiol_valeratedienogest→?; validate in prostate_cancer cell model. Expected: similar to levorphanol (Jaccard=0.83) clofibrate celiac_disease GAP_HIGH 0.2463 0.6 sulfanilamide 0.45 STABLE 0.85 3 0.06796 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clofibrate→?; validate in celiac_disease cell model. Expected: similar to sulfanilamide (Jaccard=0.60) terbutaline asthma GAP_HIGH 0.1846 0.5 dipivefrin 0.6 RISING 0.85 3 0.06791 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay terbutaline→?; validate in asthma cell model. Expected: similar to dipivefrin (Jaccard=0.50) testosterone_propionate breast_cancer GAP_HIGH 0.1845 0.6666666666666666 dydrogesterone 0.6 RISING 0.85 3 0.06788 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay testosterone_propionate→?; validate in breast_cancer cell model. Expected: similar to dydrogesterone (Jaccard=0.67) terbutaline uterine_cancer GAP_HIGH 0.1843 0.5 dipivefrin 0.6 RISING 0.85 3 0.0678 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay terbutaline→?; validate in uterine_cancer cell model. Expected: similar to dipivefrin (Jaccard=0.50) flurandrenolide kidney_cancer GAP_HIGH 0.1843 0.46153846153846156 medrysone 0.6 RISING 0.85 3 0.0678 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flurandrenolide→?; validate in kidney_cancer cell model. Expected: similar to medrysone (Jaccard=0.46) aminophenazone creutzfeldt-jakob_disease GAP_HIGH 0.2452 0.5 ezetimibe 0.45 STABLE 0.85 3 0.06765 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminophenazone→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to ezetimibe (Jaccard=0.50) esmolol glaucoma GAP_HIGH 0.3467 1.0 procarbazine 0.45 STABLE 0.6 3 0.06752 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay esmolol→?; validate in glaucoma cell model. Expected: similar to procarbazine (Jaccard=1.00) methotrimeprazine prostate_cancer GAP_HIGH 0.1835 0.6923076923076923 thioproperazine 0.6 RISING 0.85 3 0.06751 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methotrimeprazine→?; validate in prostate_cancer cell model. Expected: similar to thioproperazine (Jaccard=0.69) esmolol intracranial_aneurysm GAP_HIGH 0.3464 1.0 procarbazine 0.45 STABLE 0.6 3 0.06747 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay esmolol→?; validate in intracranial_aneurysm cell model. Expected: similar to procarbazine (Jaccard=1.00) benzphetamine type_1_diabetes_mellitus GAP_HIGH 0.1833 0.6 benzatropine 0.6 RISING 0.85 3 0.06743 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzphetamine→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to benzatropine (Jaccard=0.60) l-citrulline hematologic_cancer GAP_HIGH 0.1833 0.5058823529411764 l-glutamine 0.6 RISING 0.85 3 0.06743 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-citrulline→?; validate in hematologic_cancer cell model. Expected: similar to l-glutamine (Jaccard=0.51) alitretinoin hematologic_cancer GAP_HIGH 0.2594 0.7777777777777778 tretinoin 0.6 RISING 0.6 3 0.06736 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alitretinoin→?; validate in hematologic_cancer cell model. Expected: similar to tretinoin (Jaccard=0.78) arbutamine pharynx_cancer GAP_HIGH 0.1831 0.5333333333333333 masoprocol 0.6 RISING 0.85 3 0.06736 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay arbutamine→?; validate in pharynx_cancer cell model. Expected: similar to masoprocol (Jaccard=0.53) methotrimeprazine hematologic_cancer GAP_HIGH 0.183 0.6923076923076923 thioproperazine 0.6 RISING 0.85 3 0.06732 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methotrimeprazine→?; validate in hematologic_cancer cell model. Expected: similar to thioproperazine (Jaccard=0.69) esmolol malignant_glioma GAP_HIGH 0.3456 1.0 procarbazine 0.45 STABLE 0.6 3 0.06731 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay esmolol→?; validate in malignant_glioma cell model. Expected: similar to procarbazine (Jaccard=1.00) dapsone leprosy GAP_HIGH 0.2437 0.625 sulfamethizole 0.45 STABLE 0.85 3 0.06724 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dapsone→?; validate in leprosy cell model. Expected: similar to sulfamethizole (Jaccard=0.62) alverine esophageal_cancer GAP_HIGH 0.1826 0.5454545454545454 tamoxifen 0.6 RISING 0.85 3 0.06718 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alverine→?; validate in esophageal_cancer cell model. Expected: similar to tamoxifen (Jaccard=0.55) amodiaquine focal_segmental_glomerulosclerosis GAP_HIGH 0.2434 0.6086956521739131 chlorprothixene 0.45 STABLE 0.85 3 0.06716 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amodiaquine→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to chlorprothixene (Jaccard=0.61) arbutamine muscle_cancer GAP_HIGH 0.1824 0.5333333333333333 masoprocol 0.6 RISING 0.85 3 0.0671 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay arbutamine→?; validate in muscle_cancer cell model. Expected: similar to masoprocol (Jaccard=0.53) flavin_adenine_dinucleotide stomach_cancer GAP_HIGH 0.1824 0.4 nelarabine 0.6 RISING 0.85 3 0.0671 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flavin_adenine_dinucleotide→?; validate in stomach_cancer cell model. Expected: similar to nelarabine (Jaccard=0.40) labetalol gilles_de_la_tourette_syndrome GAP_HIGH 0.2815 0.6 alvimopan 0.55 STABLE 0.6 3 0.06701 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay labetalol→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to alvimopan (Jaccard=0.60) clofibrate crohns_disease GAP_HIGH 0.2428 0.6 sulfanilamide 0.45 STABLE 0.85 3 0.06699 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clofibrate→?; validate in crohns_disease cell model. Expected: similar to sulfanilamide (Jaccard=0.60) penicillamine idiopathic_pulmonary_fibrosis GAP_HIGH 0.2427 0.4230769230769231 acetylcysteine 0.45 STABLE 0.85 3 0.06696 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay penicillamine→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to acetylcysteine (Jaccard=0.42) alverine type_1_diabetes_mellitus GAP_HIGH 0.1819 0.5454545454545454 benzatropine 0.6 RISING 0.85 3 0.06692 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alverine→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to benzatropine (Jaccard=0.55) quazepam chronic_kidney_failure GAP_HIGH 0.3434 0.8333333333333334 cinolazepam 0.45 STABLE 0.6 3 0.06688 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quazepam→?; validate in chronic_kidney_failure cell model. Expected: similar to cinolazepam (Jaccard=0.83) flavin_adenine_dinucleotide skin_cancer GAP_HIGH 0.1817 0.4 nelarabine 0.6 RISING 0.85 3 0.06685 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flavin_adenine_dinucleotide→?; validate in skin_cancer cell model. Expected: similar to nelarabine (Jaccard=0.40) clofibrate gout GAP_HIGH 0.2422 0.6 sulfanilamide 0.45 STABLE 0.85 3 0.06683 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clofibrate→?; validate in gout cell model. Expected: similar to sulfanilamide (Jaccard=0.60) tamoxifen type_1_diabetes_mellitus GAP_HIGH 0.1544 0.5555555555555556 benzatropine 0.6 RISING 1.0 3 0.06683 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tamoxifen→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to benzatropine (Jaccard=0.56) imatinib hematologic_cancer GAP_HIGH 0.1544 0.39473684210526316 ponatinib 0.6 RISING 1.0 3 0.06683 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay imatinib→?; validate in hematologic_cancer cell model. Expected: similar to ponatinib (Jaccard=0.39) arformoterol azoospermia GAP_HIGH 0.342 1.0 ritodrine 0.45 STABLE 0.6 3 0.06661 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay arformoterol→?; validate in azoospermia cell model. Expected: similar to ritodrine (Jaccard=1.00) mepenzolate rheumatoid_arthritis GAP_HIGH 0.2716 0.75 disopyramide 0.4 STABLE 0.85 3 0.06661 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mepenzolate→?; validate in rheumatoid_arthritis cell model. Expected: similar to disopyramide (Jaccard=0.75) vindesine larynx_cancer GAP_HIGH 0.181 0.375 vinblastine 0.6 RISING 0.85 3 0.06659 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vindesine→?; validate in larynx_cancer cell model. Expected: similar to vinblastine (Jaccard=0.38) glisoxepide idiopathic_pulmonary_fibrosis GAP_HIGH 0.2413 0.5 zafirlukast 0.45 STABLE 0.85 3 0.06658 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glisoxepide→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to zafirlukast (Jaccard=0.50) penicillamine glaucoma GAP_HIGH 0.2413 0.4 l-histidine 0.45 STABLE 0.85 3 0.06658 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay penicillamine→?; validate in glaucoma cell model. Expected: similar to l-histidine (Jaccard=0.40) amodiaquine chronic_kidney_failure GAP_HIGH 0.2412 0.6086956521739131 chlorprothixene 0.45 STABLE 0.85 3 0.06655 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amodiaquine→?; validate in chronic_kidney_failure cell model. Expected: similar to chlorprothixene (Jaccard=0.61) sodium_tetradecyl_sulfate ocular_cancer GAP_HIGH 0.1809 0.1875 dihomo-gamma-linolenic_acid 0.6 RISING 0.85 3 0.06655 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sodium_tetradecyl_sulfate→?; validate in ocular_cancer cell model. Expected: similar to dihomo-gamma-linolenic_acid (Jaccard=0.19) glisoxepide gout GAP_HIGH 0.241 0.5 tolazamide 0.45 STABLE 0.85 3 0.0665 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glisoxepide→?; validate in gout cell model. Expected: similar to tolazamide (Jaccard=0.50) diclofenamide urinary_bladder_cancer GAP_HIGH 0.1806 0.3333333333333333 hydrochlorothiazide 0.6 RISING 0.85 3 0.06644 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diclofenamide→?; validate in urinary_bladder_cancer cell model. Expected: similar to hydrochlorothiazide (Jaccard=0.33) spironolactone hypertension GAP_HIGH 0.1353 0.42857142857142855 drospirenone 0.8 RAPID_RISE 0.85 3 0.06637 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay spironolactone→?; validate in hypertension cell model. Expected: similar to drospirenone (Jaccard=0.43) pyrimethamine rheumatoid_arthritis GAP_HIGH 0.2702 0.6 triamterene 0.4 STABLE 0.85 3 0.06627 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pyrimethamine→?; validate in rheumatoid_arthritis cell model. Expected: similar to triamterene (Jaccard=0.60) bethanidine systemic_lupus_erythematosus GAP_HIGH 0.1801 0.5909090909090909 phenelzine 0.6 RISING 0.85 3 0.06626 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bethanidine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to phenelzine (Jaccard=0.59) penicillamine refractive_error GAP_HIGH 0.24 0.4 l-histidine 0.45 STABLE 0.85 3 0.06622 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay penicillamine→?; validate in refractive_error cell model. Expected: similar to l-histidine (Jaccard=0.40) amodiaquine membranous_glomerulonephritis GAP_HIGH 0.2398 0.6086956521739131 chlorprothixene 0.45 STABLE 0.85 3 0.06616 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amodiaquine→?; validate in membranous_glomerulonephritis cell model. Expected: similar to chlorprothixene (Jaccard=0.61) l-ornithine systemic_lupus_erythematosus GAP_HIGH 0.1798 0.2727272727272727 penicillamine 0.6 RISING 0.85 3 0.06615 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-ornithine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to penicillamine (Jaccard=0.27) crizotinib lung_cancer GAP_HIGH 0.1796 0.5714285714285714 sunitinib 0.6 RISING 0.85 3 0.06607 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay crizotinib→?; validate in lung_cancer cell model. Expected: similar to sunitinib (Jaccard=0.57) arformoterol narcolepsy GAP_HIGH 0.3389 1.0 ritodrine 0.45 STABLE 0.6 3 0.06601 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay arformoterol→?; validate in narcolepsy cell model. Expected: similar to ritodrine (Jaccard=1.00) methotrimeprazine systemic_lupus_erythematosus GAP_HIGH 0.1793 0.6923076923076923 thioproperazine 0.6 RISING 0.85 3 0.06596 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methotrimeprazine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to thioproperazine (Jaccard=0.69) glisoxepide chronic_obstructive_pulmonary_disease GAP_HIGH 0.239 0.5 zafirlukast 0.45 STABLE 0.85 3 0.06594 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glisoxepide→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to zafirlukast (Jaccard=0.50) tripelennamine polycystic_ovary_syndrome GAP_HIGH 0.1953 0.625 mepyramine 0.55 STABLE 0.85 3 0.06586 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tripelennamine→?; validate in polycystic_ovary_syndrome cell model. Expected: similar to mepyramine (Jaccard=0.62) amitriptyline multiple_sclerosis GAP_HIGH 0.179 0.75 doxepin 0.6 RISING 0.85 3 0.06585 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amitriptyline→?; validate in multiple_sclerosis cell model. Expected: similar to doxepin (Jaccard=0.75) cinchocaine prostate_cancer GAP_HIGH 0.1789 0.4583333333333333 oxybuprocaine 0.6 RISING 0.85 3 0.06582 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cinchocaine→?; validate in prostate_cancer cell model. Expected: similar to oxybuprocaine (Jaccard=0.46) amitriptyline systemic_lupus_erythematosus GAP_HIGH 0.1787 0.75 doxepin 0.6 RISING 0.85 3 0.06574 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amitriptyline→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to doxepin (Jaccard=0.75) milnacipran atopic_dermatitis GAP_HIGH 0.3375 1.0 remifentanil 0.45 STABLE 0.6 3 0.06573 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay milnacipran→?; validate in atopic_dermatitis cell model. Expected: similar to remifentanil (Jaccard=1.00) quazepam ankylosing_spondylitis GAP_HIGH 0.3375 0.8333333333333334 cinolazepam 0.45 STABLE 0.6 3 0.06573 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quazepam→?; validate in ankylosing_spondylitis cell model. Expected: similar to cinolazepam (Jaccard=0.83) fludiazepam obesity GAP_HIGH 0.1898 0.7 chlordiazepoxide 0.8 RAPID_RISE 0.6 3 0.06572 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fludiazepam→?; validate in obesity cell model. Expected: similar to chlordiazepoxide (Jaccard=0.70) clozapine gout GAP_HIGH 0.2024 0.7692307692307693 phenindione 0.45 STABLE 1.0 3 0.0657 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clozapine→?; validate in gout cell model. Expected: similar to phenindione (Jaccard=0.77) milnacipran migraine GAP_HIGH 0.3372 1.0 remifentanil 0.45 STABLE 0.6 3 0.06567 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay milnacipran→?; validate in migraine cell model. Expected: similar to remifentanil (Jaccard=1.00) arformoterol chronic_obstructive_pulmonary_disease GAP_HIGH 0.3371 1.0 ritodrine 0.45 STABLE 0.6 3 0.06565 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay arformoterol→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to ritodrine (Jaccard=1.00) alverine germ_cell_cancer GAP_HIGH 0.1784 0.5454545454545454 tamoxifen 0.6 RISING 0.85 3 0.06563 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alverine→?; validate in germ_cell_cancer cell model. Expected: similar to tamoxifen (Jaccard=0.55) docetaxel melanoma GAP_HIGH 0.1895 0.6 paclitaxel 0.8 RAPID_RISE 0.6 3 0.06561 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay docetaxel→?; validate in melanoma cell model. Expected: similar to paclitaxel (Jaccard=0.60) mepyramine gilles_de_la_tourette_syndrome GAP_HIGH 0.1945 0.5 brompheniramine 0.55 STABLE 0.85 3 0.06559 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mepyramine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to brompheniramine (Jaccard=0.50) glisoxepide atopic_dermatitis GAP_HIGH 0.2376 0.5 zafirlukast 0.45 STABLE 0.85 3 0.06556 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glisoxepide→?; validate in atopic_dermatitis cell model. Expected: similar to zafirlukast (Jaccard=0.50) arformoterol attention_deficit_hyperactivity_disorder GAP_HIGH 0.3361 1.0 ritodrine 0.45 STABLE 0.6 3 0.06546 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay arformoterol→?; validate in attention_deficit_hyperactivity_disorder cell model. Expected: similar to ritodrine (Jaccard=1.00) gliclazide systemic_lupus_erythematosus GAP_HIGH 0.1778 0.47058823529411764 chlorpropamide 0.6 RISING 0.85 3 0.06541 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay gliclazide→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to chlorpropamide (Jaccard=0.47) l-tryptophan thyroid_cancer GAP_HIGH 0.1888 0.4444444444444444 liothyronine 0.8 RAPID_RISE 0.6 3 0.06537 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-tryptophan→?; validate in thyroid_cancer cell model. Expected: similar to liothyronine (Jaccard=0.44) triamterene type_1_diabetes_mellitus GAP_HIGH 0.2514 0.5 methylphenidate 0.6 RISING 0.6 3 0.06528 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay triamterene→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to methylphenidate (Jaccard=0.50) sulfadiazine malaria GAP_HIGH 0.2365 0.65 sulfapyridine 0.45 STABLE 0.85 3 0.06525 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfadiazine→?; validate in malaria cell model. Expected: similar to sulfapyridine (Jaccard=0.65) methohexital duodenum_cancer GAP_HIGH 0.2512 0.5 clobazam 0.6 RISING 0.6 3 0.06523 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methohexital→?; validate in duodenum_cancer cell model. Expected: similar to clobazam (Jaccard=0.50) methohexital gallbladder_cancer GAP_HIGH 0.2512 0.5 clobazam 0.6 RISING 0.6 3 0.06523 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methohexital→?; validate in gallbladder_cancer cell model. Expected: similar to clobazam (Jaccard=0.50) halazepam gilles_de_la_tourette_syndrome GAP_HIGH 0.2739 0.6666666666666666 midazolam 0.55 STABLE 0.6 3 0.0652 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay halazepam→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to midazolam (Jaccard=0.67) acetylcysteine focal_segmental_glomerulosclerosis GAP_HIGH 0.2362 0.4444444444444444 calcium_acetate 0.45 STABLE 0.85 3 0.06517 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acetylcysteine→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to calcium_acetate (Jaccard=0.44) doxycycline chronic_obstructive_pulmonary_disease GAP_HIGH 0.236 0.4666666666666667 tetracycline 0.45 STABLE 0.85 3 0.06512 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxycycline→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to tetracycline (Jaccard=0.47) clozapine ankylosing_spondylitis GAP_HIGH 0.2006 0.7692307692307693 phenindione 0.45 STABLE 1.0 3 0.06512 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clozapine→?; validate in ankylosing_spondylitis cell model. Expected: similar to phenindione (Jaccard=0.77) amoxapine gilles_de_la_tourette_syndrome GAP_HIGH 0.193 0.64 loxapine 0.55 STABLE 0.85 3 0.06509 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amoxapine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to loxapine (Jaccard=0.64) penicillamine narcolepsy GAP_HIGH 0.2355 0.4 l-histidine 0.45 STABLE 0.85 3 0.06498 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay penicillamine→?; validate in narcolepsy cell model. Expected: similar to l-histidine (Jaccard=0.40) methohexital lung_cancer GAP_HIGH 0.2497 0.5 clobazam 0.6 RISING 0.6 3 0.06484 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methohexital→?; validate in lung_cancer cell model. Expected: similar to clobazam (Jaccard=0.50) clomipramine systemic_lupus_erythematosus GAP_HIGH 0.1762 0.8181818181818182 chlorprothixene 0.6 RISING 0.85 3 0.06482 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clomipramine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to chlorprothixene (Jaccard=0.82) melatonin alzheimers_disease GAP_HIGH 0.1871 0.5 eletriptan 0.8 RAPID_RISE 0.6 3 0.06478 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay melatonin→?; validate in alzheimers_disease cell model. Expected: similar to eletriptan (Jaccard=0.50) melatonin parkinsons_disease GAP_HIGH 0.1871 0.5 eletriptan 0.8 RAPID_RISE 0.6 3 0.06478 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay melatonin→?; validate in parkinsons_disease cell model. Expected: similar to eletriptan (Jaccard=0.50) methadyl_acetate malignant_mesothelioma GAP_HIGH 0.2347 0.75 tamoxifen 0.45 STABLE 0.85 3 0.06476 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methadyl_acetate→?; validate in malignant_mesothelioma cell model. Expected: similar to tamoxifen (Jaccard=0.75) irbesartan type_2_diabetes_mellitus GAP_HIGH 0.1869 0.3333333333333333 hydralazine 0.8 RAPID_RISE 0.6 3 0.06471 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay irbesartan→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to hydralazine (Jaccard=0.33) sulfaphenazole leprosy GAP_HIGH 0.2345 0.55 sulfapyridine 0.45 STABLE 0.85 3 0.0647 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfaphenazole→?; validate in leprosy cell model. Expected: similar to sulfapyridine (Jaccard=0.55) erlotinib lung_cancer GAP_HIGH 0.1493 0.4666666666666667 afatinib 0.6 RISING 1.0 3 0.06462 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay erlotinib→?; validate in lung_cancer cell model. Expected: similar to afatinib (Jaccard=0.47) remifentanil epilepsy_syndrome GAP_HIGH 0.3725 1.0 milnacipran 0.4 STABLE 0.6 3 0.06449 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay remifentanil→?; validate in epilepsy_syndrome cell model. Expected: similar to milnacipran (Jaccard=1.00) dinoprost_tromethamine penile_cancer GAP_HIGH 0.1751 0.2 pemetrexed 0.6 RISING 0.85 3 0.06442 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dinoprost_tromethamine→?; validate in penile_cancer cell model. Expected: similar to pemetrexed (Jaccard=0.20) losartan hypertension GAP_HIGH 0.186 0.4 rescinnamine 0.8 RAPID_RISE 0.6 3 0.0644 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay losartan→?; validate in hypertension cell model. Expected: similar to rescinnamine (Jaccard=0.40) methadyl_acetate primary_biliary_cirrhosis GAP_HIGH 0.2332 0.75 tamoxifen 0.45 STABLE 0.85 3 0.06434 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methadyl_acetate→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to tamoxifen (Jaccard=0.75) methdilazine prostate_cancer GAP_HIGH 0.1749 0.6666666666666666 azelastine 0.6 RISING 0.85 3 0.06434 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methdilazine→?; validate in prostate_cancer cell model. Expected: similar to azelastine (Jaccard=0.67) bepridil hypertension GAP_HIGH 0.1858 0.6666666666666666 antazoline 0.8 RAPID_RISE 0.6 3 0.06433 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bepridil→?; validate in hypertension cell model. Expected: similar to antazoline (Jaccard=0.67) acetylcysteine membranous_glomerulonephritis GAP_HIGH 0.2326 0.4444444444444444 calcium_acetate 0.45 STABLE 0.85 3 0.06418 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acetylcysteine→?; validate in membranous_glomerulonephritis cell model. Expected: similar to calcium_acetate (Jaccard=0.44) methdilazine hematologic_cancer GAP_HIGH 0.1744 0.6666666666666666 azelastine 0.6 RISING 0.85 3 0.06416 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methdilazine→?; validate in hematologic_cancer cell model. Expected: similar to azelastine (Jaccard=0.67) phenylephrine metabolic_syndrome_x GAP_HIGH 0.1902 0.5 salbutamol 0.55 STABLE 0.85 3 0.06414 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenylephrine→?; validate in metabolic_syndrome_x cell model. Expected: similar to salbutamol (Jaccard=0.50) glutethimide ankylosing_spondylitis GAP_HIGH 0.2319 0.6 ethotoin 0.45 STABLE 0.85 3 0.06398 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glutethimide→?; validate in ankylosing_spondylitis cell model. Expected: similar to ethotoin (Jaccard=0.60) ranolazine migraine GAP_HIGH 0.2318 0.5714285714285714 methocarbamol 0.45 STABLE 0.85 3 0.06396 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ranolazine→?; validate in migraine cell model. Expected: similar to methocarbamol (Jaccard=0.57) ranolazine osteoarthritis GAP_HIGH 0.2314 0.5714285714285714 methocarbamol 0.45 STABLE 0.85 3 0.06385 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ranolazine→?; validate in osteoarthritis cell model. Expected: similar to methocarbamol (Jaccard=0.57) losartan type_2_diabetes_mellitus GAP_HIGH 0.1844 0.4 rescinnamine 0.8 RAPID_RISE 0.6 3 0.06385 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay losartan→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to rescinnamine (Jaccard=0.40) flunarizine hypertension GAP_HIGH 0.13 0.2727272727272727 papaverine 0.8 RAPID_RISE 0.85 3 0.06377 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flunarizine→?; validate in hypertension cell model. Expected: similar to papaverine (Jaccard=0.27) methsuximide gilles_de_la_tourette_syndrome GAP_HIGH 0.1889 0.36 loxapine 0.55 STABLE 0.85 3 0.0637 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methsuximide→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to loxapine (Jaccard=0.36) agomelatine panic_disorder GAP_HIGH 0.2308 0.6363636363636364 tolmetin 0.45 STABLE 0.85 3 0.06368 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay agomelatine→?; validate in panic_disorder cell model. Expected: similar to tolmetin (Jaccard=0.64) glutethimide attention_deficit_hyperactivity_disorder GAP_HIGH 0.2308 0.6 ethotoin 0.45 STABLE 0.85 3 0.06368 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glutethimide→?; validate in attention_deficit_hyperactivity_disorder cell model. Expected: similar to ethotoin (Jaccard=0.60) primidone creutzfeldt-jakob_disease GAP_HIGH 0.2306 0.5 ezetimibe 0.45 STABLE 0.85 3 0.06363 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay primidone→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to ezetimibe (Jaccard=0.50) levomilnacipran type_1_diabetes_mellitus GAP_HIGH 0.245 0.7142857142857143 cyclopentolate 0.6 RISING 0.6 3 0.06362 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levomilnacipran→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to cyclopentolate (Jaccard=0.71) glutethimide conduct_disorder GAP_HIGH 0.2305 0.6 ethotoin 0.45 STABLE 0.85 3 0.0636 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glutethimide→?; validate in conduct_disorder cell model. Expected: similar to ethotoin (Jaccard=0.60) glutethimide panic_disorder GAP_HIGH 0.2305 0.6 ethotoin 0.45 STABLE 0.85 3 0.0636 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glutethimide→?; validate in panic_disorder cell model. Expected: similar to ethotoin (Jaccard=0.60) methdilazine muscle_cancer GAP_HIGH 0.1722 0.6666666666666666 azelastine 0.6 RISING 0.85 3 0.06335 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methdilazine→?; validate in muscle_cancer cell model. Expected: similar to azelastine (Jaccard=0.67) nabumetone rheumatoid_arthritis GAP_HIGH 0.2582 0.8888888888888888 midodrine 0.4 STABLE 0.85 3 0.06333 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nabumetone→?; validate in rheumatoid_arthritis cell model. Expected: similar to midodrine (Jaccard=0.89) quinethazone esophageal_cancer GAP_HIGH 0.1719 0.3076923076923077 etoricoxib 0.6 RISING 0.85 3 0.06324 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinethazone→?; validate in esophageal_cancer cell model. Expected: similar to etoricoxib (Jaccard=0.31) quinacrine focal_segmental_glomerulosclerosis GAP_HIGH 0.2288 0.6086956521739131 chlorprothixene 0.45 STABLE 0.85 3 0.06313 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinacrine→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to chlorprothixene (Jaccard=0.61) ethotoin prostate_cancer GAP_HIGH 0.2427 0.76 phenytoin 0.6 RISING 0.6 3 0.06303 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethotoin→?; validate in prostate_cancer cell model. Expected: similar to phenytoin (Jaccard=0.76) doxylamine chronic_obstructive_pulmonary_disease GAP_HIGH 0.2284 0.6666666666666666 orphenadrine 0.45 STABLE 0.85 3 0.06302 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxylamine→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to orphenadrine (Jaccard=0.67) ethotoin mediastinal_cancer GAP_HIGH 0.2426 0.76 phenytoin 0.6 RISING 0.6 3 0.063 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethotoin→?; validate in mediastinal_cancer cell model. Expected: similar to phenytoin (Jaccard=0.76) difenoxin chronic_kidney_failure GAP_HIGH 0.2283 0.6153846153846154 clotrimazole 0.45 STABLE 0.85 3 0.06299 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay difenoxin→?; validate in chronic_kidney_failure cell model. Expected: similar to clotrimazole (Jaccard=0.62) propofol duodenum_cancer GAP_HIGH 0.242 0.6153846153846154 clobazam 0.6 RISING 0.6 3 0.06284 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propofol→?; validate in duodenum_cancer cell model. Expected: similar to clobazam (Jaccard=0.62) propofol gallbladder_cancer GAP_HIGH 0.242 0.6153846153846154 clobazam 0.6 RISING 0.6 3 0.06284 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propofol→?; validate in gallbladder_cancer cell model. Expected: similar to clobazam (Jaccard=0.62) clonazepam parkinsons_disease GAP_HIGH 0.1815 0.625 amoxapine 0.8 RAPID_RISE 0.6 3 0.06284 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clonazepam→?; validate in parkinsons_disease cell model. Expected: similar to amoxapine (Jaccard=0.62) aminoglutethimide coronary_artery_disease GAP_HIGH 0.2561 0.6 clofibrate 0.4 STABLE 0.85 3 0.06281 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminoglutethimide→?; validate in coronary_artery_disease cell model. Expected: similar to clofibrate (Jaccard=0.60) metolazone bone_cancer GAP_HIGH 0.1707 0.2 clodronate 0.6 RISING 0.85 3 0.0628 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay metolazone→?; validate in bone_cancer cell model. Expected: similar to clodronate (Jaccard=0.20) baclofen larynx_cancer GAP_HIGH 0.4029 1.0 procarbazine 0.6 RISING 0.6 3 0.06278 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay baclofen→?; validate in larynx_cancer cell model. Expected: similar to procarbazine (Jaccard=1.00) difenoxin azoospermia GAP_HIGH 0.2271 0.6153846153846154 clotrimazole 0.45 STABLE 0.85 3 0.06266 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay difenoxin→?; validate in azoospermia cell model. Expected: similar to clotrimazole (Jaccard=0.62) eprosartan epilepsy_syndrome GAP_HIGH 0.3618 1.0 telmisartan 0.4 STABLE 0.6 3 0.06264 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay eprosartan→?; validate in epilepsy_syndrome cell model. Expected: similar to telmisartan (Jaccard=1.00) sodium_tetradecyl_sulfate glaucoma GAP_HIGH 0.227 0.3 sodium_lauryl_sulfate 0.45 STABLE 0.85 3 0.06263 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sodium_tetradecyl_sulfate→?; validate in glaucoma cell model. Expected: similar to sodium_lauryl_sulfate (Jaccard=0.30) doxylamine psoriasis GAP_HIGH 0.2268 0.6666666666666666 orphenadrine 0.45 STABLE 0.85 3 0.06258 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxylamine→?; validate in psoriasis cell model. Expected: similar to orphenadrine (Jaccard=0.67) quinacrine chronic_kidney_failure GAP_HIGH 0.2266 0.6086956521739131 chlorprothixene 0.45 STABLE 0.85 3 0.06252 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinacrine→?; validate in chronic_kidney_failure cell model. Expected: similar to chlorprothixene (Jaccard=0.61) amiloride pagets_disease_of_bone GAP_HIGH 0.2266 0.25 histamine_phosphate 0.45 STABLE 0.85 3 0.06252 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amiloride→?; validate in pagets_disease_of_bone cell model. Expected: similar to histamine_phosphate (Jaccard=0.25) lenalidomide hematologic_cancer GAP_HIGH 0.1699 0.42857142857142855 menadione 0.6 RISING 0.85 3 0.0625 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lenalidomide→?; validate in hematologic_cancer cell model. Expected: similar to menadione (Jaccard=0.43) phenelzine acquired_immunodeficiency_syndrome GAP_HIGH 0.1853 0.5555555555555556 nateglinide 0.55 STABLE 0.85 3 0.06249 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenelzine→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to nateglinide (Jaccard=0.56) propofol lung_cancer GAP_HIGH 0.2405 0.6153846153846154 clobazam 0.6 RISING 0.6 3 0.06245 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propofol→?; validate in lung_cancer cell model. Expected: similar to clobazam (Jaccard=0.62) propofol rectum_cancer GAP_HIGH 0.2405 0.6153846153846154 clobazam 0.6 RISING 0.6 3 0.06245 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propofol→?; validate in rectum_cancer cell model. Expected: similar to clobazam (Jaccard=0.62) eprosartan schizophrenia GAP_HIGH 0.3606 1.0 telmisartan 0.4 STABLE 0.6 3 0.06243 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay eprosartan→?; validate in schizophrenia cell model. Expected: similar to telmisartan (Jaccard=1.00) eprosartan bipolar_disorder GAP_HIGH 0.3604 1.0 telmisartan 0.4 STABLE 0.6 3 0.06239 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay eprosartan→?; validate in bipolar_disorder cell model. Expected: similar to telmisartan (Jaccard=1.00) quinethazone kidney_cancer GAP_HIGH 0.1696 0.3076923076923077 etoricoxib 0.6 RISING 0.85 3 0.06239 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinethazone→?; validate in kidney_cancer cell model. Expected: similar to etoricoxib (Jaccard=0.31) difenoxin malignant_mesothelioma GAP_HIGH 0.2258 0.6153846153846154 clotrimazole 0.45 STABLE 0.85 3 0.0623 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay difenoxin→?; validate in malignant_mesothelioma cell model. Expected: similar to clotrimazole (Jaccard=0.62) vitamin_c larynx_cancer GAP_HIGH 0.2398 0.3333333333333333 vincristine 0.6 RISING 0.6 3 0.06227 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vitamin_c→?; validate in larynx_cancer cell model. Expected: similar to vincristine (Jaccard=0.33) doxylamine vitiligo GAP_HIGH 0.2253 0.6666666666666666 orphenadrine 0.45 STABLE 0.85 3 0.06216 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxylamine→?; validate in vitiligo cell model. Expected: similar to orphenadrine (Jaccard=0.67) mepenzolate coronary_artery_disease GAP_HIGH 0.2534 0.6666666666666666 bepridil 0.4 STABLE 0.85 3 0.06215 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mepenzolate→?; validate in coronary_artery_disease cell model. Expected: similar to bepridil (Jaccard=0.67) quinacrine membranous_glomerulonephritis GAP_HIGH 0.2252 0.6086956521739131 chlorprothixene 0.45 STABLE 0.85 3 0.06214 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinacrine→?; validate in membranous_glomerulonephritis cell model. Expected: similar to chlorprothixene (Jaccard=0.61) phenmetrazine atherosclerosis GAP_HIGH 0.2252 0.5555555555555556 clofibrate 0.45 STABLE 0.85 3 0.06214 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenmetrazine→?; validate in atherosclerosis cell model. Expected: similar to clofibrate (Jaccard=0.56) baclofen head_and_neck_cancer GAP_HIGH 0.3987 1.0 procarbazine 0.6 RISING 0.6 3 0.06212 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay baclofen→?; validate in head_and_neck_cancer cell model. Expected: similar to procarbazine (Jaccard=1.00) adinazolam gilles_de_la_tourette_syndrome GAP_HIGH 0.2609 0.7142857142857143 midazolam 0.55 STABLE 0.6 3 0.06211 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay adinazolam→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to midazolam (Jaccard=0.71) hydrocortisone kidney_cancer GAP_HIGH 0.1688 0.6363636363636364 testolactone 0.6 RISING 0.85 3 0.0621 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay hydrocortisone→?; validate in kidney_cancer cell model. Expected: similar to testolactone (Jaccard=0.64) clenbuterol refractive_error GAP_HIGH 0.3186 1.0 epinephrine 0.45 STABLE 0.6 3 0.06205 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clenbuterol→?; validate in refractive_error cell model. Expected: similar to epinephrine (Jaccard=1.00) l-cysteine glaucoma GAP_HIGH 0.2247 0.6229508196721312 l-serine 0.45 STABLE 0.85 3 0.062 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-cysteine→?; validate in glaucoma cell model. Expected: similar to l-serine (Jaccard=0.62) naftifine urinary_bladder_cancer GAP_HIGH 0.1685 0.6296296296296297 diphenhydramine 0.6 RISING 0.85 3 0.06199 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay naftifine→?; validate in urinary_bladder_cancer cell model. Expected: similar to diphenhydramine (Jaccard=0.63) indapamide hypertension GAP_HIGH 0.1261 0.2222222222222222 tamsulosin 0.8 RAPID_RISE 0.85 3 0.06185 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay indapamide→?; validate in hypertension cell model. Expected: similar to tamsulosin (Jaccard=0.22) bromodiphenhydramine stomach_cancer GAP_HIGH 0.1679 0.5 brompheniramine 0.6 RISING 0.85 3 0.06177 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bromodiphenhydramine→?; validate in stomach_cancer cell model. Expected: similar to brompheniramine (Jaccard=0.50) dydrogesterone head_and_neck_cancer GAP_HIGH 0.1679 0.47058823529411764 medrysone 0.6 RISING 0.85 3 0.06177 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dydrogesterone→?; validate in head_and_neck_cancer cell model. Expected: similar to medrysone (Jaccard=0.47) vitamin_c esophageal_cancer GAP_HIGH 0.2378 0.3333333333333333 vincristine 0.6 RISING 0.6 3 0.06175 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vitamin_c→?; validate in esophageal_cancer cell model. Expected: similar to vincristine (Jaccard=0.33) dapsone malaria GAP_HIGH 0.2236 0.625 sulfamethizole 0.45 STABLE 0.85 3 0.06169 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dapsone→?; validate in malaria cell model. Expected: similar to sulfamethizole (Jaccard=0.62) deferasirox type_1_diabetes_mellitus GAP_HIGH 0.2374 0.5 linaclotide 0.6 RISING 0.6 3 0.06165 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay deferasirox→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to linaclotide (Jaccard=0.50) sulfamethizole type_1_diabetes_mellitus GAP_HIGH 0.1674 0.4 sulfapyridine 0.6 RISING 0.85 3 0.06158 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfamethizole→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to sulfapyridine (Jaccard=0.40) melphalan larynx_cancer GAP_HIGH 0.2371 0.6363636363636364 procarbazine 0.6 RISING 0.6 3 0.06157 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay melphalan→?; validate in larynx_cancer cell model. Expected: similar to procarbazine (Jaccard=0.64) olsalazine ulcerative_colitis GAP_HIGH 0.1255 0.375 sulfaphenazole 0.8 RAPID_RISE 0.85 3 0.06156 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay olsalazine→?; validate in ulcerative_colitis cell model. Expected: similar to sulfaphenazole (Jaccard=0.38) l-carnitine esophageal_cancer GAP_HIGH 0.1672 0.25 raloxifene 0.6 RISING 0.85 3 0.06151 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-carnitine→?; validate in esophageal_cancer cell model. Expected: similar to raloxifene (Jaccard=0.25) choline bone_cancer GAP_HIGH 0.167 0.2 histamine_phosphate 0.6 RISING 0.85 3 0.06144 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay choline→?; validate in bone_cancer cell model. Expected: similar to histamine_phosphate (Jaccard=0.20) phenelzine pharynx_cancer GAP_HIGH 0.1669 0.5555555555555556 nateglinide 0.6 RISING 0.85 3 0.0614 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenelzine→?; validate in pharynx_cancer cell model. Expected: similar to nateglinide (Jaccard=0.56) clenbuterol idiopathic_pulmonary_fibrosis GAP_HIGH 0.3146 1.0 epinephrine 0.45 STABLE 0.6 3 0.06127 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clenbuterol→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to epinephrine (Jaccard=1.00) phenylpropanolamine muscle_cancer GAP_HIGH 0.1662 0.55 bethanidine 0.6 RISING 0.85 3 0.06114 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenylpropanolamine→?; validate in muscle_cancer cell model. Expected: similar to bethanidine (Jaccard=0.55) ethynodiol germ_cell_cancer GAP_HIGH 0.2354 0.6666666666666666 megestrol_acetate 0.6 RISING 0.6 3 0.06113 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethynodiol→?; validate in germ_cell_cancer cell model. Expected: similar to megestrol_acetate (Jaccard=0.67) hydrochlorothiazide nephrolithiasis GAP_HIGH 0.2215 0.45454545454545453 polythiazide 0.45 STABLE 0.85 3 0.06112 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay hydrochlorothiazide→?; validate in nephrolithiasis cell model. Expected: similar to polythiazide (Jaccard=0.45) rimexolone metabolic_syndrome_x GAP_HIGH 0.1808 0.625 amcinonide 0.55 STABLE 0.85 3 0.06097 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay rimexolone→?; validate in metabolic_syndrome_x cell model. Expected: similar to amcinonide (Jaccard=0.62) methdilazine gilles_de_la_tourette_syndrome GAP_HIGH 0.1807 0.6666666666666666 azelastine 0.55 STABLE 0.85 3 0.06094 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methdilazine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to azelastine (Jaccard=0.67) cortisone_acetate kidney_cancer GAP_HIGH 0.1656 0.46153846153846156 medrysone 0.6 RISING 0.85 3 0.06092 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cortisone_acetate→?; validate in kidney_cancer cell model. Expected: similar to medrysone (Jaccard=0.46) afatinib prostate_cancer GAP_HIGH 0.1654 0.4666666666666667 erlotinib 0.6 RISING 0.85 3 0.06085 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay afatinib→?; validate in prostate_cancer cell model. Expected: similar to erlotinib (Jaccard=0.47) olanzapine panic_disorder GAP_HIGH 0.1874 0.6 ziprasidone 0.45 STABLE 1.0 3 0.06083 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay olanzapine→?; validate in panic_disorder cell model. Expected: similar to ziprasidone (Jaccard=0.60) clenbuterol chronic_obstructive_pulmonary_disease GAP_HIGH 0.3123 1.0 epinephrine 0.45 STABLE 0.6 3 0.06082 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clenbuterol→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to epinephrine (Jaccard=1.00) raloxifene breast_cancer GAP_HIGH 0.2341 0.75 alcaftadine 0.6 RISING 0.6 3 0.06079 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay raloxifene→?; validate in breast_cancer cell model. Expected: similar to alcaftadine (Jaccard=0.75) trimethoprim penile_cancer GAP_HIGH 0.234 0.5 pemetrexed 0.6 RISING 0.6 3 0.06077 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trimethoprim→?; validate in penile_cancer cell model. Expected: similar to pemetrexed (Jaccard=0.50) phenylpropanolamine pancreatic_cancer GAP_HIGH 0.1651 0.55 bethanidine 0.6 RISING 0.85 3 0.06074 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenylpropanolamine→?; validate in pancreatic_cancer cell model. Expected: similar to bethanidine (Jaccard=0.55) antazoline crohns_disease GAP_HIGH 0.2197 0.6666666666666666 bepridil 0.45 STABLE 0.85 3 0.06062 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay antazoline→?; validate in crohns_disease cell model. Expected: similar to bepridil (Jaccard=0.67) hydrocortisone prostate_cancer GAP_HIGH 0.1646 0.6363636363636364 testolactone 0.6 RISING 0.85 3 0.06055 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay hydrocortisone→?; validate in prostate_cancer cell model. Expected: similar to testolactone (Jaccard=0.64) floctafenine alzheimers_disease GAP_HIGH 0.1234 0.26666666666666666 mefenamic_acid 0.8 RAPID_RISE 0.85 3 0.06053 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay floctafenine→?; validate in alzheimers_disease cell model. Expected: similar to mefenamic_acid (Jaccard=0.27) floctafenine parkinsons_disease GAP_HIGH 0.1234 0.26666666666666666 mefenamic_acid 0.8 RAPID_RISE 0.85 3 0.06053 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay floctafenine→?; validate in parkinsons_disease cell model. Expected: similar to mefenamic_acid (Jaccard=0.27) solifenacin membranous_glomerulonephritis GAP_HIGH 0.3107 0.6 alvimopan 0.45 STABLE 0.6 3 0.06051 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay solifenacin→?; validate in membranous_glomerulonephritis cell model. Expected: similar to alvimopan (Jaccard=0.60) tranylcypromine leprosy GAP_HIGH 0.2193 0.5555555555555556 phenmetrazine 0.45 STABLE 0.85 3 0.06051 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tranylcypromine→?; validate in leprosy cell model. Expected: similar to phenmetrazine (Jaccard=0.56) melphalan head_and_neck_cancer GAP_HIGH 0.2329 0.6363636363636364 procarbazine 0.6 RISING 0.6 3 0.06048 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay melphalan→?; validate in head_and_neck_cancer cell model. Expected: similar to procarbazine (Jaccard=0.64) tioguanine bone_cancer GAP_HIGH 0.1644 0.18181818181818182 tetrahydrofolic_acid 0.6 RISING 0.85 3 0.06048 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tioguanine→?; validate in bone_cancer cell model. Expected: similar to tetrahydrofolic_acid (Jaccard=0.18) cinnarizine hypertension GAP_HIGH 0.1233 0.2857142857142857 mepenzolate 0.8 RAPID_RISE 0.85 3 0.06048 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cinnarizine→?; validate in hypertension cell model. Expected: similar to mepenzolate (Jaccard=0.29) ribavirin liver_cancer GAP_HIGH 0.2328 0.5909090909090909 vidarabine 0.6 RISING 0.6 3 0.06045 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ribavirin→?; validate in liver_cancer cell model. Expected: similar to vidarabine (Jaccard=0.59) trimethoprim prostate_cancer GAP_HIGH 0.2325 0.5 pemetrexed 0.6 RISING 0.6 3 0.06038 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trimethoprim→?; validate in prostate_cancer cell model. Expected: similar to pemetrexed (Jaccard=0.50) trimethoprim mediastinal_cancer GAP_HIGH 0.2323 0.5 pemetrexed 0.6 RISING 0.6 3 0.06032 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trimethoprim→?; validate in mediastinal_cancer cell model. Expected: similar to pemetrexed (Jaccard=0.50) hydrochlorothiazide chronic_kidney_failure GAP_HIGH 0.2183 0.4444444444444444 methyclothiazide 0.45 STABLE 0.85 3 0.06023 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay hydrochlorothiazide→?; validate in chronic_kidney_failure cell model. Expected: similar to methyclothiazide (Jaccard=0.44) doxylamine azoospermia GAP_HIGH 0.2182 0.6 disopyramide 0.45 STABLE 0.85 3 0.0602 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxylamine→?; validate in azoospermia cell model. Expected: similar to disopyramide (Jaccard=0.60) sulfanilamide atherosclerosis GAP_HIGH 0.2181 0.6 clofibrate 0.45 STABLE 0.85 3 0.06018 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfanilamide→?; validate in atherosclerosis cell model. Expected: similar to clofibrate (Jaccard=0.60) dydrogesterone mediastinal_cancer GAP_HIGH 0.1635 0.47058823529411764 medrysone 0.6 RISING 0.85 3 0.06015 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dydrogesterone→?; validate in mediastinal_cancer cell model. Expected: similar to medrysone (Jaccard=0.47) deferasirox thymus_cancer GAP_HIGH 0.2315 0.5 linaclotide 0.6 RISING 0.6 3 0.06012 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay deferasirox→?; validate in thymus_cancer cell model. Expected: similar to linaclotide (Jaccard=0.50) dydrogesterone thymus_cancer GAP_HIGH 0.1634 0.47058823529411764 medrysone 0.6 RISING 0.85 3 0.06011 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dydrogesterone→?; validate in thymus_cancer cell model. Expected: similar to medrysone (Jaccard=0.47) choline larynx_cancer GAP_HIGH 0.1634 0.25 vincristine 0.6 RISING 0.85 3 0.06011 CRITICAL Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay choline→?; validate in larynx_cancer cell model. Expected: similar to vincristine (Jaccard=0.25) phenmetrazine nephrolithiasis GAP_HIGH 0.2173 0.5555555555555556 probenecid 0.45 STABLE 0.85 3 0.05996 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenmetrazine→?; validate in nephrolithiasis cell model. Expected: similar to probenecid (Jaccard=0.56) antazoline chronic_obstructive_pulmonary_disease GAP_HIGH 0.217 0.6666666666666666 bepridil 0.45 STABLE 0.85 3 0.05987 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay antazoline→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to bepridil (Jaccard=0.67) tolazamide osteoporosis GAP_HIGH 0.2169 0.4666666666666667 chlorpropamide 0.45 STABLE 0.85 3 0.05985 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolazamide→?; validate in osteoporosis cell model. Expected: similar to chlorpropamide (Jaccard=0.47) bromodiphenhydramine gilles_de_la_tourette_syndrome GAP_HIGH 0.1774 0.5 brompheniramine 0.55 STABLE 0.85 3 0.05982 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bromodiphenhydramine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to brompheniramine (Jaccard=0.50) moricizine prostate_cancer GAP_HIGH 0.1626 0.5 thioproperazine 0.6 RISING 0.85 3 0.05982 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay moricizine→?; validate in prostate_cancer cell model. Expected: similar to thioproperazine (Jaccard=0.50) antazoline pancreatitis GAP_HIGH 0.2167 0.6666666666666666 bepridil 0.45 STABLE 0.85 3 0.05979 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay antazoline→?; validate in pancreatitis cell model. Expected: similar to bepridil (Jaccard=0.67) choline hypothyroidism GAP_HIGH 0.2167 0.25 methimazole 0.45 STABLE 0.85 3 0.05979 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay choline→?; validate in hypothyroidism cell model. Expected: similar to methimazole (Jaccard=0.25) ceruletide esophageal_cancer GAP_HIGH 0.1625 0.2 goserelin 0.6 RISING 0.85 3 0.05978 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ceruletide→?; validate in esophageal_cancer cell model. Expected: similar to goserelin (Jaccard=0.20) moricizine hematologic_cancer GAP_HIGH 0.1621 0.5 thioproperazine 0.6 RISING 0.85 3 0.05963 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay moricizine→?; validate in hematologic_cancer cell model. Expected: similar to thioproperazine (Jaccard=0.50) tolazamide systemic_scleroderma GAP_HIGH 0.2159 0.4666666666666667 chlorpropamide 0.45 STABLE 0.85 3 0.05957 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolazamide→?; validate in systemic_scleroderma cell model. Expected: similar to chlorpropamide (Jaccard=0.47) paricalcitol chronic_kidney_failure GAP_HIGH 0.3056 0.8571428571428571 dihydrotachysterol 0.45 STABLE 0.6 3 0.05952 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay paricalcitol→?; validate in chronic_kidney_failure cell model. Expected: similar to dihydrotachysterol (Jaccard=0.86) dydrogesterone pharynx_cancer GAP_HIGH 0.1617 0.47058823529411764 medrysone 0.6 RISING 0.85 3 0.05949 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dydrogesterone→?; validate in pharynx_cancer cell model. Expected: similar to medrysone (Jaccard=0.47) mefenamic_acid pharynx_cancer GAP_HIGH 0.1613 0.5384615384615384 clonidine 0.6 RISING 0.85 3 0.05934 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mefenamic_acid→?; validate in pharynx_cancer cell model. Expected: similar to clonidine (Jaccard=0.54) selegiline hematologic_cancer GAP_HIGH 0.1613 0.4 phenformin 0.6 RISING 0.85 3 0.05934 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay selegiline→?; validate in hematologic_cancer cell model. Expected: similar to phenformin (Jaccard=0.40) antipyrine ankylosing_spondylitis GAP_HIGH 0.2149 0.6818181818181818 ethotoin 0.45 STABLE 0.85 3 0.05929 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay antipyrine→?; validate in ankylosing_spondylitis cell model. Expected: similar to ethotoin (Jaccard=0.68) papaverine focal_segmental_glomerulosclerosis GAP_HIGH 0.2147 0.45 bevantolol 0.45 STABLE 0.85 3 0.05924 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay papaverine→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to bevantolol (Jaccard=0.45) treprostinil thyroid_cancer GAP_HIGH 0.1709 0.25 metipranolol 0.8 RAPID_RISE 0.6 3 0.05917 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay treprostinil→?; validate in thyroid_cancer cell model. Expected: similar to metipranolol (Jaccard=0.25) sulfaphenazole malaria GAP_HIGH 0.2143 0.55 sulfapyridine 0.45 STABLE 0.85 3 0.05913 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfaphenazole→?; validate in malaria cell model. Expected: similar to sulfapyridine (Jaccard=0.55) mefenamic_acid salivary_gland_cancer GAP_HIGH 0.1607 0.5384615384615384 clonidine 0.6 RISING 0.85 3 0.05912 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mefenamic_acid→?; validate in salivary_gland_cancer cell model. Expected: similar to clonidine (Jaccard=0.54) papaverine glaucoma GAP_HIGH 0.2141 0.45 bevantolol 0.45 STABLE 0.85 3 0.05907 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay papaverine→?; validate in glaucoma cell model. Expected: similar to bevantolol (Jaccard=0.45) diphenidol stomach_cancer GAP_HIGH 0.2274 0.625 bepridil 0.6 RISING 0.6 3 0.05905 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphenidol→?; validate in stomach_cancer cell model. Expected: similar to bepridil (Jaccard=0.62) l-methionine glaucoma GAP_HIGH 0.214 0.5967741935483871 l-serine 0.45 STABLE 0.85 3 0.05905 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-methionine→?; validate in glaucoma cell model. Expected: similar to l-serine (Jaccard=0.60) zidovudine lymphatic_system_cancer GAP_HIGH 0.1605 0.3333333333333333 emtricitabine 0.6 RISING 0.85 3 0.05905 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zidovudine→?; validate in lymphatic_system_cancer cell model. Expected: similar to emtricitabine (Jaccard=0.33) diphenidol pancreatic_cancer GAP_HIGH 0.2273 0.625 bepridil 0.6 RISING 0.6 3 0.05903 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphenidol→?; validate in pancreatic_cancer cell model. Expected: similar to bepridil (Jaccard=0.62) mefenamic_acid ocular_cancer GAP_HIGH 0.1604 0.5384615384615384 clonidine 0.6 RISING 0.85 3 0.05901 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mefenamic_acid→?; validate in ocular_cancer cell model. Expected: similar to clonidine (Jaccard=0.54) sulfamethizole duodenum_cancer GAP_HIGH 0.1604 0.4 sulfapyridine 0.6 RISING 0.85 3 0.05901 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfamethizole→?; validate in duodenum_cancer cell model. Expected: similar to sulfapyridine (Jaccard=0.40) nimodipine rheumatoid_arthritis GAP_HIGH 0.2403 0.6666666666666666 nisoldipine 0.4 STABLE 0.85 3 0.05894 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nimodipine→?; validate in rheumatoid_arthritis cell model. Expected: similar to nisoldipine (Jaccard=0.67) diphenidol systemic_lupus_erythematosus GAP_HIGH 0.2269 0.625 bepridil 0.6 RISING 0.6 3 0.05892 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphenidol→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to bepridil (Jaccard=0.62) prochlorperazine focal_segmental_glomerulosclerosis GAP_HIGH 0.2135 0.75 mequitazine 0.45 STABLE 0.85 3 0.05891 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prochlorperazine→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to mequitazine (Jaccard=0.75) betamethasone brain_cancer GAP_HIGH 0.1601 0.5882352941176471 amcinonide 0.6 RISING 0.85 3 0.0589 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay betamethasone→?; validate in brain_cancer cell model. Expected: similar to amcinonide (Jaccard=0.59) antipyrine atopic_dermatitis GAP_HIGH 0.2134 0.6818181818181818 ethotoin 0.45 STABLE 0.85 3 0.05888 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay antipyrine→?; validate in atopic_dermatitis cell model. Expected: similar to ethotoin (Jaccard=0.68) antipyrine conduct_disorder GAP_HIGH 0.2134 0.6818181818181818 ethotoin 0.45 STABLE 0.85 3 0.05888 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay antipyrine→?; validate in conduct_disorder cell model. Expected: similar to ethotoin (Jaccard=0.68) antipyrine allergic_rhinitis GAP_HIGH 0.2133 0.6818181818181818 ethotoin 0.45 STABLE 0.85 3 0.05885 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay antipyrine→?; validate in allergic_rhinitis cell model. Expected: similar to ethotoin (Jaccard=0.68) tioguanine multiple_sclerosis GAP_HIGH 0.2665 0.5 adenine 0.6 RISING 0.85 3 0.05882 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tioguanine→?; validate in multiple_sclerosis cell model. Expected: similar to adenine (Jaccard=0.50) ponatinib stomach_cancer GAP_HIGH 0.1598 0.39473684210526316 imatinib 0.6 RISING 0.85 3 0.05879 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ponatinib→?; validate in stomach_cancer cell model. Expected: similar to imatinib (Jaccard=0.39) quazepam coronary_artery_disease GAP_HIGH 0.3392 0.8333333333333334 cinolazepam 0.4 STABLE 0.6 3 0.05872 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quazepam→?; validate in coronary_artery_disease cell model. Expected: similar to cinolazepam (Jaccard=0.83) papaverine chronic_kidney_failure GAP_HIGH 0.2125 0.45 bevantolol 0.45 STABLE 0.85 3 0.05863 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay papaverine→?; validate in chronic_kidney_failure cell model. Expected: similar to bevantolol (Jaccard=0.45) succinic_acid narcolepsy GAP_HIGH 0.2125 0.3103448275862069 l-asparagine 0.45 STABLE 0.85 3 0.05863 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay succinic_acid→?; validate in narcolepsy cell model. Expected: similar to l-asparagine (Jaccard=0.31) ranolazine focal_segmental_glomerulosclerosis GAP_HIGH 0.2124 0.4375 propranolol 0.45 STABLE 0.85 3 0.0586 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ranolazine→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to propranolol (Jaccard=0.44) ramipril dilated_cardiomyopathy GAP_HIGH 0.3006 1.0 trandolapril 0.45 STABLE 0.6 3 0.05855 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ramipril→?; validate in dilated_cardiomyopathy cell model. Expected: similar to trandolapril (Jaccard=1.00) betamethasone kidney_cancer GAP_HIGH 0.1591 0.5882352941176471 amcinonide 0.6 RISING 0.85 3 0.05853 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay betamethasone→?; validate in kidney_cancer cell model. Expected: similar to amcinonide (Jaccard=0.59) ponatinib skin_cancer GAP_HIGH 0.1591 0.39473684210526316 imatinib 0.6 RISING 0.85 3 0.05853 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ponatinib→?; validate in skin_cancer cell model. Expected: similar to imatinib (Jaccard=0.39) temazepam ulcerative_colitis GAP_HIGH 0.1688 0.6153846153846154 diazepam 0.8 RAPID_RISE 0.6 3 0.05845 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay temazepam→?; validate in ulcerative_colitis cell model. Expected: similar to diazepam (Jaccard=0.62) droperidol crohns_disease GAP_HIGH 0.3 1.0 bepotastine 0.45 STABLE 0.6 3 0.05843 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay droperidol→?; validate in crohns_disease cell model. Expected: similar to bepotastine (Jaccard=1.00) norelgestromin vascular_cancer GAP_HIGH 0.225 0.625 trilostane 0.6 RISING 0.6 3 0.05843 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay norelgestromin→?; validate in vascular_cancer cell model. Expected: similar to trilostane (Jaccard=0.62) colchicine bone_cancer GAP_HIGH 0.1587 0.16666666666666666 histamine_phosphate 0.6 RISING 0.85 3 0.05838 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay colchicine→?; validate in bone_cancer cell model. Expected: similar to histamine_phosphate (Jaccard=0.17) mepyramine systemic_scleroderma GAP_HIGH 0.2115 0.625 tripelennamine 0.45 STABLE 0.85 3 0.05836 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mepyramine→?; validate in systemic_scleroderma cell model. Expected: similar to tripelennamine (Jaccard=0.62) hydrochlorothiazide autistic_disorder GAP_HIGH 0.2115 0.4444444444444444 methyclothiazide 0.45 STABLE 0.85 3 0.05836 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay hydrochlorothiazide→?; validate in autistic_disorder cell model. Expected: similar to methyclothiazide (Jaccard=0.44) papaverine azoospermia GAP_HIGH 0.2114 0.45 bevantolol 0.45 STABLE 0.85 3 0.05833 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay papaverine→?; validate in azoospermia cell model. Expected: similar to bevantolol (Jaccard=0.45) prochlorperazine chronic_kidney_failure GAP_HIGH 0.2113 0.75 mequitazine 0.45 STABLE 0.85 3 0.0583 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prochlorperazine→?; validate in chronic_kidney_failure cell model. Expected: similar to mequitazine (Jaccard=0.75) papaverine membranous_glomerulonephritis GAP_HIGH 0.2112 0.45 bevantolol 0.45 STABLE 0.85 3 0.05827 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay papaverine→?; validate in membranous_glomerulonephritis cell model. Expected: similar to bevantolol (Jaccard=0.45) nicardipine gilles_de_la_tourette_syndrome GAP_HIGH 0.1728 0.25 ezetimibe 0.55 STABLE 0.85 3 0.05827 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nicardipine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to ezetimibe (Jaccard=0.25) acetic_acid intracranial_aneurysm GAP_HIGH 0.211 0.25 hydroxyurea 0.45 STABLE 0.85 3 0.05822 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acetic_acid→?; validate in intracranial_aneurysm cell model. Expected: similar to hydroxyurea (Jaccard=0.25) levomilnacipran atopic_dermatitis GAP_HIGH 0.2989 1.0 remifentanil 0.45 STABLE 0.6 3 0.05821 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levomilnacipran→?; validate in atopic_dermatitis cell model. Expected: similar to remifentanil (Jaccard=1.00) ceruletide germ_cell_cancer GAP_HIGH 0.1582 0.2 goserelin 0.6 RISING 0.85 3 0.0582 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ceruletide→?; validate in germ_cell_cancer cell model. Expected: similar to goserelin (Jaccard=0.20) levomilnacipran migraine GAP_HIGH 0.2986 1.0 remifentanil 0.45 STABLE 0.6 3 0.05816 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levomilnacipran→?; validate in migraine cell model. Expected: similar to remifentanil (Jaccard=1.00) aminosalicylic_acid esophageal_cancer GAP_HIGH 0.158 0.5 mesalazine 0.6 RISING 0.85 3 0.05813 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminosalicylic_acid→?; validate in esophageal_cancer cell model. Expected: similar to mesalazine (Jaccard=0.50) phenindamine pancreatic_cancer GAP_HIGH 0.158 0.4 indecainide 0.6 RISING 0.85 3 0.05813 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenindamine→?; validate in pancreatic_cancer cell model. Expected: similar to indecainide (Jaccard=0.40) l-phenylalanine pharynx_cancer GAP_HIGH 0.158 0.36363636363636365 lacosamide 0.6 RISING 0.85 3 0.05813 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-phenylalanine→?; validate in pharynx_cancer cell model. Expected: similar to lacosamide (Jaccard=0.36) amobarbital epilepsy_syndrome GAP_HIGH 0.3354 1.0 butethal 0.4 STABLE 0.6 3 0.05807 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amobarbital→?; validate in epilepsy_syndrome cell model. Expected: similar to butethal (Jaccard=1.00) prochlorperazine azoospermia GAP_HIGH 0.2101 0.75 mequitazine 0.45 STABLE 0.85 3 0.05797 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prochlorperazine→?; validate in azoospermia cell model. Expected: similar to mequitazine (Jaccard=0.75) acetic_acid malignant_glioma GAP_HIGH 0.2101 0.25 hydroxyurea 0.45 STABLE 0.85 3 0.05797 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acetic_acid→?; validate in malignant_glioma cell model. Expected: similar to hydroxyurea (Jaccard=0.25) prochlorperazine membranous_glomerulonephritis GAP_HIGH 0.2099 0.75 mequitazine 0.45 STABLE 0.85 3 0.05791 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prochlorperazine→?; validate in membranous_glomerulonephritis cell model. Expected: similar to mequitazine (Jaccard=0.75) succinic_acid autistic_disorder GAP_HIGH 0.2099 0.3103448275862069 l-asparagine 0.45 STABLE 0.85 3 0.05791 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay succinic_acid→?; validate in autistic_disorder cell model. Expected: similar to l-asparagine (Jaccard=0.31) succinic_acid nicotine_dependence GAP_HIGH 0.2099 0.3103448275862069 l-asparagine 0.45 STABLE 0.85 3 0.05791 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay succinic_acid→?; validate in nicotine_dependence cell model. Expected: similar to l-asparagine (Jaccard=0.31) phenindamine skin_cancer GAP_HIGH 0.1574 0.4 indecainide 0.6 RISING 0.85 3 0.05791 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenindamine→?; validate in skin_cancer cell model. Expected: similar to indecainide (Jaccard=0.40) l-phenylalanine salivary_gland_cancer GAP_HIGH 0.1574 0.36363636363636365 lacosamide 0.6 RISING 0.85 3 0.05791 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-phenylalanine→?; validate in salivary_gland_cancer cell model. Expected: similar to lacosamide (Jaccard=0.36) droperidol chronic_obstructive_pulmonary_disease GAP_HIGH 0.2972 1.0 bepotastine 0.45 STABLE 0.6 3 0.05788 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay droperidol→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to bepotastine (Jaccard=1.00) clotiazepam chronic_kidney_failure GAP_HIGH 0.2972 0.8333333333333334 cinolazepam 0.45 STABLE 0.6 3 0.05788 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clotiazepam→?; validate in chronic_kidney_failure cell model. Expected: similar to cinolazepam (Jaccard=0.83) droperidol pancreatitis GAP_HIGH 0.297 1.0 bepotastine 0.45 STABLE 0.6 3 0.05784 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay droperidol→?; validate in pancreatitis cell model. Expected: similar to bepotastine (Jaccard=1.00) dronedarone nephrolithiasis GAP_HIGH 0.2094 0.4166666666666667 proparacaine 0.45 STABLE 0.85 3 0.05778 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dronedarone→?; validate in nephrolithiasis cell model. Expected: similar to proparacaine (Jaccard=0.42) succinic_acid conduct_disorder GAP_HIGH 0.2094 0.3103448275862069 l-asparagine 0.45 STABLE 0.85 3 0.05778 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay succinic_acid→?; validate in conduct_disorder cell model. Expected: similar to l-asparagine (Jaccard=0.31) levonorgestrel brain_cancer GAP_HIGH 0.2224 0.6666666666666666 desogestrel 0.6 RISING 0.6 3 0.05775 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levonorgestrel→?; validate in brain_cancer cell model. Expected: similar to desogestrel (Jaccard=0.67) propericiazine chronic_obstructive_pulmonary_disease GAP_HIGH 0.2091 0.8181818181818182 perphenazine 0.45 STABLE 0.85 3 0.05769 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propericiazine→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to perphenazine (Jaccard=0.82) l-histidine systemic_lupus_erythematosus GAP_HIGH 0.1568 0.4 penicillamine 0.6 RISING 0.85 3 0.05768 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-histidine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to penicillamine (Jaccard=0.40) carbidopa restless_legs_syndrome GAP_HIGH 0.2422 0.9375 methyldopa 0.55 STABLE 0.6 3 0.05765 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carbidopa→?; validate in restless_legs_syndrome cell model. Expected: similar to methyldopa (Jaccard=0.94) sulfanilamide leprosy GAP_HIGH 0.2088 0.45454545454545453 phenmetrazine 0.45 STABLE 0.85 3 0.05761 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfanilamide→?; validate in leprosy cell model. Expected: similar to phenmetrazine (Jaccard=0.45) droperidol psoriasis GAP_HIGH 0.2957 1.0 bepotastine 0.45 STABLE 0.6 3 0.05759 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay droperidol→?; validate in psoriasis cell model. Expected: similar to bepotastine (Jaccard=1.00) amphetamine pagets_disease_of_bone GAP_HIGH 0.2087 0.25 histamine_phosphate 0.45 STABLE 0.85 3 0.05758 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amphetamine→?; validate in pagets_disease_of_bone cell model. Expected: similar to histamine_phosphate (Jaccard=0.25) equilin larynx_cancer GAP_HIGH 0.2216 0.3333333333333333 methimazole 0.6 RISING 0.6 3 0.05755 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay equilin→?; validate in larynx_cancer cell model. Expected: similar to methimazole (Jaccard=0.33) procaine polycystic_ovary_syndrome GAP_HIGH 0.1705 0.5789473684210527 chloroprocaine 0.55 STABLE 0.85 3 0.0575 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay procaine→?; validate in polycystic_ovary_syndrome cell model. Expected: similar to chloroprocaine (Jaccard=0.58) stanozolol brain_cancer GAP_HIGH 0.2214 0.5555555555555556 cortisone_acetate 0.6 RISING 0.6 3 0.05749 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay stanozolol→?; validate in brain_cancer cell model. Expected: similar to cortisone_acetate (Jaccard=0.56) norepinephrine systemic_scleroderma GAP_HIGH 0.2083 0.5714285714285714 isoetarine 0.45 STABLE 0.85 3 0.05747 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay norepinephrine→?; validate in systemic_scleroderma cell model. Expected: similar to isoetarine (Jaccard=0.57) clozapine schizophrenia GAP_HIGH 0.1991 0.7692307692307693 phenindione 0.4 STABLE 1.0 3 0.05745 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clozapine→?; validate in schizophrenia cell model. Expected: similar to phenindione (Jaccard=0.77) clozapine bipolar_disorder GAP_HIGH 0.1989 0.7692307692307693 phenindione 0.4 STABLE 1.0 3 0.05739 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clozapine→?; validate in bipolar_disorder cell model. Expected: similar to phenindione (Jaccard=0.77) ceruletide mediastinal_cancer GAP_HIGH 0.1559 0.2 goserelin 0.6 RISING 0.85 3 0.05735 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ceruletide→?; validate in mediastinal_cancer cell model. Expected: similar to goserelin (Jaccard=0.20) allylestrenol brain_cancer GAP_HIGH 0.2207 0.5555555555555556 ethynodiol 0.6 RISING 0.6 3 0.05731 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay allylestrenol→?; validate in brain_cancer cell model. Expected: similar to ethynodiol (Jaccard=0.56) dydrogesterone primary_biliary_cirrhosis GAP_HIGH 0.2077 0.6666666666666666 testosterone_propionate 0.45 STABLE 0.85 3 0.05731 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dydrogesterone→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to testosterone_propionate (Jaccard=0.67) isradipine brain_cancer GAP_HIGH 0.1557 0.2 desoximetasone 0.6 RISING 0.85 3 0.05728 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isradipine→?; validate in brain_cancer cell model. Expected: similar to desoximetasone (Jaccard=0.20) ranolazine epilepsy_syndrome GAP_HIGH 0.2335 0.5714285714285714 methocarbamol 0.4 STABLE 0.85 3 0.05727 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ranolazine→?; validate in epilepsy_syndrome cell model. Expected: similar to methocarbamol (Jaccard=0.57) stanozolol head_and_neck_cancer GAP_HIGH 0.2205 0.5555555555555556 cortisone_acetate 0.6 RISING 0.6 3 0.05726 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay stanozolol→?; validate in head_and_neck_cancer cell model. Expected: similar to cortisone_acetate (Jaccard=0.56) dextrothyroxine meningioma GAP_HIGH 0.2075 0.25 methimazole 0.45 STABLE 0.85 3 0.05725 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dextrothyroxine→?; validate in meningioma cell model. Expected: similar to methimazole (Jaccard=0.25) norepinephrine psoriatic_arthritis GAP_HIGH 0.2074 0.5714285714285714 isoetarine 0.45 STABLE 0.85 3 0.05722 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay norepinephrine→?; validate in psoriatic_arthritis cell model. Expected: similar to isoetarine (Jaccard=0.57) amcinonide amyotrophic_lateral_sclerosis GAP_HIGH 0.1555 0.5238095238095238 fludrocortisone 0.6 RISING 0.85 3 0.05721 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amcinonide→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to fludrocortisone (Jaccard=0.52) chlorthalidone creutzfeldt-jakob_disease GAP_HIGH 0.2072 0.5 clozapine 0.45 STABLE 0.85 3 0.05717 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorthalidone→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to clozapine (Jaccard=0.50) gefitinib kidney_cancer GAP_HIGH 0.1551 0.6060606060606061 vandetanib 0.6 RISING 0.85 3 0.05706 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay gefitinib→?; validate in kidney_cancer cell model. Expected: similar to vandetanib (Jaccard=0.61) betamethasone prostate_cancer GAP_HIGH 0.155 0.5882352941176471 amcinonide 0.6 RISING 0.85 3 0.05702 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay betamethasone→?; validate in prostate_cancer cell model. Expected: similar to amcinonide (Jaccard=0.59) vinblastine kidney_cancer GAP_HIGH 0.155 0.375 vindesine 0.6 RISING 0.85 3 0.05702 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vinblastine→?; validate in kidney_cancer cell model. Expected: similar to vindesine (Jaccard=0.38) chlorthalidone chronic_obstructive_pulmonary_disease GAP_HIGH 0.2066 0.5 clozapine 0.45 STABLE 0.85 3 0.057 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorthalidone→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to clozapine (Jaccard=0.50) chlordiazepoxide alcohol_dependence GAP_HIGH 0.2064 0.7 fludiazepam 0.45 STABLE 0.85 3 0.05695 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlordiazepoxide→?; validate in alcohol_dependence cell model. Expected: similar to fludiazepam (Jaccard=0.70) agomelatine epilepsy_syndrome GAP_HIGH 0.2321 0.6363636363636364 tolmetin 0.4 STABLE 0.85 3 0.05692 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay agomelatine→?; validate in epilepsy_syndrome cell model. Expected: similar to tolmetin (Jaccard=0.64) fluspirilene crohns_disease GAP_HIGH 0.2922 1.0 bepotastine 0.45 STABLE 0.6 3 0.05691 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluspirilene→?; validate in crohns_disease cell model. Expected: similar to bepotastine (Jaccard=1.00) l-aspartic_acid systemic_lupus_erythematosus GAP_HIGH 0.1546 0.23076923076923078 penicillamine 0.6 RISING 0.85 3 0.05688 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-aspartic_acid→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to penicillamine (Jaccard=0.23) lercanidipine gilles_de_la_tourette_syndrome GAP_HIGH 0.1685 0.25 ezetimibe 0.55 STABLE 0.85 3 0.05682 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lercanidipine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to ezetimibe (Jaccard=0.25) norelgestromin brain_cancer GAP_HIGH 0.2184 0.5555555555555556 megestrol_acetate 0.6 RISING 0.6 3 0.05672 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay norelgestromin→?; validate in brain_cancer cell model. Expected: similar to megestrol_acetate (Jaccard=0.56) riboflavin pharynx_cancer GAP_HIGH 0.2184 0.48484848484848486 adenosine_triphosphate 0.6 RISING 0.6 3 0.05672 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay riboflavin→?; validate in pharynx_cancer cell model. Expected: similar to adenosine_triphosphate (Jaccard=0.48) ospemifene obesity GAP_HIGH 0.1637 0.42857142857142855 candesartan 0.8 RAPID_RISE 0.6 3 0.05668 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ospemifene→?; validate in obesity cell model. Expected: similar to candesartan (Jaccard=0.43) testolactone dilated_cardiomyopathy GAP_HIGH 0.2053 0.6363636363636364 hydrocortisone 0.45 STABLE 0.85 3 0.05665 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay testolactone→?; validate in dilated_cardiomyopathy cell model. Expected: similar to hydrocortisone (Jaccard=0.64) tripelennamine gilles_de_la_tourette_syndrome GAP_HIGH 0.1679 0.42857142857142855 brompheniramine 0.55 STABLE 0.85 3 0.05662 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tripelennamine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to brompheniramine (Jaccard=0.43) agomelatine schizophrenia GAP_HIGH 0.2308 0.6363636363636364 tolmetin 0.4 STABLE 0.85 3 0.05661 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay agomelatine→?; validate in schizophrenia cell model. Expected: similar to tolmetin (Jaccard=0.64) clotiazepam nicotine_dependence GAP_HIGH 0.2904 0.8333333333333334 cinolazepam 0.45 STABLE 0.6 3 0.05656 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clotiazepam→?; validate in nicotine_dependence cell model. Expected: similar to cinolazepam (Jaccard=0.83) aminosalicylic_acid germ_cell_cancer GAP_HIGH 0.1537 0.5 mesalazine 0.6 RISING 0.85 3 0.05654 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminosalicylic_acid→?; validate in germ_cell_cancer cell model. Expected: similar to mesalazine (Jaccard=0.50) riboflavin salivary_gland_cancer GAP_HIGH 0.2177 0.48484848484848486 adenosine_triphosphate 0.6 RISING 0.6 3 0.05653 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay riboflavin→?; validate in salivary_gland_cancer cell model. Expected: similar to adenosine_triphosphate (Jaccard=0.48) testosterone_propionate pharynx_cancer GAP_HIGH 0.1535 0.5 progesterone 0.6 RISING 0.85 3 0.05647 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay testosterone_propionate→?; validate in pharynx_cancer cell model. Expected: similar to progesterone (Jaccard=0.50) equilin head_and_neck_cancer GAP_HIGH 0.2174 0.3333333333333333 methimazole 0.6 RISING 0.6 3 0.05646 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay equilin→?; validate in head_and_neck_cancer cell model. Expected: similar to methimazole (Jaccard=0.33) fluspirilene chronic_obstructive_pulmonary_disease GAP_HIGH 0.2895 1.0 bepotastine 0.45 STABLE 0.6 3 0.05638 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluspirilene→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to bepotastine (Jaccard=1.00) halazepam alcohol_dependence GAP_HIGH 0.2895 0.6666666666666666 midazolam 0.45 STABLE 0.6 3 0.05638 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay halazepam→?; validate in alcohol_dependence cell model. Expected: similar to midazolam (Jaccard=0.67) chlorpromazine kidney_cancer GAP_HIGH 0.1532 0.56 quinacrine 0.6 RISING 0.85 3 0.05636 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorpromazine→?; validate in kidney_cancer cell model. Expected: similar to quinacrine (Jaccard=0.56) sunitinib pancreatic_cancer GAP_HIGH 0.1532 0.47058823529411764 pazopanib 0.6 RISING 0.85 3 0.05636 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sunitinib→?; validate in pancreatic_cancer cell model. Expected: similar to pazopanib (Jaccard=0.47) cyclizine type_1_diabetes_mellitus GAP_HIGH 0.1532 0.4166666666666667 benzatropine 0.6 RISING 0.85 3 0.05636 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyclizine→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to benzatropine (Jaccard=0.42) fluspirilene pancreatitis GAP_HIGH 0.2893 1.0 bepotastine 0.45 STABLE 0.6 3 0.05635 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluspirilene→?; validate in pancreatitis cell model. Expected: similar to bepotastine (Jaccard=1.00) aminosalicylic_acid penile_cancer GAP_HIGH 0.1531 0.5 mesalazine 0.6 RISING 0.85 3 0.05632 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminosalicylic_acid→?; validate in penile_cancer cell model. Expected: similar to mesalazine (Jaccard=0.50) levonorgestrel hematologic_cancer GAP_HIGH 0.2168 0.6666666666666666 desogestrel 0.6 RISING 0.6 3 0.0563 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levonorgestrel→?; validate in hematologic_cancer cell model. Expected: similar to desogestrel (Jaccard=0.67) vandetanib duodenum_cancer GAP_HIGH 0.153 0.6060606060606061 gefitinib 0.6 RISING 0.85 3 0.05629 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vandetanib→?; validate in duodenum_cancer cell model. Expected: similar to gefitinib (Jaccard=0.61) vandetanib gallbladder_cancer GAP_HIGH 0.153 0.6060606060606061 gefitinib 0.6 RISING 0.85 3 0.05629 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vandetanib→?; validate in gallbladder_cancer cell model. Expected: similar to gefitinib (Jaccard=0.61) vinblastine germ_cell_cancer GAP_HIGH 0.153 0.375 vindesine 0.6 RISING 0.85 3 0.05629 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vinblastine→?; validate in germ_cell_cancer cell model. Expected: similar to vindesine (Jaccard=0.38) dihomo-gamma-linolenic_acid peripheral_nervous_system_neoplasm GAP_HIGH 0.2039 0.46153846153846156 carboprost_tromethamine 0.45 STABLE 0.85 3 0.05626 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dihomo-gamma-linolenic_acid→?; validate in peripheral_nervous_system_neoplasm cell model. Expected: similar to carboprost_tromethamine (Jaccard=0.46) testosterone_propionate salivary_gland_cancer GAP_HIGH 0.1528 0.5 progesterone 0.6 RISING 0.85 3 0.05621 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay testosterone_propionate→?; validate in salivary_gland_cancer cell model. Expected: similar to progesterone (Jaccard=0.50) l-glutamine pharynx_cancer GAP_HIGH 0.1526 0.43617021276595747 l-serine 0.6 RISING 0.85 3 0.05614 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-glutamine→?; validate in pharynx_cancer cell model. Expected: similar to l-serine (Jaccard=0.44) tioguanine lymphatic_system_cancer GAP_HIGH 0.1525 0.18181818181818182 tetrahydrofolic_acid 0.6 RISING 0.85 3 0.0561 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tioguanine→?; validate in lymphatic_system_cancer cell model. Expected: similar to tetrahydrofolic_acid (Jaccard=0.18) l-asparagine glaucoma GAP_HIGH 0.2032 0.36666666666666664 l-serine 0.45 STABLE 0.85 3 0.05607 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-asparagine→?; validate in glaucoma cell model. Expected: similar to l-serine (Jaccard=0.37) dihomo-gamma-linolenic_acid sarcoma GAP_HIGH 0.2031 0.46153846153846156 carboprost_tromethamine 0.45 STABLE 0.85 3 0.05604 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dihomo-gamma-linolenic_acid→?; validate in sarcoma cell model. Expected: similar to carboprost_tromethamine (Jaccard=0.46) tolazamide idiopathic_pulmonary_fibrosis GAP_HIGH 0.203 0.4 zafirlukast 0.45 STABLE 0.85 3 0.05601 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolazamide→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to zafirlukast (Jaccard=0.40) zolmitriptan psoriasis GAP_HIGH 0.2874 0.8181818181818182 midodrine 0.45 STABLE 0.6 3 0.05598 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zolmitriptan→?; validate in psoriasis cell model. Expected: similar to midodrine (Jaccard=0.82) zolmitriptan migraine GAP_HIGH 0.2873 0.8181818181818182 midodrine 0.45 STABLE 0.6 3 0.05596 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zolmitriptan→?; validate in migraine cell model. Expected: similar to midodrine (Jaccard=0.82) zolmitriptan osteoporosis GAP_HIGH 0.2873 0.8181818181818182 midodrine 0.45 STABLE 0.6 3 0.05596 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zolmitriptan→?; validate in osteoporosis cell model. Expected: similar to midodrine (Jaccard=0.82) orphenadrine migraine GAP_HIGH 0.2028 0.6666666666666666 doxylamine 0.45 STABLE 0.85 3 0.05596 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay orphenadrine→?; validate in migraine cell model. Expected: similar to doxylamine (Jaccard=0.67) l-glutamine salivary_gland_cancer GAP_HIGH 0.152 0.43617021276595747 l-serine 0.6 RISING 0.85 3 0.05592 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-glutamine→?; validate in salivary_gland_cancer cell model. Expected: similar to l-serine (Jaccard=0.44) amiloride malignant_glioma GAP_HIGH 0.2026 0.3333333333333333 vincristine 0.45 STABLE 0.85 3 0.0559 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amiloride→?; validate in malignant_glioma cell model. Expected: similar to vincristine (Jaccard=0.33) l-glutamine muscle_cancer GAP_HIGH 0.1519 0.43617021276595747 l-serine 0.6 RISING 0.85 3 0.05588 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-glutamine→?; validate in muscle_cancer cell model. Expected: similar to l-serine (Jaccard=0.44) allylestrenol hematologic_cancer GAP_HIGH 0.2151 0.5555555555555556 ethynodiol 0.6 RISING 0.6 3 0.05586 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay allylestrenol→?; validate in hematologic_cancer cell model. Expected: similar to ethynodiol (Jaccard=0.56) sodium_lauryl_sulfate creutzfeldt-jakob_disease GAP_HIGH 0.2024 0.3333333333333333 tetrabenazine 0.45 STABLE 0.85 3 0.05585 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sodium_lauryl_sulfate→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to tetrabenazine (Jaccard=0.33) mequitazine hematologic_cancer GAP_HIGH 0.1517 0.5 nefazodone 0.6 RISING 0.85 3 0.05581 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mequitazine→?; validate in hematologic_cancer cell model. Expected: similar to nefazodone (Jaccard=0.50) equilin penile_cancer GAP_HIGH 0.2146 0.3333333333333333 methimazole 0.6 RISING 0.6 3 0.05573 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay equilin→?; validate in penile_cancer cell model. Expected: similar to methimazole (Jaccard=0.33) ethylmorphine asthma GAP_HIGH 0.1515 0.3333333333333333 doxapram 0.6 RISING 0.85 3 0.05573 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethylmorphine→?; validate in asthma cell model. Expected: similar to doxapram (Jaccard=0.33) colchicine larynx_cancer GAP_HIGH 0.1514 0.2 vincristine 0.6 RISING 0.85 3 0.0557 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay colchicine→?; validate in larynx_cancer cell model. Expected: similar to vincristine (Jaccard=0.20) medrysone esophageal_cancer GAP_HIGH 0.1511 0.42857142857142855 hydrocortisone 0.6 RISING 0.85 3 0.05559 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay medrysone→?; validate in esophageal_cancer cell model. Expected: similar to hydrocortisone (Jaccard=0.43) quinethazone uterine_fibroid GAP_HIGH 0.2014 0.4444444444444444 hydrochlorothiazide 0.45 STABLE 0.85 3 0.05557 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinethazone→?; validate in uterine_fibroid cell model. Expected: similar to hydrochlorothiazide (Jaccard=0.44) methsuximide malaria GAP_HIGH 0.2014 0.3888888888888889 methylphenobarbital 0.45 STABLE 0.85 3 0.05557 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methsuximide→?; validate in malaria cell model. Expected: similar to methylphenobarbital (Jaccard=0.39) menadione stomach_cancer GAP_HIGH 0.1507 0.42857142857142855 lenalidomide 0.6 RISING 0.85 3 0.05544 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay menadione→?; validate in stomach_cancer cell model. Expected: similar to lenalidomide (Jaccard=0.43) ibuprofen focal_segmental_glomerulosclerosis GAP_HIGH 0.1707 0.2857142857142857 bumetanide 0.45 STABLE 1.0 3 0.05541 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ibuprofen→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to bumetanide (Jaccard=0.29) pargyline ocular_cancer GAP_HIGH 0.1505 0.4375 phenylpropanolamine 0.6 RISING 0.85 3 0.05537 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pargyline→?; validate in ocular_cancer cell model. Expected: similar to phenylpropanolamine (Jaccard=0.44) medrysone type_1_diabetes_mellitus GAP_HIGH 0.1505 0.42857142857142855 hydrocortisone 0.6 RISING 0.85 3 0.05537 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay medrysone→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to hydrocortisone (Jaccard=0.43) vinblastine hematologic_cancer GAP_HIGH 0.1504 0.375 vindesine 0.6 RISING 0.85 3 0.05533 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vinblastine→?; validate in hematologic_cancer cell model. Expected: similar to vindesine (Jaccard=0.38) voacamine larynx_cancer GAP_HIGH 0.1504 0.3333333333333333 vinblastine 0.6 RISING 0.85 3 0.05533 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay voacamine→?; validate in larynx_cancer cell model. Expected: similar to vinblastine (Jaccard=0.33) methacholine crohns_disease GAP_HIGH 0.2003 0.25 homatropine_methylbromide 0.45 STABLE 0.85 3 0.05527 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methacholine→?; validate in crohns_disease cell model. Expected: similar to homatropine_methylbromide (Jaccard=0.25) gemcitabine larynx_cancer GAP_HIGH 0.1501 0.3333333333333333 capecitabine 0.6 RISING 0.85 3 0.05522 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay gemcitabine→?; validate in larynx_cancer cell model. Expected: similar to capecitabine (Jaccard=0.33) amlodipine gilles_de_la_tourette_syndrome GAP_HIGH 0.1637 0.25 ezetimibe 0.55 STABLE 0.85 3 0.0552 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amlodipine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to ezetimibe (Jaccard=0.25) menadione skin_cancer GAP_HIGH 0.15 0.42857142857142855 lenalidomide 0.6 RISING 0.85 3 0.05518 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay menadione→?; validate in skin_cancer cell model. Expected: similar to lenalidomide (Jaccard=0.43) tranylcypromine atherosclerosis GAP_HIGH 0.1998 0.5555555555555556 clofibrate 0.45 STABLE 0.85 3 0.05513 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tranylcypromine→?; validate in atherosclerosis cell model. Expected: similar to clofibrate (Jaccard=0.56) drostanolone brain_cancer GAP_HIGH 0.1498 0.35 estradiol_valeratedienogest 0.6 RISING 0.85 3 0.05511 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay drostanolone→?; validate in brain_cancer cell model. Expected: similar to estradiol_valeratedienogest (Jaccard=0.35) doxapram azoospermia GAP_HIGH 0.2828 0.7142857142857143 bepridil 0.45 STABLE 0.6 3 0.05508 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxapram→?; validate in azoospermia cell model. Expected: similar to bepridil (Jaccard=0.71) talbutal breast_cancer GAP_HIGH 0.212 0.4 primidone 0.6 RISING 0.6 3 0.05505 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay talbutal→?; validate in breast_cancer cell model. Expected: similar to primidone (Jaccard=0.40) butabarbital creutzfeldt-jakob_disease GAP_HIGH 0.2826 0.7333333333333333 clobazam 0.45 STABLE 0.6 3 0.05504 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay butabarbital→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to clobazam (Jaccard=0.73) isoprenaline atherosclerosis GAP_HIGH 0.1992 0.6666666666666666 mesalazine 0.45 STABLE 0.85 3 0.05496 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isoprenaline→?; validate in atherosclerosis cell model. Expected: similar to mesalazine (Jaccard=0.67) mequitazine muscle_cancer GAP_HIGH 0.1494 0.5 nefazodone 0.6 RISING 0.85 3 0.05496 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mequitazine→?; validate in muscle_cancer cell model. Expected: similar to nefazodone (Jaccard=0.50) pheniramine hematologic_cancer GAP_HIGH 0.1493 0.5333333333333333 clofedanol 0.6 RISING 0.85 3 0.05493 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pheniramine→?; validate in hematologic_cancer cell model. Expected: similar to clofedanol (Jaccard=0.53) amcinonide dilated_cardiomyopathy GAP_HIGH 0.199 0.625 rimexolone 0.45 STABLE 0.85 3 0.05491 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amcinonide→?; validate in dilated_cardiomyopathy cell model. Expected: similar to rimexolone (Jaccard=0.62) indomethacin thyroid_cancer GAP_HIGH 0.1586 0.375 thalidomide 0.8 RAPID_RISE 0.6 3 0.05491 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay indomethacin→?; validate in thyroid_cancer cell model. Expected: similar to thalidomide (Jaccard=0.38) heptabarbital kidney_cancer GAP_HIGH 0.2114 0.4 quinacrine 0.6 RISING 0.6 3 0.0549 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay heptabarbital→?; validate in kidney_cancer cell model. Expected: similar to quinacrine (Jaccard=0.40) benzatropine autistic_disorder GAP_HIGH 0.1987 0.625 bepridil 0.45 STABLE 0.85 3 0.05482 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzatropine→?; validate in autistic_disorder cell model. Expected: similar to bepridil (Jaccard=0.62) salbutamol pharynx_cancer GAP_HIGH 0.2108 0.6 dipivefrin 0.6 RISING 0.6 3 0.05474 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay salbutamol→?; validate in pharynx_cancer cell model. Expected: similar to dipivefrin (Jaccard=0.60) acetophenazine idiopathic_pulmonary_fibrosis GAP_HIGH 0.1984 0.6666666666666666 cetirizine 0.45 STABLE 0.85 3 0.05474 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acetophenazine→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to cetirizine (Jaccard=0.67) nicardipine coronary_artery_disease GAP_HIGH 0.223 0.5 lercanidipine 0.4 STABLE 0.85 3 0.05469 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nicardipine→?; validate in coronary_artery_disease cell model. Expected: similar to lercanidipine (Jaccard=0.50) doxapram crohns_disease GAP_HIGH 0.2806 0.7142857142857143 bepridil 0.45 STABLE 0.6 3 0.05465 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxapram→?; validate in crohns_disease cell model. Expected: similar to bepridil (Jaccard=0.71) pheniramine duodenum_cancer GAP_HIGH 0.1485 0.5333333333333333 clofedanol 0.6 RISING 0.85 3 0.05463 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pheniramine→?; validate in duodenum_cancer cell model. Expected: similar to clofedanol (Jaccard=0.53) pheniramine gallbladder_cancer GAP_HIGH 0.1485 0.5333333333333333 clofedanol 0.6 RISING 0.85 3 0.05463 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pheniramine→?; validate in gallbladder_cancer cell model. Expected: similar to clofedanol (Jaccard=0.53) quinacrine coronary_artery_disease GAP_HIGH 0.2224 0.6086956521739131 chlorprothixene 0.4 STABLE 0.85 3 0.05455 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinacrine→?; validate in coronary_artery_disease cell model. Expected: similar to chlorprothixene (Jaccard=0.61) ritodrine refractive_error GAP_HIGH 0.1977 0.4 arbutamine 0.45 STABLE 0.85 3 0.05455 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ritodrine→?; validate in refractive_error cell model. Expected: similar to arbutamine (Jaccard=0.40) zidovudine hematologic_cancer GAP_HIGH 0.1482 0.3333333333333333 emtricitabine 0.6 RISING 0.85 3 0.05452 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zidovudine→?; validate in hematologic_cancer cell model. Expected: similar to emtricitabine (Jaccard=0.33) doxapram narcolepsy GAP_HIGH 0.2797 0.7142857142857143 bepridil 0.45 STABLE 0.6 3 0.05448 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxapram→?; validate in narcolepsy cell model. Expected: similar to bepridil (Jaccard=0.71) dextroamphetamine atherosclerosis GAP_HIGH 0.1974 0.5454545454545454 phentermine 0.45 STABLE 0.85 3 0.05447 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dextroamphetamine→?; validate in atherosclerosis cell model. Expected: similar to phentermine (Jaccard=0.55) vinblastine lung_cancer GAP_HIGH 0.148 0.375 vindesine 0.6 RISING 0.85 3 0.05445 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vinblastine→?; validate in lung_cancer cell model. Expected: similar to vindesine (Jaccard=0.38) naloxone urinary_bladder_cancer GAP_HIGH 0.148 0.3333333333333333 estramustine 0.6 RISING 0.85 3 0.05445 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay naloxone→?; validate in urinary_bladder_cancer cell model. Expected: similar to estramustine (Jaccard=0.33) sotalol salivary_gland_cancer GAP_HIGH 0.2094 0.6153846153846154 atenolol 0.6 RISING 0.6 3 0.05438 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sotalol→?; validate in salivary_gland_cancer cell model. Expected: similar to atenolol (Jaccard=0.62) metolazone pagets_disease_of_bone GAP_HIGH 0.1971 0.2 clodronate 0.45 STABLE 0.85 3 0.05438 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay metolazone→?; validate in pagets_disease_of_bone cell model. Expected: similar to clodronate (Jaccard=0.20) salbutamol asthma GAP_HIGH 0.2092 0.6 dipivefrin 0.6 RISING 0.6 3 0.05433 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay salbutamol→?; validate in asthma cell model. Expected: similar to dipivefrin (Jaccard=0.60) alfacalcidol vaginal_cancer GAP_HIGH 0.209 0.5 calcipotriol 0.6 RISING 0.6 3 0.05427 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alfacalcidol→?; validate in vaginal_cancer cell model. Expected: similar to calcipotriol (Jaccard=0.50) paclitaxel amyotrophic_lateral_sclerosis GAP_HIGH 0.2089 0.6666666666666666 rasagiline 0.6 RISING 1.0 3 0.05425 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay paclitaxel→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to rasagiline (Jaccard=0.67) doxapram creutzfeldt-jakob_disease GAP_HIGH 0.2785 0.7142857142857143 bepridil 0.45 STABLE 0.6 3 0.05424 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxapram→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to bepridil (Jaccard=0.71) calcipotriol psoriasis GAP_HIGH 0.2783 0.8333333333333334 paricalcitol 0.45 STABLE 0.6 3 0.0542 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay calcipotriol→?; validate in psoriasis cell model. Expected: similar to paricalcitol (Jaccard=0.83) orphenadrine azoospermia GAP_HIGH 0.1964 0.6 disopyramide 0.45 STABLE 0.85 3 0.05419 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay orphenadrine→?; validate in azoospermia cell model. Expected: similar to disopyramide (Jaccard=0.60) nateglinide systemic_lupus_erythematosus GAP_HIGH 0.1473 0.5555555555555556 phenelzine 0.6 RISING 0.85 3 0.05419 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nateglinide→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to phenelzine (Jaccard=0.56) nilvadipine coronary_artery_disease GAP_HIGH 0.2208 0.5 lercanidipine 0.4 STABLE 0.85 3 0.05415 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nilvadipine→?; validate in coronary_artery_disease cell model. Expected: similar to lercanidipine (Jaccard=0.50) labetalol membranous_glomerulonephritis GAP_HIGH 0.278 0.6 alvimopan 0.45 STABLE 0.6 3 0.05414 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay labetalol→?; validate in membranous_glomerulonephritis cell model. Expected: similar to alvimopan (Jaccard=0.60) nateglinide skin_cancer GAP_HIGH 0.1471 0.5555555555555556 phenelzine 0.6 RISING 0.85 3 0.05412 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nateglinide→?; validate in skin_cancer cell model. Expected: similar to phenelzine (Jaccard=0.56) acetophenazine chronic_obstructive_pulmonary_disease GAP_HIGH 0.1961 0.6666666666666666 nefazodone 0.45 STABLE 0.85 3 0.05411 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acetophenazine→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to nefazodone (Jaccard=0.67) bethanidine atherosclerosis GAP_HIGH 0.1961 0.5909090909090909 phenelzine 0.45 STABLE 0.85 3 0.05411 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bethanidine→?; validate in atherosclerosis cell model. Expected: similar to phenelzine (Jaccard=0.59) candesartan urinary_bladder_cancer GAP_HIGH 0.2083 0.42857142857142855 ospemifene 0.6 RISING 0.6 3 0.05409 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay candesartan→?; validate in urinary_bladder_cancer cell model. Expected: similar to ospemifene (Jaccard=0.43) paclitaxel multiple_sclerosis GAP_HIGH 0.2081 0.6666666666666666 rasagiline 0.6 RISING 1.0 3 0.05404 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay paclitaxel→?; validate in multiple_sclerosis cell model. Expected: similar to rasagiline (Jaccard=0.67) desogestrel alopecia_areata GAP_HIGH 0.2771 0.8 norethindrone 0.45 STABLE 0.6 3 0.05397 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay desogestrel→?; validate in alopecia_areata cell model. Expected: similar to norethindrone (Jaccard=0.80) naloxone vaginal_cancer GAP_HIGH 0.1467 0.3333333333333333 estramustine 0.6 RISING 0.85 3 0.05397 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay naloxone→?; validate in vaginal_cancer cell model. Expected: similar to estramustine (Jaccard=0.33) zidovudine pharynx_cancer GAP_HIGH 0.1467 0.3333333333333333 pentostatin 0.6 RISING 0.85 3 0.05397 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zidovudine→?; validate in pharynx_cancer cell model. Expected: similar to pentostatin (Jaccard=0.33) sotalol skin_cancer GAP_HIGH 0.2076 0.6153846153846154 atenolol 0.6 RISING 0.6 3 0.05391 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sotalol→?; validate in skin_cancer cell model. Expected: similar to atenolol (Jaccard=0.62) amobarbital kidney_cancer GAP_HIGH 0.2074 0.38095238095238093 quinacrine 0.6 RISING 0.6 3 0.05386 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amobarbital→?; validate in kidney_cancer cell model. Expected: similar to quinacrine (Jaccard=0.38) adinazolam alcohol_dependence GAP_HIGH 0.2765 0.7142857142857143 midazolam 0.45 STABLE 0.6 3 0.05385 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay adinazolam→?; validate in alcohol_dependence cell model. Expected: similar to midazolam (Jaccard=0.71) anileridine polycystic_ovary_syndrome GAP_HIGH 0.1596 0.4166666666666667 milnacipran 0.55 STABLE 0.85 3 0.05382 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay anileridine→?; validate in polycystic_ovary_syndrome cell model. Expected: similar to milnacipran (Jaccard=0.42) nimodipine gilles_de_la_tourette_syndrome GAP_HIGH 0.1596 0.23076923076923078 ifenprodil 0.55 STABLE 0.85 3 0.05382 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nimodipine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to ifenprodil (Jaccard=0.23) aprobarbital kidney_cancer GAP_HIGH 0.2071 0.38095238095238093 quinacrine 0.6 RISING 0.6 3 0.05378 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aprobarbital→?; validate in kidney_cancer cell model. Expected: similar to quinacrine (Jaccard=0.38) butethal kidney_cancer GAP_HIGH 0.2071 0.38095238095238093 quinacrine 0.6 RISING 0.6 3 0.05378 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay butethal→?; validate in kidney_cancer cell model. Expected: similar to quinacrine (Jaccard=0.38) tolterodine celiac_disease GAP_HIGH 0.1949 0.5714285714285714 reboxetine 0.45 STABLE 0.85 3 0.05378 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolterodine→?; validate in celiac_disease cell model. Expected: similar to reboxetine (Jaccard=0.57) orlistat glaucoma GAP_HIGH 0.2761 0.5 sodium_lauryl_sulfate 0.45 STABLE 0.6 3 0.05377 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay orlistat→?; validate in glaucoma cell model. Expected: similar to sodium_lauryl_sulfate (Jaccard=0.50) dimetacrine esophageal_cancer GAP_HIGH 0.146 0.5 toremifene 0.6 RISING 0.85 3 0.05371 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dimetacrine→?; validate in esophageal_cancer cell model. Expected: similar to toremifene (Jaccard=0.50) antazoline coronary_artery_disease GAP_HIGH 0.2188 0.6666666666666666 bepridil 0.4 STABLE 0.85 3 0.05366 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay antazoline→?; validate in coronary_artery_disease cell model. Expected: similar to bepridil (Jaccard=0.67) testolactone amyotrophic_lateral_sclerosis GAP_HIGH 0.1456 0.4583333333333333 fludrocortisone 0.6 RISING 0.85 3 0.05356 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay testolactone→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to fludrocortisone (Jaccard=0.46) nitisinone multiple_sclerosis GAP_HIGH 0.2426 0.3333333333333333 nitrofural 0.6 RISING 0.85 3 0.05355 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nitisinone→?; validate in multiple_sclerosis cell model. Expected: similar to nitrofural (Jaccard=0.33) desogestrel intracranial_aneurysm GAP_HIGH 0.2748 0.8 norethindrone 0.45 STABLE 0.6 3 0.05352 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay desogestrel→?; validate in intracranial_aneurysm cell model. Expected: similar to norethindrone (Jaccard=0.80) indecainide gilles_de_la_tourette_syndrome GAP_HIGH 0.1587 0.42857142857142855 tolterodine 0.55 STABLE 0.85 3 0.05352 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay indecainide→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to tolterodine (Jaccard=0.43) promethazine esophageal_cancer GAP_HIGH 0.1454 0.5 tamoxifen 0.6 RISING 0.85 3 0.05349 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay promethazine→?; validate in esophageal_cancer cell model. Expected: similar to tamoxifen (Jaccard=0.50) trilostane brain_cancer GAP_HIGH 0.2058 0.5555555555555556 cortisone_acetate 0.6 RISING 0.6 3 0.05344 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trilostane→?; validate in brain_cancer cell model. Expected: similar to cortisone_acetate (Jaccard=0.56) etonogestrel vascular_cancer GAP_HIGH 0.2056 0.6 medroxyprogesterone_acetate 0.6 RISING 0.6 3 0.05339 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay etonogestrel→?; validate in vascular_cancer cell model. Expected: similar to medroxyprogesterone_acetate (Jaccard=0.60) imipramine gout GAP_HIGH 0.1935 0.5714285714285714 desipramine 0.45 STABLE 0.85 3 0.05339 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay imipramine→?; validate in gout cell model. Expected: similar to desipramine (Jaccard=0.57) choline pagets_disease_of_bone GAP_HIGH 0.1935 0.2 histamine_phosphate 0.45 STABLE 0.85 3 0.05339 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay choline→?; validate in pagets_disease_of_bone cell model. Expected: similar to histamine_phosphate (Jaccard=0.20) desogestrel malignant_glioma GAP_HIGH 0.274 0.8 norethindrone 0.45 STABLE 0.6 3 0.05337 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay desogestrel→?; validate in malignant_glioma cell model. Expected: similar to norethindrone (Jaccard=0.80) erlotinib esophageal_cancer GAP_HIGH 0.1233 0.2727272727272727 lapatinib 0.6 RISING 1.0 3 0.05337 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay erlotinib→?; validate in esophageal_cancer cell model. Expected: similar to lapatinib (Jaccard=0.27) desipramine acquired_immunodeficiency_syndrome GAP_HIGH 0.1582 0.42857142857142855 alvimopan 0.55 STABLE 0.85 3 0.05335 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay desipramine→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to alvimopan (Jaccard=0.43) orphenadrine narcolepsy GAP_HIGH 0.1933 0.6 disopyramide 0.45 STABLE 0.85 3 0.05333 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay orphenadrine→?; validate in narcolepsy cell model. Expected: similar to disopyramide (Jaccard=0.60) mequitazine gilles_de_la_tourette_syndrome GAP_HIGH 0.158 0.5 nefazodone 0.55 STABLE 0.85 3 0.05328 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mequitazine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to nefazodone (Jaccard=0.50) l-cysteine epilepsy_syndrome GAP_HIGH 0.2171 0.6229508196721312 l-serine 0.4 STABLE 0.85 3 0.05325 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-cysteine→?; validate in epilepsy_syndrome cell model. Expected: similar to l-serine (Jaccard=0.62) trilostane head_and_neck_cancer GAP_HIGH 0.205 0.5555555555555556 cortisone_acetate 0.6 RISING 0.6 3 0.05324 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trilostane→?; validate in head_and_neck_cancer cell model. Expected: similar to cortisone_acetate (Jaccard=0.56) promethazine type_1_diabetes_mellitus GAP_HIGH 0.1447 0.5 benzatropine 0.6 RISING 0.85 3 0.05323 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay promethazine→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to benzatropine (Jaccard=0.50) olanzapine gilles_de_la_tourette_syndrome GAP_HIGH 0.1341 0.25 aripiprazole 0.55 STABLE 1.0 3 0.0532 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay olanzapine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to aripiprazole (Jaccard=0.25) mepyramine chronic_kidney_failure GAP_HIGH 0.1925 0.5 brompheniramine 0.45 STABLE 0.85 3 0.05311 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mepyramine→?; validate in chronic_kidney_failure cell model. Expected: similar to brompheniramine (Jaccard=0.50) phenindamine metabolic_syndrome_x GAP_HIGH 0.1575 0.4 indecainide 0.55 STABLE 0.85 3 0.05311 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenindamine→?; validate in metabolic_syndrome_x cell model. Expected: similar to indecainide (Jaccard=0.40) tolterodine malignant_mesothelioma GAP_HIGH 0.1923 0.5714285714285714 reboxetine 0.45 STABLE 0.85 3 0.05306 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolterodine→?; validate in malignant_mesothelioma cell model. Expected: similar to reboxetine (Jaccard=0.57) testosterone_propionate head_and_neck_cancer GAP_HIGH 0.1442 0.42105263157894735 medrysone 0.6 RISING 0.85 3 0.05305 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay testosterone_propionate→?; validate in head_and_neck_cancer cell model. Expected: similar to medrysone (Jaccard=0.42) alpha-linolenic_acid refractive_error GAP_HIGH 0.1922 0.2222222222222222 dihomo-gamma-linolenic_acid 0.45 STABLE 0.85 3 0.05303 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alpha-linolenic_acid→?; validate in refractive_error cell model. Expected: similar to dihomo-gamma-linolenic_acid (Jaccard=0.22) imipramine creutzfeldt-jakob_disease GAP_HIGH 0.1921 0.5714285714285714 desipramine 0.45 STABLE 0.85 3 0.053 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay imipramine→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to desipramine (Jaccard=0.57) tranylcypromine nephrolithiasis GAP_HIGH 0.192 0.5555555555555556 probenecid 0.45 STABLE 0.85 3 0.05298 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tranylcypromine→?; validate in nephrolithiasis cell model. Expected: similar to probenecid (Jaccard=0.56) halazepam chronic_kidney_failure GAP_HIGH 0.2718 0.6666666666666666 midazolam 0.45 STABLE 0.6 3 0.05294 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay halazepam→?; validate in chronic_kidney_failure cell model. Expected: similar to midazolam (Jaccard=0.67) imipramine ankylosing_spondylitis GAP_HIGH 0.1917 0.5714285714285714 desipramine 0.45 STABLE 0.85 3 0.05289 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay imipramine→?; validate in ankylosing_spondylitis cell model. Expected: similar to desipramine (Jaccard=0.57) atenolol intracranial_aneurysm GAP_HIGH 0.2714 0.875 procarbazine 0.45 STABLE 0.6 3 0.05286 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay atenolol→?; validate in intracranial_aneurysm cell model. Expected: similar to procarbazine (Jaccard=0.88) mepyramine azoospermia GAP_HIGH 0.1913 0.5 brompheniramine 0.45 STABLE 0.85 3 0.05278 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mepyramine→?; validate in azoospermia cell model. Expected: similar to brompheniramine (Jaccard=0.50) sotalol larynx_cancer GAP_HIGH 0.2032 0.5384615384615384 procarbazine 0.6 RISING 0.6 3 0.05277 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sotalol→?; validate in larynx_cancer cell model. Expected: similar to procarbazine (Jaccard=0.54) isoprenaline celiac_disease GAP_HIGH 0.1912 0.6666666666666666 mesalazine 0.45 STABLE 0.85 3 0.05276 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isoprenaline→?; validate in celiac_disease cell model. Expected: similar to mesalazine (Jaccard=0.67) linaclotide atherosclerosis GAP_HIGH 0.3185 0.5 deferasirox 0.45 STABLE 0.85 3 0.05273 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay linaclotide→?; validate in atherosclerosis cell model. Expected: similar to deferasirox (Jaccard=0.50) chlordiazepoxide duodenum_cancer GAP_HIGH 0.1433 0.46153846153846156 loxapine 0.6 RISING 0.85 3 0.05272 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlordiazepoxide→?; validate in duodenum_cancer cell model. Expected: similar to loxapine (Jaccard=0.46) atenolol malignant_glioma GAP_HIGH 0.2706 0.875 procarbazine 0.45 STABLE 0.6 3 0.0527 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay atenolol→?; validate in malignant_glioma cell model. Expected: similar to procarbazine (Jaccard=0.88) proparacaine systemic_lupus_erythematosus GAP_HIGH 0.2387 0.6875 oxybuprocaine 0.6 RISING 0.85 3 0.05269 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay proparacaine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to oxybuprocaine (Jaccard=0.69) lercanidipine rheumatoid_arthritis GAP_HIGH 0.2148 0.5 amlodipine 0.4 STABLE 0.85 3 0.05268 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lercanidipine→?; validate in rheumatoid_arthritis cell model. Expected: similar to amlodipine (Jaccard=0.50) desogestrel meningioma GAP_HIGH 0.2704 0.8 norethindrone 0.45 STABLE 0.6 3 0.05266 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay desogestrel→?; validate in meningioma cell model. Expected: similar to norethindrone (Jaccard=0.80) furosemide chronic_kidney_failure GAP_HIGH 0.1908 0.5 indapamide 0.45 STABLE 0.85 3 0.05264 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay furosemide→?; validate in chronic_kidney_failure cell model. Expected: similar to indapamide (Jaccard=0.50) azatadine gilles_de_la_tourette_syndrome GAP_HIGH 0.156 0.42857142857142855 temazepam 0.55 STABLE 0.85 3 0.05261 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay azatadine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to temazepam (Jaccard=0.43) naftifine esophageal_cancer GAP_HIGH 0.143 0.43478260869565216 toremifene 0.6 RISING 0.85 3 0.05261 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay naftifine→?; validate in esophageal_cancer cell model. Expected: similar to toremifene (Jaccard=0.43) methamphetamine atherosclerosis GAP_HIGH 0.1905 0.5454545454545454 phentermine 0.45 STABLE 0.85 3 0.05256 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methamphetamine→?; validate in atherosclerosis cell model. Expected: similar to phentermine (Jaccard=0.55) metaraminol salivary_gland_cancer GAP_HIGH 0.2023 0.42857142857142855 phenylephrine 0.6 RISING 0.6 3 0.05253 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay metaraminol→?; validate in salivary_gland_cancer cell model. Expected: similar to phenylephrine (Jaccard=0.43) estriol brain_cancer GAP_HIGH 0.2021 0.375 estrone 0.6 RISING 0.6 3 0.05248 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estriol→?; validate in brain_cancer cell model. Expected: similar to estrone (Jaccard=0.38) sorafenib liver_cancer GAP_HIGH 0.1426 0.42105263157894735 pazopanib 0.6 RISING 0.85 3 0.05246 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sorafenib→?; validate in liver_cancer cell model. Expected: similar to pazopanib (Jaccard=0.42) erlotinib larynx_cancer GAP_HIGH 0.1212 0.25 docetaxel 0.6 RISING 1.0 3 0.05246 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay erlotinib→?; validate in larynx_cancer cell model. Expected: similar to docetaxel (Jaccard=0.25) pemetrexed malignant_glioma GAP_HIGH 0.2688 0.6666666666666666 capecitabine 0.45 STABLE 0.6 3 0.05235 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pemetrexed→?; validate in malignant_glioma cell model. Expected: similar to capecitabine (Jaccard=0.67) phenylephrine systemic_scleroderma GAP_HIGH 0.1896 0.5 salbutamol 0.45 STABLE 0.85 3 0.05231 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenylephrine→?; validate in systemic_scleroderma cell model. Expected: similar to salbutamol (Jaccard=0.50) oxcarbazepine multiple_sclerosis GAP_HIGH 0.1422 0.4166666666666667 phenindione 0.6 RISING 0.85 3 0.05231 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxcarbazepine→?; validate in multiple_sclerosis cell model. Expected: similar to phenindione (Jaccard=0.42) estriol duodenum_cancer GAP_HIGH 0.2014 0.4 etonogestrel 0.6 RISING 0.6 3 0.0523 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estriol→?; validate in duodenum_cancer cell model. Expected: similar to etonogestrel (Jaccard=0.40) phenmetrazine coronary_artery_disease GAP_HIGH 0.2129 0.5555555555555556 clofibrate 0.4 STABLE 0.85 3 0.05222 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenmetrazine→?; validate in coronary_artery_disease cell model. Expected: similar to clofibrate (Jaccard=0.56) prazepam creutzfeldt-jakob_disease GAP_HIGH 0.2675 0.7 estazolam 0.45 STABLE 0.6 3 0.0521 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prazepam→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to estazolam (Jaccard=0.70) metaraminol skin_cancer GAP_HIGH 0.2005 0.42857142857142855 phenylephrine 0.6 RISING 0.6 3 0.05207 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay metaraminol→?; validate in skin_cancer cell model. Expected: similar to phenylephrine (Jaccard=0.43) phenoxybenzamine narcolepsy GAP_HIGH 0.1887 0.5833333333333334 benzphetamine 0.45 STABLE 0.85 3 0.05207 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenoxybenzamine→?; validate in narcolepsy cell model. Expected: similar to benzphetamine (Jaccard=0.58) hydrochlorothiazide epilepsy_syndrome GAP_HIGH 0.2122 0.4444444444444444 methyclothiazide 0.4 STABLE 0.85 3 0.05204 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay hydrochlorothiazide→?; validate in epilepsy_syndrome cell model. Expected: similar to methyclothiazide (Jaccard=0.44) prazepam ankylosing_spondylitis GAP_HIGH 0.2671 0.7 estazolam 0.45 STABLE 0.6 3 0.05202 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prazepam→?; validate in ankylosing_spondylitis cell model. Expected: similar to estazolam (Jaccard=0.70) epoprostenol pharynx_cancer GAP_HIGH 0.2003 0.3333333333333333 travoprost 0.6 RISING 0.6 3 0.05201 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay epoprostenol→?; validate in pharynx_cancer cell model. Expected: similar to travoprost (Jaccard=0.33) amoxapine chronic_kidney_failure GAP_HIGH 0.1883 0.625 chlordiazepoxide 0.45 STABLE 0.85 3 0.05195 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amoxapine→?; validate in chronic_kidney_failure cell model. Expected: similar to chlordiazepoxide (Jaccard=0.62) rimexolone amyotrophic_lateral_sclerosis GAP_HIGH 0.1412 0.42857142857142855 fludrocortisone 0.6 RISING 0.85 3 0.05195 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay rimexolone→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to fludrocortisone (Jaccard=0.43) promethazine germ_cell_cancer GAP_HIGH 0.1411 0.5 tamoxifen 0.6 RISING 0.85 3 0.05191 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay promethazine→?; validate in germ_cell_cancer cell model. Expected: similar to tamoxifen (Jaccard=0.50) halazepam sclerosing_cholangitis GAP_HIGH 0.2664 0.6666666666666666 midazolam 0.45 STABLE 0.6 3 0.05189 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay halazepam→?; validate in sclerosing_cholangitis cell model. Expected: similar to midazolam (Jaccard=0.67) levonordefrin systemic_lupus_erythematosus GAP_HIGH 0.1998 0.6363636363636364 isoprenaline 0.6 RISING 0.6 3 0.05189 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levonordefrin→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to isoprenaline (Jaccard=0.64) sodium_tetradecyl_sulfate refractive_error GAP_HIGH 0.1878 0.1875 dihomo-gamma-linolenic_acid 0.45 STABLE 0.85 3 0.05182 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sodium_tetradecyl_sulfate→?; validate in refractive_error cell model. Expected: similar to dihomo-gamma-linolenic_acid (Jaccard=0.19) hydromorphone prostate_cancer GAP_HIGH 0.1408 0.25 dextromethorphan 0.6 RISING 0.85 3 0.0518 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay hydromorphone→?; validate in prostate_cancer cell model. Expected: similar to dextromethorphan (Jaccard=0.25) levonordefrin type_1_diabetes_mellitus GAP_HIGH 0.1993 0.5882352941176471 carbidopa 0.6 RISING 0.6 3 0.05176 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levonordefrin→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to carbidopa (Jaccard=0.59) azelastine focal_segmental_glomerulosclerosis GAP_HIGH 0.1876 0.6666666666666666 methdilazine 0.45 STABLE 0.85 3 0.05176 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay azelastine→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to methdilazine (Jaccard=0.67) prazepam conduct_disorder GAP_HIGH 0.2656 0.7 estazolam 0.45 STABLE 0.6 3 0.05173 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prazepam→?; validate in conduct_disorder cell model. Expected: similar to estazolam (Jaccard=0.70) phenoxybenzamine creutzfeldt-jakob_disease GAP_HIGH 0.1875 0.5833333333333334 benzphetamine 0.45 STABLE 0.85 3 0.05173 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenoxybenzamine→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to benzphetamine (Jaccard=0.58) dobutamine peripheral_nervous_system_neoplasm GAP_HIGH 0.1874 0.5 isoetarine 0.45 STABLE 0.85 3 0.05171 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dobutamine→?; validate in peripheral_nervous_system_neoplasm cell model. Expected: similar to isoetarine (Jaccard=0.50) chloroprocaine azoospermia GAP_HIGH 0.1872 0.5789473684210527 procaine 0.45 STABLE 0.85 3 0.05165 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chloroprocaine→?; validate in azoospermia cell model. Expected: similar to procaine (Jaccard=0.58) phenoxybenzamine chronic_obstructive_pulmonary_disease GAP_HIGH 0.1869 0.5833333333333334 benzphetamine 0.45 STABLE 0.85 3 0.05157 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenoxybenzamine→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to benzphetamine (Jaccard=0.58) oxaprozin ulcerative_colitis GAP_HIGH 0.1489 0.5333333333333333 phenindione 0.8 RAPID_RISE 0.6 3 0.05156 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxaprozin→?; validate in ulcerative_colitis cell model. Expected: similar to phenindione (Jaccard=0.53) suprofen larynx_cancer GAP_HIGH 0.1985 0.6363636363636364 procarbazine 0.6 RISING 0.6 3 0.05155 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay suprofen→?; validate in larynx_cancer cell model. Expected: similar to procarbazine (Jaccard=0.64) furosemide gout GAP_HIGH 0.1868 0.5 indapamide 0.45 STABLE 0.85 3 0.05154 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay furosemide→?; validate in gout cell model. Expected: similar to indapamide (Jaccard=0.50) vindesine psoriatic_arthritis GAP_HIGH 0.3112 0.875 voacamine 0.45 STABLE 0.85 3 0.05152 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vindesine→?; validate in psoriatic_arthritis cell model. Expected: similar to voacamine (Jaccard=0.88) epoprostenol uterine_cancer GAP_HIGH 0.1984 0.3333333333333333 travoprost 0.6 RISING 0.6 3 0.05152 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay epoprostenol→?; validate in uterine_cancer cell model. Expected: similar to travoprost (Jaccard=0.33) mestranol kidney_cancer GAP_HIGH 0.1982 0.5789473684210527 ethinyl_estradiol 0.6 RISING 0.6 3 0.05147 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mestranol→?; validate in kidney_cancer cell model. Expected: similar to ethinyl_estradiol (Jaccard=0.58) dobutamine sarcoma GAP_HIGH 0.1865 0.5 isoetarine 0.45 STABLE 0.85 3 0.05146 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dobutamine→?; validate in sarcoma cell model. Expected: similar to isoetarine (Jaccard=0.50) amoxapine focal_segmental_glomerulosclerosis GAP_HIGH 0.1863 0.6 chlorprothixene 0.45 STABLE 0.85 3 0.0514 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amoxapine→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to chlorprothixene (Jaccard=0.60) epoprostenol testicular_cancer GAP_HIGH 0.1978 0.3333333333333333 travoprost 0.6 RISING 0.6 3 0.05137 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay epoprostenol→?; validate in testicular_cancer cell model. Expected: similar to travoprost (Jaccard=0.33) trandolapril hypertension GAP_HIGH 0.1483 0.375 cilazapril 0.8 RAPID_RISE 0.6 3 0.05135 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trandolapril→?; validate in hypertension cell model. Expected: similar to cilazapril (Jaccard=0.38) dextroamphetamine crohns_disease GAP_HIGH 0.186 0.5454545454545454 phentermine 0.45 STABLE 0.85 3 0.05132 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dextroamphetamine→?; validate in crohns_disease cell model. Expected: similar to phentermine (Jaccard=0.55) talbutal barretts_esophagus GAP_HIGH 0.2632 0.25 pantoprazole 0.45 STABLE 0.6 3 0.05126 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay talbutal→?; validate in barretts_esophagus cell model. Expected: similar to pantoprazole (Jaccard=0.25) methsuximide focal_segmental_glomerulosclerosis GAP_HIGH 0.1856 0.34615384615384615 clomipramine 0.45 STABLE 0.85 3 0.05121 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methsuximide→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to clomipramine (Jaccard=0.35) brompheniramine prostate_cancer GAP_HIGH 0.1391 0.375 carbinoxamine 0.6 RISING 0.85 3 0.05117 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay brompheniramine→?; validate in prostate_cancer cell model. Expected: similar to carbinoxamine (Jaccard=0.38) azelastine chronic_kidney_failure GAP_HIGH 0.1854 0.6666666666666666 methdilazine 0.45 STABLE 0.85 3 0.05115 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay azelastine→?; validate in chronic_kidney_failure cell model. Expected: similar to methdilazine (Jaccard=0.67) isocarboxazid panic_disorder GAP_HIGH 0.2625 0.75 phenformin 0.45 STABLE 0.6 3 0.05113 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isocarboxazid→?; validate in panic_disorder cell model. Expected: similar to phenformin (Jaccard=0.75) dextroamphetamine narcolepsy GAP_HIGH 0.1851 0.5454545454545454 phentermine 0.45 STABLE 0.85 3 0.05107 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dextroamphetamine→?; validate in narcolepsy cell model. Expected: similar to phentermine (Jaccard=0.55) colchicine pagets_disease_of_bone GAP_HIGH 0.1851 0.16666666666666666 histamine_phosphate 0.45 STABLE 0.85 3 0.05107 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay colchicine→?; validate in pagets_disease_of_bone cell model. Expected: similar to histamine_phosphate (Jaccard=0.17) brompheniramine hematologic_cancer GAP_HIGH 0.1386 0.375 carbinoxamine 0.6 RISING 0.85 3 0.05099 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay brompheniramine→?; validate in hematologic_cancer cell model. Expected: similar to carbinoxamine (Jaccard=0.38) arbutamine narcolepsy GAP_HIGH 0.1846 0.5333333333333333 masoprocol 0.45 STABLE 0.85 3 0.05093 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay arbutamine→?; validate in narcolepsy cell model. Expected: similar to masoprocol (Jaccard=0.53) aminolevulinic_acid narcolepsy GAP_HIGH 0.1846 0.2857142857142857 aminocaproic_acid 0.45 STABLE 0.85 3 0.05093 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminolevulinic_acid→?; validate in narcolepsy cell model. Expected: similar to aminocaproic_acid (Jaccard=0.29) norepinephrine rheumatoid_arthritis GAP_HIGH 0.2076 0.5714285714285714 isoetarine 0.4 STABLE 0.85 3 0.05092 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay norepinephrine→?; validate in rheumatoid_arthritis cell model. Expected: similar to isoetarine (Jaccard=0.57) amlodipine coronary_artery_disease GAP_HIGH 0.2076 0.5 lercanidipine 0.4 STABLE 0.85 3 0.05092 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amlodipine→?; validate in coronary_artery_disease cell model. Expected: similar to lercanidipine (Jaccard=0.50) methylphenobarbital gilles_de_la_tourette_syndrome GAP_HIGH 0.2138 0.45454545454545453 remifentanil 0.55 STABLE 0.6 3 0.05089 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methylphenobarbital→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to remifentanil (Jaccard=0.45) chloroprocaine gout GAP_HIGH 0.1844 0.5789473684210527 procaine 0.45 STABLE 0.85 3 0.05088 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chloroprocaine→?; validate in gout cell model. Expected: similar to procaine (Jaccard=0.58) acepromazine systemic_lupus_erythematosus GAP_HIGH 0.1383 0.5 nortriptyline 0.6 RISING 0.85 3 0.05088 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acepromazine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to nortriptyline (Jaccard=0.50) linaclotide crohns_disease GAP_HIGH 0.3071 0.5 deferasirox 0.45 STABLE 0.85 3 0.05084 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay linaclotide→?; validate in crohns_disease cell model. Expected: similar to deferasirox (Jaccard=0.50) prochlorperazine coronary_artery_disease GAP_HIGH 0.2071 0.75 mequitazine 0.4 STABLE 0.85 3 0.05079 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prochlorperazine→?; validate in coronary_artery_disease cell model. Expected: similar to mequitazine (Jaccard=0.75) azelastine membranous_glomerulonephritis GAP_HIGH 0.184 0.6666666666666666 methdilazine 0.45 STABLE 0.85 3 0.05077 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay azelastine→?; validate in membranous_glomerulonephritis cell model. Expected: similar to methdilazine (Jaccard=0.67) furosemide autistic_disorder GAP_HIGH 0.184 0.5 indapamide 0.45 STABLE 0.85 3 0.05077 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay furosemide→?; validate in autistic_disorder cell model. Expected: similar to indapamide (Jaccard=0.50) furosemide nicotine_dependence GAP_HIGH 0.184 0.5 indapamide 0.45 STABLE 0.85 3 0.05077 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay furosemide→?; validate in nicotine_dependence cell model. Expected: similar to indapamide (Jaccard=0.50) clotiazepam coronary_artery_disease GAP_HIGH 0.293 0.8333333333333334 cinolazepam 0.4 STABLE 0.6 3 0.05073 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clotiazepam→?; validate in coronary_artery_disease cell model. Expected: similar to cinolazepam (Jaccard=0.83) ethopropazine hematologic_cancer GAP_HIGH 0.1378 0.5 thioproperazine 0.6 RISING 0.85 3 0.05069 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethopropazine→?; validate in hematologic_cancer cell model. Expected: similar to thioproperazine (Jaccard=0.50) clonidine atherosclerosis GAP_HIGH 0.1836 0.5384615384615384 mefenamic_acid 0.45 STABLE 0.85 3 0.05066 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clonidine→?; validate in atherosclerosis cell model. Expected: similar to mefenamic_acid (Jaccard=0.54) spirapril rheumatoid_arthritis GAP_HIGH 0.2925 0.75 quinapril 0.4 STABLE 0.6 3 0.05064 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay spirapril→?; validate in rheumatoid_arthritis cell model. Expected: similar to quinapril (Jaccard=0.75) l-methionine epilepsy_syndrome GAP_HIGH 0.2064 0.5967741935483871 l-serine 0.4 STABLE 0.85 3 0.05062 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-methionine→?; validate in epilepsy_syndrome cell model. Expected: similar to l-serine (Jaccard=0.60) hydromorphone urinary_bladder_cancer GAP_HIGH 0.1376 0.25 dextromethorphan 0.6 RISING 0.85 3 0.05062 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay hydromorphone→?; validate in urinary_bladder_cancer cell model. Expected: similar to dextromethorphan (Jaccard=0.25) furosemide allergic_rhinitis GAP_HIGH 0.1834 0.5 indapamide 0.45 STABLE 0.85 3 0.0506 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay furosemide→?; validate in allergic_rhinitis cell model. Expected: similar to indapamide (Jaccard=0.50) methsuximide chronic_kidney_failure GAP_HIGH 0.1834 0.34615384615384615 clomipramine 0.45 STABLE 0.85 3 0.0506 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methsuximide→?; validate in chronic_kidney_failure cell model. Expected: similar to clomipramine (Jaccard=0.35) alprazolam gilles_de_la_tourette_syndrome GAP_HIGH 0.2124 0.55 chlordiazepoxide 0.55 STABLE 0.6 3 0.05056 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alprazolam→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to chlordiazepoxide (Jaccard=0.55) pirenzepine focal_segmental_glomerulosclerosis GAP_HIGH 0.183 0.6153846153846154 perphenazine 0.45 STABLE 0.85 3 0.05049 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pirenzepine→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to perphenazine (Jaccard=0.62) sulfanilamide coronary_artery_disease GAP_HIGH 0.2058 0.6 clofibrate 0.4 STABLE 0.85 3 0.05047 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfanilamide→?; validate in coronary_artery_disease cell model. Expected: similar to clofibrate (Jaccard=0.60) suprofen head_and_neck_cancer GAP_HIGH 0.1943 0.6363636363636364 procarbazine 0.6 RISING 0.6 3 0.05046 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay suprofen→?; validate in head_and_neck_cancer cell model. Expected: similar to procarbazine (Jaccard=0.64) adinazolam chronic_kidney_failure GAP_HIGH 0.2589 0.7142857142857143 midazolam 0.45 STABLE 0.6 3 0.05042 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay adinazolam→?; validate in chronic_kidney_failure cell model. Expected: similar to midazolam (Jaccard=0.71) diphemanil_methylsulfate idiopathic_pulmonary_fibrosis GAP_HIGH 0.1827 0.5454545454545454 diethylstilbestrol 0.45 STABLE 0.85 3 0.05041 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphemanil_methylsulfate→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to diethylstilbestrol (Jaccard=0.55) spirapril creutzfeldt-jakob_disease GAP_HIGH 0.2588 0.6 moexipril 0.45 STABLE 0.6 3 0.0504 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay spirapril→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to moexipril (Jaccard=0.60) calcitriol osteoporosis GAP_HIGH 0.2587 0.7142857142857143 paricalcitol 0.45 STABLE 0.6 3 0.05039 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay calcitriol→?; validate in osteoporosis cell model. Expected: similar to paricalcitol (Jaccard=0.71) calcitriol psoriasis GAP_HIGH 0.2587 0.7142857142857143 paricalcitol 0.45 STABLE 0.6 3 0.05039 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay calcitriol→?; validate in psoriasis cell model. Expected: similar to paricalcitol (Jaccard=0.71) etonogestrel brain_cancer GAP_HIGH 0.194 0.5 desogestrel 0.6 RISING 0.6 3 0.05038 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay etonogestrel→?; validate in brain_cancer cell model. Expected: similar to desogestrel (Jaccard=0.50) propranolol hypertension GAP_HIGH 0.1455 0.5 methocarbamol 0.8 RAPID_RISE 0.6 3 0.05038 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propranolol→?; validate in hypertension cell model. Expected: similar to methocarbamol (Jaccard=0.50) zolmitriptan coronary_artery_disease GAP_HIGH 0.2908 0.8181818181818182 midodrine 0.4 STABLE 0.6 3 0.05034 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zolmitriptan→?; validate in coronary_artery_disease cell model. Expected: similar to midodrine (Jaccard=0.82) dextroamphetamine attention_deficit_hyperactivity_disorder GAP_HIGH 0.1823 0.5454545454545454 phentermine 0.45 STABLE 0.85 3 0.0503 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dextroamphetamine→?; validate in attention_deficit_hyperactivity_disorder cell model. Expected: similar to phentermine (Jaccard=0.55) zuclopenthixol prostate_cancer GAP_HIGH 0.1934 0.7857142857142857 pirenzepine 0.6 RISING 0.6 3 0.05022 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zuclopenthixol→?; validate in prostate_cancer cell model. Expected: similar to pirenzepine (Jaccard=0.79) methsuximide membranous_glomerulonephritis GAP_HIGH 0.182 0.34615384615384615 clomipramine 0.45 STABLE 0.85 3 0.05022 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methsuximide→?; validate in membranous_glomerulonephritis cell model. Expected: similar to clomipramine (Jaccard=0.35) aminolevulinic_acid autistic_disorder GAP_HIGH 0.182 0.2857142857142857 aminocaproic_acid 0.45 STABLE 0.85 3 0.05022 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminolevulinic_acid→?; validate in autistic_disorder cell model. Expected: similar to aminocaproic_acid (Jaccard=0.29) aminolevulinic_acid nicotine_dependence GAP_HIGH 0.182 0.2857142857142857 aminocaproic_acid 0.45 STABLE 0.85 3 0.05022 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminolevulinic_acid→?; validate in nicotine_dependence cell model. Expected: similar to aminocaproic_acid (Jaccard=0.29) brompheniramine lung_cancer GAP_HIGH 0.1363 0.375 carbinoxamine 0.6 RISING 0.85 3 0.05014 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay brompheniramine→?; validate in lung_cancer cell model. Expected: similar to carbinoxamine (Jaccard=0.38) progesterone uterine_cancer GAP_HIGH 0.1362 0.5 testosterone_propionate 0.6 RISING 0.85 3 0.05011 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay progesterone→?; validate in uterine_cancer cell model. Expected: similar to testosterone_propionate (Jaccard=0.50) fluspirilene epilepsy_syndrome GAP_HIGH 0.2894 1.0 droperidol 0.4 STABLE 0.6 3 0.0501 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluspirilene→?; validate in epilepsy_syndrome cell model. Expected: similar to droperidol (Jaccard=1.00) benzphetamine celiac_disease GAP_HIGH 0.1815 0.6 benzatropine 0.45 STABLE 0.85 3 0.05008 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzphetamine→?; validate in celiac_disease cell model. Expected: similar to benzatropine (Jaccard=0.60) bethanidine glaucoma GAP_HIGH 0.1815 0.55 phenylpropanolamine 0.45 STABLE 0.85 3 0.05008 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bethanidine→?; validate in glaucoma cell model. Expected: similar to phenylpropanolamine (Jaccard=0.55) azelastine gout GAP_HIGH 0.1814 0.6666666666666666 methdilazine 0.45 STABLE 0.85 3 0.05005 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay azelastine→?; validate in gout cell model. Expected: similar to methdilazine (Jaccard=0.67) pentostatin multiple_sclerosis GAP_HIGH 0.3206 0.6666666666666666 emtricitabine 0.6 RISING 0.6 3 0.04996 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pentostatin→?; validate in multiple_sclerosis cell model. Expected: similar to emtricitabine (Jaccard=0.67) fulvestrant brain_cancer GAP_HIGH 0.192 0.5454545454545454 estradiol_valeratedienogest 0.6 RISING 0.6 3 0.04986 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fulvestrant→?; validate in brain_cancer cell model. Expected: similar to estradiol_valeratedienogest (Jaccard=0.55) caffeine glaucoma GAP_HIGH 0.1807 0.26666666666666666 l-carnitine 0.45 STABLE 0.85 3 0.04986 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay caffeine→?; validate in glaucoma cell model. Expected: similar to l-carnitine (Jaccard=0.27) l-citrulline peripheral_nervous_system_neoplasm GAP_HIGH 0.1806 0.5058823529411764 l-glutamine 0.45 STABLE 0.85 3 0.04983 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-citrulline→?; validate in peripheral_nervous_system_neoplasm cell model. Expected: similar to l-glutamine (Jaccard=0.51) isopropamide esophageal_cancer GAP_HIGH 0.1354 0.3333333333333333 tamoxifen 0.6 RISING 0.85 3 0.04981 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isopropamide→?; validate in esophageal_cancer cell model. Expected: similar to tamoxifen (Jaccard=0.33) desipramine gilles_de_la_tourette_syndrome GAP_HIGH 0.1476 0.42857142857142855 alvimopan 0.55 STABLE 0.85 3 0.04978 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay desipramine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to alvimopan (Jaccard=0.43) diphemanil_methylsulfate chronic_obstructive_pulmonary_disease GAP_HIGH 0.1803 0.5454545454545454 diethylstilbestrol 0.45 STABLE 0.85 3 0.04975 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphemanil_methylsulfate→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to diethylstilbestrol (Jaccard=0.55) bethanidine refractive_error GAP_HIGH 0.1802 0.55 phenylpropanolamine 0.45 STABLE 0.85 3 0.04972 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bethanidine→?; validate in refractive_error cell model. Expected: similar to phenylpropanolamine (Jaccard=0.55) oxazepam gilles_de_la_tourette_syndrome GAP_HIGH 0.2088 0.6666666666666666 temazepam 0.55 STABLE 0.6 3 0.0497 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxazepam→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to temazepam (Jaccard=0.67) alverine celiac_disease GAP_HIGH 0.1801 0.5454545454545454 benzatropine 0.45 STABLE 0.85 3 0.04969 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alverine→?; validate in celiac_disease cell model. Expected: similar to benzatropine (Jaccard=0.55) fulvestrant kidney_cancer GAP_HIGH 0.191 0.5454545454545454 estradiol_valeratedienogest 0.6 RISING 0.6 3 0.0496 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fulvestrant→?; validate in kidney_cancer cell model. Expected: similar to estradiol_valeratedienogest (Jaccard=0.55) drospirenone esophageal_cancer GAP_HIGH 0.1348 0.42857142857142855 fludrocortisone 0.6 RISING 0.85 3 0.04959 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay drospirenone→?; validate in esophageal_cancer cell model. Expected: similar to fludrocortisone (Jaccard=0.43) phensuximide duodenum_cancer GAP_HIGH 0.1348 0.38636363636363635 clomipramine 0.6 RISING 0.85 3 0.04959 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phensuximide→?; validate in duodenum_cancer cell model. Expected: similar to clomipramine (Jaccard=0.39) docetaxel prostate_cancer GAP_HIGH 0.1908 0.6 paclitaxel 0.6 RISING 0.6 3 0.04955 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay docetaxel→?; validate in prostate_cancer cell model. Expected: similar to paclitaxel (Jaccard=0.60) pirenzepine azoospermia GAP_HIGH 0.1796 0.6153846153846154 perphenazine 0.45 STABLE 0.85 3 0.04955 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pirenzepine→?; validate in azoospermia cell model. Expected: similar to perphenazine (Jaccard=0.62) isopropamide type_1_diabetes_mellitus GAP_HIGH 0.1347 0.3333333333333333 benzatropine 0.6 RISING 0.85 3 0.04955 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isopropamide→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to benzatropine (Jaccard=0.33) sulfapyridine hematologic_cancer GAP_HIGH 0.1347 0.2916666666666667 olsalazine 0.6 RISING 0.85 3 0.04955 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfapyridine→?; validate in hematologic_cancer cell model. Expected: similar to olsalazine (Jaccard=0.29) bepotastine penile_cancer GAP_HIGH 0.1347 0.23529411764705882 loperamide 0.6 RISING 0.85 3 0.04955 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bepotastine→?; validate in penile_cancer cell model. Expected: similar to loperamide (Jaccard=0.24) salbutamol chronic_obstructive_pulmonary_disease GAP_HIGH 0.2543 0.8 pirbuterol 0.45 STABLE 0.6 3 0.04953 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay salbutamol→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to pirbuterol (Jaccard=0.80) caffeine refractive_error GAP_HIGH 0.1795 0.26666666666666666 l-carnitine 0.45 STABLE 0.85 3 0.04953 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay caffeine→?; validate in refractive_error cell model. Expected: similar to l-carnitine (Jaccard=0.27) tamoxifen celiac_disease GAP_HIGH 0.1526 0.5555555555555556 benzatropine 0.45 STABLE 1.0 3 0.04953 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tamoxifen→?; validate in celiac_disease cell model. Expected: similar to benzatropine (Jaccard=0.56) pirenzepine membranous_glomerulonephritis GAP_HIGH 0.1794 0.6153846153846154 perphenazine 0.45 STABLE 0.85 3 0.0495 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pirenzepine→?; validate in membranous_glomerulonephritis cell model. Expected: similar to perphenazine (Jaccard=0.62) caffeine idiopathic_pulmonary_fibrosis GAP_HIGH 0.1794 0.2857142857142857 dyphylline 0.45 STABLE 0.85 3 0.0495 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay caffeine→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to dyphylline (Jaccard=0.29) conivaptan rheumatoid_arthritis GAP_HIGH 0.2856 0.6666666666666666 pitavastatin 0.4 STABLE 0.6 3 0.04944 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay conivaptan→?; validate in rheumatoid_arthritis cell model. Expected: similar to pitavastatin (Jaccard=0.67) l-ornithine systemic_scleroderma GAP_HIGH 0.1792 0.2727272727272727 penicillamine 0.45 STABLE 0.85 3 0.04944 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-ornithine→?; validate in systemic_scleroderma cell model. Expected: similar to penicillamine (Jaccard=0.27) fludiazepam systemic_lupus_erythematosus GAP_HIGH 0.1903 0.7 chlordiazepoxide 0.6 RISING 0.6 3 0.04942 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fludiazepam→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to chlordiazepoxide (Jaccard=0.70) amitriptyline migraine GAP_HIGH 0.179 0.75 doxepin 0.45 STABLE 0.85 3 0.04939 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amitriptyline→?; validate in migraine cell model. Expected: similar to doxepin (Jaccard=0.75) methamphetamine crohns_disease GAP_HIGH 0.179 0.5454545454545454 phentermine 0.45 STABLE 0.85 3 0.04939 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methamphetamine→?; validate in crohns_disease cell model. Expected: similar to phentermine (Jaccard=0.55) adinazolam sclerosing_cholangitis GAP_HIGH 0.2535 0.7142857142857143 midazolam 0.45 STABLE 0.6 3 0.04937 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay adinazolam→?; validate in sclerosing_cholangitis cell model. Expected: similar to midazolam (Jaccard=0.71) benzatropine coronary_artery_disease GAP_HIGH 0.2013 0.625 bepridil 0.4 STABLE 0.85 3 0.04937 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzatropine→?; validate in coronary_artery_disease cell model. Expected: similar to bepridil (Jaccard=0.62) telmisartan coronary_artery_disease GAP_HIGH 0.285 1.0 eprosartan 0.4 STABLE 0.6 3 0.04934 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay telmisartan→?; validate in coronary_artery_disease cell model. Expected: similar to eprosartan (Jaccard=1.00) drospirenone type_1_diabetes_mellitus GAP_HIGH 0.1341 0.42857142857142855 fludrocortisone 0.6 RISING 0.85 3 0.04933 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay drospirenone→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to fludrocortisone (Jaccard=0.43) salbutamol allergic_rhinitis GAP_HIGH 0.2529 0.8 pirbuterol 0.45 STABLE 0.6 3 0.04926 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay salbutamol→?; validate in allergic_rhinitis cell model. Expected: similar to pirbuterol (Jaccard=0.80) quinethazone rheumatoid_arthritis GAP_HIGH 0.2008 0.4444444444444444 hydrochlorothiazide 0.4 STABLE 0.85 3 0.04925 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinethazone→?; validate in rheumatoid_arthritis cell model. Expected: similar to hydrochlorothiazide (Jaccard=0.44) probenecid prostate_cancer GAP_HIGH 0.1896 0.5833333333333334 chloroprocaine 0.6 RISING 0.6 3 0.04924 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay probenecid→?; validate in prostate_cancer cell model. Expected: similar to chloroprocaine (Jaccard=0.58) trifluoperazine prostate_cancer GAP_HIGH 0.1337 0.46153846153846156 pirenzepine 0.6 RISING 0.85 3 0.04919 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trifluoperazine→?; validate in prostate_cancer cell model. Expected: similar to pirenzepine (Jaccard=0.46) methadone esophageal_cancer GAP_HIGH 0.1336 0.5 toremifene 0.6 RISING 0.85 3 0.04915 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methadone→?; validate in esophageal_cancer cell model. Expected: similar to toremifene (Jaccard=0.50) methamphetamine narcolepsy GAP_HIGH 0.1781 0.5454545454545454 phentermine 0.45 STABLE 0.85 3 0.04914 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methamphetamine→?; validate in narcolepsy cell model. Expected: similar to phentermine (Jaccard=0.55) gliclazide osteoporosis GAP_HIGH 0.1781 0.47058823529411764 chlorpropamide 0.45 STABLE 0.85 3 0.04914 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay gliclazide→?; validate in osteoporosis cell model. Expected: similar to chlorpropamide (Jaccard=0.47) benzphetamine crohns_disease GAP_HIGH 0.178 0.6 benzatropine 0.45 STABLE 0.85 3 0.04911 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzphetamine→?; validate in crohns_disease cell model. Expected: similar to benzatropine (Jaccard=0.60) aprindine duodenum_cancer GAP_HIGH 0.1335 0.3333333333333333 desipramine 0.6 RISING 0.85 3 0.04911 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aprindine→?; validate in duodenum_cancer cell model. Expected: similar to desipramine (Jaccard=0.33) aprindine gallbladder_cancer GAP_HIGH 0.1335 0.3333333333333333 desipramine 0.6 RISING 0.85 3 0.04911 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aprindine→?; validate in gallbladder_cancer cell model. Expected: similar to desipramine (Jaccard=0.33) norepinephrine pagets_disease_of_bone GAP_HIGH 0.1779 0.16666666666666666 histamine_phosphate 0.45 STABLE 0.85 3 0.04909 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay norepinephrine→?; validate in pagets_disease_of_bone cell model. Expected: similar to histamine_phosphate (Jaccard=0.17) tripelennamine coronary_artery_disease GAP_HIGH 0.2001 0.625 mepyramine 0.4 STABLE 0.85 3 0.04908 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tripelennamine→?; validate in coronary_artery_disease cell model. Expected: similar to mepyramine (Jaccard=0.62) olsalazine kidney_cancer GAP_HIGH 0.1334 0.375 sulfaphenazole 0.6 RISING 0.85 3 0.04908 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay olsalazine→?; validate in kidney_cancer cell model. Expected: similar to sulfaphenazole (Jaccard=0.38) dimetacrine gilles_de_la_tourette_syndrome GAP_HIGH 0.1455 0.5 toremifene 0.55 STABLE 0.85 3 0.04907 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dimetacrine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to toremifene (Jaccard=0.50) clonidine focal_segmental_glomerulosclerosis GAP_HIGH 0.1777 0.5384615384615384 mefenamic_acid 0.45 STABLE 0.85 3 0.04903 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clonidine→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to mefenamic_acid (Jaccard=0.54) methohexital leprosy GAP_HIGH 0.2516 0.38095238095238093 phensuximide 0.45 STABLE 0.6 3 0.049 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methohexital→?; validate in leprosy cell model. Expected: similar to phensuximide (Jaccard=0.38) alverine malignant_mesothelioma GAP_HIGH 0.1776 0.5454545454545454 tamoxifen 0.45 STABLE 0.85 3 0.049 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alverine→?; validate in malignant_mesothelioma cell model. Expected: similar to tamoxifen (Jaccard=0.55) benzphetamine primary_biliary_cirrhosis GAP_HIGH 0.1774 0.6 benzatropine 0.45 STABLE 0.85 3 0.04895 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzphetamine→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to benzatropine (Jaccard=0.60) mitiglinide pharynx_cancer GAP_HIGH 0.133 0.3333333333333333 nateglinide 0.6 RISING 0.85 3 0.04893 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mitiglinide→?; validate in pharynx_cancer cell model. Expected: similar to nateglinide (Jaccard=0.33) benzphetamine gout GAP_HIGH 0.1773 0.6 benzatropine 0.45 STABLE 0.85 3 0.04892 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzphetamine→?; validate in gout cell model. Expected: similar to benzatropine (Jaccard=0.60) carprofen larynx_cancer GAP_HIGH 0.3136 1.0 procarbazine 0.6 RISING 0.6 3 0.04886 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carprofen→?; validate in larynx_cancer cell model. Expected: similar to procarbazine (Jaccard=1.00) gliclazide systemic_scleroderma GAP_HIGH 0.1771 0.47058823529411764 chlorpropamide 0.45 STABLE 0.85 3 0.04886 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay gliclazide→?; validate in systemic_scleroderma cell model. Expected: similar to chlorpropamide (Jaccard=0.47) alimemazine gilles_de_la_tourette_syndrome GAP_HIGH 0.1449 0.4444444444444444 trimipramine 0.55 STABLE 0.85 3 0.04886 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alimemazine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to trimipramine (Jaccard=0.44) methohexital creutzfeldt-jakob_disease GAP_HIGH 0.2508 0.5 clobazam 0.45 STABLE 0.6 3 0.04885 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methohexital→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to clobazam (Jaccard=0.50) danazol vascular_cancer GAP_HIGH 0.1881 0.5714285714285714 medroxyprogesterone_acetate 0.6 RISING 0.6 3 0.04885 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay danazol→?; validate in vascular_cancer cell model. Expected: similar to medroxyprogesterone_acetate (Jaccard=0.57) clomipramine panic_disorder GAP_HIGH 0.1769 0.8181818181818182 chlorprothixene 0.45 STABLE 0.85 3 0.04881 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clomipramine→?; validate in panic_disorder cell model. Expected: similar to chlorprothixene (Jaccard=0.82) drospirenone head_and_neck_cancer GAP_HIGH 0.1326 0.42857142857142855 fludrocortisone 0.6 RISING 0.85 3 0.04878 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay drospirenone→?; validate in head_and_neck_cancer cell model. Expected: similar to fludrocortisone (Jaccard=0.43) atomoxetine gilles_de_la_tourette_syndrome GAP_HIGH 0.1446 0.4444444444444444 reboxetine 0.55 STABLE 0.85 3 0.04876 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay atomoxetine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to reboxetine (Jaccard=0.44) salsalate type_1_diabetes_mellitus GAP_HIGH 0.1324 0.38095238095238093 bromfenac 0.6 RISING 0.85 3 0.04871 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay salsalate→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to bromfenac (Jaccard=0.38) chlorpromazine chronic_obstructive_pulmonary_disease GAP_HIGH 0.1765 0.75 clomipramine 0.45 STABLE 0.85 3 0.0487 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorpromazine→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to clomipramine (Jaccard=0.75) bepridil type_1_diabetes_mellitus GAP_HIGH 0.1873 0.625 benzatropine 0.6 RISING 0.6 3 0.04864 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bepridil→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to benzatropine (Jaccard=0.62) triamterene celiac_disease GAP_HIGH 0.2496 0.5 methylphenidate 0.45 STABLE 0.6 3 0.04861 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay triamterene→?; validate in celiac_disease cell model. Expected: similar to methylphenidate (Jaccard=0.50) benzatropine schizophrenia GAP_HIGH 0.1982 0.625 bepridil 0.4 STABLE 0.85 3 0.04861 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzatropine→?; validate in schizophrenia cell model. Expected: similar to bepridil (Jaccard=0.62) docetaxel stomach_cancer GAP_HIGH 0.1871 0.6 paclitaxel 0.6 RISING 0.6 3 0.04859 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay docetaxel→?; validate in stomach_cancer cell model. Expected: similar to paclitaxel (Jaccard=0.60) talbutal larynx_cancer GAP_HIGH 0.1871 0.25 pantoprazole 0.6 RISING 0.6 3 0.04859 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay talbutal→?; validate in larynx_cancer cell model. Expected: similar to pantoprazole (Jaccard=0.25) docetaxel pancreatic_cancer GAP_HIGH 0.187 0.6 paclitaxel 0.6 RISING 0.6 3 0.04856 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay docetaxel→?; validate in pancreatic_cancer cell model. Expected: similar to paclitaxel (Jaccard=0.60) l-carnitine malaria GAP_HIGH 0.1759 0.26666666666666666 caffeine 0.45 STABLE 0.85 3 0.04853 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-carnitine→?; validate in malaria cell model. Expected: similar to caffeine (Jaccard=0.27) clomipramine systemic_scleroderma GAP_HIGH 0.1756 0.8181818181818182 chlorprothixene 0.45 STABLE 0.85 3 0.04845 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clomipramine→?; validate in systemic_scleroderma cell model. Expected: similar to chlorprothixene (Jaccard=0.82) naftifine celiac_disease GAP_HIGH 0.1756 0.6296296296296297 diphenhydramine 0.45 STABLE 0.85 3 0.04845 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay naftifine→?; validate in celiac_disease cell model. Expected: similar to diphenhydramine (Jaccard=0.63) tamoxifen crohns_disease GAP_HIGH 0.1492 0.5555555555555556 benzatropine 0.45 STABLE 1.0 3 0.04843 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tamoxifen→?; validate in crohns_disease cell model. Expected: similar to benzatropine (Jaccard=0.56) doxapram coronary_artery_disease GAP_HIGH 0.2797 0.7142857142857143 bepridil 0.4 STABLE 0.6 3 0.04842 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxapram→?; validate in coronary_artery_disease cell model. Expected: similar to bepridil (Jaccard=0.71) phenelzine idiopathic_pulmonary_fibrosis GAP_HIGH 0.1755 0.5909090909090909 bethanidine 0.45 STABLE 0.85 3 0.04842 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenelzine→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to bethanidine (Jaccard=0.59) clonidine chronic_kidney_failure GAP_HIGH 0.1755 0.5384615384615384 mefenamic_acid 0.45 STABLE 0.85 3 0.04842 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clonidine→?; validate in chronic_kidney_failure cell model. Expected: similar to mefenamic_acid (Jaccard=0.54) bromodiphenhydramine chronic_kidney_failure GAP_HIGH 0.1754 0.5 brompheniramine 0.45 STABLE 0.85 3 0.0484 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bromodiphenhydramine→?; validate in chronic_kidney_failure cell model. Expected: similar to brompheniramine (Jaccard=0.50) chlorpromazine conduct_disorder GAP_HIGH 0.1752 0.75 clomipramine 0.45 STABLE 0.85 3 0.04834 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorpromazine→?; validate in conduct_disorder cell model. Expected: similar to clomipramine (Jaccard=0.75) isopropamide germ_cell_cancer GAP_HIGH 0.1311 0.3333333333333333 tamoxifen 0.6 RISING 0.85 3 0.04823 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isopropamide→?; validate in germ_cell_cancer cell model. Expected: similar to tamoxifen (Jaccard=0.33) carprofen head_and_neck_cancer GAP_HIGH 0.3094 1.0 procarbazine 0.6 RISING 0.6 3 0.04821 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carprofen→?; validate in head_and_neck_cancer cell model. Expected: similar to procarbazine (Jaccard=1.00) tamoxifen gout GAP_HIGH 0.1485 0.5555555555555556 benzatropine 0.45 STABLE 1.0 3 0.0482 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tamoxifen→?; validate in gout cell model. Expected: similar to benzatropine (Jaccard=0.56) fosphenytoin prostate_cancer GAP_HIGH 0.1854 0.5833333333333334 phenytoin 0.6 RISING 0.6 3 0.04815 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fosphenytoin→?; validate in prostate_cancer cell model. Expected: similar to phenytoin (Jaccard=0.58) doxepin testicular_cancer GAP_HIGH 0.1853 0.75 amitriptyline 0.6 RISING 0.6 3 0.04812 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxepin→?; validate in testicular_cancer cell model. Expected: similar to amitriptyline (Jaccard=0.75) fosphenytoin mediastinal_cancer GAP_HIGH 0.1852 0.5833333333333334 phenytoin 0.6 RISING 0.6 3 0.04809 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fosphenytoin→?; validate in mediastinal_cancer cell model. Expected: similar to phenytoin (Jaccard=0.58) fosphenytoin thymus_cancer GAP_HIGH 0.1851 0.5833333333333334 phenytoin 0.6 RISING 0.6 3 0.04807 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fosphenytoin→?; validate in thymus_cancer cell model. Expected: similar to phenytoin (Jaccard=0.58) talbutal esophageal_cancer GAP_HIGH 0.185 0.25 pantoprazole 0.6 RISING 0.6 3 0.04804 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay talbutal→?; validate in esophageal_cancer cell model. Expected: similar to pantoprazole (Jaccard=0.25) clonidine membranous_glomerulonephritis GAP_HIGH 0.1741 0.5384615384615384 mefenamic_acid 0.45 STABLE 0.85 3 0.04804 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clonidine→?; validate in membranous_glomerulonephritis cell model. Expected: similar to mefenamic_acid (Jaccard=0.54) propericiazine crohns_disease GAP_HIGH 0.174 0.6153846153846154 pirenzepine 0.45 STABLE 0.85 3 0.04801 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propericiazine→?; validate in crohns_disease cell model. Expected: similar to pirenzepine (Jaccard=0.62) pargyline idiopathic_pulmonary_fibrosis GAP_HIGH 0.1739 0.5384615384615384 phentermine 0.45 STABLE 0.85 3 0.04798 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pargyline→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to phentermine (Jaccard=0.54) triamterene crohns_disease GAP_HIGH 0.2462 0.5 methylphenidate 0.45 STABLE 0.6 3 0.04795 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay triamterene→?; validate in crohns_disease cell model. Expected: similar to methylphenidate (Jaccard=0.50) l-asparagine epilepsy_syndrome GAP_HIGH 0.1955 0.36666666666666664 l-serine 0.4 STABLE 0.85 3 0.04795 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-asparagine→?; validate in epilepsy_syndrome cell model. Expected: similar to l-serine (Jaccard=0.37) norethindrone kidney_cancer GAP_HIGH 0.1303 0.35 ethinyl_estradiol 0.6 RISING 0.85 3 0.04794 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay norethindrone→?; validate in kidney_cancer cell model. Expected: similar to ethinyl_estradiol (Jaccard=0.35) triamterene idiopathic_pulmonary_fibrosis GAP_HIGH 0.2458 0.5 methylphenidate 0.45 STABLE 0.6 3 0.04787 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay triamterene→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to methylphenidate (Jaccard=0.50) promazine crohns_disease GAP_HIGH 0.1733 0.75 dimetacrine 0.45 STABLE 0.85 3 0.04782 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay promazine→?; validate in crohns_disease cell model. Expected: similar to dimetacrine (Jaccard=0.75) propericiazine gout GAP_HIGH 0.1733 0.6153846153846154 pirenzepine 0.45 STABLE 0.85 3 0.04782 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propericiazine→?; validate in gout cell model. Expected: similar to pirenzepine (Jaccard=0.62) triamterene gout GAP_HIGH 0.2455 0.5 methylphenidate 0.45 STABLE 0.6 3 0.04781 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay triamterene→?; validate in gout cell model. Expected: similar to methylphenidate (Jaccard=0.50) pipotiazine chronic_obstructive_pulmonary_disease GAP_HIGH 0.1732 0.75 perphenazine 0.45 STABLE 0.85 3 0.04779 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pipotiazine→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to perphenazine (Jaccard=0.75) chloroprocaine leprosy GAP_HIGH 0.1732 0.35714285714285715 phenmetrazine 0.45 STABLE 0.85 3 0.04779 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chloroprocaine→?; validate in leprosy cell model. Expected: similar to phenmetrazine (Jaccard=0.36) ethotoin azoospermia GAP_HIGH 0.2453 0.76 phenytoin 0.45 STABLE 0.6 3 0.04778 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethotoin→?; validate in azoospermia cell model. Expected: similar to phenytoin (Jaccard=0.76) ergocalciferol vaginal_cancer GAP_HIGH 0.1839 0.42857142857142855 calcipotriol 0.6 RISING 0.6 3 0.04776 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ergocalciferol→?; validate in vaginal_cancer cell model. Expected: similar to calcipotriol (Jaccard=0.43) clomipramine azoospermia GAP_HIGH 0.1731 0.75 chlorpromazine 0.45 STABLE 0.85 3 0.04776 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clomipramine→?; validate in azoospermia cell model. Expected: similar to chlorpromazine (Jaccard=0.75) phenelzine pancreatitis GAP_HIGH 0.1729 0.5909090909090909 bethanidine 0.45 STABLE 0.85 3 0.04771 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenelzine→?; validate in pancreatitis cell model. Expected: similar to bethanidine (Jaccard=0.59) cyclopentolate mediastinal_cancer GAP_HIGH 0.1295 0.3333333333333333 reboxetine 0.6 RISING 0.85 3 0.04764 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyclopentolate→?; validate in mediastinal_cancer cell model. Expected: similar to reboxetine (Jaccard=0.33) calcitriol chronic_kidney_failure GAP_HIGH 0.2443 0.625 dihydrotachysterol 0.45 STABLE 0.6 3 0.04758 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay calcitriol→?; validate in chronic_kidney_failure cell model. Expected: similar to dihydrotachysterol (Jaccard=0.62) metaraminol type_1_diabetes_mellitus GAP_HIGH 0.1831 0.3333333333333333 cyclandelate 0.6 RISING 0.6 3 0.04755 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay metaraminol→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to cyclandelate (Jaccard=0.33) ethotoin malignant_mesothelioma GAP_HIGH 0.244 0.76 phenytoin 0.45 STABLE 0.6 3 0.04752 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethotoin→?; validate in malignant_mesothelioma cell model. Expected: similar to phenytoin (Jaccard=0.76) talbutal head_and_neck_cancer GAP_HIGH 0.1829 0.25 pantoprazole 0.6 RISING 0.6 3 0.0475 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay talbutal→?; validate in head_and_neck_cancer cell model. Expected: similar to pantoprazole (Jaccard=0.25) warfarin gilles_de_la_tourette_syndrome GAP_HIGH 0.1196 0.3333333333333333 modafinil 0.55 STABLE 1.0 3 0.04745 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay warfarin→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to modafinil (Jaccard=0.33) vismodegib kidney_cancer GAP_HIGH 0.1827 0.5714285714285714 sulfaphenazole 0.6 RISING 0.6 3 0.04744 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vismodegib→?; validate in kidney_cancer cell model. Expected: similar to sulfaphenazole (Jaccard=0.57) naftifine idiopathic_pulmonary_fibrosis GAP_HIGH 0.1718 0.6296296296296297 diphenhydramine 0.45 STABLE 0.85 3 0.0474 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay naftifine→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to diphenhydramine (Jaccard=0.63) loxapine focal_segmental_glomerulosclerosis GAP_HIGH 0.1718 0.5769230769230769 clomipramine 0.45 STABLE 0.85 3 0.0474 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay loxapine→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to clomipramine (Jaccard=0.58) phentermine osteoporosis GAP_HIGH 0.1718 0.5454545454545454 dextroamphetamine 0.45 STABLE 0.85 3 0.0474 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phentermine→?; validate in osteoporosis cell model. Expected: similar to dextroamphetamine (Jaccard=0.55) ethotoin crohns_disease GAP_HIGH 0.2432 0.76 phenytoin 0.45 STABLE 0.6 3 0.04737 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethotoin→?; validate in crohns_disease cell model. Expected: similar to phenytoin (Jaccard=0.76) azatadine alcohol_dependence GAP_HIGH 0.1716 0.42857142857142855 temazepam 0.45 STABLE 0.85 3 0.04735 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay azatadine→?; validate in alcohol_dependence cell model. Expected: similar to temazepam (Jaccard=0.43) drospirenone polycystic_ovary_syndrome GAP_HIGH 0.1399 0.5294117647058824 dydrogesterone 0.55 STABLE 0.85 3 0.04718 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay drospirenone→?; validate in polycystic_ovary_syndrome cell model. Expected: similar to dydrogesterone (Jaccard=0.53) propofol creutzfeldt-jakob_disease GAP_HIGH 0.2417 0.6153846153846154 clobazam 0.45 STABLE 0.6 3 0.04707 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propofol→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to clobazam (Jaccard=0.62) cilazapril creutzfeldt-jakob_disease GAP_HIGH 0.2417 0.6 moexipril 0.45 STABLE 0.6 3 0.04707 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cilazapril→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to moexipril (Jaccard=0.60) promazine chronic_obstructive_pulmonary_disease GAP_HIGH 0.1706 0.75 dimetacrine 0.45 STABLE 0.85 3 0.04707 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay promazine→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to dimetacrine (Jaccard=0.75) estazolam gilles_de_la_tourette_syndrome GAP_HIGH 0.1973 0.5625 fludiazepam 0.55 STABLE 0.6 3 0.04697 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estazolam→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to fludiazepam (Jaccard=0.56) cilazapril rheumatoid_arthritis GAP_HIGH 0.271 0.75 quinapril 0.4 STABLE 0.6 3 0.04692 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cilazapril→?; validate in rheumatoid_arthritis cell model. Expected: similar to quinapril (Jaccard=0.75) perphenazine crohns_disease GAP_HIGH 0.1698 0.6153846153846154 pirenzepine 0.45 STABLE 0.85 3 0.04685 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay perphenazine→?; validate in crohns_disease cell model. Expected: similar to pirenzepine (Jaccard=0.62) diphenylpyraline duodenum_cancer GAP_HIGH 0.1273 0.45454545454545453 diphenhydramine 0.6 RISING 0.85 3 0.04683 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphenylpyraline→?; validate in duodenum_cancer cell model. Expected: similar to diphenhydramine (Jaccard=0.45) zafirlukast kidney_cancer GAP_HIGH 0.1803 0.4117647058823529 gliclazide 0.6 RISING 0.6 3 0.04682 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zafirlukast→?; validate in kidney_cancer cell model. Expected: similar to gliclazide (Jaccard=0.41) naftifine ankylosing_spondylitis GAP_HIGH 0.1696 0.6296296296296297 diphenhydramine 0.45 STABLE 0.85 3 0.0468 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay naftifine→?; validate in ankylosing_spondylitis cell model. Expected: similar to diphenhydramine (Jaccard=0.63) loxapine chronic_kidney_failure GAP_HIGH 0.1696 0.5769230769230769 clomipramine 0.45 STABLE 0.85 3 0.0468 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay loxapine→?; validate in chronic_kidney_failure cell model. Expected: similar to clomipramine (Jaccard=0.58) bromodiphenhydramine ankylosing_spondylitis GAP_HIGH 0.1695 0.5 brompheniramine 0.45 STABLE 0.85 3 0.04677 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bromodiphenhydramine→?; validate in ankylosing_spondylitis cell model. Expected: similar to brompheniramine (Jaccard=0.50) estrone prostate_cancer GAP_HIGH 0.1271 0.4 mestranol 0.6 RISING 0.85 3 0.04676 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estrone→?; validate in prostate_cancer cell model. Expected: similar to mestranol (Jaccard=0.40) baclofen glaucoma GAP_HIGH 0.3998 1.0 procarbazine 0.45 STABLE 0.6 3 0.04672 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay baclofen→?; validate in glaucoma cell model. Expected: similar to procarbazine (Jaccard=1.00) baclofen intracranial_aneurysm GAP_HIGH 0.3996 1.0 procarbazine 0.45 STABLE 0.6 3 0.0467 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay baclofen→?; validate in intracranial_aneurysm cell model. Expected: similar to procarbazine (Jaccard=1.00) perphenazine gout GAP_HIGH 0.1691 0.6153846153846154 pirenzepine 0.45 STABLE 0.85 3 0.04666 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay perphenazine→?; validate in gout cell model. Expected: similar to pirenzepine (Jaccard=0.62) baclofen malignant_glioma GAP_HIGH 0.3987 1.0 procarbazine 0.45 STABLE 0.6 3 0.04659 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay baclofen→?; validate in malignant_glioma cell model. Expected: similar to procarbazine (Jaccard=1.00) reboxetine type_1_diabetes_mellitus GAP_HIGH 0.1266 0.3333333333333333 cyclopentolate 0.6 RISING 0.85 3 0.04657 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay reboxetine→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to cyclopentolate (Jaccard=0.33) indapamide urinary_bladder_cancer GAP_HIGH 0.1266 0.2222222222222222 tamsulosin 0.6 RISING 0.85 3 0.04657 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay indapamide→?; validate in urinary_bladder_cancer cell model. Expected: similar to tamsulosin (Jaccard=0.22) promazine gilles_de_la_tourette_syndrome GAP_HIGH 0.138 0.4838709677419355 clofedanol 0.55 STABLE 0.85 3 0.04654 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay promazine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to clofedanol (Jaccard=0.48) selegiline atherosclerosis GAP_HIGH 0.1685 0.375 phentermine 0.45 STABLE 0.85 3 0.04649 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay selegiline→?; validate in atherosclerosis cell model. Expected: similar to phentermine (Jaccard=0.38) epirubicin thyroid_cancer GAP_HIGH 0.1341 0.2857142857142857 podofilox 0.8 RAPID_RISE 0.6 3 0.04643 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay epirubicin→?; validate in thyroid_cancer cell model. Expected: similar to podofilox (Jaccard=0.29) mesalazine idiopathic_pulmonary_fibrosis GAP_HIGH 0.1682 0.6666666666666666 isoprenaline 0.45 STABLE 0.85 3 0.04641 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mesalazine→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to isoprenaline (Jaccard=0.67) loxapine membranous_glomerulonephritis GAP_HIGH 0.1682 0.5769230769230769 clomipramine 0.45 STABLE 0.85 3 0.04641 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay loxapine→?; validate in membranous_glomerulonephritis cell model. Expected: similar to clomipramine (Jaccard=0.58) clomipramine pancreatitis GAP_HIGH 0.168 0.75 chlorpromazine 0.45 STABLE 0.85 3 0.04635 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clomipramine→?; validate in pancreatitis cell model. Expected: similar to chlorpromazine (Jaccard=0.75) halazepam coronary_artery_disease GAP_HIGH 0.2676 0.6666666666666666 midazolam 0.4 STABLE 0.6 3 0.04633 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay halazepam→?; validate in coronary_artery_disease cell model. Expected: similar to midazolam (Jaccard=0.67) raloxifene idiopathic_pulmonary_fibrosis GAP_HIGH 0.2378 0.75 alcaftadine 0.45 STABLE 0.6 3 0.04631 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay raloxifene→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to alcaftadine (Jaccard=0.75) pentobarbital duodenum_cancer GAP_HIGH 0.1783 0.29411764705882354 clobazam 0.6 RISING 0.6 3 0.0463 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pentobarbital→?; validate in duodenum_cancer cell model. Expected: similar to clobazam (Jaccard=0.29) pentobarbital gallbladder_cancer GAP_HIGH 0.1783 0.29411764705882354 clobazam 0.6 RISING 0.6 3 0.0463 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pentobarbital→?; validate in gallbladder_cancer cell model. Expected: similar to clobazam (Jaccard=0.29) tripelennamine azoospermia GAP_HIGH 0.1678 0.4444444444444444 bromodiphenhydramine 0.45 STABLE 0.85 3 0.0463 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tripelennamine→?; validate in azoospermia cell model. Expected: similar to bromodiphenhydramine (Jaccard=0.44) ethynodiol malignant_glioma GAP_HIGH 0.2375 0.6666666666666666 megestrol_acetate 0.45 STABLE 0.6 3 0.04626 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethynodiol→?; validate in malignant_glioma cell model. Expected: similar to megestrol_acetate (Jaccard=0.67) loxapine crohns_disease GAP_HIGH 0.1674 0.5833333333333334 azelastine 0.45 STABLE 0.85 3 0.04619 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay loxapine→?; validate in crohns_disease cell model. Expected: similar to azelastine (Jaccard=0.58) mefenamic_acid refractive_error GAP_HIGH 0.1673 0.5384615384615384 clonidine 0.45 STABLE 0.85 3 0.04616 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mefenamic_acid→?; validate in refractive_error cell model. Expected: similar to clonidine (Jaccard=0.54) salsalate duodenum_cancer GAP_HIGH 0.1254 0.38095238095238093 bromfenac 0.6 RISING 0.85 3 0.04613 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay salsalate→?; validate in duodenum_cancer cell model. Expected: similar to bromfenac (Jaccard=0.38) indapamide vaginal_cancer GAP_HIGH 0.1253 0.2222222222222222 tamsulosin 0.6 RISING 0.85 3 0.0461 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay indapamide→?; validate in vaginal_cancer cell model. Expected: similar to tamsulosin (Jaccard=0.22) aminocaproic_acid migraine GAP_HIGH 0.1668 0.2857142857142857 aminolevulinic_acid 0.45 STABLE 0.85 3 0.04602 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminocaproic_acid→?; validate in migraine cell model. Expected: similar to aminolevulinic_acid (Jaccard=0.29) alvimopan duodenum_cancer GAP_HIGH 0.1767 0.42857142857142855 desipramine 0.6 RISING 0.6 3 0.04589 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alvimopan→?; validate in duodenum_cancer cell model. Expected: similar to desipramine (Jaccard=0.43) alvimopan gallbladder_cancer GAP_HIGH 0.1767 0.42857142857142855 desipramine 0.6 RISING 0.6 3 0.04589 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alvimopan→?; validate in gallbladder_cancer cell model. Expected: similar to desipramine (Jaccard=0.43) raloxifene chronic_obstructive_pulmonary_disease GAP_HIGH 0.2355 0.75 alcaftadine 0.45 STABLE 0.6 3 0.04587 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay raloxifene→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to alcaftadine (Jaccard=0.75) l-carnitine idiopathic_pulmonary_fibrosis GAP_HIGH 0.1662 0.2727272727272727 alcaftadine 0.45 STABLE 0.85 3 0.04586 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-carnitine→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to alcaftadine (Jaccard=0.27) clotrimazole metabolic_syndrome_x GAP_HIGH 0.136 0.42857142857142855 papaverine 0.55 STABLE 0.85 3 0.04586 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clotrimazole→?; validate in metabolic_syndrome_x cell model. Expected: similar to papaverine (Jaccard=0.43) salicylate-sodium kidney_cancer GAP_HIGH 0.1246 0.3076923076923077 sulfaphenazole 0.6 RISING 0.85 3 0.04584 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay salicylate-sodium→?; validate in kidney_cancer cell model. Expected: similar to sulfaphenazole (Jaccard=0.31) tripelennamine chronic_kidney_failure GAP_HIGH 0.1658 0.42857142857142855 brompheniramine 0.45 STABLE 0.85 3 0.04575 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tripelennamine→?; validate in chronic_kidney_failure cell model. Expected: similar to brompheniramine (Jaccard=0.43) desipramine chronic_obstructive_pulmonary_disease GAP_HIGH 0.1657 0.5714285714285714 imipramine 0.45 STABLE 0.85 3 0.04572 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay desipramine→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to imipramine (Jaccard=0.57) raloxifene nicotine_dependence GAP_HIGH 0.2347 0.75 alcaftadine 0.45 STABLE 0.6 3 0.04571 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay raloxifene→?; validate in nicotine_dependence cell model. Expected: similar to alcaftadine (Jaccard=0.75) moexipril esophageal_cancer GAP_HIGH 0.1758 0.3333333333333333 topotecan 0.6 RISING 0.6 3 0.04565 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay moexipril→?; validate in esophageal_cancer cell model. Expected: similar to topotecan (Jaccard=0.33) l-ornithine panic_disorder GAP_HIGH 0.1654 0.2222222222222222 l-lysine 0.45 STABLE 0.85 3 0.04564 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-ornithine→?; validate in panic_disorder cell model. Expected: similar to l-lysine (Jaccard=0.22) diphemanil_methylsulfate focal_segmental_glomerulosclerosis GAP_HIGH 0.1653 0.4444444444444444 dimetacrine 0.45 STABLE 0.85 3 0.04561 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphemanil_methylsulfate→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to dimetacrine (Jaccard=0.44) melphalan glaucoma GAP_HIGH 0.234 0.6363636363636364 procarbazine 0.45 STABLE 0.6 3 0.04557 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay melphalan→?; validate in glaucoma cell model. Expected: similar to procarbazine (Jaccard=0.64) alpha-linolenic_acid barretts_esophagus GAP_LOW 0.2134 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04556 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking alpha-linolenic_acid vs barretts_esophagus targets. Cross-check alpha-linolenic_acid pharmacophore against barretts_esophagus pathway. dronedarone barretts_esophagus GAP_LOW 0.2134 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04556 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking dronedarone vs barretts_esophagus targets. Cross-check dronedarone pharmacophore against barretts_esophagus pathway. sodium_lauryl_sulfate barretts_esophagus GAP_LOW 0.2134 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04556 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking sodium_lauryl_sulfate vs barretts_esophagus targets. Cross-check sodium_lauryl_sulfate pharmacophore against barretts_esophagus pathway. succinic_acid barretts_esophagus GAP_LOW 0.2134 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04556 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking succinic_acid vs barretts_esophagus targets. Cross-check succinic_acid pharmacophore against barretts_esophagus pathway. moricizine azoospermia GAP_HIGH 0.1651 0.5 thioproperazine 0.45 STABLE 0.85 3 0.04555 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay moricizine→?; validate in azoospermia cell model. Expected: similar to thioproperazine (Jaccard=0.50) trimethoprim malignant_mesothelioma GAP_HIGH 0.2338 0.5 pemetrexed 0.45 STABLE 0.6 3 0.04554 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trimethoprim→?; validate in malignant_mesothelioma cell model. Expected: similar to pemetrexed (Jaccard=0.50) melphalan intracranial_aneurysm GAP_HIGH 0.2337 0.6363636363636364 procarbazine 0.45 STABLE 0.6 3 0.04552 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay melphalan→?; validate in intracranial_aneurysm cell model. Expected: similar to procarbazine (Jaccard=0.64) alvimopan lung_cancer GAP_HIGH 0.1751 0.42857142857142855 desipramine 0.6 RISING 0.6 3 0.04547 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alvimopan→?; validate in lung_cancer cell model. Expected: similar to desipramine (Jaccard=0.43) estrone breast_cancer GAP_HIGH 0.1235 0.4 mestranol 0.6 RISING 0.85 3 0.04543 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estrone→?; validate in breast_cancer cell model. Expected: similar to mestranol (Jaccard=0.40) trimethoprim meningioma GAP_HIGH 0.2332 0.5 pemetrexed 0.45 STABLE 0.6 3 0.04542 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trimethoprim→?; validate in meningioma cell model. Expected: similar to pemetrexed (Jaccard=0.50) dextroamphetamine coronary_artery_disease GAP_HIGH 0.1851 0.5454545454545454 phentermine 0.4 STABLE 0.85 3 0.0454 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dextroamphetamine→?; validate in coronary_artery_disease cell model. Expected: similar to phentermine (Jaccard=0.55) l-carnitine creutzfeldt-jakob_disease GAP_HIGH 0.1645 0.2727272727272727 cyproheptadine 0.45 STABLE 0.85 3 0.04539 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-carnitine→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to cyproheptadine (Jaccard=0.27) melphalan malignant_glioma GAP_HIGH 0.2329 0.6363636363636364 procarbazine 0.45 STABLE 0.6 3 0.04536 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay melphalan→?; validate in malignant_glioma cell model. Expected: similar to procarbazine (Jaccard=0.64) anileridine narcolepsy GAP_HIGH 0.1644 0.4166666666666667 milnacipran 0.45 STABLE 0.85 3 0.04536 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay anileridine→?; validate in narcolepsy cell model. Expected: similar to milnacipran (Jaccard=0.42) clobazam malaria GAP_HIGH 0.2328 0.7333333333333333 butabarbital 0.45 STABLE 0.6 3 0.04534 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clobazam→?; validate in malaria cell model. Expected: similar to butabarbital (Jaccard=0.73) phenindamine azoospermia GAP_HIGH 0.1643 0.4 indecainide 0.45 STABLE 0.85 3 0.04533 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenindamine→?; validate in azoospermia cell model. Expected: similar to indecainide (Jaccard=0.40) tofisopam focal_segmental_glomerulosclerosis GAP_HIGH 0.2327 0.55 bevantolol 0.45 STABLE 0.6 3 0.04532 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tofisopam→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to bevantolol (Jaccard=0.55) pimozide gilles_de_la_tourette_syndrome GAP_HIGH 0.1343 0.25 ezetimibe 0.55 STABLE 0.85 3 0.04529 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pimozide→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to ezetimibe (Jaccard=0.25) trimipramine duodenum_cancer GAP_HIGH 0.1231 0.4444444444444444 alimemazine 0.6 RISING 0.85 3 0.04529 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trimipramine→?; validate in duodenum_cancer cell model. Expected: similar to alimemazine (Jaccard=0.44) trimipramine gallbladder_cancer GAP_HIGH 0.1231 0.4444444444444444 alimemazine 0.6 RISING 0.85 3 0.04529 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trimipramine→?; validate in gallbladder_cancer cell model. Expected: similar to alimemazine (Jaccard=0.44) fludiazepam metabolic_syndrome_x GAP_HIGH 0.1902 0.7 chlordiazepoxide 0.55 STABLE 0.6 3 0.04528 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fludiazepam→?; validate in metabolic_syndrome_x cell model. Expected: similar to chlordiazepoxide (Jaccard=0.70) aprindine gilles_de_la_tourette_syndrome GAP_HIGH 0.1341 0.3 tolterodine 0.55 STABLE 0.85 3 0.04522 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aprindine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to tolterodine (Jaccard=0.30) vismodegib skin_cancer GAP_HIGH 0.1741 0.5714285714285714 sulfaphenazole 0.6 RISING 0.6 3 0.04521 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vismodegib→?; validate in skin_cancer cell model. Expected: similar to sulfaphenazole (Jaccard=0.57) tofisopam glaucoma GAP_HIGH 0.2321 0.55 bevantolol 0.45 STABLE 0.6 3 0.0452 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tofisopam→?; validate in glaucoma cell model. Expected: similar to bevantolol (Jaccard=0.55) captopril penile_cancer GAP_HIGH 0.1737 0.3333333333333333 crizotinib 0.6 RISING 0.6 3 0.04511 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay captopril→?; validate in penile_cancer cell model. Expected: similar to crizotinib (Jaccard=0.33) bethanidine coronary_artery_disease GAP_HIGH 0.1838 0.5909090909090909 phenelzine 0.4 STABLE 0.85 3 0.04508 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bethanidine→?; validate in coronary_artery_disease cell model. Expected: similar to phenelzine (Jaccard=0.59) nateglinide atherosclerosis GAP_HIGH 0.1633 0.5555555555555556 phenelzine 0.45 STABLE 0.85 3 0.04506 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nateglinide→?; validate in atherosclerosis cell model. Expected: similar to phenelzine (Jaccard=0.56) spirapril coronary_artery_disease GAP_HIGH 0.2601 0.6 moexipril 0.4 STABLE 0.6 3 0.04503 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay spirapril→?; validate in coronary_artery_disease cell model. Expected: similar to moexipril (Jaccard=0.60) diphemanil_methylsulfate chronic_kidney_failure GAP_HIGH 0.1631 0.4444444444444444 dimetacrine 0.45 STABLE 0.85 3 0.045 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphemanil_methylsulfate→?; validate in chronic_kidney_failure cell model. Expected: similar to dimetacrine (Jaccard=0.44) aceprometazine celiac_disease GAP_HIGH 0.1629 0.4 mepenzolate 0.45 STABLE 0.85 3 0.04495 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aceprometazine→?; validate in celiac_disease cell model. Expected: similar to mepenzolate (Jaccard=0.40) loperamide systemic_lupus_erythematosus GAP_HIGH 0.1221 0.42105263157894735 diphemanil_methylsulfate 0.6 RISING 0.85 3 0.04492 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay loperamide→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to diphemanil_methylsulfate (Jaccard=0.42) tofisopam chronic_kidney_failure GAP_HIGH 0.2305 0.55 bevantolol 0.45 STABLE 0.6 3 0.04489 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tofisopam→?; validate in chronic_kidney_failure cell model. Expected: similar to bevantolol (Jaccard=0.55) desipramine vitiligo GAP_HIGH 0.1627 0.5714285714285714 imipramine 0.45 STABLE 0.85 3 0.04489 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay desipramine→?; validate in vitiligo cell model. Expected: similar to imipramine (Jaccard=0.57) l-phenylalanine azoospermia GAP_HIGH 0.1626 0.36363636363636365 lacosamide 0.45 STABLE 0.85 3 0.04486 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-phenylalanine→?; validate in azoospermia cell model. Expected: similar to lacosamide (Jaccard=0.36) arbutamine epilepsy_syndrome GAP_HIGH 0.1828 0.5333333333333333 masoprocol 0.4 STABLE 0.85 3 0.04483 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay arbutamine→?; validate in epilepsy_syndrome cell model. Expected: similar to masoprocol (Jaccard=0.53) deferasirox sclerosing_cholangitis GAP_HIGH 0.2301 0.5 linaclotide 0.45 STABLE 0.6 3 0.04482 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay deferasirox→?; validate in sclerosing_cholangitis cell model. Expected: similar to linaclotide (Jaccard=0.50) zafirlukast pancreatic_cancer GAP_HIGH 0.1723 0.4117647058823529 gliclazide 0.6 RISING 0.6 3 0.04474 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zafirlukast→?; validate in pancreatic_cancer cell model. Expected: similar to gliclazide (Jaccard=0.41) thioproperazine chronic_obstructive_pulmonary_disease GAP_HIGH 0.1621 0.6923076923076923 perphenazine 0.45 STABLE 0.85 3 0.04473 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thioproperazine→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to perphenazine (Jaccard=0.69) moricizine narcolepsy GAP_HIGH 0.1621 0.5 thioproperazine 0.45 STABLE 0.85 3 0.04473 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay moricizine→?; validate in narcolepsy cell model. Expected: similar to thioproperazine (Jaccard=0.50) atomoxetine autistic_disorder GAP_HIGH 0.162 0.6 phenprocoumon 0.45 STABLE 0.85 3 0.0447 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay atomoxetine→?; validate in autistic_disorder cell model. Expected: similar to phenprocoumon (Jaccard=0.60) quinapril creutzfeldt-jakob_disease GAP_HIGH 0.2294 0.5 moexipril 0.45 STABLE 0.6 3 0.04468 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinapril→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to moexipril (Jaccard=0.50) tofisopam azoospermia GAP_HIGH 0.2293 0.55 bevantolol 0.45 STABLE 0.6 3 0.04466 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tofisopam→?; validate in azoospermia cell model. Expected: similar to bevantolol (Jaccard=0.55) deferasirox pancreatitis GAP_HIGH 0.2292 0.5 linaclotide 0.45 STABLE 0.6 3 0.04464 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay deferasirox→?; validate in pancreatitis cell model. Expected: similar to linaclotide (Jaccard=0.50) tofisopam membranous_glomerulonephritis GAP_HIGH 0.2291 0.55 bevantolol 0.45 STABLE 0.6 3 0.04462 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tofisopam→?; validate in membranous_glomerulonephritis cell model. Expected: similar to bevantolol (Jaccard=0.55) doxycycline barretts_esophagus GAP_LOW 0.209 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04462 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking doxycycline vs barretts_esophagus targets. Cross-check doxycycline pharmacophore against barretts_esophagus pathway. atomoxetine attention_deficit_hyperactivity_disorder GAP_HIGH 0.1617 0.6 phenprocoumon 0.45 STABLE 0.85 3 0.04462 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay atomoxetine→?; validate in attention_deficit_hyperactivity_disorder cell model. Expected: similar to phenprocoumon (Jaccard=0.60) diphemanil_methylsulfate membranous_glomerulonephritis GAP_HIGH 0.1617 0.4444444444444444 dimetacrine 0.45 STABLE 0.85 3 0.04462 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphemanil_methylsulfate→?; validate in membranous_glomerulonephritis cell model. Expected: similar to dimetacrine (Jaccard=0.44) diphenidol chronic_obstructive_pulmonary_disease GAP_HIGH 0.2288 0.625 bepridil 0.45 STABLE 0.6 3 0.04456 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphenidol→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to bepridil (Jaccard=0.62) sulfamethizole primary_biliary_cirrhosis GAP_HIGH 0.1615 0.4 sulfapyridine 0.45 STABLE 0.85 3 0.04456 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfamethizole→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to sulfapyridine (Jaccard=0.40) dexamethasone larynx_cancer GAP_HIGH 0.1211 0.2857142857142857 doxorubicin 0.6 RISING 0.85 3 0.04455 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dexamethasone→?; validate in larynx_cancer cell model. Expected: similar to doxorubicin (Jaccard=0.29) l-citrulline epilepsy_syndrome GAP_HIGH 0.1814 0.5058823529411764 l-glutamine 0.4 STABLE 0.85 3 0.04449 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-citrulline→?; validate in epilepsy_syndrome cell model. Expected: similar to l-glutamine (Jaccard=0.51) vitamin_a muscle_cancer GAP_HIGH 0.1713 0.3333333333333333 bexarotene 0.6 RISING 0.6 3 0.04448 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vitamin_a→?; validate in muscle_cancer cell model. Expected: similar to bexarotene (Jaccard=0.33) vitamin_a ocular_cancer GAP_HIGH 0.1712 0.3333333333333333 bexarotene 0.6 RISING 0.6 3 0.04446 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vitamin_a→?; validate in ocular_cancer cell model. Expected: similar to bexarotene (Jaccard=0.33) azelastine coronary_artery_disease GAP_HIGH 0.1812 0.6666666666666666 methdilazine 0.4 STABLE 0.85 3 0.04444 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay azelastine→?; validate in coronary_artery_disease cell model. Expected: similar to methdilazine (Jaccard=0.67) treprostinil pharynx_cancer GAP_HIGH 0.1711 0.25 metipranolol 0.6 RISING 0.6 3 0.04443 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay treprostinil→?; validate in pharynx_cancer cell model. Expected: similar to metipranolol (Jaccard=0.25) vitamin_a urinary_bladder_cancer GAP_HIGH 0.1709 0.3333333333333333 bexarotene 0.6 RISING 0.6 3 0.04438 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vitamin_a→?; validate in urinary_bladder_cancer cell model. Expected: similar to bexarotene (Jaccard=0.33) azacitidine systemic_lupus_erythematosus GAP_HIGH 0.2008 0.4782608695652174 vidarabine 0.6 RISING 0.85 3 0.04432 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay azacitidine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to vidarabine (Jaccard=0.48) vandetanib ulcerative_colitis GAP_HIGH 0.1505 0.6060606060606061 gefitinib 0.8 RAPID_RISE 0.85 3 0.04429 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vandetanib→?; validate in ulcerative_colitis cell model. Expected: similar to gefitinib (Jaccard=0.61) levorphanol esophageal_cancer GAP_HIGH 0.1705 0.46153846153846156 fulvestrant 0.6 RISING 0.6 3 0.04428 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levorphanol→?; validate in esophageal_cancer cell model. Expected: similar to fulvestrant (Jaccard=0.46) l-phenylalanine crohns_disease GAP_HIGH 0.1604 0.36363636363636365 lacosamide 0.45 STABLE 0.85 3 0.04426 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-phenylalanine→?; validate in crohns_disease cell model. Expected: similar to lacosamide (Jaccard=0.36) vitamin_a stomach_cancer GAP_HIGH 0.1704 0.3333333333333333 bexarotene 0.6 RISING 0.6 3 0.04425 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vitamin_a→?; validate in stomach_cancer cell model. Expected: similar to bexarotene (Jaccard=0.33) chlordiazepoxide gout GAP_HIGH 0.1603 0.5555555555555556 diazepam 0.45 STABLE 0.85 3 0.04423 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlordiazepoxide→?; validate in gout cell model. Expected: similar to diazepam (Jaccard=0.56) ketoprofen ulcerative_colitis GAP_HIGH 0.1277 0.3333333333333333 indomethacin 0.8 RAPID_RISE 0.6 3 0.04422 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ketoprofen→?; validate in ulcerative_colitis cell model. Expected: similar to indomethacin (Jaccard=0.33) moricizine pancreatitis GAP_HIGH 0.16 0.5 thioproperazine 0.45 STABLE 0.85 3 0.04415 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay moricizine→?; validate in pancreatitis cell model. Expected: similar to thioproperazine (Jaccard=0.50) anileridine systemic_scleroderma GAP_HIGH 0.16 0.4166666666666667 milnacipran 0.45 STABLE 0.85 3 0.04415 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay anileridine→?; validate in systemic_scleroderma cell model. Expected: similar to milnacipran (Jaccard=0.42) l-glutamine glaucoma GAP_HIGH 0.1599 0.43617021276595747 l-serine 0.45 STABLE 0.85 3 0.04412 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-glutamine→?; validate in glaucoma cell model. Expected: similar to l-serine (Jaccard=0.44) dextropropoxyphene focal_segmental_glomerulosclerosis GAP_HIGH 0.2265 0.4 propiomazine 0.45 STABLE 0.6 3 0.04411 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dextropropoxyphene→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to propiomazine (Jaccard=0.40) adinazolam coronary_artery_disease GAP_HIGH 0.2547 0.7142857142857143 midazolam 0.4 STABLE 0.6 3 0.04409 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay adinazolam→?; validate in coronary_artery_disease cell model. Expected: similar to midazolam (Jaccard=0.71) conjugated_estrogens prostate_cancer GAP_HIGH 0.1693 0.4 estriol 0.6 RISING 0.6 3 0.04396 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay conjugated_estrogens→?; validate in prostate_cancer cell model. Expected: similar to estriol (Jaccard=0.40) diphenhydramine focal_segmental_glomerulosclerosis GAP_HIGH 0.1593 0.6296296296296297 naftifine 0.45 STABLE 0.85 3 0.04395 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphenhydramine→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to naftifine (Jaccard=0.63) spironolactone dilated_cardiomyopathy GAP_HIGH 0.1593 0.42857142857142855 drospirenone 0.45 STABLE 0.85 3 0.04395 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay spironolactone→?; validate in dilated_cardiomyopathy cell model. Expected: similar to drospirenone (Jaccard=0.43) methocarbamol focal_segmental_glomerulosclerosis GAP_HIGH 0.2254 0.5 propranolol 0.45 STABLE 0.6 3 0.0439 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methocarbamol→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to propranolol (Jaccard=0.50) nortriptyline focal_segmental_glomerulosclerosis GAP_HIGH 0.159 0.5 acepromazine 0.45 STABLE 0.85 3 0.04387 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nortriptyline→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to acepromazine (Jaccard=0.50) pargyline glaucoma GAP_HIGH 0.1587 0.4375 phenylpropanolamine 0.45 STABLE 0.85 3 0.04379 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pargyline→?; validate in glaucoma cell model. Expected: similar to phenylpropanolamine (Jaccard=0.44) aminolevulinic_acid barretts_esophagus GAP_LOW 0.2051 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04378 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking aminolevulinic_acid vs barretts_esophagus targets. Cross-check aminolevulinic_acid pharmacophore against barretts_esophagus pathway. caffeine barretts_esophagus GAP_LOW 0.2051 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04378 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking caffeine vs barretts_esophagus targets. Cross-check caffeine pharmacophore against barretts_esophagus pathway. dihomo-gamma-linolenic_acid barretts_esophagus GAP_LOW 0.2051 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04378 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking dihomo-gamma-linolenic_acid vs barretts_esophagus targets. Cross-check dihomo-gamma-linolenic_acid pharmacophore against barretts_esophagus pathway. sodium_tetradecyl_sulfate barretts_esophagus GAP_LOW 0.2051 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04378 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking sodium_tetradecyl_sulfate vs barretts_esophagus targets. Cross-check sodium_tetradecyl_sulfate pharmacophore against barretts_esophagus pathway. methocarbamol glaucoma GAP_HIGH 0.2247 0.5 propranolol 0.45 STABLE 0.6 3 0.04376 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methocarbamol→?; validate in glaucoma cell model. Expected: similar to propranolol (Jaccard=0.50) ethinyl_estradiol prostate_cancer GAP_HIGH 0.1685 0.5789473684210527 mestranol 0.6 RISING 0.6 3 0.04376 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethinyl_estradiol→?; validate in prostate_cancer cell model. Expected: similar to mestranol (Jaccard=0.58) carbidopa thyroid_cancer GAP_HIGH 0.1263 0.35 l-dopa 0.8 RAPID_RISE 0.6 3 0.04373 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carbidopa→?; validate in thyroid_cancer cell model. Expected: similar to l-dopa (Jaccard=0.35) oxazepam alcohol_dependence GAP_HIGH 0.2244 0.6666666666666666 temazepam 0.45 STABLE 0.6 3 0.04371 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxazepam→?; validate in alcohol_dependence cell model. Expected: similar to temazepam (Jaccard=0.67) dextropropoxyphene chronic_kidney_failure GAP_HIGH 0.2244 0.4 propiomazine 0.45 STABLE 0.6 3 0.04371 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dextropropoxyphene→?; validate in chronic_kidney_failure cell model. Expected: similar to propiomazine (Jaccard=0.40) methamphetamine coronary_artery_disease GAP_HIGH 0.1782 0.5454545454545454 phentermine 0.4 STABLE 0.85 3 0.04371 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methamphetamine→?; validate in coronary_artery_disease cell model. Expected: similar to phentermine (Jaccard=0.55) flunarizine metabolic_syndrome_x GAP_HIGH 0.1293 0.2727272727272727 papaverine 0.55 STABLE 0.85 3 0.0436 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flunarizine→?; validate in metabolic_syndrome_x cell model. Expected: similar to papaverine (Jaccard=0.27) isradipine alopecia_areata GAP_HIGH 0.158 0.2 desoximetasone 0.45 STABLE 0.85 3 0.04359 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isradipine→?; validate in alopecia_areata cell model. Expected: similar to desoximetasone (Jaccard=0.20) olanzapine focal_segmental_glomerulosclerosis GAP_HIGH 0.1343 0.25 cholecalciferol 0.45 STABLE 1.0 3 0.04359 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay olanzapine→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to cholecalciferol (Jaccard=0.25) ziprasidone alcohol_dependence GAP_HIGH 0.1578 0.25 temazepam 0.45 STABLE 0.85 3 0.04354 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ziprasidone→?; validate in alcohol_dependence cell model. Expected: similar to temazepam (Jaccard=0.25) methocarbamol refractive_error GAP_HIGH 0.2235 0.5 propranolol 0.45 STABLE 0.6 3 0.04353 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methocarbamol→?; validate in refractive_error cell model. Expected: similar to propranolol (Jaccard=0.50) amitriptyline rheumatoid_arthritis GAP_HIGH 0.1774 0.75 doxepin 0.4 STABLE 0.85 3 0.04351 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amitriptyline→?; validate in rheumatoid_arthritis cell model. Expected: similar to doxepin (Jaccard=0.75) cladribine multiple_sclerosis GAP_HIGH 0.197 0.5 emtricitabine 0.6 RISING 0.85 3 0.04348 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cladribine→?; validate in multiple_sclerosis cell model. Expected: similar to emtricitabine (Jaccard=0.50) methocarbamol chronic_kidney_failure GAP_HIGH 0.2232 0.5 propranolol 0.45 STABLE 0.6 3 0.04347 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methocarbamol→?; validate in chronic_kidney_failure cell model. Expected: similar to propranolol (Jaccard=0.50) dextropropoxyphene azoospermia GAP_HIGH 0.2232 0.4 propiomazine 0.45 STABLE 0.6 3 0.04347 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dextropropoxyphene→?; validate in azoospermia cell model. Expected: similar to propiomazine (Jaccard=0.40) chlorprothixene kidney_cancer GAP_HIGH 0.1673 0.6086956521739131 quinacrine 0.6 RISING 0.6 3 0.04345 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorprothixene→?; validate in kidney_cancer cell model. Expected: similar to quinacrine (Jaccard=0.61) dextropropoxyphene membranous_glomerulonephritis GAP_HIGH 0.223 0.4 propiomazine 0.45 STABLE 0.6 3 0.04343 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dextropropoxyphene→?; validate in membranous_glomerulonephritis cell model. Expected: similar to propiomazine (Jaccard=0.40) pargyline refractive_error GAP_HIGH 0.1574 0.4375 phenylpropanolamine 0.45 STABLE 0.85 3 0.04343 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pargyline→?; validate in refractive_error cell model. Expected: similar to phenylpropanolamine (Jaccard=0.44) dexamethasone brain_cancer GAP_HIGH 0.1178 0.2857142857142857 doxorubicin 0.6 RISING 0.85 3 0.04334 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dexamethasone→?; validate in brain_cancer cell model. Expected: similar to doxorubicin (Jaccard=0.29) diethylstilbestrol prostate_cancer GAP_HIGH 0.1667 0.5454545454545454 diphemanil_methylsulfate 0.6 RISING 0.6 3 0.04329 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diethylstilbestrol→?; validate in prostate_cancer cell model. Expected: similar to diphemanil_methylsulfate (Jaccard=0.55) nortriptyline chronic_kidney_failure GAP_HIGH 0.1569 0.5 doxepin 0.45 STABLE 0.85 3 0.04329 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nortriptyline→?; validate in chronic_kidney_failure cell model. Expected: similar to doxepin (Jaccard=0.50) phenobarbital autistic_disorder GAP_HIGH 0.222 0.5384615384615384 ketazolam 0.45 STABLE 0.6 3 0.04324 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenobarbital→?; validate in autistic_disorder cell model. Expected: similar to ketazolam (Jaccard=0.54) methocarbamol azoospermia GAP_HIGH 0.222 0.5 propranolol 0.45 STABLE 0.6 3 0.04324 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methocarbamol→?; validate in azoospermia cell model. Expected: similar to propranolol (Jaccard=0.50) diethylstilbestrol mediastinal_cancer GAP_HIGH 0.1665 0.5454545454545454 diphemanil_methylsulfate 0.6 RISING 0.6 3 0.04324 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diethylstilbestrol→?; validate in mediastinal_cancer cell model. Expected: similar to diphemanil_methylsulfate (Jaccard=0.55) phenobarbital attention_deficit_hyperactivity_disorder GAP_HIGH 0.2218 0.5384615384615384 ketazolam 0.45 STABLE 0.6 3 0.0432 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenobarbital→?; validate in attention_deficit_hyperactivity_disorder cell model. Expected: similar to ketazolam (Jaccard=0.54) olmesartan coronary_artery_disease GAP_HIGH 0.2495 0.5714285714285714 eprosartan 0.4 STABLE 0.6 3 0.04319 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay olmesartan→?; validate in coronary_artery_disease cell model. Expected: similar to eprosartan (Jaccard=0.57) levorphanol germ_cell_cancer GAP_HIGH 0.1663 0.46153846153846156 fulvestrant 0.6 RISING 0.6 3 0.04319 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levorphanol→?; validate in germ_cell_cancer cell model. Expected: similar to fulvestrant (Jaccard=0.46) etidronic_acid pagets_disease_of_bone GAP_HIGH 0.5215 1.0 clodronate 0.45 STABLE 0.85 3 0.04317 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay etidronic_acid→?; validate in pagets_disease_of_bone cell model. Expected: similar to clodronate (Jaccard=1.00) clofarabine systemic_lupus_erythematosus GAP_HIGH 0.1955 0.4782608695652174 vidarabine 0.6 RISING 0.85 3 0.04315 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clofarabine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to vidarabine (Jaccard=0.48) chlorpropamide atherosclerosis GAP_HIGH 0.1564 0.25925925925925924 bezafibrate 0.45 STABLE 0.85 3 0.04315 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorpropamide→?; validate in atherosclerosis cell model. Expected: similar to bezafibrate (Jaccard=0.26) phenobarbital panic_disorder GAP_HIGH 0.2215 0.5384615384615384 ketazolam 0.45 STABLE 0.6 3 0.04314 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenobarbital→?; validate in panic_disorder cell model. Expected: similar to ketazolam (Jaccard=0.54) chlorpropamide idiopathic_pulmonary_fibrosis GAP_HIGH 0.1563 0.3157894736842105 zafirlukast 0.45 STABLE 0.85 3 0.04313 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorpropamide→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to zafirlukast (Jaccard=0.32) clonazepam gilles_de_la_tourette_syndrome GAP_HIGH 0.1811 0.5652173913043478 chlordiazepoxide 0.55 STABLE 0.6 3 0.04311 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clonazepam→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to chlordiazepoxide (Jaccard=0.57) l-histidine systemic_scleroderma GAP_HIGH 0.1562 0.4 penicillamine 0.45 STABLE 0.85 3 0.0431 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-histidine→?; validate in systemic_scleroderma cell model. Expected: similar to penicillamine (Jaccard=0.40) carvedilol larynx_cancer GAP_HIGH 0.1658 0.25 docetaxel 0.6 RISING 0.6 3 0.04306 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carvedilol→?; validate in larynx_cancer cell model. Expected: similar to docetaxel (Jaccard=0.25) tetracycline barretts_esophagus GAP_LOW 0.2015 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04302 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking tetracycline vs barretts_esophagus targets. Cross-check tetracycline pharmacophore against barretts_esophagus pathway. diphenhydramine membranous_glomerulonephritis GAP_HIGH 0.1558 0.6296296296296297 naftifine 0.45 STABLE 0.85 3 0.04299 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphenhydramine→?; validate in membranous_glomerulonephritis cell model. Expected: similar to naftifine (Jaccard=0.63) pheniramine focal_segmental_glomerulosclerosis GAP_HIGH 0.1558 0.5333333333333333 clofedanol 0.45 STABLE 0.85 3 0.04299 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pheniramine→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to clofedanol (Jaccard=0.53) chlorpromazine schizophrenia GAP_HIGH 0.1752 0.75 clomipramine 0.4 STABLE 0.85 3 0.04297 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorpromazine→?; validate in schizophrenia cell model. Expected: similar to clomipramine (Jaccard=0.75) nortriptyline azoospermia GAP_HIGH 0.1557 0.5 doxepin 0.45 STABLE 0.85 3 0.04296 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nortriptyline→?; validate in azoospermia cell model. Expected: similar to doxepin (Jaccard=0.50) stanozolol malignant_glioma GAP_HIGH 0.2205 0.5555555555555556 cortisone_acetate 0.45 STABLE 0.6 3 0.04295 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay stanozolol→?; validate in malignant_glioma cell model. Expected: similar to cortisone_acetate (Jaccard=0.56) chlorpromazine bipolar_disorder GAP_HIGH 0.175 0.75 clomipramine 0.4 STABLE 0.85 3 0.04292 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorpromazine→?; validate in bipolar_disorder cell model. Expected: similar to clomipramine (Jaccard=0.75) diazepam gilles_de_la_tourette_syndrome GAP_HIGH 0.1802 0.625 fludiazepam 0.55 STABLE 0.6 3 0.0429 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diazepam→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to fludiazepam (Jaccard=0.62) nortriptyline membranous_glomerulonephritis GAP_HIGH 0.1555 0.5 acepromazine 0.45 STABLE 0.85 3 0.0429 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nortriptyline→?; validate in membranous_glomerulonephritis cell model. Expected: similar to acepromazine (Jaccard=0.50) l-tyrosine larynx_cancer GAP_HIGH 0.1166 0.2692307692307692 procarbazine 0.6 RISING 0.85 3 0.0429 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-tyrosine→?; validate in larynx_cancer cell model. Expected: similar to procarbazine (Jaccard=0.27) olmesartan epilepsy_syndrome GAP_HIGH 0.2476 0.5714285714285714 telmisartan 0.4 STABLE 0.6 3 0.04287 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay olmesartan→?; validate in epilepsy_syndrome cell model. Expected: similar to telmisartan (Jaccard=0.57) progesterone esophageal_cancer GAP_HIGH 0.1165 0.32 fluoxymesterone 0.6 RISING 0.85 3 0.04286 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay progesterone→?; validate in esophageal_cancer cell model. Expected: similar to fluoxymesterone (Jaccard=0.32) fenbufen gout GAP_HIGH 0.2199 0.6666666666666666 phenindione 0.45 STABLE 0.6 3 0.04283 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fenbufen→?; validate in gout cell model. Expected: similar to phenindione (Jaccard=0.67) ethinyl_estradiol breast_cancer GAP_HIGH 0.1649 0.5789473684210527 mestranol 0.6 RISING 0.6 3 0.04282 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethinyl_estradiol→?; validate in breast_cancer cell model. Expected: similar to mestranol (Jaccard=0.58) irbesartan lymphatic_system_cancer GAP_HIGH 0.1647 0.16666666666666666 vinblastine 0.6 RISING 0.6 3 0.04277 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay irbesartan→?; validate in lymphatic_system_cancer cell model. Expected: similar to vinblastine (Jaccard=0.17) trifluoperazine alcohol_dependence GAP_HIGH 0.155 0.46153846153846156 temazepam 0.45 STABLE 0.85 3 0.04277 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trifluoperazine→?; validate in alcohol_dependence cell model. Expected: similar to temazepam (Jaccard=0.46) modafinil parkinsons_disease GAP_HIGH 0.1234 0.45454545454545453 diphenylpyraline 0.8 RAPID_RISE 0.6 3 0.04273 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay modafinil→?; validate in parkinsons_disease cell model. Expected: similar to diphenylpyraline (Jaccard=0.45) olmesartan schizophrenia GAP_HIGH 0.2463 0.5714285714285714 telmisartan 0.4 STABLE 0.6 3 0.04264 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay olmesartan→?; validate in schizophrenia cell model. Expected: similar to telmisartan (Jaccard=0.57) olmesartan bipolar_disorder GAP_HIGH 0.2462 0.5714285714285714 telmisartan 0.4 STABLE 0.6 3 0.04262 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay olmesartan→?; validate in bipolar_disorder cell model. Expected: similar to telmisartan (Jaccard=0.57) levorphanol mediastinal_cancer GAP_HIGH 0.164 0.46153846153846156 fulvestrant 0.6 RISING 0.6 3 0.04259 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levorphanol→?; validate in mediastinal_cancer cell model. Expected: similar to fulvestrant (Jaccard=0.46) ergocalciferol osteoporosis GAP_HIGH 0.2185 0.5714285714285714 paricalcitol 0.45 STABLE 0.6 3 0.04256 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ergocalciferol→?; validate in osteoporosis cell model. Expected: similar to paricalcitol (Jaccard=0.57) aminocaproic_acid glaucoma GAP_HIGH 0.1542 0.19696969696969696 l-serine 0.45 STABLE 0.85 3 0.04255 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminocaproic_acid→?; validate in glaucoma cell model. Expected: similar to l-serine (Jaccard=0.20) loxapine schizophrenia GAP_HIGH 0.1734 0.64 amoxapine 0.4 STABLE 0.85 3 0.04253 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay loxapine→?; validate in schizophrenia cell model. Expected: similar to amoxapine (Jaccard=0.64) l-dopa systemic_lupus_erythematosus GAP_HIGH 0.1637 0.5454545454545454 isoetarine 0.6 RISING 0.6 3 0.04251 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-dopa→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to isoetarine (Jaccard=0.55) azatadine chronic_kidney_failure GAP_HIGH 0.154 0.42857142857142855 temazepam 0.45 STABLE 0.85 3 0.04249 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay azatadine→?; validate in chronic_kidney_failure cell model. Expected: similar to temazepam (Jaccard=0.43) chlorpropamide chronic_obstructive_pulmonary_disease GAP_HIGH 0.154 0.3157894736842105 zafirlukast 0.45 STABLE 0.85 3 0.04249 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorpropamide→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to zafirlukast (Jaccard=0.32) l-aspartic_acid systemic_scleroderma GAP_HIGH 0.154 0.23076923076923078 penicillamine 0.45 STABLE 0.85 3 0.04249 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-aspartic_acid→?; validate in systemic_scleroderma cell model. Expected: similar to penicillamine (Jaccard=0.23) moexipril acquired_immunodeficiency_syndrome GAP_HIGH 0.1784 0.3 lisinopril 0.55 STABLE 0.6 3 0.04247 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay moexipril→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to lisinopril (Jaccard=0.30) azatadine focal_segmental_glomerulosclerosis GAP_HIGH 0.1539 0.4166666666666667 trifluoperazine 0.45 STABLE 0.85 3 0.04246 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay azatadine→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to trifluoperazine (Jaccard=0.42) fenbufen chronic_obstructive_pulmonary_disease GAP_HIGH 0.2179 0.6666666666666666 phenindione 0.45 STABLE 0.6 3 0.04244 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fenbufen→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to phenindione (Jaccard=0.67) dimetindene chronic_kidney_failure GAP_HIGH 0.2179 0.625 doxepin 0.45 STABLE 0.6 3 0.04244 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dimetindene→?; validate in chronic_kidney_failure cell model. Expected: similar to doxepin (Jaccard=0.62) methotrimeprazine chronic_obstructive_pulmonary_disease GAP_HIGH 0.1537 0.5384615384615384 perphenazine 0.45 STABLE 0.85 3 0.04241 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methotrimeprazine→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to perphenazine (Jaccard=0.54) chloroprocaine atherosclerosis GAP_HIGH 0.1536 0.35714285714285715 clofibrate 0.45 STABLE 0.85 3 0.04238 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chloroprocaine→?; validate in atherosclerosis cell model. Expected: similar to clofibrate (Jaccard=0.36) norelgestromin malignant_glioma GAP_HIGH 0.2175 0.5555555555555556 megestrol_acetate 0.45 STABLE 0.6 3 0.04236 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay norelgestromin→?; validate in malignant_glioma cell model. Expected: similar to megestrol_acetate (Jaccard=0.56) cinnarizine gilles_de_la_tourette_syndrome GAP_HIGH 0.1255 0.25 flunarizine 0.55 STABLE 0.85 3 0.04232 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cinnarizine→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to flunarizine (Jaccard=0.25) fenbufen autistic_disorder GAP_HIGH 0.2171 0.6666666666666666 phenindione 0.45 STABLE 0.6 3 0.04228 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fenbufen→?; validate in autistic_disorder cell model. Expected: similar to phenindione (Jaccard=0.67) fenbufen nicotine_dependence GAP_HIGH 0.2171 0.6666666666666666 phenindione 0.45 STABLE 0.6 3 0.04228 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fenbufen→?; validate in nicotine_dependence cell model. Expected: similar to phenindione (Jaccard=0.67) olanzapine barretts_esophagus GAP_LOW 0.1681 0.0 pantoprazole 0.45 STABLE 1.0 5 0.04222 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking olanzapine vs barretts_esophagus targets. Cross-check olanzapine pharmacophore against barretts_esophagus pathway. dimetindene azoospermia GAP_HIGH 0.2167 0.625 doxepin 0.45 STABLE 0.6 3 0.04221 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dimetindene→?; validate in azoospermia cell model. Expected: similar to doxepin (Jaccard=0.62) aminosalicylic_acid malignant_mesothelioma GAP_HIGH 0.1529 0.5 mesalazine 0.45 STABLE 0.85 3 0.04219 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminosalicylic_acid→?; validate in malignant_mesothelioma cell model. Expected: similar to mesalazine (Jaccard=0.50) l-serine systemic_lupus_erythematosus GAP_HIGH 0.1144 0.2786885245901639 penicillamine 0.6 RISING 0.85 3 0.04209 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-serine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to penicillamine (Jaccard=0.28) cilazapril coronary_artery_disease GAP_HIGH 0.2429 0.6 moexipril 0.4 STABLE 0.6 3 0.04205 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cilazapril→?; validate in coronary_artery_disease cell model. Expected: similar to moexipril (Jaccard=0.60) aminosalicylic_acid meningioma GAP_HIGH 0.1523 0.5 mesalazine 0.45 STABLE 0.85 3 0.04202 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aminosalicylic_acid→?; validate in meningioma cell model. Expected: similar to mesalazine (Jaccard=0.50) clonidine coronary_artery_disease GAP_HIGH 0.1713 0.5384615384615384 mefenamic_acid 0.4 STABLE 0.85 3 0.04201 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clonidine→?; validate in coronary_artery_disease cell model. Expected: similar to mefenamic_acid (Jaccard=0.54) pheniramine membranous_glomerulonephritis GAP_HIGH 0.1522 0.5333333333333333 clofedanol 0.45 STABLE 0.85 3 0.04199 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pheniramine→?; validate in membranous_glomerulonephritis cell model. Expected: similar to clofedanol (Jaccard=0.53) mequitazine idiopathic_pulmonary_fibrosis GAP_HIGH 0.1522 0.5 cetirizine 0.45 STABLE 0.85 3 0.04199 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mequitazine→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to cetirizine (Jaccard=0.50) lacosamide atherosclerosis GAP_HIGH 0.1521 0.38461538461538464 phentermine 0.45 STABLE 0.85 3 0.04197 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lacosamide→?; validate in atherosclerosis cell model. Expected: similar to phentermine (Jaccard=0.38) methdilazine azoospermia GAP_HIGH 0.152 0.52 chlorpromazine 0.45 STABLE 0.85 3 0.04194 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methdilazine→?; validate in azoospermia cell model. Expected: similar to chlorpromazine (Jaccard=0.52) ethylmorphine autistic_disorder GAP_HIGH 0.152 0.3333333333333333 doxapram 0.45 STABLE 0.85 3 0.04194 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethylmorphine→?; validate in autistic_disorder cell model. Expected: similar to doxapram (Jaccard=0.33) anisindione focal_segmental_glomerulosclerosis GAP_HIGH 0.152 0.2 cyamemazine 0.45 STABLE 0.85 3 0.04194 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay anisindione→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to cyamemazine (Jaccard=0.20) cyclopentolate malaria GAP_HIGH 0.1519 0.38461538461538464 methylphenobarbital 0.45 STABLE 0.85 3 0.04191 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyclopentolate→?; validate in malaria cell model. Expected: similar to methylphenobarbital (Jaccard=0.38) ethylmorphine attention_deficit_hyperactivity_disorder GAP_HIGH 0.1518 0.3333333333333333 doxapram 0.45 STABLE 0.85 3 0.04188 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethylmorphine→?; validate in attention_deficit_hyperactivity_disorder cell model. Expected: similar to doxapram (Jaccard=0.33) cyclizine celiac_disease GAP_HIGH 0.1514 0.4166666666666667 benzatropine 0.45 STABLE 0.85 3 0.04177 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyclizine→?; validate in celiac_disease cell model. Expected: similar to benzatropine (Jaccard=0.42) clotrimazole penile_cancer GAP_HIGH 0.1135 0.2777777777777778 ifenprodil 0.6 RISING 0.85 3 0.04176 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clotrimazole→?; validate in penile_cancer cell model. Expected: similar to ifenprodil (Jaccard=0.28) zolpidem attention_deficit_hyperactivity_disorder GAP_HIGH 0.2143 0.5 ketorolac 0.45 STABLE 0.6 3 0.04174 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zolpidem→?; validate in attention_deficit_hyperactivity_disorder cell model. Expected: similar to ketorolac (Jaccard=0.50) candesartan azoospermia GAP_HIGH 0.2141 0.42857142857142855 ospemifene 0.45 STABLE 0.6 3 0.0417 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay candesartan→?; validate in azoospermia cell model. Expected: similar to ospemifene (Jaccard=0.43) zolpidem conduct_disorder GAP_HIGH 0.214 0.5 ketorolac 0.45 STABLE 0.6 3 0.04168 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zolpidem→?; validate in conduct_disorder cell model. Expected: similar to ketorolac (Jaccard=0.50) zolpidem panic_disorder GAP_HIGH 0.214 0.5 ketorolac 0.45 STABLE 0.6 3 0.04168 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zolpidem→?; validate in panic_disorder cell model. Expected: similar to ketorolac (Jaccard=0.50) conjugated_estrogens brain_cancer GAP_HIGH 0.1605 0.3333333333333333 estrone 0.6 RISING 0.6 3 0.04168 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay conjugated_estrogens→?; validate in brain_cancer cell model. Expected: similar to estrone (Jaccard=0.33) dimetindene gout GAP_HIGH 0.2138 0.625 doxepin 0.45 STABLE 0.6 3 0.04164 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dimetindene→?; validate in gout cell model. Expected: similar to doxepin (Jaccard=0.62) pargyline pancreatitis GAP_HIGH 0.1509 0.4375 phenylpropanolamine 0.45 STABLE 0.85 3 0.04164 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pargyline→?; validate in pancreatitis cell model. Expected: similar to phenylpropanolamine (Jaccard=0.44) nicardipine barretts_esophagus GAP_LOW 0.195 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04163 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking nicardipine vs barretts_esophagus targets. Cross-check nicardipine pharmacophore against barretts_esophagus pathway. nilvadipine barretts_esophagus GAP_LOW 0.195 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04163 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking nilvadipine vs barretts_esophagus targets. Cross-check nilvadipine pharmacophore against barretts_esophagus pathway. tauroursodeoxycholic_acid barretts_esophagus GAP_LOW 0.195 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04163 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking tauroursodeoxycholic_acid vs barretts_esophagus targets. Cross-check tauroursodeoxycholic_acid pharmacophore against barretts_esophagus pathway. indecainide celiac_disease GAP_HIGH 0.1508 0.4 phenindamine 0.45 STABLE 0.85 3 0.04161 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay indecainide→?; validate in celiac_disease cell model. Expected: similar to phenindamine (Jaccard=0.40) dimetindene narcolepsy GAP_HIGH 0.2136 0.625 doxepin 0.45 STABLE 0.6 3 0.0416 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dimetindene→?; validate in narcolepsy cell model. Expected: similar to doxepin (Jaccard=0.62) bromodiphenhydramine epilepsy_syndrome GAP_HIGH 0.1693 0.5 brompheniramine 0.4 STABLE 0.85 3 0.04152 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bromodiphenhydramine→?; validate in epilepsy_syndrome cell model. Expected: similar to brompheniramine (Jaccard=0.50) acenocoumarol duodenum_cancer GAP_HIGH 0.1598 0.4 clobazam 0.6 RISING 0.6 3 0.0415 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acenocoumarol→?; validate in duodenum_cancer cell model. Expected: similar to clobazam (Jaccard=0.40) acenocoumarol gallbladder_cancer GAP_HIGH 0.1598 0.4 clobazam 0.6 RISING 0.6 3 0.0415 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acenocoumarol→?; validate in gallbladder_cancer cell model. Expected: similar to clobazam (Jaccard=0.40) flutamide multiple_sclerosis GAP_HIGH 0.1879 0.3333333333333333 nitrofural 0.6 RISING 0.85 3 0.04148 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flutamide→?; validate in multiple_sclerosis cell model. Expected: similar to nitrofural (Jaccard=0.33) estazolam alcohol_dependence GAP_HIGH 0.2129 0.5625 fludiazepam 0.45 STABLE 0.6 3 0.04147 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estazolam→?; validate in alcohol_dependence cell model. Expected: similar to fludiazepam (Jaccard=0.56) cyclizine azoospermia GAP_HIGH 0.1501 0.4166666666666667 benzatropine 0.45 STABLE 0.85 3 0.04141 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyclizine→?; validate in azoospermia cell model. Expected: similar to benzatropine (Jaccard=0.42) bezafibrate kidney_cancer GAP_HIGH 0.1125 0.2692307692307692 gliclazide 0.6 RISING 0.85 3 0.04139 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bezafibrate→?; validate in kidney_cancer cell model. Expected: similar to gliclazide (Jaccard=0.27) acetylsalicylic_acid esophageal_cancer GAP_HIGH 0.1125 0.23529411764705882 lapatinib 0.6 RISING 0.85 3 0.04139 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acetylsalicylic_acid→?; validate in esophageal_cancer cell model. Expected: similar to lapatinib (Jaccard=0.24) mequitazine chronic_obstructive_pulmonary_disease GAP_HIGH 0.1498 0.5 nefazodone 0.45 STABLE 0.85 3 0.04133 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mequitazine→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to nefazodone (Jaccard=0.50) anisindione chronic_kidney_failure GAP_HIGH 0.1498 0.2 cyamemazine 0.45 STABLE 0.85 3 0.04133 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay anisindione→?; validate in chronic_kidney_failure cell model. Expected: similar to cyamemazine (Jaccard=0.20) diphenhydramine allergic_rhinitis GAP_HIGH 0.1497 0.6296296296296297 naftifine 0.45 STABLE 0.85 3 0.0413 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphenhydramine→?; validate in allergic_rhinitis cell model. Expected: similar to naftifine (Jaccard=0.63) indomethacin pharynx_cancer GAP_HIGH 0.1589 0.375 thalidomide 0.6 RISING 0.6 3 0.04126 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay indomethacin→?; validate in pharynx_cancer cell model. Expected: similar to thalidomide (Jaccard=0.38) indomethacin salivary_gland_cancer GAP_HIGH 0.1583 0.375 thalidomide 0.6 RISING 0.6 3 0.04111 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay indomethacin→?; validate in salivary_gland_cancer cell model. Expected: similar to thalidomide (Jaccard=0.38) indomethacin muscle_cancer GAP_HIGH 0.1582 0.375 thalidomide 0.6 RISING 0.6 3 0.04108 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay indomethacin→?; validate in muscle_cancer cell model. Expected: similar to thalidomide (Jaccard=0.38) beclomethasone psoriasis GAP_HIGH 0.2481 0.9166666666666666 rimexolone 0.45 STABLE 0.85 3 0.04107 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay beclomethasone→?; validate in psoriasis cell model. Expected: similar to rimexolone (Jaccard=0.92) diethylstilbestrol gilles_de_la_tourette_syndrome GAP_HIGH 0.1725 0.5454545454545454 diphemanil_methylsulfate 0.55 STABLE 0.6 3 0.04106 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diethylstilbestrol→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to diphemanil_methylsulfate (Jaccard=0.55) tiaprofenic_acid vulva_cancer GAP_HIGH 0.1116 0.3 salsalate 0.6 RISING 0.85 3 0.04106 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tiaprofenic_acid→?; validate in vulva_cancer cell model. Expected: similar to salsalate (Jaccard=0.30) amlodipine barretts_esophagus GAP_LOW 0.1922 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04103 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking amlodipine vs barretts_esophagus targets. Cross-check amlodipine pharmacophore against barretts_esophagus pathway. enalapril type_1_diabetes_mellitus GAP_HIGH 0.158 0.35714285714285715 lisinopril 0.6 RISING 0.6 3 0.04103 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay enalapril→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to lisinopril (Jaccard=0.36) procaine leprosy GAP_HIGH 0.1486 0.25 phenmetrazine 0.45 STABLE 0.85 3 0.041 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay procaine→?; validate in leprosy cell model. Expected: similar to phenmetrazine (Jaccard=0.25) alprazolam chronic_kidney_failure GAP_HIGH 0.2103 0.55 chlordiazepoxide 0.45 STABLE 0.6 3 0.04096 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alprazolam→?; validate in chronic_kidney_failure cell model. Expected: similar to chlordiazepoxide (Jaccard=0.55) anisindione membranous_glomerulonephritis GAP_HIGH 0.1484 0.2 cyamemazine 0.45 STABLE 0.85 3 0.04095 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay anisindione→?; validate in membranous_glomerulonephritis cell model. Expected: similar to cyamemazine (Jaccard=0.20) pipotiazine crohns_disease GAP_HIGH 0.1482 0.5714285714285714 pirenzepine 0.45 STABLE 0.85 3 0.04089 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pipotiazine→?; validate in crohns_disease cell model. Expected: similar to pirenzepine (Jaccard=0.57) thiamylal azoospermia GAP_HIGH 0.2099 0.3333333333333333 fosphenytoin 0.45 STABLE 0.6 3 0.04088 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thiamylal→?; validate in azoospermia cell model. Expected: similar to fosphenytoin (Jaccard=0.33) alprazolam creutzfeldt-jakob_disease GAP_HIGH 0.2098 0.5714285714285714 estazolam 0.45 STABLE 0.6 3 0.04086 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alprazolam→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to estazolam (Jaccard=0.57) cyclizine crohns_disease GAP_HIGH 0.148 0.4166666666666667 benzatropine 0.45 STABLE 0.85 3 0.04084 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyclizine→?; validate in crohns_disease cell model. Expected: similar to benzatropine (Jaccard=0.42) raloxifene epilepsy_syndrome GAP_HIGH 0.2354 0.75 alcaftadine 0.4 STABLE 0.6 3 0.04075 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay raloxifene→?; validate in epilepsy_syndrome cell model. Expected: similar to alcaftadine (Jaccard=0.75) pipotiazine gout GAP_HIGH 0.1475 0.5714285714285714 pirenzepine 0.45 STABLE 0.85 3 0.0407 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pipotiazine→?; validate in gout cell model. Expected: similar to pirenzepine (Jaccard=0.57) heptabarbital focal_segmental_glomerulosclerosis GAP_HIGH 0.2089 0.38095238095238093 chlorprothixene 0.45 STABLE 0.6 3 0.04069 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay heptabarbital→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to chlorprothixene (Jaccard=0.38) alpha-linolenic_acid hypothyroidism GAP_LOW 0.1905 0.0 methimazole 0.45 STABLE 0.85 5 0.04067 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking alpha-linolenic_acid vs hypothyroidism targets. Cross-check alpha-linolenic_acid pharmacophore against hypothyroidism pathway. sulfapyridine atherosclerosis GAP_HIGH 0.1471 0.2916666666666667 olsalazine 0.45 STABLE 0.85 3 0.04059 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfapyridine→?; validate in atherosclerosis cell model. Expected: similar to olsalazine (Jaccard=0.29) l-ornithine schizophrenia GAP_HIGH 0.1654 0.2222222222222222 l-lysine 0.4 STABLE 0.85 3 0.04057 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-ornithine→?; validate in schizophrenia cell model. Expected: similar to l-lysine (Jaccard=0.22) trandolapril schizophrenia GAP_HIGH 0.2343 0.7777777777777778 lisinopril 0.4 STABLE 0.6 3 0.04056 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trandolapril→?; validate in schizophrenia cell model. Expected: similar to lisinopril (Jaccard=0.78) ziprasidone idiopathic_pulmonary_fibrosis GAP_HIGH 0.147 0.3 azatadine 0.45 STABLE 0.85 3 0.04056 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ziprasidone→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to azatadine (Jaccard=0.30) candesartan attention_deficit_hyperactivity_disorder GAP_HIGH 0.2082 0.42857142857142855 ospemifene 0.45 STABLE 0.6 3 0.04055 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay candesartan→?; validate in attention_deficit_hyperactivity_disorder cell model. Expected: similar to ospemifene (Jaccard=0.43) sotalol sarcoma GAP_HIGH 0.208 0.6153846153846154 atenolol 0.45 STABLE 0.6 3 0.04051 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sotalol→?; validate in sarcoma cell model. Expected: similar to atenolol (Jaccard=0.62) alprazolam alcohol_dependence GAP_HIGH 0.208 0.46153846153846156 midazolam 0.45 STABLE 0.6 3 0.04051 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alprazolam→?; validate in alcohol_dependence cell model. Expected: similar to midazolam (Jaccard=0.46) candesartan panic_disorder GAP_HIGH 0.208 0.42857142857142855 ospemifene 0.45 STABLE 0.6 3 0.04051 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay candesartan→?; validate in panic_disorder cell model. Expected: similar to ospemifene (Jaccard=0.43) alprazolam panic_disorder GAP_HIGH 0.2079 0.5714285714285714 estazolam 0.45 STABLE 0.6 3 0.04049 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alprazolam→?; validate in panic_disorder cell model. Expected: similar to estazolam (Jaccard=0.57) candesartan atopic_dermatitis GAP_HIGH 0.2079 0.42857142857142855 ospemifene 0.45 STABLE 0.6 3 0.04049 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay candesartan→?; validate in atopic_dermatitis cell model. Expected: similar to ospemifene (Jaccard=0.43) calcium_acetate barretts_esophagus GAP_LOW 0.1896 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04048 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking calcium_acetate vs barretts_esophagus targets. Cross-check calcium_acetate pharmacophore against barretts_esophagus pathway. isradipine barretts_esophagus GAP_LOW 0.1896 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04048 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking isradipine vs barretts_esophagus targets. Cross-check isradipine pharmacophore against barretts_esophagus pathway. lercanidipine barretts_esophagus GAP_LOW 0.1896 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04048 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking lercanidipine vs barretts_esophagus targets. Cross-check lercanidipine pharmacophore against barretts_esophagus pathway. nimodipine barretts_esophagus GAP_LOW 0.1896 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04048 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking nimodipine vs barretts_esophagus targets. Cross-check nimodipine pharmacophore against barretts_esophagus pathway. nisoldipine barretts_esophagus GAP_LOW 0.1896 0.0 pantoprazole 0.45 STABLE 0.85 5 0.04048 HIGH Full discovery pipeline needed: ~5 years Low-priority: Computational docking nisoldipine vs barretts_esophagus targets. Cross-check nisoldipine pharmacophore against barretts_esophagus pathway. tolmetin type_1_diabetes_mellitus GAP_HIGH 0.1559 0.3888888888888889 bromfenac 0.6 RISING 0.6 3 0.04048 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolmetin→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to bromfenac (Jaccard=0.39) thiamylal crohns_disease GAP_HIGH 0.2077 0.3333333333333333 fosphenytoin 0.45 STABLE 0.6 3 0.04045 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thiamylal→?; validate in crohns_disease cell model. Expected: similar to fosphenytoin (Jaccard=0.33) dimetacrine celiac_disease GAP_HIGH 0.1465 0.5185185185185185 diphenhydramine 0.45 STABLE 0.85 3 0.04042 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dimetacrine→?; validate in celiac_disease cell model. Expected: similar to diphenhydramine (Jaccard=0.52) atropine crohns_disease GAP_HIGH 0.1465 0.3333333333333333 homatropine_methylbromide 0.45 STABLE 0.85 3 0.04042 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay atropine→?; validate in crohns_disease cell model. Expected: similar to homatropine_methylbromide (Jaccard=0.33) methylphenobarbital narcolepsy GAP_HIGH 0.2075 0.45454545454545453 milnacipran 0.45 STABLE 0.6 3 0.04041 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methylphenobarbital→?; validate in narcolepsy cell model. Expected: similar to milnacipran (Jaccard=0.45) dipivefrin systemic_lupus_erythematosus GAP_HIGH 0.259 0.75 pirbuterol 0.6 RISING 0.6 3 0.04036 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dipivefrin→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to pirbuterol (Jaccard=0.75) voacamine malignant_glioma GAP_HIGH 0.1462 0.3333333333333333 vinblastine 0.45 STABLE 0.85 3 0.04034 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay voacamine→?; validate in malignant_glioma cell model. Expected: similar to vinblastine (Jaccard=0.33) naproxen larynx_cancer GAP_HIGH 0.1553 0.4375 procarbazine 0.6 RISING 0.6 3 0.04033 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay naproxen→?; validate in larynx_cancer cell model. Expected: similar to procarbazine (Jaccard=0.44) medrysone malignant_mesothelioma GAP_HIGH 0.1461 0.42857142857142855 hydrocortisone 0.45 STABLE 0.85 3 0.04031 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay medrysone→?; validate in malignant_mesothelioma cell model. Expected: similar to hydrocortisone (Jaccard=0.43) oxazepam chronic_kidney_failure GAP_HIGH 0.2068 0.6666666666666666 temazepam 0.45 STABLE 0.6 3 0.04028 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxazepam→?; validate in chronic_kidney_failure cell model. Expected: similar to temazepam (Jaccard=0.67) thiamylal narcolepsy GAP_HIGH 0.2068 0.3333333333333333 fosphenytoin 0.45 STABLE 0.6 3 0.04028 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thiamylal→?; validate in narcolepsy cell model. Expected: similar to fosphenytoin (Jaccard=0.33) heptabarbital chronic_kidney_failure GAP_HIGH 0.2067 0.38095238095238093 chlorprothixene 0.45 STABLE 0.6 3 0.04026 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay heptabarbital→?; validate in chronic_kidney_failure cell model. Expected: similar to chlorprothixene (Jaccard=0.38) clobazam focal_segmental_glomerulosclerosis GAP_HIGH 0.2066 0.631578947368421 chlorprothixene 0.45 STABLE 0.6 3 0.04024 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clobazam→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to chlorprothixene (Jaccard=0.63) propiomazine celiac_disease GAP_HIGH 0.1458 0.4 mepenzolate 0.45 STABLE 0.85 3 0.04023 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propiomazine→?; validate in celiac_disease cell model. Expected: similar to mepenzolate (Jaccard=0.40) anisindione gout GAP_HIGH 0.1458 0.2 carbamazepine 0.45 STABLE 0.85 3 0.04023 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay anisindione→?; validate in gout cell model. Expected: similar to carbamazepine (Jaccard=0.20) propafenone focal_segmental_glomerulosclerosis GAP_HIGH 0.1457 0.3888888888888889 propranolol 0.45 STABLE 0.85 3 0.0402 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propafenone→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to propranolol (Jaccard=0.39) olsalazine leprosy GAP_HIGH 0.1457 0.2916666666666667 sulfapyridine 0.45 STABLE 0.85 3 0.0402 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay olsalazine→?; validate in leprosy cell model. Expected: similar to sulfapyridine (Jaccard=0.29) methylphenobarbital creutzfeldt-jakob_disease GAP_HIGH 0.2063 0.45454545454545453 milnacipran 0.45 STABLE 0.6 3 0.04018 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methylphenobarbital→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to milnacipran (Jaccard=0.45) enalapril acquired_immunodeficiency_syndrome GAP_HIGH 0.1688 0.35714285714285715 lisinopril 0.55 STABLE 0.6 3 0.04018 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay enalapril→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to lisinopril (Jaccard=0.36) indecainide sclerosing_cholangitis GAP_HIGH 0.1453 0.4 phenindamine 0.45 STABLE 0.85 3 0.04009 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay indecainide→?; validate in sclerosing_cholangitis cell model. Expected: similar to phenindamine (Jaccard=0.40) benazepril narcolepsy GAP_HIGH 0.2058 0.42857142857142855 l-arginine 0.45 STABLE 0.6 3 0.04008 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benazepril→?; validate in narcolepsy cell model. Expected: similar to l-arginine (Jaccard=0.43) ketazolam malaria GAP_HIGH 0.2057 0.5384615384615384 phenobarbital 0.45 STABLE 0.6 3 0.04006 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ketazolam→?; validate in malaria cell model. Expected: similar to phenobarbital (Jaccard=0.54) thiamylal creutzfeldt-jakob_disease GAP_HIGH 0.2056 0.3333333333333333 fosphenytoin 0.45 STABLE 0.6 3 0.04004 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thiamylal→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to fosphenytoin (Jaccard=0.33) propafenone glaucoma GAP_HIGH 0.1451 0.3888888888888889 propranolol 0.45 STABLE 0.85 3 0.04004 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propafenone→?; validate in glaucoma cell model. Expected: similar to propranolol (Jaccard=0.39) levonordefrin atherosclerosis GAP_HIGH 0.2055 0.5882352941176471 carbidopa 0.45 STABLE 0.6 3 0.04002 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levonordefrin→?; validate in atherosclerosis cell model. Expected: similar to carbidopa (Jaccard=0.59) amobarbital focal_segmental_glomerulosclerosis GAP_HIGH 0.2055 0.36363636363636365 chlorprothixene 0.45 STABLE 0.6 3 0.04002 HIGH Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amobarbital→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to chlorprothixene (Jaccard=0.36) heptabarbital membranous_glomerulonephritis GAP_HIGH 0.2053 0.38095238095238093 chlorprothixene 0.45 STABLE 0.6 3 0.03999 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay heptabarbital→?; validate in membranous_glomerulonephritis cell model. Expected: similar to chlorprothixene (Jaccard=0.38) ramipril schizophrenia GAP_HIGH 0.2309 0.7777777777777778 lisinopril 0.4 STABLE 0.6 3 0.03997 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ramipril→?; validate in schizophrenia cell model. Expected: similar to lisinopril (Jaccard=0.78) thiamylal ankylosing_spondylitis GAP_HIGH 0.2052 0.3333333333333333 fosphenytoin 0.45 STABLE 0.6 3 0.03997 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thiamylal→?; validate in ankylosing_spondylitis cell model. Expected: similar to fosphenytoin (Jaccard=0.33) diphenidol coronary_artery_disease GAP_HIGH 0.2307 0.625 bepridil 0.4 STABLE 0.6 3 0.03994 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphenidol→?; validate in coronary_artery_disease cell model. Expected: similar to bepridil (Jaccard=0.62) l-aspartic_acid barretts_esophagus GAP_LOW 0.1871 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03994 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking l-aspartic_acid vs barretts_esophagus targets. Cross-check l-aspartic_acid pharmacophore against barretts_esophagus pathway. l-carnitine barretts_esophagus GAP_LOW 0.1871 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03994 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking l-carnitine vs barretts_esophagus targets. Cross-check l-carnitine pharmacophore against barretts_esophagus pathway. l-citrulline barretts_esophagus GAP_LOW 0.1871 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03994 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking l-citrulline vs barretts_esophagus targets. Cross-check l-citrulline pharmacophore against barretts_esophagus pathway. l-ornithine barretts_esophagus GAP_LOW 0.1871 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03994 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking l-ornithine vs barretts_esophagus targets. Cross-check l-ornithine pharmacophore against barretts_esophagus pathway. trilostane malignant_glioma GAP_HIGH 0.205 0.5555555555555556 cortisone_acetate 0.45 STABLE 0.6 3 0.03993 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trilostane→?; validate in malignant_glioma cell model. Expected: similar to cortisone_acetate (Jaccard=0.56) aprobarbital focal_segmental_glomerulosclerosis GAP_HIGH 0.205 0.36363636363636365 chlorprothixene 0.45 STABLE 0.6 3 0.03993 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aprobarbital→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to chlorprothixene (Jaccard=0.36) butethal focal_segmental_glomerulosclerosis GAP_HIGH 0.205 0.36363636363636365 chlorprothixene 0.45 STABLE 0.6 3 0.03993 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay butethal→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to chlorprothixene (Jaccard=0.36) warfarin leprosy GAP_HIGH 0.123 0.2 phenmetrazine 0.45 STABLE 1.0 3 0.03993 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay warfarin→?; validate in leprosy cell model. Expected: similar to phenmetrazine (Jaccard=0.20) quinapril coronary_artery_disease GAP_HIGH 0.2306 0.5 moexipril 0.4 STABLE 0.6 3 0.03992 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinapril→?; validate in coronary_artery_disease cell model. Expected: similar to moexipril (Jaccard=0.50) lisinopril barretts_esophagus GAP_LOW 0.1589 0.0 pantoprazole 0.45 STABLE 1.0 5 0.03991 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking lisinopril vs barretts_esophagus targets. Cross-check lisinopril pharmacophore against barretts_esophagus pathway. practolol hematologic_cancer GAP_HIGH 0.1536 0.3076923076923077 l-tyrosine 0.6 RISING 0.6 3 0.03989 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay practolol→?; validate in hematologic_cancer cell model. Expected: similar to l-tyrosine (Jaccard=0.31) anileridine epilepsy_syndrome GAP_HIGH 0.1625 0.4166666666666667 milnacipran 0.4 STABLE 0.85 3 0.03985 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay anileridine→?; validate in epilepsy_syndrome cell model. Expected: similar to milnacipran (Jaccard=0.42) clobazam chronic_kidney_failure GAP_HIGH 0.2044 0.631578947368421 chlorprothixene 0.45 STABLE 0.6 3 0.03981 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clobazam→?; validate in chronic_kidney_failure cell model. Expected: similar to chlorprothixene (Jaccard=0.63) acetylsalicylic_acid germ_cell_cancer GAP_HIGH 0.1082 0.23529411764705882 lapatinib 0.6 RISING 0.85 3 0.03981 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acetylsalicylic_acid→?; validate in germ_cell_cancer cell model. Expected: similar to lapatinib (Jaccard=0.24) alimemazine crohns_disease GAP_HIGH 0.1442 0.47058823529411764 dimetacrine 0.45 STABLE 0.85 3 0.03979 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alimemazine→?; validate in crohns_disease cell model. Expected: similar to dimetacrine (Jaccard=0.47) valsartan coronary_artery_disease GAP_HIGH 0.2298 0.5714285714285714 eprosartan 0.4 STABLE 0.6 3 0.03978 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay valsartan→?; validate in coronary_artery_disease cell model. Expected: similar to eprosartan (Jaccard=0.57) doxycycline hypothyroidism GAP_LOW 0.1862 0.0 methimazole 0.45 STABLE 0.85 5 0.03975 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking doxycycline vs hypothyroidism targets. Cross-check doxycycline pharmacophore against hypothyroidism pathway. oxcarbazepine chronic_obstructive_pulmonary_disease GAP_HIGH 0.1439 0.4166666666666667 phenindione 0.45 STABLE 0.85 3 0.0397 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxcarbazepine→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to phenindione (Jaccard=0.42) orlistat refractive_error GAP_HIGH 0.2038 0.25 dihomo-gamma-linolenic_acid 0.45 STABLE 0.6 3 0.03969 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay orlistat→?; validate in refractive_error cell model. Expected: similar to dihomo-gamma-linolenic_acid (Jaccard=0.25) practolol duodenum_cancer GAP_HIGH 0.1528 0.3076923076923077 l-tyrosine 0.6 RISING 0.6 3 0.03968 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay practolol→?; validate in duodenum_cancer cell model. Expected: similar to l-tyrosine (Jaccard=0.31) practolol gallbladder_cancer GAP_HIGH 0.1528 0.3076923076923077 l-tyrosine 0.6 RISING 0.6 3 0.03968 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay practolol→?; validate in gallbladder_cancer cell model. Expected: similar to l-tyrosine (Jaccard=0.31) propafenone refractive_error GAP_HIGH 0.1438 0.3888888888888889 propranolol 0.45 STABLE 0.85 3 0.03968 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propafenone→?; validate in refractive_error cell model. Expected: similar to propranolol (Jaccard=0.39) benazepril autistic_disorder GAP_HIGH 0.2033 0.42857142857142855 l-arginine 0.45 STABLE 0.6 3 0.0396 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benazepril→?; validate in autistic_disorder cell model. Expected: similar to l-arginine (Jaccard=0.43) benazepril nicotine_dependence GAP_HIGH 0.2033 0.42857142857142855 l-arginine 0.45 STABLE 0.6 3 0.0396 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benazepril→?; validate in nicotine_dependence cell model. Expected: similar to l-arginine (Jaccard=0.43) amobarbital chronic_kidney_failure GAP_HIGH 0.2033 0.36363636363636365 chlorprothixene 0.45 STABLE 0.6 3 0.0396 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amobarbital→?; validate in chronic_kidney_failure cell model. Expected: similar to chlorprothixene (Jaccard=0.36) phenylpropanolamine osteoporosis GAP_HIGH 0.1434 0.4375 pargyline 0.45 STABLE 0.85 3 0.03957 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenylpropanolamine→?; validate in osteoporosis cell model. Expected: similar to pargyline (Jaccard=0.44) phenindamine coronary_artery_disease GAP_HIGH 0.1613 0.4 indecainide 0.4 STABLE 0.85 3 0.03956 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenindamine→?; validate in coronary_artery_disease cell model. Expected: similar to indecainide (Jaccard=0.40) clobazam membranous_glomerulonephritis GAP_HIGH 0.203 0.631578947368421 chlorprothixene 0.45 STABLE 0.6 3 0.03954 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clobazam→?; validate in membranous_glomerulonephritis cell model. Expected: similar to chlorprothixene (Jaccard=0.63) benazepril attention_deficit_hyperactivity_disorder GAP_HIGH 0.203 0.42857142857142855 l-arginine 0.45 STABLE 0.6 3 0.03954 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benazepril→?; validate in attention_deficit_hyperactivity_disorder cell model. Expected: similar to l-arginine (Jaccard=0.43) aprobarbital chronic_kidney_failure GAP_HIGH 0.2028 0.36363636363636365 chlorprothixene 0.45 STABLE 0.6 3 0.0395 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aprobarbital→?; validate in chronic_kidney_failure cell model. Expected: similar to chlorprothixene (Jaccard=0.36) butethal chronic_kidney_failure GAP_HIGH 0.2028 0.36363636363636365 chlorprothixene 0.45 STABLE 0.6 3 0.0395 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay butethal→?; validate in chronic_kidney_failure cell model. Expected: similar to chlorprothixene (Jaccard=0.36) valsartan epilepsy_syndrome GAP_HIGH 0.2279 0.5714285714285714 telmisartan 0.4 STABLE 0.6 3 0.03945 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay valsartan→?; validate in epilepsy_syndrome cell model. Expected: similar to telmisartan (Jaccard=0.57) aminocaproic_acid barretts_esophagus GAP_LOW 0.1848 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03945 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking aminocaproic_acid vs barretts_esophagus targets. Cross-check aminocaproic_acid pharmacophore against barretts_esophagus pathway. oxazepam narcolepsy GAP_HIGH 0.2025 0.6666666666666666 temazepam 0.45 STABLE 0.6 3 0.03944 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxazepam→?; validate in narcolepsy cell model. Expected: similar to temazepam (Jaccard=0.67) acepromazine crohns_disease GAP_HIGH 0.1429 0.5 nortriptyline 0.45 STABLE 0.85 3 0.03943 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acepromazine→?; validate in crohns_disease cell model. Expected: similar to nortriptyline (Jaccard=0.50) promethazine celiac_disease GAP_HIGH 0.1429 0.5 benzatropine 0.45 STABLE 0.85 3 0.03943 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay promethazine→?; validate in celiac_disease cell model. Expected: similar to benzatropine (Jaccard=0.50) phentermine glaucoma GAP_HIGH 0.1429 0.35714285714285715 phenylpropanolamine 0.45 STABLE 0.85 3 0.03943 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phentermine→?; validate in glaucoma cell model. Expected: similar to phenylpropanolamine (Jaccard=0.36) dimetacrine idiopathic_pulmonary_fibrosis GAP_HIGH 0.1427 0.5185185185185185 diphenhydramine 0.45 STABLE 0.85 3 0.03937 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dimetacrine→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to diphenhydramine (Jaccard=0.52) propiomazine crohns_disease GAP_HIGH 0.1424 0.4 mepenzolate 0.45 STABLE 0.85 3 0.03929 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propiomazine→?; validate in crohns_disease cell model. Expected: similar to mepenzolate (Jaccard=0.40) metaraminol peripheral_nervous_system_neoplasm GAP_HIGH 0.2017 0.42857142857142855 phenylephrine 0.45 STABLE 0.6 3 0.03928 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay metaraminol→?; validate in peripheral_nervous_system_neoplasm cell model. Expected: similar to phenylephrine (Jaccard=0.43) goserelin prostate_cancer GAP_HIGH 0.1511 0.2 ceruletide 0.6 RISING 0.6 3 0.03924 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay goserelin→?; validate in prostate_cancer cell model. Expected: similar to ceruletide (Jaccard=0.20) acepromazine gout GAP_HIGH 0.1422 0.5 nortriptyline 0.45 STABLE 0.85 3 0.03924 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acepromazine→?; validate in gout cell model. Expected: similar to nortriptyline (Jaccard=0.50) alimemazine sclerosing_cholangitis GAP_HIGH 0.1422 0.47058823529411764 dimetacrine 0.45 STABLE 0.85 3 0.03924 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alimemazine→?; validate in sclerosing_cholangitis cell model. Expected: similar to dimetacrine (Jaccard=0.47) medrysone pancreatitis GAP_HIGH 0.1422 0.42857142857142855 hydrocortisone 0.45 STABLE 0.85 3 0.03924 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay medrysone→?; validate in pancreatitis cell model. Expected: similar to hydrocortisone (Jaccard=0.43) l-histidine idiopathic_pulmonary_fibrosis GAP_HIGH 0.1422 0.3225806451612903 acetylcysteine 0.45 STABLE 0.85 3 0.03924 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-histidine→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to acetylcysteine (Jaccard=0.32) valsartan schizophrenia GAP_HIGH 0.2266 0.5714285714285714 telmisartan 0.4 STABLE 0.6 3 0.03923 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay valsartan→?; validate in schizophrenia cell model. Expected: similar to telmisartan (Jaccard=0.57) aprobarbital membranous_glomerulonephritis GAP_HIGH 0.2014 0.36363636363636365 chlorprothixene 0.45 STABLE 0.6 3 0.03923 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aprobarbital→?; validate in membranous_glomerulonephritis cell model. Expected: similar to chlorprothixene (Jaccard=0.36) butethal membranous_glomerulonephritis GAP_HIGH 0.2014 0.36363636363636365 chlorprothixene 0.45 STABLE 0.6 3 0.03923 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay butethal→?; validate in membranous_glomerulonephritis cell model. Expected: similar to chlorprothixene (Jaccard=0.36) valsartan bipolar_disorder GAP_HIGH 0.2265 0.5714285714285714 telmisartan 0.4 STABLE 0.6 3 0.03921 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay valsartan→?; validate in bipolar_disorder cell model. Expected: similar to telmisartan (Jaccard=0.57) phensuximide focal_segmental_glomerulosclerosis GAP_HIGH 0.1421 0.38636363636363635 clomipramine 0.45 STABLE 0.85 3 0.03921 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phensuximide→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to clomipramine (Jaccard=0.39) phenformin atherosclerosis GAP_HIGH 0.2012 0.5 phentermine 0.45 STABLE 0.6 3 0.03919 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenformin→?; validate in atherosclerosis cell model. Expected: similar to phentermine (Jaccard=0.50) reboxetine idiopathic_pulmonary_fibrosis GAP_HIGH 0.142 0.4444444444444444 atomoxetine 0.45 STABLE 0.85 3 0.03918 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay reboxetine→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to atomoxetine (Jaccard=0.44) metaraminol sarcoma GAP_HIGH 0.2009 0.42857142857142855 phenylephrine 0.45 STABLE 0.6 3 0.03913 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay metaraminol→?; validate in sarcoma cell model. Expected: similar to phenylephrine (Jaccard=0.43) diethylpropion idiopathic_pulmonary_fibrosis GAP_HIGH 0.2008 0.5833333333333334 ephedrine 0.45 STABLE 0.6 3 0.03911 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diethylpropion→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to ephedrine (Jaccard=0.58) phentermine refractive_error GAP_HIGH 0.1417 0.35714285714285715 phenylpropanolamine 0.45 STABLE 0.85 3 0.0391 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phentermine→?; validate in refractive_error cell model. Expected: similar to phenylpropanolamine (Jaccard=0.36) selegiline epilepsy_syndrome GAP_HIGH 0.1594 0.4 phenformin 0.4 STABLE 0.85 3 0.03909 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay selegiline→?; validate in epilepsy_syndrome cell model. Expected: similar to phenformin (Jaccard=0.40) regadenoson systemic_lupus_erythematosus GAP_HIGH 0.2507 0.6363636363636364 vidarabine 0.6 RISING 0.6 3 0.03906 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay regadenoson→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to vidarabine (Jaccard=0.64) ospemifene metabolic_syndrome_x GAP_HIGH 0.1641 0.42857142857142855 candesartan 0.55 STABLE 0.6 3 0.03906 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ospemifene→?; validate in metabolic_syndrome_x cell model. Expected: similar to candesartan (Jaccard=0.43) alimemazine chronic_obstructive_pulmonary_disease GAP_HIGH 0.1415 0.47058823529411764 dimetacrine 0.45 STABLE 0.85 3 0.03904 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alimemazine→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to dimetacrine (Jaccard=0.47) ketazolam gout GAP_HIGH 0.2004 0.5714285714285714 phenindione 0.45 STABLE 0.6 3 0.03903 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ketazolam→?; validate in gout cell model. Expected: similar to phenindione (Jaccard=0.57) nabumetone barretts_esophagus GAP_LOW 0.1826 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03898 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking nabumetone vs barretts_esophagus targets. Cross-check nabumetone pharmacophore against barretts_esophagus pathway. fentanyl prostate_cancer GAP_HIGH 0.15 0.5555555555555556 diphenylpyraline 0.6 RISING 0.6 3 0.03895 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fentanyl→?; validate in prostate_cancer cell model. Expected: similar to diphenylpyraline (Jaccard=0.56) sotalol intracranial_aneurysm GAP_HIGH 0.1999 0.5384615384615384 procarbazine 0.45 STABLE 0.6 3 0.03893 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sotalol→?; validate in intracranial_aneurysm cell model. Expected: similar to procarbazine (Jaccard=0.54) aminolevulinic_acid hypothyroidism GAP_LOW 0.1823 0.0 methimazole 0.45 STABLE 0.85 5 0.03892 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking aminolevulinic_acid vs hypothyroidism targets. Cross-check aminolevulinic_acid pharmacophore against hypothyroidism pathway. caffeine hypothyroidism GAP_LOW 0.1823 0.0 methimazole 0.45 STABLE 0.85 5 0.03892 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking caffeine vs hypothyroidism targets. Cross-check caffeine pharmacophore against hypothyroidism pathway. sodium_tetradecyl_sulfate hypothyroidism GAP_LOW 0.1823 0.0 methimazole 0.45 STABLE 0.85 5 0.03892 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking sodium_tetradecyl_sulfate vs hypothyroidism targets. Cross-check sodium_tetradecyl_sulfate pharmacophore against hypothyroidism pathway. aspartame acquired_immunodeficiency_syndrome GAP_HIGH 0.1635 0.2857142857142857 alvimopan 0.55 STABLE 0.6 3 0.03892 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aspartame→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to alvimopan (Jaccard=0.29) anisotropine_methylbromide alcohol_dependence GAP_HIGH 0.141 0.16666666666666666 heroin 0.45 STABLE 0.85 3 0.0389 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay anisotropine_methylbromide→?; validate in alcohol_dependence cell model. Expected: similar to heroin (Jaccard=0.17) flurbiprofen duodenum_cancer GAP_HIGH 0.1496 0.5333333333333333 chlorprothixene 0.6 RISING 0.6 3 0.03885 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flurbiprofen→?; validate in duodenum_cancer cell model. Expected: similar to chlorprothixene (Jaccard=0.53) procaine atherosclerosis GAP_HIGH 0.1408 0.3157894736842105 clofibrate 0.45 STABLE 0.85 3 0.03885 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay procaine→?; validate in atherosclerosis cell model. Expected: similar to clofibrate (Jaccard=0.32) ospemifene polycystic_ovary_syndrome GAP_HIGH 0.1631 0.42857142857142855 candesartan 0.55 STABLE 0.6 3 0.03883 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ospemifene→?; validate in polycystic_ovary_syndrome cell model. Expected: similar to candesartan (Jaccard=0.43) fentanyl hematologic_cancer GAP_HIGH 0.1495 0.5555555555555556 diphenylpyraline 0.6 RISING 0.6 3 0.03882 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fentanyl→?; validate in hematologic_cancer cell model. Expected: similar to diphenylpyraline (Jaccard=0.56) chlorphenesin barretts_esophagus GAP_HIGH 0.1992 0.16666666666666666 pantoprazole 0.45 STABLE 0.6 3 0.0388 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorphenesin→?; validate in barretts_esophagus cell model. Expected: similar to pantoprazole (Jaccard=0.17) thioproperazine crohns_disease GAP_HIGH 0.1405 0.5333333333333333 pirenzepine 0.45 STABLE 0.85 3 0.03877 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thioproperazine→?; validate in crohns_disease cell model. Expected: similar to pirenzepine (Jaccard=0.53) mesalazine crohns_disease GAP_HIGH 0.1405 0.5 aminosalicylic_acid 0.45 STABLE 0.85 3 0.03877 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mesalazine→?; validate in crohns_disease cell model. Expected: similar to aminosalicylic_acid (Jaccard=0.50) sulfapyridine glaucoma GAP_HIGH 0.1405 0.2916666666666667 olsalazine 0.45 STABLE 0.85 3 0.03877 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfapyridine→?; validate in glaucoma cell model. Expected: similar to olsalazine (Jaccard=0.29) propiomazine sclerosing_cholangitis GAP_HIGH 0.1403 0.4 mepenzolate 0.45 STABLE 0.85 3 0.03871 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propiomazine→?; validate in sclerosing_cholangitis cell model. Expected: similar to mepenzolate (Jaccard=0.40) lacosamide idiopathic_pulmonary_fibrosis GAP_HIGH 0.1403 0.38461538461538464 phentermine 0.45 STABLE 0.85 3 0.03871 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lacosamide→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to phentermine (Jaccard=0.38) cinolazepam creutzfeldt-jakob_disease GAP_HIGH 0.1987 0.5555555555555556 estazolam 0.45 STABLE 0.6 3 0.0387 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cinolazepam→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to estazolam (Jaccard=0.56) ketazolam ankylosing_spondylitis GAP_HIGH 0.1985 0.5714285714285714 phenindione 0.45 STABLE 0.6 3 0.03866 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ketazolam→?; validate in ankylosing_spondylitis cell model. Expected: similar to phenindione (Jaccard=0.57) atomoxetine malignant_mesothelioma GAP_HIGH 0.1401 0.4444444444444444 reboxetine 0.45 STABLE 0.85 3 0.03866 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay atomoxetine→?; validate in malignant_mesothelioma cell model. Expected: similar to reboxetine (Jaccard=0.44) ketazolam chronic_obstructive_pulmonary_disease GAP_HIGH 0.1984 0.5714285714285714 phenindione 0.45 STABLE 0.6 3 0.03864 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ketazolam→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to phenindione (Jaccard=0.57) levonordefrin psoriatic_arthritis GAP_HIGH 0.1983 0.6363636363636364 isoprenaline 0.45 STABLE 0.6 3 0.03862 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levonordefrin→?; validate in psoriatic_arthritis cell model. Expected: similar to isoprenaline (Jaccard=0.64) acepromazine pancreatitis GAP_HIGH 0.1399 0.5 nortriptyline 0.45 STABLE 0.85 3 0.0386 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acepromazine→?; validate in pancreatitis cell model. Expected: similar to nortriptyline (Jaccard=0.50) phensuximide chronic_kidney_failure GAP_HIGH 0.1399 0.38636363636363635 clomipramine 0.45 STABLE 0.85 3 0.0386 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phensuximide→?; validate in chronic_kidney_failure cell model. Expected: similar to clomipramine (Jaccard=0.39) thioproperazine gout GAP_HIGH 0.1398 0.5333333333333333 pirenzepine 0.45 STABLE 0.85 3 0.03857 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thioproperazine→?; validate in gout cell model. Expected: similar to pirenzepine (Jaccard=0.53) diphenylpyraline malaria GAP_HIGH 0.1398 0.45454545454545453 modafinil 0.45 STABLE 0.85 3 0.03857 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphenylpyraline→?; validate in malaria cell model. Expected: similar to modafinil (Jaccard=0.45) chlorprothixene narcolepsy GAP_HIGH 0.198 0.8181818181818182 clomipramine 0.45 STABLE 0.6 3 0.03856 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorprothixene→?; validate in narcolepsy cell model. Expected: similar to clomipramine (Jaccard=0.82) phenobarbital epilepsy_syndrome GAP_HIGH 0.2227 0.5384615384615384 ketazolam 0.4 STABLE 0.6 3 0.03855 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenobarbital→?; validate in epilepsy_syndrome cell model. Expected: similar to ketazolam (Jaccard=0.54) choline barretts_esophagus GAP_LOW 0.1806 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03855 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking choline vs barretts_esophagus targets. Cross-check choline pharmacophore against barretts_esophagus pathway. gliclazide barretts_esophagus GAP_LOW 0.1806 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03855 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking gliclazide vs barretts_esophagus targets. Cross-check gliclazide pharmacophore against barretts_esophagus pathway. propafenone epilepsy_syndrome GAP_HIGH 0.1572 0.5 methocarbamol 0.4 STABLE 0.85 3 0.03855 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propafenone→?; validate in epilepsy_syndrome cell model. Expected: similar to methocarbamol (Jaccard=0.50) ketazolam focal_segmental_glomerulosclerosis GAP_HIGH 0.1977 0.5238095238095238 chlorpromazine 0.45 STABLE 0.6 3 0.0385 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ketazolam→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to chlorpromazine (Jaccard=0.52) propiomazine pancreatitis GAP_HIGH 0.1394 0.4 mepenzolate 0.45 STABLE 0.85 3 0.03846 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propiomazine→?; validate in pancreatitis cell model. Expected: similar to mepenzolate (Jaccard=0.40) diethylpropion psoriasis GAP_HIGH 0.1969 0.5833333333333334 ephedrine 0.45 STABLE 0.6 3 0.03835 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diethylpropion→?; validate in psoriasis cell model. Expected: similar to ephedrine (Jaccard=0.58) thiothixene hematologic_cancer GAP_HIGH 0.1476 0.5909090909090909 zuclopenthixol 0.6 RISING 0.6 3 0.03833 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thiothixene→?; validate in hematologic_cancer cell model. Expected: similar to zuclopenthixol (Jaccard=0.59) goserelin breast_cancer GAP_HIGH 0.1475 0.2 ceruletide 0.6 RISING 0.6 3 0.0383 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay goserelin→?; validate in breast_cancer cell model. Expected: similar to ceruletide (Jaccard=0.20) spironolactone primary_biliary_cirrhosis GAP_HIGH 0.1387 0.42857142857142855 drospirenone 0.45 STABLE 0.85 3 0.03827 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay spironolactone→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to drospirenone (Jaccard=0.43) phensuximide membranous_glomerulonephritis GAP_HIGH 0.1385 0.38636363636363635 clomipramine 0.45 STABLE 0.85 3 0.03821 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phensuximide→?; validate in membranous_glomerulonephritis cell model. Expected: similar to clomipramine (Jaccard=0.39) warfarin celiac_disease GAP_HIGH 0.1177 0.3333333333333333 modafinil 0.45 STABLE 1.0 3 0.03821 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay warfarin→?; validate in celiac_disease cell model. Expected: similar to modafinil (Jaccard=0.33) fentanyl lung_cancer GAP_HIGH 0.1471 0.5555555555555556 diphenylpyraline 0.6 RISING 0.6 3 0.0382 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fentanyl→?; validate in lung_cancer cell model. Expected: similar to diphenylpyraline (Jaccard=0.56) colchicine barretts_esophagus GAP_LOW 0.1787 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03815 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking colchicine vs barretts_esophagus targets. Cross-check colchicine pharmacophore against barretts_esophagus pathway. dyphylline barretts_esophagus GAP_LOW 0.1787 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03815 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking dyphylline vs barretts_esophagus targets. Cross-check dyphylline pharmacophore against barretts_esophagus pathway. midodrine barretts_esophagus GAP_LOW 0.1787 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03815 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking midodrine vs barretts_esophagus targets. Cross-check midodrine pharmacophore against barretts_esophagus pathway. theophylline barretts_esophagus GAP_LOW 0.1787 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03815 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking theophylline vs barretts_esophagus targets. Cross-check theophylline pharmacophore against barretts_esophagus pathway. diazepam alcohol_dependence GAP_HIGH 0.1958 0.625 fludiazepam 0.45 STABLE 0.6 3 0.03813 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diazepam→?; validate in alcohol_dependence cell model. Expected: similar to fludiazepam (Jaccard=0.62) tetracycline hypothyroidism GAP_LOW 0.1786 0.0 methimazole 0.45 STABLE 0.85 5 0.03813 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking tetracycline vs hypothyroidism targets. Cross-check tetracycline pharmacophore against hypothyroidism pathway. dextropropoxyphene coronary_artery_disease GAP_HIGH 0.2201 0.4 propiomazine 0.4 STABLE 0.6 3 0.0381 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dextropropoxyphene→?; validate in coronary_artery_disease cell model. Expected: similar to propiomazine (Jaccard=0.40) suprofen glaucoma GAP_HIGH 0.1953 0.6363636363636364 procarbazine 0.45 STABLE 0.6 3 0.03804 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay suprofen→?; validate in glaucoma cell model. Expected: similar to procarbazine (Jaccard=0.64) estazolam chronic_kidney_failure GAP_HIGH 0.1953 0.5625 fludiazepam 0.45 STABLE 0.6 3 0.03804 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estazolam→?; validate in chronic_kidney_failure cell model. Expected: similar to fludiazepam (Jaccard=0.56) suprofen intracranial_aneurysm GAP_HIGH 0.1951 0.6363636363636364 procarbazine 0.45 STABLE 0.6 3 0.038 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay suprofen→?; validate in intracranial_aneurysm cell model. Expected: similar to procarbazine (Jaccard=0.64) methadone focal_segmental_glomerulosclerosis GAP_HIGH 0.1377 0.53125 clofedanol 0.45 STABLE 0.85 3 0.03799 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methadone→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to clofedanol (Jaccard=0.53) hydromorphone autistic_disorder GAP_HIGH 0.1377 0.25 dextromethorphan 0.45 STABLE 0.85 3 0.03799 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay hydromorphone→?; validate in autistic_disorder cell model. Expected: similar to dextromethorphan (Jaccard=0.25) salicylate-sodium leprosy GAP_HIGH 0.1376 0.23809523809523808 sulfapyridine 0.45 STABLE 0.85 3 0.03797 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay salicylate-sodium→?; validate in leprosy cell model. Expected: similar to sulfapyridine (Jaccard=0.24) clobazam epilepsy_syndrome GAP_HIGH 0.2192 0.7333333333333333 butabarbital 0.4 STABLE 0.6 3 0.03795 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clobazam→?; validate in epilepsy_syndrome cell model. Expected: similar to butabarbital (Jaccard=0.73) mitiglinide azoospermia GAP_HIGH 0.1375 0.3333333333333333 nateglinide 0.45 STABLE 0.85 3 0.03794 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mitiglinide→?; validate in azoospermia cell model. Expected: similar to nateglinide (Jaccard=0.33) tolbutamide coronary_artery_disease GAP_HIGH 0.1544 0.25 eprosartan 0.4 STABLE 0.85 3 0.03787 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolbutamide→?; validate in coronary_artery_disease cell model. Expected: similar to eprosartan (Jaccard=0.25) l-aspartic_acid epilepsy_syndrome GAP_HIGH 0.1544 0.2222222222222222 aminocaproic_acid 0.4 STABLE 0.85 3 0.03787 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-aspartic_acid→?; validate in epilepsy_syndrome cell model. Expected: similar to aminocaproic_acid (Jaccard=0.22) suprofen malignant_glioma GAP_HIGH 0.1943 0.6363636363636364 procarbazine 0.45 STABLE 0.6 3 0.03784 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay suprofen→?; validate in malignant_glioma cell model. Expected: similar to procarbazine (Jaccard=0.64) fludiazepam narcolepsy GAP_HIGH 0.194 0.7 chlordiazepoxide 0.45 STABLE 0.6 3 0.03778 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fludiazepam→?; validate in narcolepsy cell model. Expected: similar to chlordiazepoxide (Jaccard=0.70) flurazepam gilles_de_la_tourette_syndrome GAP_HIGH 0.1587 0.3333333333333333 midazolam 0.55 STABLE 0.6 3 0.03778 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flurazepam→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to midazolam (Jaccard=0.33) zuclopenthixol crohns_disease GAP_HIGH 0.1938 0.7857142857142857 pirenzepine 0.45 STABLE 0.6 3 0.03775 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zuclopenthixol→?; validate in crohns_disease cell model. Expected: similar to pirenzepine (Jaccard=0.79) melatonin chronic_kidney_failure GAP_HIGH 0.1938 0.5 eletriptan 0.45 STABLE 0.6 3 0.03775 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay melatonin→?; validate in chronic_kidney_failure cell model. Expected: similar to eletriptan (Jaccard=0.50) nitrazepam gilles_de_la_tourette_syndrome GAP_HIGH 0.1586 0.375 midazolam 0.55 STABLE 0.6 3 0.03775 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nitrazepam→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to midazolam (Jaccard=0.38) atropine atherosclerosis GAP_HIGH 0.1366 0.25 clofibrate 0.45 STABLE 0.85 3 0.03769 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay atropine→?; validate in atherosclerosis cell model. Expected: similar to clofibrate (Jaccard=0.25) bepridil celiac_disease GAP_HIGH 0.1933 0.6666666666666666 mepenzolate 0.45 STABLE 0.6 3 0.03765 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bepridil→?; validate in celiac_disease cell model. Expected: similar to mepenzolate (Jaccard=0.67) zuclopenthixol gout GAP_HIGH 0.1931 0.7857142857142857 pirenzepine 0.45 STABLE 0.6 3 0.03761 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zuclopenthixol→?; validate in gout cell model. Expected: similar to pirenzepine (Jaccard=0.79) thioproperazine malignant_mesothelioma GAP_HIGH 0.1363 0.5 ethopropazine 0.45 STABLE 0.85 3 0.03761 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thioproperazine→?; validate in malignant_mesothelioma cell model. Expected: similar to ethopropazine (Jaccard=0.50) ergocalciferol rheumatoid_arthritis GAP_HIGH 0.2169 0.5714285714285714 paricalcitol 0.4 STABLE 0.6 3 0.03755 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ergocalciferol→?; validate in rheumatoid_arthritis cell model. Expected: similar to paricalcitol (Jaccard=0.57) ethylmorphine epilepsy_syndrome GAP_HIGH 0.1528 0.3333333333333333 doxapram 0.4 STABLE 0.85 3 0.03748 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethylmorphine→?; validate in epilepsy_syndrome cell model. Expected: similar to doxapram (Jaccard=0.33) bepotastine azoospermia GAP_HIGH 0.1358 0.23529411764705882 loperamide 0.45 STABLE 0.85 3 0.03747 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bepotastine→?; validate in azoospermia cell model. Expected: similar to loperamide (Jaccard=0.24) chlorpropamide barretts_esophagus GAP_LOW 0.1753 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03742 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking chlorpropamide vs barretts_esophagus targets. Cross-check chlorpropamide pharmacophore against barretts_esophagus pathway. naloxone barretts_esophagus GAP_LOW 0.1753 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03742 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking naloxone vs barretts_esophagus targets. Cross-check naloxone pharmacophore against barretts_esophagus pathway. tolbutamide barretts_esophagus GAP_LOW 0.1753 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03742 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking tolbutamide vs barretts_esophagus targets. Cross-check tolbutamide pharmacophore against barretts_esophagus pathway. tolbutamide epilepsy_syndrome GAP_HIGH 0.1525 0.25 telmisartan 0.4 STABLE 0.85 3 0.0374 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolbutamide→?; validate in epilepsy_syndrome cell model. Expected: similar to telmisartan (Jaccard=0.25) phenformin azoospermia GAP_HIGH 0.1919 0.5 phentermine 0.45 STABLE 0.6 3 0.03738 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenformin→?; validate in azoospermia cell model. Expected: similar to phentermine (Jaccard=0.50) mitiglinide crohns_disease GAP_HIGH 0.1354 0.3333333333333333 nateglinide 0.45 STABLE 0.85 3 0.03736 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mitiglinide→?; validate in crohns_disease cell model. Expected: similar to nateglinide (Jaccard=0.33) procarbazine crohns_disease GAP_HIGH 0.2254 0.6363636363636364 suprofen 0.45 STABLE 0.85 3 0.03731 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay procarbazine→?; validate in crohns_disease cell model. Expected: similar to suprofen (Jaccard=0.64) doxycycline pagets_disease_of_bone GAP_LOW 0.1747 0.0 ibandronate 0.45 STABLE 0.85 5 0.03729 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking doxycycline vs pagets_disease_of_bone targets. Cross-check doxycycline pharmacophore against pagets_disease_of_bone pathway. pasireotide atherosclerosis GAP_HIGH 0.2252 0.3333333333333333 deferasirox 0.45 STABLE 0.85 3 0.03728 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pasireotide→?; validate in atherosclerosis cell model. Expected: similar to deferasirox (Jaccard=0.33) tolmetin ankylosing_spondylitis GAP_HIGH 0.1914 0.6363636363636364 agomelatine 0.45 STABLE 0.6 3 0.03728 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolmetin→?; validate in ankylosing_spondylitis cell model. Expected: similar to agomelatine (Jaccard=0.64) zolpidem epilepsy_syndrome GAP_HIGH 0.2153 0.5 ketorolac 0.4 STABLE 0.6 3 0.03727 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zolpidem→?; validate in epilepsy_syndrome cell model. Expected: similar to ketorolac (Jaccard=0.50) zuclopenthixol ankylosing_spondylitis GAP_HIGH 0.1913 0.7857142857142857 pirenzepine 0.45 STABLE 0.6 3 0.03726 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zuclopenthixol→?; validate in ankylosing_spondylitis cell model. Expected: similar to pirenzepine (Jaccard=0.79) chlorcyclizine alcohol_dependence GAP_HIGH 0.1349 0.3333333333333333 temazepam 0.45 STABLE 0.85 3 0.03722 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorcyclizine→?; validate in alcohol_dependence cell model. Expected: similar to temazepam (Jaccard=0.33) zuclopenthixol pancreatitis GAP_HIGH 0.1909 0.7857142857142857 pirenzepine 0.45 STABLE 0.6 3 0.03718 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zuclopenthixol→?; validate in pancreatitis cell model. Expected: similar to pirenzepine (Jaccard=0.79) entecavir osteoarthritis GAP_HIGH 0.2245 0.47368421052631576 vidarabine 0.45 STABLE 0.85 3 0.03716 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay entecavir→?; validate in osteoarthritis cell model. Expected: similar to vidarabine (Jaccard=0.47) fludiazepam psoriasis GAP_HIGH 0.1906 0.7 chlordiazepoxide 0.45 STABLE 0.6 3 0.03712 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fludiazepam→?; validate in psoriasis cell model. Expected: similar to chlordiazepoxide (Jaccard=0.70) tolbutamide schizophrenia GAP_HIGH 0.1513 0.25 telmisartan 0.4 STABLE 0.85 3 0.03711 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolbutamide→?; validate in schizophrenia cell model. Expected: similar to telmisartan (Jaccard=0.25) aprindine gout GAP_HIGH 0.1345 0.3333333333333333 desipramine 0.45 STABLE 0.85 3 0.03711 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aprindine→?; validate in gout cell model. Expected: similar to desipramine (Jaccard=0.33) brompheniramine celiac_disease GAP_HIGH 0.1345 0.3333333333333333 reboxetine 0.45 STABLE 0.85 3 0.03711 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay brompheniramine→?; validate in celiac_disease cell model. Expected: similar to reboxetine (Jaccard=0.33) doxepin crohns_disease GAP_HIGH 0.1903 0.75 amitriptyline 0.45 STABLE 0.6 3 0.03706 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxepin→?; validate in crohns_disease cell model. Expected: similar to amitriptyline (Jaccard=0.75) zolpidem schizophrenia GAP_HIGH 0.214 0.5 ketorolac 0.4 STABLE 0.6 3 0.03705 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zolpidem→?; validate in schizophrenia cell model. Expected: similar to ketorolac (Jaccard=0.50) estazolam nicotine_dependence GAP_HIGH 0.1902 0.5714285714285714 alprazolam 0.45 STABLE 0.6 3 0.03704 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estazolam→?; validate in nicotine_dependence cell model. Expected: similar to alprazolam (Jaccard=0.57) methadone membranous_glomerulonephritis GAP_HIGH 0.1341 0.53125 clofedanol 0.45 STABLE 0.85 3 0.037 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methadone→?; validate in membranous_glomerulonephritis cell model. Expected: similar to clofedanol (Jaccard=0.53) trifluoperazine crohns_disease GAP_HIGH 0.1341 0.46153846153846156 pirenzepine 0.45 STABLE 0.85 3 0.037 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trifluoperazine→?; validate in crohns_disease cell model. Expected: similar to pirenzepine (Jaccard=0.46) dimetindene coronary_artery_disease GAP_HIGH 0.2136 0.625 doxepin 0.4 STABLE 0.6 3 0.03698 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dimetindene→?; validate in coronary_artery_disease cell model. Expected: similar to doxepin (Jaccard=0.62) phenformin crohns_disease GAP_HIGH 0.1898 0.5 phentermine 0.45 STABLE 0.6 3 0.03697 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenformin→?; validate in crohns_disease cell model. Expected: similar to phentermine (Jaccard=0.50) entecavir psoriatic_arthritis GAP_HIGH 0.2232 0.47368421052631576 vidarabine 0.45 STABLE 0.85 3 0.03695 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay entecavir→?; validate in psoriatic_arthritis cell model. Expected: similar to vidarabine (Jaccard=0.47) phenformin idiopathic_pulmonary_fibrosis GAP_HIGH 0.1894 0.5 phentermine 0.45 STABLE 0.6 3 0.03689 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenformin→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to phentermine (Jaccard=0.50) butenafine glaucoma GAP_HIGH 0.1337 0.25 propranolol 0.45 STABLE 0.85 3 0.03689 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay butenafine→?; validate in glaucoma cell model. Expected: similar to propranolol (Jaccard=0.25) liothyronine acquired_immunodeficiency_syndrome GAP_HIGH 0.1094 0.15384615384615385 mitiglinide 0.55 STABLE 0.85 3 0.03689 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay liothyronine→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to mitiglinide (Jaccard=0.15) promazine malignant_mesothelioma GAP_HIGH 0.1335 0.4838709677419355 clofedanol 0.45 STABLE 0.85 3 0.03683 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay promazine→?; validate in malignant_mesothelioma cell model. Expected: similar to clofedanol (Jaccard=0.48) tolmetin osteoarthritis GAP_HIGH 0.189 0.6363636363636364 agomelatine 0.45 STABLE 0.6 3 0.03681 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolmetin→?; validate in osteoarthritis cell model. Expected: similar to agomelatine (Jaccard=0.64) methadone celiac_disease GAP_HIGH 0.1334 0.5161290322580645 diphenhydramine 0.45 STABLE 0.85 3 0.03681 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methadone→?; validate in celiac_disease cell model. Expected: similar to diphenhydramine (Jaccard=0.52) trifluoperazine gout GAP_HIGH 0.1334 0.46153846153846156 pirenzepine 0.45 STABLE 0.85 3 0.03681 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trifluoperazine→?; validate in gout cell model. Expected: similar to pirenzepine (Jaccard=0.46) telmisartan type_1_diabetes_mellitus GAP_HIGH 0.1417 0.25 tolbutamide 0.6 RISING 0.6 3 0.0368 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay telmisartan→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to tolbutamide (Jaccard=0.25) adenine bone_cancer GAP_LOW 0.1293 0.13333333333333333 tetrahydrofolic_acid 0.6 RISING 0.85 5 0.0368 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking adenine vs bone_cancer targets. Cross-check adenine pharmacophore against bone_cancer pathway. l-glutamine barretts_esophagus GAP_LOW 0.1722 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03676 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking l-glutamine vs barretts_esophagus targets. Cross-check l-glutamine pharmacophore against barretts_esophagus pathway. nilvadipine hypothyroidism GAP_LOW 0.1722 0.0 methimazole 0.45 STABLE 0.85 5 0.03676 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking nilvadipine vs hypothyroidism targets. Cross-check nilvadipine pharmacophore against hypothyroidism pathway. diethylpropion osteoporosis GAP_HIGH 0.1887 0.5454545454545454 tropicamide 0.45 STABLE 0.6 3 0.03675 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diethylpropion→?; validate in osteoporosis cell model. Expected: similar to tropicamide (Jaccard=0.55) diphenhydramine schizophrenia GAP_HIGH 0.1498 0.6296296296296297 naftifine 0.4 STABLE 0.85 3 0.03674 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphenhydramine→?; validate in schizophrenia cell model. Expected: similar to naftifine (Jaccard=0.63) masoprocol systemic_scleroderma GAP_HIGH 0.1884 0.6666666666666666 levonordefrin 0.45 STABLE 0.6 3 0.03669 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay masoprocol→?; validate in systemic_scleroderma cell model. Expected: similar to levonordefrin (Jaccard=0.67) isopropamide celiac_disease GAP_HIGH 0.1329 0.3333333333333333 benzatropine 0.45 STABLE 0.85 3 0.03667 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isopropamide→?; validate in celiac_disease cell model. Expected: similar to benzatropine (Jaccard=0.33) bepridil sclerosing_cholangitis GAP_HIGH 0.1878 0.6666666666666666 mepenzolate 0.45 STABLE 0.6 3 0.03658 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bepridil→?; validate in sclerosing_cholangitis cell model. Expected: similar to mepenzolate (Jaccard=0.67) flunarizine celiac_disease GAP_HIGH 0.1325 0.25 cinnarizine 0.45 STABLE 0.85 3 0.03656 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flunarizine→?; validate in celiac_disease cell model. Expected: similar to cinnarizine (Jaccard=0.25) pseudoephedrine leprosy GAP_HIGH 0.1325 0.25 pomalidomide 0.45 STABLE 0.85 3 0.03656 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pseudoephedrine→?; validate in leprosy cell model. Expected: similar to pomalidomide (Jaccard=0.25) triflupromazine chronic_obstructive_pulmonary_disease GAP_HIGH 0.1324 0.4 acepromazine 0.45 STABLE 0.85 3 0.03653 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay triflupromazine→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to acepromazine (Jaccard=0.40) butenafine refractive_error GAP_HIGH 0.1324 0.25 propranolol 0.45 STABLE 0.85 3 0.03653 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay butenafine→?; validate in refractive_error cell model. Expected: similar to propranolol (Jaccard=0.25) olanzapine hypothyroidism GAP_LOW 0.1453 0.0 methimazole 0.45 STABLE 1.0 5 0.03649 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking olanzapine vs hypothyroidism targets. Cross-check olanzapine pharmacophore against hypothyroidism pathway. bepridil ankylosing_spondylitis GAP_HIGH 0.1873 0.6666666666666666 mepenzolate 0.45 STABLE 0.6 3 0.03648 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bepridil→?; validate in ankylosing_spondylitis cell model. Expected: similar to mepenzolate (Jaccard=0.67) clofedanol penile_cancer GAP_HIGH 0.1404 0.53125 methadone 0.6 RISING 0.6 3 0.03646 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clofedanol→?; validate in penile_cancer cell model. Expected: similar to methadone (Jaccard=0.53) l-tryptophan osteoporosis GAP_HIGH 0.1871 0.4444444444444444 liothyronine 0.45 STABLE 0.6 3 0.03644 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-tryptophan→?; validate in osteoporosis cell model. Expected: similar to liothyronine (Jaccard=0.44) melatonin autistic_disorder GAP_HIGH 0.187 0.5 eletriptan 0.45 STABLE 0.6 3 0.03642 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay melatonin→?; validate in autistic_disorder cell model. Expected: similar to eletriptan (Jaccard=0.50) atropine alopecia_areata GAP_HIGH 0.132 0.25 alclometasone 0.45 STABLE 0.85 3 0.03642 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay atropine→?; validate in alopecia_areata cell model. Expected: similar to alclometasone (Jaccard=0.25) aspartame gilles_de_la_tourette_syndrome GAP_HIGH 0.1529 0.2857142857142857 alvimopan 0.55 STABLE 0.6 3 0.0364 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aspartame→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to alvimopan (Jaccard=0.29) diethylpropion psoriatic_arthritis GAP_HIGH 0.1868 0.5454545454545454 tropicamide 0.45 STABLE 0.6 3 0.03638 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diethylpropion→?; validate in psoriatic_arthritis cell model. Expected: similar to tropicamide (Jaccard=0.55) fosphenytoin malignant_mesothelioma GAP_HIGH 0.1867 0.5833333333333334 phenytoin 0.45 STABLE 0.6 3 0.03636 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fosphenytoin→?; validate in malignant_mesothelioma cell model. Expected: similar to phenytoin (Jaccard=0.58) carprofen glaucoma GAP_HIGH 0.3104 1.0 procarbazine 0.45 STABLE 0.6 3 0.03627 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carprofen→?; validate in glaucoma cell model. Expected: similar to procarbazine (Jaccard=1.00) doxepin atopic_dermatitis GAP_HIGH 0.1862 0.75 amitriptyline 0.45 STABLE 0.6 3 0.03627 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxepin→?; validate in atopic_dermatitis cell model. Expected: similar to amitriptyline (Jaccard=0.75) carprofen intracranial_aneurysm GAP_HIGH 0.3102 1.0 procarbazine 0.45 STABLE 0.6 3 0.03625 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carprofen→?; validate in intracranial_aneurysm cell model. Expected: similar to procarbazine (Jaccard=1.00) carprofen malignant_glioma GAP_HIGH 0.3094 1.0 procarbazine 0.45 STABLE 0.6 3 0.03616 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carprofen→?; validate in malignant_glioma cell model. Expected: similar to procarbazine (Jaccard=1.00) amlodipine hypothyroidism GAP_LOW 0.1694 0.0 methimazole 0.45 STABLE 0.85 5 0.03616 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking amlodipine vs hypothyroidism targets. Cross-check amlodipine pharmacophore against hypothyroidism pathway. cyclopentolate malignant_mesothelioma GAP_HIGH 0.131 0.3333333333333333 reboxetine 0.45 STABLE 0.85 3 0.03614 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyclopentolate→?; validate in malignant_mesothelioma cell model. Expected: similar to reboxetine (Jaccard=0.33) podofilox esophageal_cancer GAP_HIGH 0.139 0.2857142857142857 epirubicin 0.6 RISING 0.6 3 0.0361 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay podofilox→?; validate in esophageal_cancer cell model. Expected: similar to epirubicin (Jaccard=0.29) l-tryptophan psoriatic_arthritis GAP_HIGH 0.1853 0.4444444444444444 liothyronine 0.45 STABLE 0.6 3 0.03609 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-tryptophan→?; validate in psoriatic_arthritis cell model. Expected: similar to liothyronine (Jaccard=0.44) triflupromazine psoriasis GAP_HIGH 0.1308 0.4 acepromazine 0.45 STABLE 0.85 3 0.03609 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay triflupromazine→?; validate in psoriasis cell model. Expected: similar to acepromazine (Jaccard=0.40) dienestrol esophageal_cancer GAP_HIGH 0.1389 0.2 fulvestrant 0.6 RISING 0.6 3 0.03607 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dienestrol→?; validate in esophageal_cancer cell model. Expected: similar to fulvestrant (Jaccard=0.20) trimipramine focal_segmental_glomerulosclerosis GAP_HIGH 0.1303 0.4444444444444444 alimemazine 0.45 STABLE 0.85 3 0.03595 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trimipramine→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to alimemazine (Jaccard=0.44) ziprasidone barretts_esophagus GAP_LOW 0.1681 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03589 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking ziprasidone vs barretts_esophagus targets. Cross-check ziprasidone pharmacophore against barretts_esophagus pathway. thiothixene prostate_cancer GAP_HIGH 0.1382 0.5238095238095238 pirenzepine 0.6 RISING 0.6 3 0.03589 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thiothixene→?; validate in prostate_cancer cell model. Expected: similar to pirenzepine (Jaccard=0.52) cinolazepam gilles_de_la_tourette_syndrome GAP_HIGH 0.1507 0.3125 fludiazepam 0.55 STABLE 0.6 3 0.03587 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cinolazepam→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to fludiazepam (Jaccard=0.31) warfarin barretts_esophagus GAP_LOW 0.1428 0.0 pantoprazole 0.45 STABLE 1.0 5 0.03586 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking warfarin vs barretts_esophagus targets. Cross-check warfarin pharmacophore against barretts_esophagus pathway. phenprocoumon celiac_disease GAP_HIGH 0.1839 0.6 atomoxetine 0.45 STABLE 0.6 3 0.03582 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenprocoumon→?; validate in celiac_disease cell model. Expected: similar to atomoxetine (Jaccard=0.60) salicylate-sodium refractive_error GAP_HIGH 0.1297 0.3333333333333333 droxidopa 0.45 STABLE 0.85 3 0.03579 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay salicylate-sodium→?; validate in refractive_error cell model. Expected: similar to droxidopa (Jaccard=0.33) nateglinide rheumatoid_arthritis GAP_HIGH 0.1459 0.5555555555555556 phenelzine 0.4 STABLE 0.85 3 0.03578 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nateglinide→?; validate in rheumatoid_arthritis cell model. Expected: similar to phenelzine (Jaccard=0.56) etidronic_acid amyotrophic_lateral_sclerosis GAP_HIGH 0.162 0.25 gabapentin 0.6 RISING 0.85 3 0.03576 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay etidronic_acid→?; validate in amyotrophic_lateral_sclerosis cell model. Expected: similar to gabapentin (Jaccard=0.25) cinnarizine azoospermia GAP_HIGH 0.1296 0.2857142857142857 mepenzolate 0.45 STABLE 0.85 3 0.03576 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cinnarizine→?; validate in azoospermia cell model. Expected: similar to mepenzolate (Jaccard=0.29) l-tryptophan hypothyroidism GAP_HIGH 0.1833 0.2 methimazole 0.45 STABLE 0.6 3 0.0357 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-tryptophan→?; validate in hypothyroidism cell model. Expected: similar to methimazole (Jaccard=0.20) triflupromazine vitiligo GAP_HIGH 0.1294 0.4 acepromazine 0.45 STABLE 0.85 3 0.0357 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay triflupromazine→?; validate in vitiligo cell model. Expected: similar to acepromazine (Jaccard=0.40) tetracycline pagets_disease_of_bone GAP_LOW 0.1671 0.0 ibandronate 0.45 STABLE 0.85 5 0.03567 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking tetracycline vs pagets_disease_of_bone targets. Cross-check tetracycline pharmacophore against pagets_disease_of_bone pathway. streptozocin dilated_cardiomyopathy GAP_HIGH 0.1831 0.25 milrinone 0.45 STABLE 0.6 3 0.03566 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay streptozocin→?; validate in dilated_cardiomyopathy cell model. Expected: similar to milrinone (Jaccard=0.25) midazolam epilepsy_syndrome GAP_HIGH 0.2059 0.7142857142857143 adinazolam 0.4 STABLE 0.6 3 0.03565 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay midazolam→?; validate in epilepsy_syndrome cell model. Expected: similar to adinazolam (Jaccard=0.71) isocarboxazid atherosclerosis GAP_HIGH 0.1829 0.375 phentermine 0.45 STABLE 0.6 3 0.03562 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isocarboxazid→?; validate in atherosclerosis cell model. Expected: similar to phentermine (Jaccard=0.38) calcium_acetate hypothyroidism GAP_LOW 0.1667 0.0 methimazole 0.45 STABLE 0.85 5 0.03559 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking calcium_acetate vs hypothyroidism targets. Cross-check calcium_acetate pharmacophore against hypothyroidism pathway. isradipine hypothyroidism GAP_LOW 0.1667 0.0 methimazole 0.45 STABLE 0.85 5 0.03559 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking isradipine vs hypothyroidism targets. Cross-check isradipine pharmacophore against hypothyroidism pathway. lercanidipine hypothyroidism GAP_LOW 0.1667 0.0 methimazole 0.45 STABLE 0.85 5 0.03559 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking lercanidipine vs hypothyroidism targets. Cross-check lercanidipine pharmacophore against hypothyroidism pathway. nimodipine hypothyroidism GAP_LOW 0.1667 0.0 methimazole 0.45 STABLE 0.85 5 0.03559 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking nimodipine vs hypothyroidism targets. Cross-check nimodipine pharmacophore against hypothyroidism pathway. nisoldipine hypothyroidism GAP_LOW 0.1667 0.0 methimazole 0.45 STABLE 0.85 5 0.03559 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking nisoldipine vs hypothyroidism targets. Cross-check nisoldipine pharmacophore against hypothyroidism pathway. phenacemide acquired_immunodeficiency_syndrome GAP_HIGH 0.1055 0.16 mitiglinide 0.55 STABLE 0.85 3 0.03558 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenacemide→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to mitiglinide (Jaccard=0.16) butenafine crohns_disease GAP_HIGH 0.1288 0.25 propranolol 0.45 STABLE 0.85 3 0.03554 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay butenafine→?; validate in crohns_disease cell model. Expected: similar to propranolol (Jaccard=0.25) podofilox kidney_cancer GAP_HIGH 0.1368 0.2857142857142857 epirubicin 0.6 RISING 0.6 3 0.03552 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay podofilox→?; validate in kidney_cancer cell model. Expected: similar to epirubicin (Jaccard=0.29) moexipril dilated_cardiomyopathy GAP_HIGH 0.1823 0.3 trandolapril 0.45 STABLE 0.6 3 0.03551 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay moexipril→?; validate in dilated_cardiomyopathy cell model. Expected: similar to trandolapril (Jaccard=0.30) diphenylpyraline idiopathic_pulmonary_fibrosis GAP_HIGH 0.1286 0.45454545454545453 diphenhydramine 0.45 STABLE 0.85 3 0.03548 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphenylpyraline→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to diphenhydramine (Jaccard=0.45) butenafine idiopathic_pulmonary_fibrosis GAP_HIGH 0.1285 0.25 propranolol 0.45 STABLE 0.85 3 0.03546 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay butenafine→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to propranolol (Jaccard=0.25) epirubicin prostate_cancer GAP_HIGH 0.1364 0.2857142857142857 podofilox 0.6 RISING 0.6 3 0.03542 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay epirubicin→?; validate in prostate_cancer cell model. Expected: similar to podofilox (Jaccard=0.29) diphenylpyraline gout GAP_HIGH 0.1283 0.45454545454545453 modafinil 0.45 STABLE 0.85 3 0.0354 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diphenylpyraline→?; validate in gout cell model. Expected: similar to modafinil (Jaccard=0.45) pasireotide crohns_disease GAP_HIGH 0.2137 0.3333333333333333 deferasirox 0.45 STABLE 0.85 3 0.03538 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pasireotide→?; validate in crohns_disease cell model. Expected: similar to deferasirox (Jaccard=0.33) streptozocin leprosy GAP_HIGH 0.1816 0.2 lenalidomide 0.45 STABLE 0.6 3 0.03537 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay streptozocin→?; validate in leprosy cell model. Expected: similar to lenalidomide (Jaccard=0.20) pimozide barretts_esophagus GAP_LOW 0.1657 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03537 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking pimozide vs barretts_esophagus targets. Cross-check pimozide pharmacophore against barretts_esophagus pathway. clonazepam autistic_disorder GAP_HIGH 0.1815 0.625 amoxapine 0.45 STABLE 0.6 3 0.03535 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clonazepam→?; validate in autistic_disorder cell model. Expected: similar to amoxapine (Jaccard=0.62) epirubicin hematologic_cancer GAP_HIGH 0.1359 0.2857142857142857 podofilox 0.6 RISING 0.6 3 0.03529 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay epirubicin→?; validate in hematologic_cancer cell model. Expected: similar to podofilox (Jaccard=0.29) oxcarbazepine epilepsy_syndrome GAP_HIGH 0.1438 0.4166666666666667 phenindione 0.4 STABLE 0.85 3 0.03527 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxcarbazepine→?; validate in epilepsy_syndrome cell model. Expected: similar to phenindione (Jaccard=0.42) toremifene penile_cancer GAP_HIGH 0.1358 0.5 methadone 0.6 RISING 0.6 3 0.03527 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay toremifene→?; validate in penile_cancer cell model. Expected: similar to methadone (Jaccard=0.50) clonazepam panic_disorder GAP_HIGH 0.181 0.625 amoxapine 0.45 STABLE 0.6 3 0.03525 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clonazepam→?; validate in panic_disorder cell model. Expected: similar to amoxapine (Jaccard=0.62) phenprocoumon crohns_disease GAP_HIGH 0.1805 0.6 atomoxetine 0.45 STABLE 0.6 3 0.03515 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenprocoumon→?; validate in crohns_disease cell model. Expected: similar to atomoxetine (Jaccard=0.60) selegiline barretts_esophagus GAP_LOW 0.1646 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03514 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking selegiline vs barretts_esophagus targets. Cross-check selegiline pharmacophore against barretts_esophagus pathway. sulfamethizole barretts_esophagus GAP_LOW 0.1646 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03514 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking sulfamethizole vs barretts_esophagus targets. Cross-check sulfamethizole pharmacophore against barretts_esophagus pathway. zafirlukast atherosclerosis GAP_HIGH 0.1802 0.375 bezafibrate 0.45 STABLE 0.6 3 0.0351 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zafirlukast→?; validate in atherosclerosis cell model. Expected: similar to bezafibrate (Jaccard=0.38) phenprocoumon idiopathic_pulmonary_fibrosis GAP_HIGH 0.1801 0.6 atomoxetine 0.45 STABLE 0.6 3 0.03508 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenprocoumon→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to atomoxetine (Jaccard=0.60) oxazepam coronary_artery_disease GAP_HIGH 0.2026 0.6666666666666666 temazepam 0.4 STABLE 0.6 3 0.03507 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxazepam→?; validate in coronary_artery_disease cell model. Expected: similar to temazepam (Jaccard=0.67) l-aspartic_acid hypothyroidism GAP_LOW 0.1643 0.0 methimazole 0.45 STABLE 0.85 5 0.03507 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking l-aspartic_acid vs hypothyroidism targets. Cross-check l-aspartic_acid pharmacophore against hypothyroidism pathway. carbinoxamine ankylosing_spondylitis GAP_HIGH 0.1268 0.375 brompheniramine 0.45 STABLE 0.85 3 0.03499 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carbinoxamine→?; validate in ankylosing_spondylitis cell model. Expected: similar to brompheniramine (Jaccard=0.38) trimipramine membranous_glomerulonephritis GAP_HIGH 0.1267 0.4444444444444444 alimemazine 0.45 STABLE 0.85 3 0.03496 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trimipramine→?; validate in membranous_glomerulonephritis cell model. Expected: similar to alimemazine (Jaccard=0.44) l-dopa type_1_diabetes_mellitus GAP_HIGH 0.1346 0.35 carbidopa 0.6 RISING 0.6 3 0.03495 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-dopa→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to carbidopa (Jaccard=0.35) ethylmorphine barretts_esophagus GAP_LOW 0.1636 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03492 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking ethylmorphine vs barretts_esophagus targets. Cross-check ethylmorphine pharmacophore against barretts_esophagus pathway. hydromorphone barretts_esophagus GAP_LOW 0.1636 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03492 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking hydromorphone vs barretts_esophagus targets. Cross-check hydromorphone pharmacophore against barretts_esophagus pathway. oxcarbazepine bipolar_disorder GAP_HIGH 0.1424 0.4166666666666667 phenindione 0.4 STABLE 0.85 3 0.03492 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxcarbazepine→?; validate in bipolar_disorder cell model. Expected: similar to phenindione (Jaccard=0.42) salsalate primary_biliary_cirrhosis GAP_HIGH 0.1265 0.38095238095238093 bromfenac 0.45 STABLE 0.85 3 0.0349 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay salsalate→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to bromfenac (Jaccard=0.38) dyphylline lymphatic_system_cancer GAP_LOW 0.1223 0.06666666666666667 gemcitabine 0.6 RISING 0.85 5 0.03481 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking dyphylline vs lymphatic_system_cancer targets. Cross-check dyphylline pharmacophore against lymphatic_system_cancer pathway. theophylline multiple_sclerosis GAP_LOW 0.1222 0.14285714285714285 furazolidone 0.6 RISING 0.85 5 0.03478 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking theophylline vs multiple_sclerosis targets. Cross-check theophylline pharmacophore against multiple_sclerosis pathway. phenprocoumon sclerosing_cholangitis GAP_HIGH 0.1784 0.6 atomoxetine 0.45 STABLE 0.6 3 0.03475 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenprocoumon→?; validate in sclerosing_cholangitis cell model. Expected: similar to atomoxetine (Jaccard=0.60) salsalate refractive_error GAP_HIGH 0.1259 0.35294117647058826 clonidine 0.45 STABLE 0.85 3 0.03474 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay salsalate→?; validate in refractive_error cell model. Expected: similar to clonidine (Jaccard=0.35) floctafenine narcolepsy GAP_HIGH 0.1259 0.26666666666666666 mefenamic_acid 0.45 STABLE 0.85 3 0.03474 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay floctafenine→?; validate in narcolepsy cell model. Expected: similar to mefenamic_acid (Jaccard=0.27) fluocinonide psoriasis GAP_HIGH 0.2097 0.7692307692307693 rimexolone 0.45 STABLE 0.85 3 0.03472 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluocinonide→?; validate in psoriasis cell model. Expected: similar to rimexolone (Jaccard=0.77) diazepam chronic_kidney_failure GAP_HIGH 0.1782 0.625 fludiazepam 0.45 STABLE 0.6 3 0.03471 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diazepam→?; validate in chronic_kidney_failure cell model. Expected: similar to fludiazepam (Jaccard=0.62) salicylate-sodium idiopathic_pulmonary_fibrosis GAP_HIGH 0.1258 0.3333333333333333 droxidopa 0.45 STABLE 0.85 3 0.03471 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay salicylate-sodium→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to droxidopa (Jaccard=0.33) pentobarbital creutzfeldt-jakob_disease GAP_HIGH 0.1779 0.29411764705882354 clobazam 0.45 STABLE 0.6 3 0.03465 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pentobarbital→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to clobazam (Jaccard=0.29) olsalazine malaria GAP_HIGH 0.1255 0.2916666666666667 sulfapyridine 0.45 STABLE 0.85 3 0.03463 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay olsalazine→?; validate in malaria cell model. Expected: similar to sulfapyridine (Jaccard=0.29) alvimopan gout GAP_HIGH 0.1777 0.42857142857142855 desipramine 0.45 STABLE 0.6 3 0.03461 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alvimopan→?; validate in gout cell model. Expected: similar to desipramine (Jaccard=0.43) lercanidipine leprosy GAP_LOW 0.162 0.1111111111111111 phenmetrazine 0.45 STABLE 0.85 5 0.03458 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking lercanidipine vs leprosy targets. Cross-check lercanidipine pharmacophore against leprosy pathway. aminocaproic_acid hypothyroidism GAP_LOW 0.162 0.0 methimazole 0.45 STABLE 0.85 5 0.03458 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking aminocaproic_acid vs hypothyroidism targets. Cross-check aminocaproic_acid pharmacophore against hypothyroidism pathway. anisindione barretts_esophagus GAP_LOW 0.1616 0.0 pantoprazole 0.45 STABLE 0.85 5 0.0345 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking anisindione vs barretts_esophagus targets. Cross-check anisindione pharmacophore against barretts_esophagus pathway. reboxetine chronic_kidney_failure GAP_HIGH 0.1247 0.3333333333333333 doxepin 0.45 STABLE 0.85 3 0.03441 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay reboxetine→?; validate in chronic_kidney_failure cell model. Expected: similar to doxepin (Jaccard=0.33) levonordefrin rheumatoid_arthritis GAP_HIGH 0.1985 0.6363636363636364 isoprenaline 0.4 STABLE 0.6 3 0.03436 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levonordefrin→?; validate in rheumatoid_arthritis cell model. Expected: similar to isoprenaline (Jaccard=0.64) doxepin gilles_de_la_tourette_syndrome GAP_HIGH 0.1442 0.4444444444444444 tolterodine 0.55 STABLE 0.6 3 0.03433 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxepin→?; validate in gilles_de_la_tourette_syndrome cell model. Expected: similar to tolterodine (Jaccard=0.44) captopril nephrolithiasis GAP_HIGH 0.1762 0.3333333333333333 sunitinib 0.45 STABLE 0.6 3 0.03432 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay captopril→?; validate in nephrolithiasis cell model. Expected: similar to sunitinib (Jaccard=0.33) lacosamide coronary_artery_disease GAP_HIGH 0.1398 0.38461538461538464 phentermine 0.4 STABLE 0.85 3 0.03429 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lacosamide→?; validate in coronary_artery_disease cell model. Expected: similar to phentermine (Jaccard=0.38) alvimopan ankylosing_spondylitis GAP_HIGH 0.1759 0.42857142857142855 desipramine 0.45 STABLE 0.6 3 0.03426 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alvimopan→?; validate in ankylosing_spondylitis cell model. Expected: similar to desipramine (Jaccard=0.43) zafirlukast gout GAP_HIGH 0.1759 0.4117647058823529 gliclazide 0.45 STABLE 0.6 3 0.03426 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zafirlukast→?; validate in gout cell model. Expected: similar to gliclazide (Jaccard=0.41) l-phenylalanine barretts_esophagus GAP_LOW 0.1598 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03411 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking l-phenylalanine vs barretts_esophagus targets. Cross-check l-phenylalanine pharmacophore against barretts_esophagus pathway. nabumetone hypothyroidism GAP_LOW 0.1598 0.0 methimazole 0.45 STABLE 0.85 5 0.03411 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking nabumetone vs hypothyroidism targets. Cross-check nabumetone pharmacophore against hypothyroidism pathway. carvedilol gestational_diabetes GAP_HIGH 0.1745 0.21428571428571427 gliclazide 0.45 STABLE 0.6 3 0.03399 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carvedilol→?; validate in gestational_diabetes cell model. Expected: similar to gliclazide (Jaccard=0.21) mazindol duodenum_cancer GAP_HIGH 0.1309 0.425 loxapine 0.6 RISING 0.6 3 0.03399 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mazindol→?; validate in duodenum_cancer cell model. Expected: similar to loxapine (Jaccard=0.42) mazindol gallbladder_cancer GAP_HIGH 0.1309 0.425 loxapine 0.6 RISING 0.6 3 0.03399 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mazindol→?; validate in gallbladder_cancer cell model. Expected: similar to loxapine (Jaccard=0.42) flurazepam alcohol_dependence GAP_HIGH 0.1743 0.3333333333333333 midazolam 0.45 STABLE 0.6 3 0.03395 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flurazepam→?; validate in alcohol_dependence cell model. Expected: similar to midazolam (Jaccard=0.33) anisotropine_methylbromide barretts_esophagus GAP_LOW 0.1589 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03392 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking anisotropine_methylbromide vs barretts_esophagus targets. Cross-check anisotropine_methylbromide pharmacophore against barretts_esophagus pathway. bepotastine barretts_esophagus GAP_LOW 0.1589 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03392 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking bepotastine vs barretts_esophagus targets. Cross-check bepotastine pharmacophore against barretts_esophagus pathway. flunarizine barretts_esophagus GAP_LOW 0.1589 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03392 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking flunarizine vs barretts_esophagus targets. Cross-check flunarizine pharmacophore against barretts_esophagus pathway. nitrazepam alcohol_dependence GAP_HIGH 0.1741 0.375 midazolam 0.45 STABLE 0.6 3 0.03391 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nitrazepam→?; validate in alcohol_dependence cell model. Expected: similar to midazolam (Jaccard=0.38) carbinoxamine focal_segmental_glomerulosclerosis GAP_HIGH 0.1228 0.3076923076923077 alimemazine 0.45 STABLE 0.85 3 0.03388 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carbinoxamine→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to alimemazine (Jaccard=0.31) lacosamide epilepsy_syndrome GAP_HIGH 0.1379 0.38461538461538464 phentermine 0.4 STABLE 0.85 3 0.03382 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lacosamide→?; validate in epilepsy_syndrome cell model. Expected: similar to phentermine (Jaccard=0.38) isocarboxazid azoospermia GAP_HIGH 0.1736 0.375 phentermine 0.45 STABLE 0.6 3 0.03381 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isocarboxazid→?; validate in azoospermia cell model. Expected: similar to phentermine (Jaccard=0.38) carvedilol alcohol_dependence GAP_HIGH 0.1736 0.2222222222222222 naloxone 0.45 STABLE 0.6 3 0.03381 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carvedilol→?; validate in alcohol_dependence cell model. Expected: similar to naloxone (Jaccard=0.22) captopril malignant_mesothelioma GAP_HIGH 0.1735 0.3333333333333333 crizotinib 0.45 STABLE 0.6 3 0.03379 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay captopril→?; validate in malignant_mesothelioma cell model. Expected: similar to crizotinib (Jaccard=0.33) prednisone crohns_disease GAP_HIGH 0.2038 0.8235294117647058 testolactone 0.45 STABLE 0.85 3 0.03374 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prednisone→?; validate in crohns_disease cell model. Expected: similar to testolactone (Jaccard=0.82) methacholine celiac_disease GAP_HIGH 0.2037 0.25 homatropine_methylbromide 0.45 STABLE 0.85 3 0.03372 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methacholine→?; validate in celiac_disease cell model. Expected: similar to homatropine_methylbromide (Jaccard=0.25) treprostinil idiopathic_pulmonary_fibrosis GAP_HIGH 0.1731 0.25 penbutolol 0.45 STABLE 0.6 3 0.03371 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay treprostinil→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to penbutolol (Jaccard=0.25) menadione hypothyroidism GAP_LOW 0.1578 0.14285714285714285 methimazole 0.45 STABLE 0.85 5 0.03369 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking menadione vs hypothyroidism targets. Cross-check menadione pharmacophore against hypothyroidism pathway. captopril meningioma GAP_HIGH 0.1729 0.3333333333333333 crizotinib 0.45 STABLE 0.6 3 0.03367 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay captopril→?; validate in meningioma cell model. Expected: similar to crizotinib (Jaccard=0.33) diazepam sclerosing_cholangitis GAP_HIGH 0.1728 0.625 fludiazepam 0.45 STABLE 0.6 3 0.03366 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diazepam→?; validate in sclerosing_cholangitis cell model. Expected: similar to fludiazepam (Jaccard=0.62) enalapril dilated_cardiomyopathy GAP_HIGH 0.1727 0.35714285714285715 trandolapril 0.45 STABLE 0.6 3 0.03364 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay enalapril→?; validate in dilated_cardiomyopathy cell model. Expected: similar to trandolapril (Jaccard=0.36) amobarbital barretts_esophagus GAP_LOW 0.2232 0.08333333333333333 pantoprazole 0.45 STABLE 0.6 5 0.03363 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking amobarbital vs barretts_esophagus targets. Cross-check amobarbital pharmacophore against barretts_esophagus pathway. estrone dilated_cardiomyopathy GAP_HIGH 0.1219 0.25 acetyldigitoxin 0.45 STABLE 0.85 3 0.03363 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estrone→?; validate in dilated_cardiomyopathy cell model. Expected: similar to acetyldigitoxin (Jaccard=0.25) nimodipine leprosy GAP_LOW 0.1575 0.1 phenmetrazine 0.45 STABLE 0.85 5 0.03362 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking nimodipine vs leprosy targets. Cross-check nimodipine pharmacophore against leprosy pathway. temazepam gout GAP_HIGH 0.1724 0.6153846153846154 diazepam 0.45 STABLE 0.6 3 0.03358 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay temazepam→?; validate in gout cell model. Expected: similar to diazepam (Jaccard=0.62) chloroprocaine barretts_esophagus GAP_LOW 0.1573 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03358 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking chloroprocaine vs barretts_esophagus targets. Cross-check chloroprocaine pharmacophore against barretts_esophagus pathway. floctafenine barretts_esophagus GAP_LOW 0.1573 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03358 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking floctafenine vs barretts_esophagus targets. Cross-check floctafenine pharmacophore against barretts_esophagus pathway. indapamide barretts_esophagus GAP_LOW 0.1573 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03358 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking indapamide vs barretts_esophagus targets. Cross-check indapamide pharmacophore against barretts_esophagus pathway. procaine barretts_esophagus GAP_LOW 0.1573 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03358 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking procaine vs barretts_esophagus targets. Cross-check procaine pharmacophore against barretts_esophagus pathway. heptabarbital barretts_esophagus GAP_LOW 0.222 0.09090909090909091 pantoprazole 0.45 STABLE 0.6 5 0.03345 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking heptabarbital vs barretts_esophagus targets. Cross-check heptabarbital pharmacophore against barretts_esophagus pathway. oxcarbazepine barretts_esophagus GAP_LOW 0.1566 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03343 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking oxcarbazepine vs barretts_esophagus targets. Cross-check oxcarbazepine pharmacophore against barretts_esophagus pathway. lisinopril hepatitis_b GAP_HIGH 0.2315 0.7777777777777778 trandolapril 0.2 DECLINING 1.0 3 0.0334 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lisinopril→?; validate in hepatitis_b cell model. Expected: similar to trandolapril (Jaccard=0.78) isocarboxazid crohns_disease GAP_HIGH 0.1715 0.375 phentermine 0.45 STABLE 0.6 3 0.0334 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isocarboxazid→?; validate in crohns_disease cell model. Expected: similar to phentermine (Jaccard=0.38) isocarboxazid idiopathic_pulmonary_fibrosis GAP_HIGH 0.1711 0.375 phentermine 0.45 STABLE 0.6 3 0.03332 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay isocarboxazid→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to phentermine (Jaccard=0.38) treprostinil ankylosing_spondylitis GAP_HIGH 0.171 0.25 mebendazole 0.45 STABLE 0.6 3 0.0333 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay treprostinil→?; validate in ankylosing_spondylitis cell model. Expected: similar to mebendazole (Jaccard=0.25) reboxetine gout GAP_HIGH 0.1207 0.3333333333333333 doxepin 0.45 STABLE 0.85 3 0.0333 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay reboxetine→?; validate in gout cell model. Expected: similar to doxepin (Jaccard=0.33) colchicine hypothyroidism GAP_LOW 0.1559 0.0 methimazole 0.45 STABLE 0.85 5 0.03328 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking colchicine vs hypothyroidism targets. Cross-check colchicine pharmacophore against hypothyroidism pathway. dyphylline hypothyroidism GAP_LOW 0.1559 0.0 methimazole 0.45 STABLE 0.85 5 0.03328 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking dyphylline vs hypothyroidism targets. Cross-check dyphylline pharmacophore against hypothyroidism pathway. midodrine hypothyroidism GAP_LOW 0.1559 0.0 methimazole 0.45 STABLE 0.85 5 0.03328 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking midodrine vs hypothyroidism targets. Cross-check midodrine pharmacophore against hypothyroidism pathway. theophylline hypothyroidism GAP_LOW 0.1559 0.0 methimazole 0.45 STABLE 0.85 5 0.03328 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking theophylline vs hypothyroidism targets. Cross-check theophylline pharmacophore against hypothyroidism pathway. pentobarbital barretts_esophagus GAP_LOW 0.2208 0.09090909090909091 pantoprazole 0.45 STABLE 0.6 5 0.03327 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking pentobarbital vs barretts_esophagus targets. Cross-check pentobarbital pharmacophore against barretts_esophagus pathway. rimexolone barretts_esophagus GAP_LOW 0.1558 0.07692307692307693 pantoprazole 0.45 STABLE 0.85 5 0.03326 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking rimexolone vs barretts_esophagus targets. Cross-check rimexolone pharmacophore against barretts_esophagus pathway. aprobarbital barretts_esophagus GAP_LOW 0.2203 0.08333333333333333 pantoprazole 0.45 STABLE 0.6 5 0.0332 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking aprobarbital vs barretts_esophagus targets. Cross-check aprobarbital pharmacophore against barretts_esophagus pathway. butethal barretts_esophagus GAP_LOW 0.2203 0.08333333333333333 pantoprazole 0.45 STABLE 0.6 5 0.0332 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking butethal vs barretts_esophagus targets. Cross-check butethal pharmacophore against barretts_esophagus pathway. bezafibrate barretts_esophagus GAP_LOW 0.1552 0.045454545454545456 pantoprazole 0.45 STABLE 0.85 5 0.03313 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking bezafibrate vs barretts_esophagus targets. Cross-check bezafibrate pharmacophore against barretts_esophagus pathway. nisoldipine pagets_disease_of_bone GAP_LOW 0.1552 0.0 ibandronate 0.45 STABLE 0.85 5 0.03313 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking nisoldipine vs pagets_disease_of_bone targets. Cross-check nisoldipine pharmacophore against pagets_disease_of_bone pathway. propafenone barretts_esophagus GAP_LOW 0.1552 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03313 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking propafenone vs barretts_esophagus targets. Cross-check propafenone pharmacophore against barretts_esophagus pathway. tiaprofenic_acid celiac_disease GAP_HIGH 0.12 0.3 salsalate 0.45 STABLE 0.85 3 0.03311 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tiaprofenic_acid→?; validate in celiac_disease cell model. Expected: similar to salsalate (Jaccard=0.30) methacholine idiopathic_pulmonary_fibrosis GAP_HIGH 0.1999 0.25 homatropine_methylbromide 0.45 STABLE 0.85 3 0.0331 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methacholine→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to homatropine_methylbromide (Jaccard=0.25) tetracycline leprosy GAP_LOW 0.155 0.03225806451612903 sulfapyridine 0.45 STABLE 0.85 5 0.03309 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking tetracycline vs leprosy targets. Cross-check tetracycline pharmacophore against leprosy pathway. estazolam coronary_artery_disease GAP_HIGH 0.1911 0.5625 fludiazepam 0.4 STABLE 0.6 3 0.03308 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estazolam→?; validate in coronary_artery_disease cell model. Expected: similar to fludiazepam (Jaccard=0.56) sulfapyridine coronary_artery_disease GAP_HIGH 0.1348 0.2916666666666667 olsalazine 0.4 STABLE 0.85 3 0.03306 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sulfapyridine→?; validate in coronary_artery_disease cell model. Expected: similar to olsalazine (Jaccard=0.29) methacholine gout GAP_HIGH 0.1996 0.25 homatropine_methylbromide 0.45 STABLE 0.85 3 0.03304 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methacholine→?; validate in gout cell model. Expected: similar to homatropine_methylbromide (Jaccard=0.25) mitiglinide coronary_artery_disease GAP_HIGH 0.1345 0.3333333333333333 nateglinide 0.4 STABLE 0.85 3 0.03299 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mitiglinide→?; validate in coronary_artery_disease cell model. Expected: similar to nateglinide (Jaccard=0.33) aprindine barretts_esophagus GAP_LOW 0.1545 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03298 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking aprindine vs barretts_esophagus targets. Cross-check aprindine pharmacophore against barretts_esophagus pathway. acenocoumarol malaria GAP_HIGH 0.1691 0.38461538461538464 phenobarbital 0.45 STABLE 0.6 3 0.03293 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acenocoumarol→?; validate in malaria cell model. Expected: similar to phenobarbital (Jaccard=0.38) salicylic_acid chronic_kidney_failure GAP_HIGH 0.1193 0.26666666666666666 tiaprofenic_acid 0.45 STABLE 0.85 3 0.03292 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay salicylic_acid→?; validate in chronic_kidney_failure cell model. Expected: similar to tiaprofenic_acid (Jaccard=0.27) carbinoxamine membranous_glomerulonephritis GAP_HIGH 0.1192 0.3076923076923077 alimemazine 0.45 STABLE 0.85 3 0.03289 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carbinoxamine→?; validate in membranous_glomerulonephritis cell model. Expected: similar to alimemazine (Jaccard=0.31) nortriptyline barretts_esophagus GAP_LOW 0.1538 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03283 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking nortriptyline vs barretts_esophagus targets. Cross-check nortriptyline pharmacophore against barretts_esophagus pathway. losartan dilated_cardiomyopathy GAP_HIGH 0.1685 0.18181818181818182 trandolapril 0.45 STABLE 0.6 3 0.03282 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay losartan→?; validate in dilated_cardiomyopathy cell model. Expected: similar to trandolapril (Jaccard=0.18) diethylstilbestrol malignant_mesothelioma GAP_HIGH 0.168 0.5454545454545454 diphemanil_methylsulfate 0.45 STABLE 0.6 3 0.03272 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diethylstilbestrol→?; validate in malignant_mesothelioma cell model. Expected: similar to diphemanil_methylsulfate (Jaccard=0.55) vismodegib leprosy GAP_HIGH 0.168 0.34782608695652173 sulfapyridine 0.45 STABLE 0.6 3 0.03272 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vismodegib→?; validate in leprosy cell model. Expected: similar to sulfapyridine (Jaccard=0.35) phenformin coronary_artery_disease GAP_HIGH 0.1889 0.5 phentermine 0.4 STABLE 0.6 3 0.0327 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenformin→?; validate in coronary_artery_disease cell model. Expected: similar to phentermine (Jaccard=0.50) nisoldipine leprosy GAP_LOW 0.1532 0.08333333333333333 phenmetrazine 0.45 STABLE 0.85 5 0.0327 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking nisoldipine vs leprosy targets. Cross-check nisoldipine pharmacophore against leprosy pathway. cinnarizine barretts_esophagus GAP_LOW 0.1532 0.0 pantoprazole 0.45 STABLE 0.85 5 0.0327 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking cinnarizine vs barretts_esophagus targets. Cross-check cinnarizine pharmacophore against barretts_esophagus pathway. phensuximide barretts_esophagus GAP_LOW 0.1532 0.0 pantoprazole 0.45 STABLE 0.85 5 0.0327 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking phensuximide vs barretts_esophagus targets. Cross-check phensuximide pharmacophore against barretts_esophagus pathway. sulfapyridine barretts_esophagus GAP_LOW 0.1532 0.0 pantoprazole 0.45 STABLE 0.85 5 0.0327 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking sulfapyridine vs barretts_esophagus targets. Cross-check sulfapyridine pharmacophore against barretts_esophagus pathway. tetracycline gestational_diabetes GAP_LOW 0.153 0.058823529411764705 tolbutamide 0.45 STABLE 0.85 5 0.03266 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking tetracycline vs gestational_diabetes targets. Cross-check tetracycline pharmacophore against gestational_diabetes pathway. amcinonide barretts_esophagus GAP_LOW 0.1528 0.06666666666666667 pantoprazole 0.45 STABLE 0.85 5 0.03262 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking amcinonide vs barretts_esophagus targets. Cross-check amcinonide pharmacophore against barretts_esophagus pathway. salicylic_acid azoospermia GAP_HIGH 0.1181 0.26666666666666666 tiaprofenic_acid 0.45 STABLE 0.85 3 0.03259 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay salicylic_acid→?; validate in azoospermia cell model. Expected: similar to tiaprofenic_acid (Jaccard=0.27) azatadine barretts_esophagus GAP_LOW 0.1526 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03258 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking azatadine vs barretts_esophagus targets. Cross-check azatadine pharmacophore against barretts_esophagus pathway. l-serine barretts_esophagus GAP_LOW 0.1526 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03258 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking l-serine vs barretts_esophagus targets. Cross-check l-serine pharmacophore against barretts_esophagus pathway. salicylic_acid barretts_esophagus GAP_LOW 0.1526 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03258 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking salicylic_acid vs barretts_esophagus targets. Cross-check salicylic_acid pharmacophore against barretts_esophagus pathway. diethylstilbestrol crohns_disease GAP_HIGH 0.1671 0.5454545454545454 diphemanil_methylsulfate 0.45 STABLE 0.6 3 0.03255 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diethylstilbestrol→?; validate in crohns_disease cell model. Expected: similar to diphemanil_methylsulfate (Jaccard=0.55) tolmetin rheumatoid_arthritis GAP_HIGH 0.1879 0.6363636363636364 agomelatine 0.4 STABLE 0.6 3 0.03253 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tolmetin→?; validate in rheumatoid_arthritis cell model. Expected: similar to agomelatine (Jaccard=0.64) naloxone hypothyroidism GAP_LOW 0.1524 0.0 methimazole 0.45 STABLE 0.85 5 0.03253 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking naloxone vs hypothyroidism targets. Cross-check naloxone pharmacophore against hypothyroidism pathway. tolbutamide hypothyroidism GAP_LOW 0.1524 0.0 methimazole 0.45 STABLE 0.85 5 0.03253 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking tolbutamide vs hypothyroidism targets. Cross-check tolbutamide pharmacophore against hypothyroidism pathway. melatonin epilepsy_syndrome GAP_HIGH 0.1877 0.5 eletriptan 0.4 STABLE 0.6 3 0.0325 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay melatonin→?; validate in epilepsy_syndrome cell model. Expected: similar to eletriptan (Jaccard=0.50) methylphenobarbital barretts_esophagus GAP_LOW 0.2154 0.08333333333333333 pantoprazole 0.45 STABLE 0.6 5 0.03246 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking methylphenobarbital vs barretts_esophagus targets. Cross-check methylphenobarbital pharmacophore against barretts_esophagus pathway. diethylpropion rheumatoid_arthritis GAP_HIGH 0.1871 0.5454545454545454 tropicamide 0.4 STABLE 0.6 3 0.03239 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diethylpropion→?; validate in rheumatoid_arthritis cell model. Expected: similar to tropicamide (Jaccard=0.55) cinolazepam alcohol_dependence GAP_HIGH 0.1663 0.3125 fludiazepam 0.45 STABLE 0.6 3 0.03239 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cinolazepam→?; validate in alcohol_dependence cell model. Expected: similar to fludiazepam (Jaccard=0.31) loperamide focal_segmental_glomerulosclerosis GAP_HIGH 0.1174 0.3333333333333333 promazine 0.45 STABLE 0.85 3 0.03239 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay loperamide→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to promazine (Jaccard=0.33) phenacemide idiopathic_pulmonary_fibrosis GAP_HIGH 0.1174 0.30434782608695654 phentermine 0.45 STABLE 0.85 3 0.03239 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenacemide→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to phentermine (Jaccard=0.30) acetylsalicylic_acid barretts_esophagus GAP_LOW 0.1515 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03234 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking acetylsalicylic_acid vs barretts_esophagus targets. Cross-check acetylsalicylic_acid pharmacophore against barretts_esophagus pathway. menadione barretts_esophagus GAP_LOW 0.1515 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03234 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking menadione vs barretts_esophagus targets. Cross-check menadione pharmacophore against barretts_esophagus pathway. mitiglinide barretts_esophagus GAP_LOW 0.1515 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03234 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking mitiglinide vs barretts_esophagus targets. Cross-check mitiglinide pharmacophore against barretts_esophagus pathway. loperamide chronic_kidney_failure GAP_HIGH 0.1172 0.3448275862068966 methadone 0.45 STABLE 0.85 3 0.03234 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay loperamide→?; validate in chronic_kidney_failure cell model. Expected: similar to methadone (Jaccard=0.34) chlorcyclizine chronic_kidney_failure GAP_HIGH 0.1172 0.3333333333333333 temazepam 0.45 STABLE 0.85 3 0.03234 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorcyclizine→?; validate in chronic_kidney_failure cell model. Expected: similar to temazepam (Jaccard=0.33) clofarabine osteoarthritis GAP_HIGH 0.1952 0.4782608695652174 vidarabine 0.45 STABLE 0.85 3 0.03232 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clofarabine→?; validate in osteoarthritis cell model. Expected: similar to vidarabine (Jaccard=0.48) testolactone barretts_esophagus GAP_LOW 0.151 0.05555555555555555 pantoprazole 0.45 STABLE 0.85 5 0.03224 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking testolactone vs barretts_esophagus targets. Cross-check testolactone pharmacophore against barretts_esophagus pathway. midazolam creutzfeldt-jakob_disease GAP_HIGH 0.1655 0.5 estazolam 0.45 STABLE 0.6 3 0.03223 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay midazolam→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to estazolam (Jaccard=0.50) levorphanol malignant_mesothelioma GAP_HIGH 0.1655 0.46153846153846156 fulvestrant 0.45 STABLE 0.6 3 0.03223 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levorphanol→?; validate in malignant_mesothelioma cell model. Expected: similar to fulvestrant (Jaccard=0.46) chlordiazepoxide barretts_esophagus GAP_LOW 0.1509 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03221 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking chlordiazepoxide vs barretts_esophagus targets. Cross-check chlordiazepoxide pharmacophore against barretts_esophagus pathway. orlistat barretts_esophagus GAP_LOW 0.2134 0.0 pantoprazole 0.45 STABLE 0.6 5 0.03216 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking orlistat vs barretts_esophagus targets. Cross-check orlistat pharmacophore against barretts_esophagus pathway. aminocaproic_acid pagets_disease_of_bone GAP_LOW 0.1505 0.0 ibandronate 0.45 STABLE 0.85 5 0.03213 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking aminocaproic_acid vs pagets_disease_of_bone targets. Cross-check aminocaproic_acid pharmacophore against pagets_disease_of_bone pathway. l-tryptophan rheumatoid_arthritis GAP_HIGH 0.1855 0.4444444444444444 liothyronine 0.4 STABLE 0.6 3 0.03211 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-tryptophan→?; validate in rheumatoid_arthritis cell model. Expected: similar to liothyronine (Jaccard=0.44) fosphenytoin coronary_artery_disease GAP_HIGH 0.185 0.5833333333333334 phenytoin 0.4 STABLE 0.6 3 0.03203 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fosphenytoin→?; validate in coronary_artery_disease cell model. Expected: similar to phenytoin (Jaccard=0.58) chlorprothixene azoospermia GAP_HIGH 0.1643 0.6 chlorpromazine 0.45 STABLE 0.6 3 0.032 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorprothixene→?; validate in azoospermia cell model. Expected: similar to chlorpromazine (Jaccard=0.60) masoprocol panic_disorder GAP_HIGH 0.1643 0.5333333333333333 arbutamine 0.45 STABLE 0.6 3 0.032 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay masoprocol→?; validate in panic_disorder cell model. Expected: similar to arbutamine (Jaccard=0.53) phentermine barretts_esophagus GAP_LOW 0.1499 0.0 pantoprazole 0.45 STABLE 0.85 5 0.032 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking phentermine vs barretts_esophagus targets. Cross-check phentermine pharmacophore against barretts_esophagus pathway. chlorphenesin larynx_cancer GAP_HIGH 0.1231 0.16666666666666666 pantoprazole 0.6 RISING 0.6 3 0.03197 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorphenesin→?; validate in larynx_cancer cell model. Expected: similar to pantoprazole (Jaccard=0.17) levorphanol primary_biliary_cirrhosis GAP_HIGH 0.1639 0.46153846153846156 fulvestrant 0.45 STABLE 0.6 3 0.03192 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levorphanol→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to fulvestrant (Jaccard=0.46) tamsulosin migraine GAP_HIGH 0.1636 0.4 methocarbamol 0.45 STABLE 0.6 3 0.03186 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tamsulosin→?; validate in migraine cell model. Expected: similar to methocarbamol (Jaccard=0.40) liothyronine hypothyroidism GAP_LOW 0.149 0.125 methimazole 0.45 STABLE 0.85 5 0.03181 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking liothyronine vs hypothyroidism targets. Cross-check liothyronine pharmacophore against hypothyroidism pathway. tamsulosin osteoarthritis GAP_HIGH 0.1631 0.4 methocarbamol 0.45 STABLE 0.6 3 0.03177 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tamsulosin→?; validate in osteoarthritis cell model. Expected: similar to methocarbamol (Jaccard=0.40) l-dopa systemic_scleroderma GAP_HIGH 0.163 0.5454545454545454 isoetarine 0.45 STABLE 0.6 3 0.03175 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-dopa→?; validate in systemic_scleroderma cell model. Expected: similar to isoetarine (Jaccard=0.55) fludrocortisone barretts_esophagus GAP_LOW 0.1486 0.05263157894736842 pantoprazole 0.45 STABLE 0.85 5 0.03172 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking fludrocortisone vs barretts_esophagus targets. Cross-check fludrocortisone pharmacophore against barretts_esophagus pathway. atomoxetine barretts_esophagus GAP_LOW 0.1484 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03168 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking atomoxetine vs barretts_esophagus targets. Cross-check atomoxetine pharmacophore against barretts_esophagus pathway. cyclizine barretts_esophagus GAP_LOW 0.1484 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03168 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking cyclizine vs barretts_esophagus targets. Cross-check cyclizine pharmacophore against barretts_esophagus pathway. indecainide barretts_esophagus GAP_LOW 0.1484 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03168 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking indecainide vs barretts_esophagus targets. Cross-check indecainide pharmacophore against barretts_esophagus pathway. nabumetone pagets_disease_of_bone GAP_LOW 0.1483 0.0 ibandronate 0.45 STABLE 0.85 5 0.03166 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking nabumetone vs pagets_disease_of_bone targets. Cross-check nabumetone pharmacophore against pagets_disease_of_bone pathway. estradiol malignant_glioma GAP_HIGH 0.1625 0.5384615384615384 estrone 0.45 STABLE 0.6 3 0.03165 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estradiol→?; validate in malignant_glioma cell model. Expected: similar to estrone (Jaccard=0.54) vindesine metabolic_syndrome_x GAP_HIGH 0.3126 0.875 voacamine 0.55 STABLE 0.85 3 0.03163 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vindesine→?; validate in metabolic_syndrome_x cell model. Expected: similar to voacamine (Jaccard=0.88) chlorprothixene atherosclerosis GAP_HIGH 0.1624 0.5333333333333333 flurbiprofen 0.45 STABLE 0.6 3 0.03163 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorprothixene→?; validate in atherosclerosis cell model. Expected: similar to flurbiprofen (Jaccard=0.53) naloxone leprosy GAP_LOW 0.148 0.14285714285714285 pomalidomide 0.45 STABLE 0.85 5 0.03159 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking naloxone vs leprosy targets. Cross-check naloxone pharmacophore against leprosy pathway. butenafine barretts_esophagus GAP_LOW 0.148 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03159 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking butenafine vs barretts_esophagus targets. Cross-check butenafine pharmacophore against barretts_esophagus pathway. l-histidine barretts_esophagus GAP_LOW 0.148 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03159 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking l-histidine vs barretts_esophagus targets. Cross-check l-histidine pharmacophore against barretts_esophagus pathway. phenylpropanolamine barretts_esophagus GAP_LOW 0.148 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03159 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking phenylpropanolamine vs barretts_esophagus targets. Cross-check phenylpropanolamine pharmacophore against barretts_esophagus pathway. pseudoephedrine barretts_esophagus GAP_LOW 0.148 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03159 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking pseudoephedrine vs barretts_esophagus targets. Cross-check pseudoephedrine pharmacophore against barretts_esophagus pathway. tiaprofenic_acid sclerosing_cholangitis GAP_HIGH 0.1145 0.3 salsalate 0.45 STABLE 0.85 3 0.03159 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tiaprofenic_acid→?; validate in sclerosing_cholangitis cell model. Expected: similar to salsalate (Jaccard=0.30) masoprocol psoriatic_arthritis GAP_HIGH 0.1621 0.5333333333333333 arbutamine 0.45 STABLE 0.6 3 0.03157 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay masoprocol→?; validate in psoriatic_arthritis cell model. Expected: similar to arbutamine (Jaccard=0.53) clonazepam epilepsy_syndrome GAP_HIGH 0.1822 0.625 amoxapine 0.4 STABLE 0.6 3 0.03154 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clonazepam→?; validate in epilepsy_syndrome cell model. Expected: similar to amoxapine (Jaccard=0.62) oxaprozin osteoarthritis GAP_HIGH 0.1619 0.6153846153846154 fenbufen 0.45 STABLE 0.6 3 0.03153 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxaprozin→?; validate in osteoarthritis cell model. Expected: similar to fenbufen (Jaccard=0.62) exemestane breast_cancer GAP_HIGH 0.1214 0.3333333333333333 testolactone 0.6 RISING 0.6 3 0.03153 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay exemestane→?; validate in breast_cancer cell model. Expected: similar to testolactone (Jaccard=0.33) lacosamide barretts_esophagus GAP_LOW 0.1475 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03149 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking lacosamide vs barretts_esophagus targets. Cross-check lacosamide pharmacophore against barretts_esophagus pathway. liothyronine barretts_esophagus GAP_LOW 0.1475 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03149 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking liothyronine vs barretts_esophagus targets. Cross-check liothyronine pharmacophore against barretts_esophagus pathway. brompheniramine barretts_esophagus GAP_LOW 0.1471 0.0 pantoprazole 0.45 STABLE 0.85 5 0.0314 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking brompheniramine vs barretts_esophagus targets. Cross-check brompheniramine pharmacophore against barretts_esophagus pathway. naproxen celiac_disease GAP_HIGH 0.1611 0.5 suprofen 0.45 STABLE 0.6 3 0.03138 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay naproxen→?; validate in celiac_disease cell model. Expected: similar to suprofen (Jaccard=0.50) l-serine systemic_scleroderma GAP_HIGH 0.1137 0.2786885245901639 penicillamine 0.45 STABLE 0.85 3 0.03137 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-serine→?; validate in systemic_scleroderma cell model. Expected: similar to penicillamine (Jaccard=0.28) triflupromazine barretts_esophagus GAP_LOW 0.1467 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03132 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking triflupromazine vs barretts_esophagus targets. Cross-check triflupromazine pharmacophore against barretts_esophagus pathway. l-tyrosine celiac_disease GAP_HIGH 0.1133 0.27586206896551724 suprofen 0.45 STABLE 0.85 3 0.03126 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-tyrosine→?; validate in celiac_disease cell model. Expected: similar to suprofen (Jaccard=0.28) l-tyrosine intracranial_aneurysm GAP_HIGH 0.1133 0.2692307692307692 procarbazine 0.45 STABLE 0.85 3 0.03126 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-tyrosine→?; validate in intracranial_aneurysm cell model. Expected: similar to procarbazine (Jaccard=0.27) carbinoxamine barretts_esophagus GAP_LOW 0.1463 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03123 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking carbinoxamine vs barretts_esophagus targets. Cross-check carbinoxamine pharmacophore against barretts_esophagus pathway. olsalazine barretts_esophagus GAP_LOW 0.1463 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03123 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking olsalazine vs barretts_esophagus targets. Cross-check olsalazine pharmacophore against barretts_esophagus pathway. acepromazine barretts_esophagus GAP_LOW 0.1459 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03115 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking acepromazine vs barretts_esophagus targets. Cross-check acepromazine pharmacophore against barretts_esophagus pathway. masoprocol atherosclerosis GAP_HIGH 0.1598 0.42857142857142855 carbidopa 0.45 STABLE 0.6 3 0.03112 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay masoprocol→?; validate in atherosclerosis cell model. Expected: similar to carbidopa (Jaccard=0.43) telmisartan gestational_diabetes GAP_HIGH 0.1598 0.25 tolbutamide 0.45 STABLE 0.6 3 0.03112 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay telmisartan→?; validate in gestational_diabetes cell model. Expected: similar to tolbutamide (Jaccard=0.25) pseudoephedrine refractive_error GAP_HIGH 0.1127 0.3 epinephrine 0.45 STABLE 0.85 3 0.0311 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pseudoephedrine→?; validate in refractive_error cell model. Expected: similar to epinephrine (Jaccard=0.30) phenprocoumon coronary_artery_disease GAP_HIGH 0.1796 0.6 atomoxetine 0.4 STABLE 0.6 3 0.03109 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenprocoumon→?; validate in coronary_artery_disease cell model. Expected: similar to atomoxetine (Jaccard=0.60) propiomazine barretts_esophagus GAP_LOW 0.1455 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03106 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking propiomazine vs barretts_esophagus targets. Cross-check propiomazine pharmacophore against barretts_esophagus pathway. tiaprofenic_acid barretts_esophagus GAP_LOW 0.1455 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03106 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking tiaprofenic_acid vs barretts_esophagus targets. Cross-check tiaprofenic_acid pharmacophore against barretts_esophagus pathway. acenocoumarol creutzfeldt-jakob_disease GAP_HIGH 0.1594 0.4 clobazam 0.45 STABLE 0.6 3 0.03105 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay acenocoumarol→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to clobazam (Jaccard=0.40) ziprasidone hypothyroidism GAP_LOW 0.1453 0.0 methimazole 0.45 STABLE 0.85 5 0.03102 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking ziprasidone vs hypothyroidism targets. Cross-check ziprasidone pharmacophore against hypothyroidism pathway. chlorprothixene pancreatitis GAP_HIGH 0.1592 0.6 chlorpromazine 0.45 STABLE 0.6 3 0.03101 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorprothixene→?; validate in pancreatitis cell model. Expected: similar to chlorpromazine (Jaccard=0.60) amcinonide alcohol_dependence GAP_HIGH 0.1124 0.18181818181818182 levorphanol 0.45 STABLE 0.85 3 0.03101 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay amcinonide→?; validate in alcohol_dependence cell model. Expected: similar to levorphanol (Jaccard=0.18) atropine barretts_esophagus GAP_LOW 0.1452 0.0 pantoprazole 0.45 STABLE 0.85 5 0.031 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking atropine vs barretts_esophagus targets. Cross-check atropine pharmacophore against barretts_esophagus pathway. salsalate barretts_esophagus GAP_LOW 0.1452 0.0 pantoprazole 0.45 STABLE 0.85 5 0.031 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking salsalate vs barretts_esophagus targets. Cross-check salsalate pharmacophore against barretts_esophagus pathway. conivaptan lymphatic_system_cancer GAP_LOW 0.1539 0.125 tenofovir 0.6 RISING 0.6 5 0.03092 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking conivaptan vs lymphatic_system_cancer targets. Cross-check conivaptan pharmacophore against lymphatic_system_cancer pathway. clotrimazole barretts_esophagus GAP_LOW 0.1444 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03083 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking clotrimazole vs barretts_esophagus targets. Cross-check clotrimazole pharmacophore against barretts_esophagus pathway. dyphylline pagets_disease_of_bone GAP_LOW 0.1444 0.0 ibandronate 0.45 STABLE 0.85 5 0.03083 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking dyphylline vs pagets_disease_of_bone targets. Cross-check dyphylline pharmacophore against pagets_disease_of_bone pathway. midodrine pagets_disease_of_bone GAP_LOW 0.1444 0.0 ibandronate 0.45 STABLE 0.85 5 0.03083 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking midodrine vs pagets_disease_of_bone targets. Cross-check midodrine pharmacophore against pagets_disease_of_bone pathway. theophylline pagets_disease_of_bone GAP_LOW 0.1444 0.0 ibandronate 0.45 STABLE 0.85 5 0.03083 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking theophylline vs pagets_disease_of_bone targets. Cross-check theophylline pharmacophore against pagets_disease_of_bone pathway. midodrine alcohol_dependence GAP_LOW 0.1441 0.1111111111111111 dextromethorphan 0.45 STABLE 0.85 5 0.03076 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking midodrine vs alcohol_dependence targets. Cross-check midodrine pharmacophore against alcohol_dependence pathway. alimemazine barretts_esophagus GAP_LOW 0.1441 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03076 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking alimemazine vs barretts_esophagus targets. Cross-check alimemazine pharmacophore against barretts_esophagus pathway. meclizine barretts_esophagus GAP_LOW 0.1441 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03076 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking meclizine vs barretts_esophagus targets. Cross-check meclizine pharmacophore against barretts_esophagus pathway. methotrimeprazine barretts_esophagus GAP_LOW 0.1441 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03076 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking methotrimeprazine vs barretts_esophagus targets. Cross-check methotrimeprazine pharmacophore against barretts_esophagus pathway. promethazine barretts_esophagus GAP_LOW 0.1441 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03076 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking promethazine vs barretts_esophagus targets. Cross-check promethazine pharmacophore against barretts_esophagus pathway. trifluoperazine barretts_esophagus GAP_LOW 0.1441 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03076 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking trifluoperazine vs barretts_esophagus targets. Cross-check trifluoperazine pharmacophore against barretts_esophagus pathway. ethopropazine crohns_disease GAP_HIGH 0.1114 0.3333333333333333 trimipramine 0.45 STABLE 0.85 3 0.03074 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethopropazine→?; validate in crohns_disease cell model. Expected: similar to trimipramine (Jaccard=0.33) ifenprodil celiac_disease GAP_HIGH 0.1574 0.4090909090909091 fentanyl 0.45 STABLE 0.6 3 0.03066 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ifenprodil→?; validate in celiac_disease cell model. Expected: similar to fentanyl (Jaccard=0.41) phenytoin epilepsy_syndrome GAP_HIGH 0.1768 0.76 ethotoin 0.4 STABLE 0.6 3 0.03061 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenytoin→?; validate in epilepsy_syndrome cell model. Expected: similar to ethotoin (Jaccard=0.76) estrone barretts_esophagus GAP_LOW 0.1434 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03061 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking estrone vs barretts_esophagus targets. Cross-check estrone pharmacophore against barretts_esophagus pathway. propericiazine barretts_esophagus GAP_LOW 0.1434 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03061 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking propericiazine vs barretts_esophagus targets. Cross-check propericiazine pharmacophore against barretts_esophagus pathway. tamsulosin azoospermia GAP_HIGH 0.1571 0.3333333333333333 propafenone 0.45 STABLE 0.6 3 0.0306 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tamsulosin→?; validate in azoospermia cell model. Expected: similar to propafenone (Jaccard=0.33) spironolactone hypothyroidism GAP_LOW 0.1433 0.125 methimazole 0.45 STABLE 0.85 5 0.03059 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking spironolactone vs hypothyroidism targets. Cross-check spironolactone pharmacophore against hypothyroidism pathway. naproxen gout GAP_HIGH 0.157 0.5 suprofen 0.45 STABLE 0.6 3 0.03058 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay naproxen→?; validate in gout cell model. Expected: similar to suprofen (Jaccard=0.50) flurbiprofen focal_segmental_glomerulosclerosis GAP_HIGH 0.1569 0.5333333333333333 chlorprothixene 0.45 STABLE 0.6 3 0.03056 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flurbiprofen→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to chlorprothixene (Jaccard=0.53) thioproperazine barretts_esophagus GAP_LOW 0.1431 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03055 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking thioproperazine vs barretts_esophagus targets. Cross-check thioproperazine pharmacophore against barretts_esophagus pathway. ethopropazine gout GAP_HIGH 0.1107 0.3333333333333333 trimipramine 0.45 STABLE 0.85 3 0.03054 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethopropazine→?; validate in gout cell model. Expected: similar to trimipramine (Jaccard=0.33) flurazepam chronic_kidney_failure GAP_HIGH 0.1567 0.3333333333333333 midazolam 0.45 STABLE 0.6 3 0.03052 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flurazepam→?; validate in chronic_kidney_failure cell model. Expected: similar to midazolam (Jaccard=0.33) pimozide hypothyroidism GAP_LOW 0.1429 0.0 methimazole 0.45 STABLE 0.85 5 0.03051 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking pimozide vs hypothyroidism targets. Cross-check pimozide pharmacophore against hypothyroidism pathway. nitrazepam chronic_kidney_failure GAP_HIGH 0.1565 0.375 midazolam 0.45 STABLE 0.6 3 0.03048 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nitrazepam→?; validate in chronic_kidney_failure cell model. Expected: similar to midazolam (Jaccard=0.38) promazine barretts_esophagus GAP_LOW 0.1428 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03048 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking promazine vs barretts_esophagus targets. Cross-check promazine pharmacophore against barretts_esophagus pathway. trimipramine barretts_esophagus GAP_LOW 0.1428 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03048 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking trimipramine vs barretts_esophagus targets. Cross-check trimipramine pharmacophore against barretts_esophagus pathway. chlorcyclizine malaria GAP_HIGH 0.1104 0.25 modafinil 0.45 STABLE 0.85 3 0.03046 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay chlorcyclizine→?; validate in malaria cell model. Expected: similar to modafinil (Jaccard=0.25) cyclopentolate barretts_esophagus GAP_LOW 0.1425 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03042 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking cyclopentolate vs barretts_esophagus targets. Cross-check cyclopentolate pharmacophore against barretts_esophagus pathway. isopropamide barretts_esophagus GAP_LOW 0.1425 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03042 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking isopropamide vs barretts_esophagus targets. Cross-check isopropamide pharmacophore against barretts_esophagus pathway. reboxetine barretts_esophagus GAP_LOW 0.1425 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03042 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking reboxetine vs barretts_esophagus targets. Cross-check reboxetine pharmacophore against barretts_esophagus pathway. spironolactone barretts_esophagus GAP_LOW 0.1425 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03042 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking spironolactone vs barretts_esophagus targets. Cross-check spironolactone pharmacophore against barretts_esophagus pathway. voacamine systemic_lupus_erythematosus GAP_HIGH 0.1378 0.3333333333333333 vinblastine 0.6 RISING 0.85 3 0.03041 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay voacamine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to vinblastine (Jaccard=0.33) dimetacrine barretts_esophagus GAP_LOW 0.1422 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03036 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking dimetacrine vs barretts_esophagus targets. Cross-check dimetacrine pharmacophore against barretts_esophagus pathway. l-tyrosine barretts_esophagus GAP_LOW 0.1422 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03036 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking l-tyrosine vs barretts_esophagus targets. Cross-check l-tyrosine pharmacophore against barretts_esophagus pathway. phenacemide barretts_esophagus GAP_LOW 0.1422 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03036 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking phenacemide vs barretts_esophagus targets. Cross-check phenacemide pharmacophore against barretts_esophagus pathway. salicylate-sodium barretts_esophagus GAP_LOW 0.1422 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03036 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking salicylate-sodium vs barretts_esophagus targets. Cross-check salicylate-sodium pharmacophore against barretts_esophagus pathway. naproxen sclerosing_cholangitis GAP_HIGH 0.1556 0.5 suprofen 0.45 STABLE 0.6 3 0.03031 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay naproxen→?; validate in sclerosing_cholangitis cell model. Expected: similar to suprofen (Jaccard=0.50) estrone hypothyroidism GAP_LOW 0.1419 0.125 methimazole 0.45 STABLE 0.85 5 0.03029 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking estrone vs hypothyroidism targets. Cross-check estrone pharmacophore against hypothyroidism pathway. drospirenone barretts_esophagus GAP_LOW 0.1419 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03029 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking drospirenone vs barretts_esophagus targets. Cross-check drospirenone pharmacophore against barretts_esophagus pathway. testosterone_propionate barretts_esophagus GAP_LOW 0.1419 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03029 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking testosterone_propionate vs barretts_esophagus targets. Cross-check testosterone_propionate pharmacophore against barretts_esophagus pathway. midodrine leprosy GAP_LOW 0.1416 0.0625 sulfamethizole 0.45 STABLE 0.85 5 0.03023 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking midodrine vs leprosy targets. Cross-check midodrine pharmacophore against leprosy pathway. ifenprodil chronic_kidney_failure GAP_HIGH 0.1551 0.4 diphenylpyraline 0.45 STABLE 0.6 3 0.03021 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ifenprodil→?; validate in chronic_kidney_failure cell model. Expected: similar to diphenylpyraline (Jaccard=0.40) progesterone barretts_esophagus GAP_LOW 0.1414 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03019 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking progesterone vs barretts_esophagus targets. Cross-check progesterone pharmacophore against barretts_esophagus pathway. warfarin hypothyroidism GAP_LOW 0.12 0.0 methimazole 0.45 STABLE 1.0 5 0.03014 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking warfarin vs hypothyroidism targets. Cross-check warfarin pharmacophore against hypothyroidism pathway. flurbiprofen chronic_kidney_failure GAP_HIGH 0.1547 0.5333333333333333 chlorprothixene 0.45 STABLE 0.6 3 0.03013 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flurbiprofen→?; validate in chronic_kidney_failure cell model. Expected: similar to chlorprothixene (Jaccard=0.53) diazepam coronary_artery_disease GAP_HIGH 0.174 0.625 fludiazepam 0.4 STABLE 0.6 3 0.03012 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diazepam→?; validate in coronary_artery_disease cell model. Expected: similar to fludiazepam (Jaccard=0.62) testolactone alcohol_dependence GAP_HIGH 0.1091 0.16 levorphanol 0.45 STABLE 0.85 3 0.0301 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay testolactone→?; validate in alcohol_dependence cell model. Expected: similar to levorphanol (Jaccard=0.16) chlorcyclizine barretts_esophagus GAP_LOW 0.1409 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03008 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking chlorcyclizine vs barretts_esophagus targets. Cross-check chlorcyclizine pharmacophore against barretts_esophagus pathway. ethopropazine barretts_esophagus GAP_LOW 0.1409 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03008 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking ethopropazine vs barretts_esophagus targets. Cross-check ethopropazine pharmacophore against barretts_esophagus pathway. hydromorphone hypothyroidism GAP_LOW 0.1408 0.0 methimazole 0.45 STABLE 0.85 5 0.03006 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking hydromorphone vs hypothyroidism targets. Cross-check hydromorphone pharmacophore against hypothyroidism pathway. phenylbutazone barretts_esophagus GAP_LOW 0.1406 0.0 pantoprazole 0.45 STABLE 0.85 5 0.03001 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking phenylbutazone vs barretts_esophagus targets. Cross-check phenylbutazone pharmacophore against barretts_esophagus pathway. medrysone barretts_esophagus GAP_LOW 0.1403 0.0 pantoprazole 0.45 STABLE 0.85 5 0.02995 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking medrysone vs barretts_esophagus targets. Cross-check medrysone pharmacophore against barretts_esophagus pathway. mesalazine barretts_esophagus GAP_LOW 0.1403 0.0 pantoprazole 0.45 STABLE 0.85 5 0.02995 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking mesalazine vs barretts_esophagus targets. Cross-check mesalazine pharmacophore against barretts_esophagus pathway. fentanyl chronic_kidney_failure GAP_HIGH 0.1537 0.5555555555555556 diphenylpyraline 0.45 STABLE 0.6 3 0.02994 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fentanyl→?; validate in chronic_kidney_failure cell model. Expected: similar to diphenylpyraline (Jaccard=0.56) practolol narcolepsy GAP_HIGH 0.1536 0.3076923076923077 l-tyrosine 0.45 STABLE 0.6 3 0.02992 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay practolol→?; validate in narcolepsy cell model. Expected: similar to l-tyrosine (Jaccard=0.31) vismodegib atherosclerosis GAP_HIGH 0.1535 0.375 olsalazine 0.45 STABLE 0.6 3 0.0299 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vismodegib→?; validate in atherosclerosis cell model. Expected: similar to olsalazine (Jaccard=0.38) loperamide barretts_esophagus GAP_LOW 0.1399 0.0 pantoprazole 0.45 STABLE 0.85 5 0.02987 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking loperamide vs barretts_esophagus targets. Cross-check loperamide pharmacophore against barretts_esophagus pathway. flurbiprofen membranous_glomerulonephritis GAP_HIGH 0.1533 0.5333333333333333 chlorprothixene 0.45 STABLE 0.6 3 0.02986 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flurbiprofen→?; validate in membranous_glomerulonephritis cell model. Expected: similar to chlorprothixene (Jaccard=0.53) ibuprofen barretts_esophagus GAP_LOW 0.1981 0.0 pantoprazole 0.45 STABLE 1.0 5 0.02985 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking ibuprofen vs barretts_esophagus targets. Cross-check ibuprofen pharmacophore against barretts_esophagus pathway. irbesartan barretts_esophagus GAP_LOW 0.1981 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02985 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking irbesartan vs barretts_esophagus targets. Cross-check irbesartan pharmacophore against barretts_esophagus pathway. losartan barretts_esophagus GAP_LOW 0.1981 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02985 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking losartan vs barretts_esophagus targets. Cross-check losartan pharmacophore against barretts_esophagus pathway. diphenylpyraline barretts_esophagus GAP_LOW 0.1394 0.0 pantoprazole 0.45 STABLE 0.85 5 0.02976 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking diphenylpyraline vs barretts_esophagus targets. Cross-check diphenylpyraline pharmacophore against barretts_esophagus pathway. oxaprozin gout GAP_HIGH 0.1525 0.5333333333333333 phenindione 0.45 STABLE 0.6 3 0.0297 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxaprozin→?; validate in gout cell model. Expected: similar to phenindione (Jaccard=0.53) methadone barretts_esophagus GAP_LOW 0.139 0.0 pantoprazole 0.45 STABLE 0.85 5 0.02967 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking methadone vs barretts_esophagus targets. Cross-check methadone pharmacophore against barretts_esophagus pathway. aspartame rheumatoid_arthritis GAP_HIGH 0.1712 0.4 labetalol 0.4 STABLE 0.6 3 0.02964 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aspartame→?; validate in rheumatoid_arthritis cell model. Expected: similar to labetalol (Jaccard=0.40) temazepam focal_segmental_glomerulosclerosis GAP_HIGH 0.1519 0.46153846153846156 trifluoperazine 0.45 STABLE 0.6 3 0.02958 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay temazepam→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to trifluoperazine (Jaccard=0.46) ifenprodil sclerosing_cholangitis GAP_HIGH 0.1519 0.4090909090909091 fentanyl 0.45 STABLE 0.6 3 0.02958 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ifenprodil→?; validate in sclerosing_cholangitis cell model. Expected: similar to fentanyl (Jaccard=0.41) diclofenac focal_segmental_glomerulosclerosis GAP_HIGH 0.1517 0.38461538461538464 chlorthalidone 0.45 STABLE 0.6 3 0.02955 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diclofenac→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to chlorthalidone (Jaccard=0.38) ifenprodil ankylosing_spondylitis GAP_HIGH 0.1514 0.4090909090909091 fentanyl 0.45 STABLE 0.6 3 0.02949 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ifenprodil→?; validate in ankylosing_spondylitis cell model. Expected: similar to fentanyl (Jaccard=0.41) epinephrine metabolic_syndrome_x GAP_HIGH 0.2914 1.0 clenbuterol 0.55 STABLE 0.85 3 0.02948 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay epinephrine→?; validate in metabolic_syndrome_x cell model. Expected: similar to clenbuterol (Jaccard=1.00) nelarabine acquired_immunodeficiency_syndrome GAP_HIGH 0.2904 0.5 emtricitabine 0.55 STABLE 0.85 3 0.02938 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nelarabine→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to emtricitabine (Jaccard=0.50) captopril barretts_esophagus GAP_LOW 0.195 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02938 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking captopril vs barretts_esophagus targets. Cross-check captopril pharmacophore against barretts_esophagus pathway. carvedilol barretts_esophagus GAP_LOW 0.195 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02938 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking carvedilol vs barretts_esophagus targets. Cross-check carvedilol pharmacophore against barretts_esophagus pathway. pravastatin barretts_esophagus GAP_LOW 0.195 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02938 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking pravastatin vs barretts_esophagus targets. Cross-check pravastatin pharmacophore against barretts_esophagus pathway. flutamide focal_segmental_glomerulosclerosis GAP_HIGH 0.1774 0.25 bumetanide 0.45 STABLE 0.85 3 0.02937 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flutamide→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to bumetanide (Jaccard=0.25) propranolol vaginal_cancer GAP_HIGH 0.1127 0.3181818181818182 tamsulosin 0.6 RISING 0.6 3 0.02927 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propranolol→?; validate in vaginal_cancer cell model. Expected: similar to tamsulosin (Jaccard=0.32) anisotropine_methylbromide coronary_artery_disease GAP_HIGH 0.1191 0.16666666666666666 nalbuphine 0.4 STABLE 0.85 3 0.02921 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay anisotropine_methylbromide→?; validate in coronary_artery_disease cell model. Expected: similar to nalbuphine (Jaccard=0.17) diclofenac chronic_kidney_failure GAP_HIGH 0.1495 0.38461538461538464 chlorthalidone 0.45 STABLE 0.6 3 0.02912 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diclofenac→?; validate in chronic_kidney_failure cell model. Expected: similar to chlorthalidone (Jaccard=0.38) docetaxel systemic_lupus_erythematosus GAP_HIGH 0.1866 0.6 paclitaxel 0.6 RISING 0.6 3 0.02908 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay docetaxel→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to paclitaxel (Jaccard=0.60) fluticasone_propionate crohns_disease GAP_HIGH 0.1755 0.5833333333333334 fluocinonide 0.45 STABLE 0.85 3 0.02905 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluticasone_propionate→?; validate in crohns_disease cell model. Expected: similar to fluocinonide (Jaccard=0.58) anisotropine_methylbromide hypothyroidism GAP_LOW 0.1361 0.0 methimazole 0.45 STABLE 0.85 5 0.02905 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking anisotropine_methylbromide vs hypothyroidism targets. Cross-check anisotropine_methylbromide pharmacophore against hypothyroidism pathway. bepotastine hypothyroidism GAP_LOW 0.1361 0.0 methimazole 0.45 STABLE 0.85 5 0.02905 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking bepotastine vs hypothyroidism targets. Cross-check bepotastine pharmacophore against hypothyroidism pathway. flunarizine hypothyroidism GAP_LOW 0.1361 0.0 methimazole 0.45 STABLE 0.85 5 0.02905 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking flunarizine vs hypothyroidism targets. Cross-check flunarizine pharmacophore against hypothyroidism pathway. conivaptan barretts_esophagus GAP_LOW 0.1922 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02896 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking conivaptan vs barretts_esophagus targets. Cross-check conivaptan pharmacophore against barretts_esophagus pathway. temazepam azoospermia GAP_HIGH 0.1485 0.46153846153846156 trifluoperazine 0.45 STABLE 0.6 3 0.02892 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay temazepam→?; validate in azoospermia cell model. Expected: similar to trifluoperazine (Jaccard=0.46) diclofenac membranous_glomerulonephritis GAP_HIGH 0.1481 0.38461538461538464 chlorthalidone 0.45 STABLE 0.6 3 0.02884 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diclofenac→?; validate in membranous_glomerulonephritis cell model. Expected: similar to chlorthalidone (Jaccard=0.38) phenylbutazone gout GAP_HIGH 0.1045 0.3125 oxcarbazepine 0.45 STABLE 0.85 3 0.02883 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenylbutazone→?; validate in gout cell model. Expected: similar to oxcarbazepine (Jaccard=0.31) meclizine malaria GAP_HIGH 0.1043 0.175 modafinil 0.45 STABLE 0.85 3 0.02878 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay meclizine→?; validate in malaria cell model. Expected: similar to modafinil (Jaccard=0.17) exemestane metabolic_syndrome_x GAP_HIGH 0.1207 0.3333333333333333 testolactone 0.55 STABLE 0.6 3 0.02873 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay exemestane→?; validate in metabolic_syndrome_x cell model. Expected: similar to testolactone (Jaccard=0.33) floctafenine hypothyroidism GAP_LOW 0.1345 0.0 methimazole 0.45 STABLE 0.85 5 0.02871 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking floctafenine vs hypothyroidism targets. Cross-check floctafenine pharmacophore against hypothyroidism pathway. indapamide hypothyroidism GAP_LOW 0.1345 0.0 methimazole 0.45 STABLE 0.85 5 0.02871 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking indapamide vs hypothyroidism targets. Cross-check indapamide pharmacophore against hypothyroidism pathway. tenofovir acquired_immunodeficiency_syndrome GAP_HIGH 0.2834 0.6 cladribine 0.55 STABLE 0.85 3 0.02867 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tenofovir→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to cladribine (Jaccard=0.60) tamsulosin epilepsy_syndrome GAP_HIGH 0.1652 0.4 methocarbamol 0.4 STABLE 0.6 3 0.0286 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tamsulosin→?; validate in epilepsy_syndrome cell model. Expected: similar to methocarbamol (Jaccard=0.40) pimozide leprosy GAP_LOW 0.1336 0.1111111111111111 phenmetrazine 0.45 STABLE 0.85 5 0.02852 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking pimozide vs leprosy targets. Cross-check pimozide pharmacophore against leprosy pathway. masoprocol schizophrenia GAP_HIGH 0.1643 0.5333333333333333 arbutamine 0.4 STABLE 0.6 3 0.02844 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay masoprocol→?; validate in schizophrenia cell model. Expected: similar to arbutamine (Jaccard=0.53) abacavir acquired_immunodeficiency_syndrome GAP_HIGH 0.2798 0.6 entecavir 0.55 STABLE 0.85 3 0.02831 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay abacavir→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to entecavir (Jaccard=0.60) propranolol migraine GAP_HIGH 0.1452 0.5 methocarbamol 0.45 STABLE 0.6 3 0.02828 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay propranolol→?; validate in migraine cell model. Expected: similar to methocarbamol (Jaccard=0.50) prednicarbate metabolic_syndrome_x GAP_HIGH 0.2787 0.8571428571428571 eplerenone 0.55 STABLE 0.85 3 0.0282 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prednicarbate→?; validate in metabolic_syndrome_x cell model. Expected: similar to eplerenone (Jaccard=0.86) ospemifene rheumatoid_arthritis GAP_HIGH 0.1629 0.42857142857142855 candesartan 0.4 STABLE 0.6 3 0.0282 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ospemifene→?; validate in rheumatoid_arthritis cell model. Expected: similar to candesartan (Jaccard=0.43) pimozide pagets_disease_of_bone GAP_LOW 0.1314 0.0 ibandronate 0.45 STABLE 0.85 5 0.02805 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking pimozide vs pagets_disease_of_bone targets. Cross-check pimozide pharmacophore against pagets_disease_of_bone pathway. diclofenac ankylosing_spondylitis GAP_HIGH 0.1437 0.38461538461538464 chlorthalidone 0.45 STABLE 0.6 3 0.02799 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diclofenac→?; validate in ankylosing_spondylitis cell model. Expected: similar to chlorthalidone (Jaccard=0.38) cinolazepam sclerosing_cholangitis GAP_HIGH 0.1433 0.3125 fludiazepam 0.45 STABLE 0.6 3 0.02791 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cinolazepam→?; validate in sclerosing_cholangitis cell model. Expected: similar to fludiazepam (Jaccard=0.31) ketorolac atherosclerosis GAP_HIGH 0.1432 0.2857142857142857 tiaprofenic_acid 0.45 STABLE 0.6 3 0.02789 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ketorolac→?; validate in atherosclerosis cell model. Expected: similar to tiaprofenic_acid (Jaccard=0.29) streptozocin barretts_esophagus GAP_LOW 0.1848 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02785 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking streptozocin vs barretts_esophagus targets. Cross-check streptozocin pharmacophore against barretts_esophagus pathway. bromfenac atherosclerosis GAP_HIGH 0.143 0.4090909090909091 naproxen 0.45 STABLE 0.6 3 0.02785 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bromfenac→?; validate in atherosclerosis cell model. Expected: similar to naproxen (Jaccard=0.41) oxaprozin rheumatoid_arthritis GAP_HIGH 0.1608 0.6153846153846154 fenbufen 0.4 STABLE 0.6 3 0.02784 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxaprozin→?; validate in rheumatoid_arthritis cell model. Expected: similar to fenbufen (Jaccard=0.62) cinnarizine hypothyroidism GAP_LOW 0.1304 0.0 methimazole 0.45 STABLE 0.85 5 0.02784 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking cinnarizine vs hypothyroidism targets. Cross-check cinnarizine pharmacophore against hypothyroidism pathway. ospemifene barretts_esophagus GAP_LOW 0.1845 0.07142857142857142 pantoprazole 0.45 STABLE 0.6 5 0.0278 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking ospemifene vs barretts_esophagus targets. Cross-check ospemifene pharmacophore against barretts_esophagus pathway. midazolam narcolepsy GAP_HIGH 0.1427 0.375 nitrazepam 0.45 STABLE 0.6 3 0.02779 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay midazolam→?; validate in narcolepsy cell model. Expected: similar to nitrazepam (Jaccard=0.38) clofedanol celiac_disease GAP_HIGH 0.1425 0.5294117647058824 diphenhydramine 0.45 STABLE 0.6 3 0.02775 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clofedanol→?; validate in celiac_disease cell model. Expected: similar to diphenhydramine (Jaccard=0.53) vitamin_c focal_segmental_glomerulosclerosis GAP_HIGH 0.2374 0.3333333333333333 amsacrine 0.45 STABLE 0.6 3 0.02774 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vitamin_c→?; validate in focal_segmental_glomerulosclerosis cell model. Expected: similar to amsacrine (Jaccard=0.33) l-serine hypothyroidism GAP_LOW 0.1298 0.0 methimazole 0.45 STABLE 0.85 5 0.02771 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking l-serine vs hypothyroidism targets. Cross-check l-serine pharmacophore against hypothyroidism pathway. salicylic_acid hypothyroidism GAP_LOW 0.1298 0.0 methimazole 0.45 STABLE 0.85 5 0.02771 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking salicylic_acid vs hypothyroidism targets. Cross-check salicylic_acid pharmacophore against hypothyroidism pathway. dienestrol dilated_cardiomyopathy GAP_HIGH 0.1421 0.15789473684210525 progesterone 0.45 STABLE 0.6 3 0.02768 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dienestrol→?; validate in dilated_cardiomyopathy cell model. Expected: similar to progesterone (Jaccard=0.16) solifenacin hepatitis_b GAP_HIGH 0.3174 0.6 alvimopan 0.2 DECLINING 0.6 3 0.02747 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay solifenacin→?; validate in hepatitis_b cell model. Expected: similar to alvimopan (Jaccard=0.60) acetylsalicylic_acid hypothyroidism GAP_LOW 0.1286 0.0 methimazole 0.45 STABLE 0.85 5 0.02745 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking acetylsalicylic_acid vs hypothyroidism targets. Cross-check acetylsalicylic_acid pharmacophore against hypothyroidism pathway. l-dopa atherosclerosis GAP_HIGH 0.1408 0.35 carbidopa 0.45 STABLE 0.6 3 0.02742 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay l-dopa→?; validate in atherosclerosis cell model. Expected: similar to carbidopa (Jaccard=0.35) progesterone hypothyroidism GAP_LOW 0.1284 0.058823529411764705 methimazole 0.45 STABLE 0.85 5 0.02741 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking progesterone vs hypothyroidism targets. Cross-check progesterone pharmacophore against hypothyroidism pathway. tretinoin bone_cancer GAP_LOW 0.136 0.125 histamine_phosphate 0.6 RISING 0.6 5 0.02733 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking tretinoin vs bone_cancer targets. Cross-check tretinoin pharmacophore against bone_cancer pathway. benzocaine crohns_disease GAP_HIGH 0.1649 0.3333333333333333 cyclandelate 0.45 STABLE 0.85 3 0.0273 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzocaine→?; validate in crohns_disease cell model. Expected: similar to cyclandelate (Jaccard=0.33) dienestrol atherosclerosis GAP_HIGH 0.1397 0.18181818181818182 mesalazine 0.45 STABLE 0.6 3 0.02721 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dienestrol→?; validate in atherosclerosis cell model. Expected: similar to mesalazine (Jaccard=0.18) clofedanol meningioma GAP_HIGH 0.1396 0.53125 methadone 0.45 STABLE 0.6 3 0.02719 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clofedanol→?; validate in meningioma cell model. Expected: similar to methadone (Jaccard=0.53) ketorolac celiac_disease GAP_HIGH 0.1395 0.3076923076923077 suprofen 0.45 STABLE 0.6 3 0.02717 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ketorolac→?; validate in celiac_disease cell model. Expected: similar to suprofen (Jaccard=0.31) midazolam psoriasis GAP_HIGH 0.1393 0.375 nitrazepam 0.45 STABLE 0.6 3 0.02713 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay midazolam→?; validate in psoriasis cell model. Expected: similar to nitrazepam (Jaccard=0.38) loperamide hypothyroidism GAP_LOW 0.127 0.058823529411764705 methimazole 0.45 STABLE 0.85 5 0.02711 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking loperamide vs hypothyroidism targets. Cross-check loperamide pharmacophore against hypothyroidism pathway. phenytoin leprosy GAP_HIGH 0.1391 0.30612244897959184 phensuximide 0.45 STABLE 0.6 3 0.02709 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenytoin→?; validate in leprosy cell model. Expected: similar to phensuximide (Jaccard=0.31) l-tyrosine hypothyroidism GAP_LOW 0.1266 0.038461538461538464 methimazole 0.45 STABLE 0.85 5 0.02703 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking l-tyrosine vs hypothyroidism targets. Cross-check l-tyrosine pharmacophore against hypothyroidism pathway. clofedanol idiopathic_pulmonary_fibrosis GAP_HIGH 0.1387 0.5294117647058824 diphenhydramine 0.45 STABLE 0.6 3 0.02701 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clofedanol→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to diphenhydramine (Jaccard=0.53) thiothixene crohns_disease GAP_HIGH 0.1386 0.5238095238095238 pirenzepine 0.45 STABLE 0.6 3 0.02699 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thiothixene→?; validate in crohns_disease cell model. Expected: similar to pirenzepine (Jaccard=0.52) mannitol bone_cancer GAP_LOW 0.1343 0.0 ibandronate 0.6 RISING 0.6 5 0.02698 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking mannitol vs bone_cancer targets. Cross-check mannitol pharmacophore against bone_cancer pathway. acetylsalicylic_acid pagets_disease_of_bone GAP_LOW 0.1264 0.05555555555555555 histamine_phosphate 0.45 STABLE 0.85 5 0.02698 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking acetylsalicylic_acid vs pagets_disease_of_bone targets. Cross-check acetylsalicylic_acid pharmacophore against pagets_disease_of_bone pathway. moexipril barretts_esophagus GAP_LOW 0.1787 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02693 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking moexipril vs barretts_esophagus targets. Cross-check moexipril pharmacophore against barretts_esophagus pathway. pentobarbital hypothyroidism GAP_LOW 0.1786 0.0 methimazole 0.45 STABLE 0.6 5 0.02691 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking pentobarbital vs hypothyroidism targets. Cross-check pentobarbital pharmacophore against hypothyroidism pathway. dyphylline leprosy GAP_LOW 0.1256 0.0 sulfapyridine 0.45 STABLE 0.85 5 0.02681 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking dyphylline vs leprosy targets. Cross-check dyphylline pharmacophore against leprosy pathway. indecainide hypothyroidism GAP_LOW 0.1256 0.0 methimazole 0.45 STABLE 0.85 5 0.02681 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking indecainide vs hypothyroidism targets. Cross-check indecainide pharmacophore against hypothyroidism pathway. theophylline leprosy GAP_LOW 0.1256 0.0 sulfapyridine 0.45 STABLE 0.85 5 0.02681 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking theophylline vs leprosy targets. Cross-check theophylline pharmacophore against leprosy pathway. l-histidine hypothyroidism GAP_LOW 0.1252 0.0 methimazole 0.45 STABLE 0.85 5 0.02673 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking l-histidine vs hypothyroidism targets. Cross-check l-histidine pharmacophore against hypothyroidism pathway. pseudoephedrine hypothyroidism GAP_LOW 0.1252 0.0 methimazole 0.45 STABLE 0.85 5 0.02673 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking pseudoephedrine vs hypothyroidism targets. Cross-check pseudoephedrine pharmacophore against hypothyroidism pathway. exemestane dilated_cardiomyopathy GAP_HIGH 0.1372 0.29411764705882354 medrysone 0.45 STABLE 0.6 3 0.02672 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay exemestane→?; validate in dilated_cardiomyopathy cell model. Expected: similar to medrysone (Jaccard=0.29) indomethacin barretts_esophagus GAP_LOW 0.1769 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02666 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking indomethacin vs barretts_esophagus targets. Cross-check indomethacin pharmacophore against barretts_esophagus pathway. treprostinil barretts_esophagus GAP_LOW 0.1769 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02666 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking treprostinil vs barretts_esophagus targets. Cross-check treprostinil pharmacophore against barretts_esophagus pathway. bezafibrate hypothyroidism GAP_LOW 0.1247 0.0 methimazole 0.45 STABLE 0.85 5 0.02662 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking bezafibrate vs hypothyroidism targets. Cross-check bezafibrate pharmacophore against hypothyroidism pathway. anisotropine_methylbromide pagets_disease_of_bone GAP_LOW 0.1246 0.0 ibandronate 0.45 STABLE 0.85 5 0.0266 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking anisotropine_methylbromide vs pagets_disease_of_bone targets. Cross-check anisotropine_methylbromide pharmacophore against pagets_disease_of_bone pathway. ifenprodil coronary_artery_disease GAP_HIGH 0.1531 0.4090909090909091 fentanyl 0.4 STABLE 0.6 3 0.02651 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ifenprodil→?; validate in coronary_artery_disease cell model. Expected: similar to fentanyl (Jaccard=0.41) ketorolac crohns_disease GAP_HIGH 0.1361 0.3076923076923077 suprofen 0.45 STABLE 0.6 3 0.02651 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ketorolac→?; validate in crohns_disease cell model. Expected: similar to suprofen (Jaccard=0.31) triflupromazine hypothyroidism GAP_LOW 0.1239 0.0 methimazole 0.45 STABLE 0.85 5 0.02645 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking triflupromazine vs hypothyroidism targets. Cross-check triflupromazine pharmacophore against hypothyroidism pathway. ibuprofen hypothyroidism GAP_LOW 0.1753 0.0 methimazole 0.45 STABLE 1.0 5 0.02642 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking ibuprofen vs hypothyroidism targets. Cross-check ibuprofen pharmacophore against hypothyroidism pathway. irbesartan hypothyroidism GAP_LOW 0.1753 0.0 methimazole 0.45 STABLE 0.6 5 0.02642 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking irbesartan vs hypothyroidism targets. Cross-check irbesartan pharmacophore against hypothyroidism pathway. losartan hypothyroidism GAP_LOW 0.1753 0.0 methimazole 0.45 STABLE 0.6 5 0.02642 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking losartan vs hypothyroidism targets. Cross-check losartan pharmacophore against hypothyroidism pathway. emtricitabine sclerosing_cholangitis GAP_HIGH 0.3191 0.6666666666666666 pentostatin 0.45 STABLE 0.85 3 0.02641 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay emtricitabine→?; validate in sclerosing_cholangitis cell model. Expected: similar to pentostatin (Jaccard=0.67) bromfenac refractive_error GAP_HIGH 0.1356 0.4117647058823529 clonidine 0.45 STABLE 0.6 3 0.02641 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bromfenac→?; validate in refractive_error cell model. Expected: similar to clonidine (Jaccard=0.41) flurazepam coronary_artery_disease GAP_HIGH 0.1525 0.3333333333333333 midazolam 0.4 STABLE 0.6 3 0.0264 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flurazepam→?; validate in coronary_artery_disease cell model. Expected: similar to midazolam (Jaccard=0.33) nitrazepam coronary_artery_disease GAP_HIGH 0.1523 0.375 midazolam 0.4 STABLE 0.6 3 0.02637 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nitrazepam→?; validate in coronary_artery_disease cell model. Expected: similar to midazolam (Jaccard=0.38) calcidiol sclerosing_cholangitis GAP_HIGH 0.1354 0.2 ursodeoxycholic_acid 0.45 STABLE 0.6 3 0.02637 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay calcidiol→?; validate in sclerosing_cholangitis cell model. Expected: similar to ursodeoxycholic_acid (Jaccard=0.20) carbinoxamine hypothyroidism GAP_LOW 0.1235 0.0 methimazole 0.45 STABLE 0.85 5 0.02636 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking carbinoxamine vs hypothyroidism targets. Cross-check carbinoxamine pharmacophore against hypothyroidism pathway. mazindol leprosy GAP_HIGH 0.1352 0.24193548387096775 phensuximide 0.45 STABLE 0.6 3 0.02633 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mazindol→?; validate in leprosy cell model. Expected: similar to phensuximide (Jaccard=0.24) toremifene meningioma GAP_HIGH 0.135 0.5 methadone 0.45 STABLE 0.6 3 0.02629 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay toremifene→?; validate in meningioma cell model. Expected: similar to methadone (Jaccard=0.50) exemestane alcohol_dependence GAP_HIGH 0.1349 0.2777777777777778 levorphanol 0.45 STABLE 0.6 3 0.02627 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay exemestane→?; validate in alcohol_dependence cell model. Expected: similar to levorphanol (Jaccard=0.28) vapreotide atherosclerosis GAP_HIGH 0.1586 0.18181818181818182 deferasirox 0.45 STABLE 0.85 3 0.02626 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vapreotide→?; validate in atherosclerosis cell model. Expected: similar to deferasirox (Jaccard=0.18) diclofenamide rheumatoid_arthritis GAP_HIGH 0.1783 0.3333333333333333 hydrochlorothiazide 0.4 STABLE 0.85 3 0.02624 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diclofenamide→?; validate in rheumatoid_arthritis cell model. Expected: similar to hydrochlorothiazide (Jaccard=0.33) tiaprofenic_acid hypothyroidism GAP_LOW 0.1227 0.0 methimazole 0.45 STABLE 0.85 5 0.02619 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking tiaprofenic_acid vs hypothyroidism targets. Cross-check tiaprofenic_acid pharmacophore against hypothyroidism pathway. toremifene idiopathic_pulmonary_fibrosis GAP_HIGH 0.1344 0.5 diethylstilbestrol 0.45 STABLE 0.6 3 0.02618 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay toremifene→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to diethylstilbestrol (Jaccard=0.50) tamsulosin barretts_esophagus GAP_LOW 0.1737 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02617 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking tamsulosin vs barretts_esophagus targets. Cross-check tamsulosin pharmacophore against barretts_esophagus pathway. zafirlukast barretts_esophagus GAP_LOW 0.1737 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02617 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking zafirlukast vs barretts_esophagus targets. Cross-check zafirlukast pharmacophore against barretts_esophagus pathway. toremifene gout GAP_HIGH 0.134 0.5 dimetacrine 0.45 STABLE 0.6 3 0.0261 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay toremifene→?; validate in gout cell model. Expected: similar to dimetacrine (Jaccard=0.50) alfacalcidol sclerosing_cholangitis GAP_HIGH 0.1339 0.2 ursodeoxycholic_acid 0.45 STABLE 0.6 3 0.02608 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alfacalcidol→?; validate in sclerosing_cholangitis cell model. Expected: similar to ursodeoxycholic_acid (Jaccard=0.20) bromfenac azoospermia GAP_HIGH 0.1337 0.4090909090909091 naproxen 0.45 STABLE 0.6 3 0.02604 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bromfenac→?; validate in azoospermia cell model. Expected: similar to naproxen (Jaccard=0.41) clotrimazole hypothyroidism GAP_LOW 0.1216 0.0 methimazole 0.45 STABLE 0.85 5 0.02596 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking clotrimazole vs hypothyroidism targets. Cross-check clotrimazole pharmacophore against hypothyroidism pathway. carvedilol hypothyroidism GAP_LOW 0.1722 0.0 methimazole 0.45 STABLE 0.6 5 0.02595 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking carvedilol vs hypothyroidism targets. Cross-check carvedilol pharmacophore against hypothyroidism pathway. pravastatin hypothyroidism GAP_LOW 0.1722 0.0 methimazole 0.45 STABLE 0.6 5 0.02595 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking pravastatin vs hypothyroidism targets. Cross-check pravastatin pharmacophore against hypothyroidism pathway. alitretinoin bone_cancer GAP_LOW 0.129 0.1 histamine_phosphate 0.6 RISING 0.6 5 0.02592 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking alitretinoin vs bone_cancer targets. Cross-check alitretinoin pharmacophore against bone_cancer pathway. meclizine hypothyroidism GAP_LOW 0.1213 0.0 methimazole 0.45 STABLE 0.85 5 0.02589 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking meclizine vs hypothyroidism targets. Cross-check meclizine pharmacophore against hypothyroidism pathway. s-adenosylmethionine systemic_lupus_erythematosus GAP_HIGH 0.1169 0.24528301886792453 ribavirin 0.6 RISING 0.85 3 0.02581 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay s-adenosylmethionine→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to ribavirin (Jaccard=0.25) calcitriol barretts_esophagus GAP_LOW 0.1708 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02574 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking calcitriol vs barretts_esophagus targets. Cross-check calcitriol pharmacophore against barretts_esophagus pathway. ergocalciferol barretts_esophagus GAP_LOW 0.1708 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02574 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking ergocalciferol vs barretts_esophagus targets. Cross-check ergocalciferol pharmacophore against barretts_esophagus pathway. telmisartan barretts_esophagus GAP_LOW 0.1708 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02574 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking telmisartan vs barretts_esophagus targets. Cross-check telmisartan pharmacophore against barretts_esophagus pathway. ketoprofen leprosy GAP_HIGH 0.1321 0.15384615384615385 pomalidomide 0.45 STABLE 0.6 3 0.02573 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ketoprofen→?; validate in leprosy cell model. Expected: similar to pomalidomide (Jaccard=0.15) lidocaine osteoarthritis GAP_HIGH 0.1551 0.4166666666666667 probenecid 0.45 STABLE 0.85 3 0.02567 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lidocaine→?; validate in osteoarthritis cell model. Expected: similar to probenecid (Jaccard=0.42) linaclotide azoospermia GAP_HIGH 0.3092 0.5 deferasirox 0.45 STABLE 0.85 3 0.02559 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay linaclotide→?; validate in azoospermia cell model. Expected: similar to deferasirox (Jaccard=0.50) conivaptan hypothyroidism GAP_LOW 0.1694 0.0 methimazole 0.45 STABLE 0.6 5 0.02553 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking conivaptan vs hypothyroidism targets. Cross-check conivaptan pharmacophore against hypothyroidism pathway. flurazepam barretts_esophagus GAP_LOW 0.1694 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02553 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking flurazepam vs barretts_esophagus targets. Cross-check flurazepam pharmacophore against barretts_esophagus pathway. paricalcitol barretts_esophagus GAP_LOW 0.1694 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02553 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking paricalcitol vs barretts_esophagus targets. Cross-check paricalcitol pharmacophore against barretts_esophagus pathway. phenacemide hypothyroidism GAP_LOW 0.1194 0.0 methimazole 0.45 STABLE 0.85 5 0.02549 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking phenacemide vs hypothyroidism targets. Cross-check phenacemide pharmacophore against hypothyroidism pathway. bromfenac narcolepsy GAP_HIGH 0.1306 0.4090909090909091 naproxen 0.45 STABLE 0.6 3 0.02544 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bromfenac→?; validate in narcolepsy cell model. Expected: similar to naproxen (Jaccard=0.41) ibuprofen leprosy GAP_LOW 0.1688 0.13333333333333333 pomalidomide 0.45 STABLE 1.0 5 0.02543 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking ibuprofen vs leprosy targets. Cross-check ibuprofen pharmacophore against leprosy pathway. fenoprofen esophageal_cancer GAP_HIGH 0.0979 0.2571428571428571 melphalan 0.6 RISING 0.6 3 0.02542 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fenoprofen→?; validate in esophageal_cancer cell model. Expected: similar to melphalan (Jaccard=0.26) adenosine_monophosphate systemic_lupus_erythematosus GAP_HIGH 0.1151 0.26229508196721313 vidarabine 0.6 RISING 0.85 3 0.0254 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay adenosine_monophosphate→?; validate in systemic_lupus_erythematosus cell model. Expected: similar to vidarabine (Jaccard=0.26) modafinil chronic_kidney_failure GAP_HIGH 0.1301 0.45454545454545453 diphenylpyraline 0.45 STABLE 0.6 3 0.02534 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay modafinil→?; validate in chronic_kidney_failure cell model. Expected: similar to diphenylpyraline (Jaccard=0.45) alfacalcidol barretts_esophagus GAP_LOW 0.1681 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02533 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking alfacalcidol vs barretts_esophagus targets. Cross-check alfacalcidol pharmacophore against barretts_esophagus pathway. calcidiol barretts_esophagus GAP_LOW 0.1681 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02533 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking calcidiol vs barretts_esophagus targets. Cross-check calcidiol pharmacophore against barretts_esophagus pathway. calcipotriol barretts_esophagus GAP_LOW 0.1681 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02533 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking calcipotriol vs barretts_esophagus targets. Cross-check calcipotriol pharmacophore against barretts_esophagus pathway. dihydrotachysterol barretts_esophagus GAP_LOW 0.1681 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02533 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking dihydrotachysterol vs barretts_esophagus targets. Cross-check dihydrotachysterol pharmacophore against barretts_esophagus pathway. mazindol chronic_obstructive_pulmonary_disease GAP_HIGH 0.13 0.425 loxapine 0.45 STABLE 0.6 3 0.02532 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mazindol→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to loxapine (Jaccard=0.42) l-serine pagets_disease_of_bone GAP_LOW 0.1183 0.0 ibandronate 0.45 STABLE 0.85 5 0.02525 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking l-serine vs pagets_disease_of_bone targets. Cross-check l-serine pharmacophore against pagets_disease_of_bone pathway. salicylic_acid pagets_disease_of_bone GAP_LOW 0.1183 0.0 ibandronate 0.45 STABLE 0.85 5 0.02525 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking salicylic_acid vs pagets_disease_of_bone targets. Cross-check salicylic_acid pharmacophore against pagets_disease_of_bone pathway. linaclotide ankylosing_spondylitis GAP_HIGH 0.3046 0.5 deferasirox 0.45 STABLE 0.85 3 0.02521 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay linaclotide→?; validate in ankylosing_spondylitis cell model. Expected: similar to deferasirox (Jaccard=0.50) chlorcyclizine hypothyroidism GAP_LOW 0.118 0.0 methimazole 0.45 STABLE 0.85 5 0.02519 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking chlorcyclizine vs hypothyroidism targets. Cross-check chlorcyclizine pharmacophore against hypothyroidism pathway. ethopropazine hypothyroidism GAP_LOW 0.118 0.0 methimazole 0.45 STABLE 0.85 5 0.02519 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking ethopropazine vs hypothyroidism targets. Cross-check ethopropazine pharmacophore against hypothyroidism pathway. tolmetin barretts_esophagus GAP_LOW 0.1669 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02515 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking tolmetin vs barretts_esophagus targets. Cross-check tolmetin pharmacophore against barretts_esophagus pathway. meclizine pagets_disease_of_bone GAP_LOW 0.1178 0.041666666666666664 clodronate 0.45 STABLE 0.85 5 0.02515 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking meclizine vs pagets_disease_of_bone targets. Cross-check meclizine pharmacophore against pagets_disease_of_bone pathway. phenylbutazone hypothyroidism GAP_LOW 0.1178 0.0 methimazole 0.45 STABLE 0.85 5 0.02515 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking phenylbutazone vs hypothyroidism targets. Cross-check phenylbutazone pharmacophore against hypothyroidism pathway. thiothixene schizophrenia GAP_HIGH 0.1445 0.5909090909090909 zuclopenthixol 0.4 STABLE 0.6 3 0.02502 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thiothixene→?; validate in schizophrenia cell model. Expected: similar to zuclopenthixol (Jaccard=0.59) pazopanib crohns_disease GAP_HIGH 0.151 0.42105263157894735 sorafenib 0.45 STABLE 0.85 3 0.025 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pazopanib→?; validate in crohns_disease cell model. Expected: similar to sorafenib (Jaccard=0.42) rimexolone hypothyroidism GAP_LOW 0.117 0.0 methimazole 0.45 STABLE 0.85 5 0.02498 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking rimexolone vs hypothyroidism targets. Cross-check rimexolone pharmacophore against hypothyroidism pathway. dienestrol barretts_esophagus GAP_LOW 0.1657 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02497 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking dienestrol vs barretts_esophagus targets. Cross-check dienestrol pharmacophore against barretts_esophagus pathway. enalapril barretts_esophagus GAP_LOW 0.1657 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02497 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking enalapril vs barretts_esophagus targets. Cross-check enalapril pharmacophore against barretts_esophagus pathway. amcinonide hypothyroidism GAP_LOW 0.1168 0.0 methimazole 0.45 STABLE 0.85 5 0.02493 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking amcinonide vs hypothyroidism targets. Cross-check amcinonide pharmacophore against hypothyroidism pathway. testolactone hypothyroidism GAP_LOW 0.1168 0.0 methimazole 0.45 STABLE 0.85 5 0.02493 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking testolactone vs hypothyroidism targets. Cross-check testolactone pharmacophore against hypothyroidism pathway. bevantolol refractive_error GAP_HIGH 0.1279 0.2916666666666667 propranolol 0.45 STABLE 0.6 3 0.02491 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bevantolol→?; validate in refractive_error cell model. Expected: similar to propranolol (Jaccard=0.29) fluorometholone metabolic_syndrome_x GAP_HIGH 0.2458 0.75 eplerenone 0.55 STABLE 0.85 3 0.02487 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluorometholone→?; validate in metabolic_syndrome_x cell model. Expected: similar to eplerenone (Jaccard=0.75) fludrocortisone hypothyroidism GAP_LOW 0.1164 0.0 methimazole 0.45 STABLE 0.85 5 0.02485 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking fludrocortisone vs hypothyroidism targets. Cross-check fludrocortisone pharmacophore against hypothyroidism pathway. progesterone pagets_disease_of_bone GAP_LOW 0.1163 0.05555555555555555 histamine_phosphate 0.45 STABLE 0.85 5 0.02483 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking progesterone vs pagets_disease_of_bone targets. Cross-check progesterone pharmacophore against pagets_disease_of_bone pathway. irbesartan alcohol_dependence GAP_LOW 0.1644 0.125 naloxone 0.45 STABLE 0.6 5 0.02477 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking irbesartan vs alcohol_dependence targets. Cross-check irbesartan pharmacophore against alcohol_dependence pathway. lamivudine osteoarthritis GAP_HIGH 0.1496 0.4090909090909091 vidarabine 0.45 STABLE 0.85 3 0.02477 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lamivudine→?; validate in osteoarthritis cell model. Expected: similar to vidarabine (Jaccard=0.41) cladribine psoriatic_arthritis GAP_HIGH 0.1496 0.32 glucosamine 0.45 STABLE 0.85 3 0.02477 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cladribine→?; validate in psoriatic_arthritis cell model. Expected: similar to glucosamine (Jaccard=0.32) carbidopa creutzfeldt-jakob_disease GAP_HIGH 0.1269 0.35 l-dopa 0.45 STABLE 0.6 3 0.02472 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay carbidopa→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to l-dopa (Jaccard=0.35) fluoxymesterone crohns_disease GAP_HIGH 0.1492 0.5217391304347826 hydrocortisone 0.45 STABLE 0.85 3 0.0247 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluoxymesterone→?; validate in crohns_disease cell model. Expected: similar to hydrocortisone (Jaccard=0.52) bevantolol idiopathic_pulmonary_fibrosis GAP_HIGH 0.1268 0.3076923076923077 propafenone 0.45 STABLE 0.6 3 0.0247 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bevantolol→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to propafenone (Jaccard=0.31) diclofenac barretts_esophagus GAP_LOW 0.1636 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02465 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking diclofenac vs barretts_esophagus targets. Cross-check diclofenac pharmacophore against barretts_esophagus pathway. practolol barretts_esophagus GAP_LOW 0.1636 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02465 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking practolol vs barretts_esophagus targets. Cross-check practolol pharmacophore against barretts_esophagus pathway. labetalol hepatitis_b GAP_HIGH 0.2847 0.6 alvimopan 0.2 DECLINING 0.6 3 0.02464 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay labetalol→?; validate in hepatitis_b cell model. Expected: similar to alvimopan (Jaccard=0.60) paclitaxel restless_legs_syndrome GAP_HIGH 0.2068 0.6666666666666666 rasagiline 0.55 STABLE 1.0 3 0.02461 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay paclitaxel→?; validate in restless_legs_syndrome cell model. Expected: similar to rasagiline (Jaccard=0.67) lamivudine psoriatic_arthritis GAP_HIGH 0.1482 0.4090909090909091 vidarabine 0.45 STABLE 0.85 3 0.02453 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lamivudine→?; validate in psoriatic_arthritis cell model. Expected: similar to vidarabine (Jaccard=0.41) modafinil narcolepsy GAP_HIGH 0.1259 0.45454545454545453 diphenylpyraline 0.45 STABLE 0.6 3 0.02452 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay modafinil→?; validate in narcolepsy cell model. Expected: similar to diphenylpyraline (Jaccard=0.45) acenocoumarol barretts_esophagus GAP_LOW 0.1626 0.0 pantoprazole 0.45 STABLE 0.6 5 0.0245 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking acenocoumarol vs barretts_esophagus targets. Cross-check acenocoumarol pharmacophore against barretts_esophagus pathway. clotrimazole leprosy GAP_LOW 0.1147 0.125 phenmetrazine 0.45 STABLE 0.85 5 0.02449 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking clotrimazole vs leprosy targets. Cross-check clotrimazole pharmacophore against leprosy pathway. streptozocin hypothyroidism GAP_LOW 0.162 0.0 methimazole 0.45 STABLE 0.6 5 0.02441 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking streptozocin vs hypothyroidism targets. Cross-check streptozocin pharmacophore against hypothyroidism pathway. pentostatin acquired_immunodeficiency_syndrome GAP_HIGH 0.3411 0.6666666666666666 emtricitabine 0.55 STABLE 0.6 3 0.02436 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pentostatin→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to emtricitabine (Jaccard=0.67) vapreotide crohns_disease GAP_HIGH 0.1471 0.18181818181818182 deferasirox 0.45 STABLE 0.85 3 0.02435 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vapreotide→?; validate in crohns_disease cell model. Expected: similar to deferasirox (Jaccard=0.18) pseudoephedrine pagets_disease_of_bone GAP_LOW 0.1137 0.0 ibandronate 0.45 STABLE 0.85 5 0.02427 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking pseudoephedrine vs pagets_disease_of_bone targets. Cross-check pseudoephedrine pharmacophore against pagets_disease_of_bone pathway. pravastatin pagets_disease_of_bone GAP_LOW 0.1607 0.0 ibandronate 0.45 STABLE 0.6 5 0.02422 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking pravastatin vs pagets_disease_of_bone targets. Cross-check pravastatin pharmacophore against pagets_disease_of_bone pathway. droxidopa azoospermia GAP_HIGH 0.1241 0.3333333333333333 salicylate-sodium 0.45 STABLE 0.6 3 0.02417 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay droxidopa→?; validate in azoospermia cell model. Expected: similar to salicylate-sodium (Jaccard=0.33) bezafibrate pagets_disease_of_bone GAP_LOW 0.1132 0.0 ibandronate 0.45 STABLE 0.85 5 0.02417 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking bezafibrate vs pagets_disease_of_bone targets. Cross-check bezafibrate pharmacophore against pagets_disease_of_bone pathway. liothyronine pagets_disease_of_bone GAP_LOW 0.1132 0.0 ibandronate 0.45 STABLE 0.85 5 0.02417 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking liothyronine vs pagets_disease_of_bone targets. Cross-check liothyronine pharmacophore against pagets_disease_of_bone pathway. latanoprost glaucoma GAP_HIGH 0.4123 1.0 tafluprost 0.45 STABLE 0.6 3 0.02409 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay latanoprost→?; validate in glaucoma cell model. Expected: similar to tafluprost (Jaccard=1.00) modafinil attention_deficit_hyperactivity_disorder GAP_HIGH 0.1231 0.45454545454545453 diphenylpyraline 0.45 STABLE 0.6 3 0.02398 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay modafinil→?; validate in attention_deficit_hyperactivity_disorder cell model. Expected: similar to diphenylpyraline (Jaccard=0.45) clodronate intracranial_aneurysm GAP_HIGH 0.2895 1.0 etidronic_acid 0.45 STABLE 0.85 3 0.02396 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clodronate→?; validate in intracranial_aneurysm cell model. Expected: similar to etidronic_acid (Jaccard=1.00) meclizine leprosy GAP_LOW 0.1122 0.1111111111111111 sulfamethizole 0.45 STABLE 0.85 5 0.02395 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking meclizine vs leprosy targets. Cross-check meclizine pharmacophore against leprosy pathway. methylprednisolone gout GAP_HIGH 0.2892 1.0 fluorometholone 0.45 STABLE 0.85 3 0.02394 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methylprednisolone→?; validate in gout cell model. Expected: similar to fluorometholone (Jaccard=1.00) ketoprofen barretts_esophagus GAP_LOW 0.1589 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02394 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking ketoprofen vs barretts_esophagus targets. Cross-check ketoprofen pharmacophore against barretts_esophagus pathway. ketorolac barretts_esophagus GAP_LOW 0.1589 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02394 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking ketorolac vs barretts_esophagus targets. Cross-check ketorolac pharmacophore against barretts_esophagus pathway. naproxen barretts_esophagus GAP_LOW 0.1589 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02394 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking naproxen vs barretts_esophagus targets. Cross-check naproxen pharmacophore against barretts_esophagus pathway. ramipril barretts_esophagus GAP_LOW 0.1589 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02394 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking ramipril vs barretts_esophagus targets. Cross-check ramipril pharmacophore against barretts_esophagus pathway. clodronate nephrolithiasis GAP_HIGH 0.2885 1.0 etidronic_acid 0.45 STABLE 0.85 3 0.02388 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clodronate→?; validate in nephrolithiasis cell model. Expected: similar to etidronic_acid (Jaccard=1.00) sunitinib crohns_disease GAP_HIGH 0.1442 0.4 sorafenib 0.45 STABLE 0.85 3 0.02387 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sunitinib→?; validate in crohns_disease cell model. Expected: similar to sorafenib (Jaccard=0.40) cinolazepam barretts_esophagus GAP_LOW 0.1581 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02382 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking cinolazepam vs barretts_esophagus targets. Cross-check cinolazepam pharmacophore against barretts_esophagus pathway. conivaptan pagets_disease_of_bone GAP_LOW 0.1579 0.0 ibandronate 0.45 STABLE 0.6 5 0.02379 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking conivaptan vs pagets_disease_of_bone targets. Cross-check conivaptan pharmacophore against pagets_disease_of_bone pathway. methylprednisolone ankylosing_spondylitis GAP_HIGH 0.2873 1.0 fluorometholone 0.45 STABLE 0.85 3 0.02378 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methylprednisolone→?; validate in ankylosing_spondylitis cell model. Expected: similar to fluorometholone (Jaccard=1.00) exemestane barretts_esophagus GAP_LOW 0.1576 0.08333333333333333 pantoprazole 0.45 STABLE 0.6 5 0.02375 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking exemestane vs barretts_esophagus targets. Cross-check exemestane pharmacophore against barretts_esophagus pathway. droxidopa leprosy GAP_HIGH 0.1218 0.1724137931034483 sulfapyridine 0.45 STABLE 0.6 3 0.02372 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay droxidopa→?; validate in leprosy cell model. Expected: similar to sulfapyridine (Jaccard=0.17) aspartame barretts_esophagus GAP_LOW 0.1573 0.0 pantoprazole 0.45 STABLE 0.6 5 0.0237 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking aspartame vs barretts_esophagus targets. Cross-check aspartame pharmacophore against barretts_esophagus pathway. nitrazepam barretts_esophagus GAP_LOW 0.1573 0.0 pantoprazole 0.45 STABLE 0.6 5 0.0237 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking nitrazepam vs barretts_esophagus targets. Cross-check nitrazepam pharmacophore against barretts_esophagus pathway. droxidopa panic_disorder GAP_HIGH 0.1217 0.35294117647058826 arbutamine 0.45 STABLE 0.6 3 0.0237 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay droxidopa→?; validate in panic_disorder cell model. Expected: similar to arbutamine (Jaccard=0.35) calcipotriol sclerosing_cholangitis GAP_HIGH 0.1217 0.16666666666666666 ursodeoxycholic_acid 0.45 STABLE 0.6 3 0.0237 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay calcipotriol→?; validate in sclerosing_cholangitis cell model. Expected: similar to ursodeoxycholic_acid (Jaccard=0.17) clodronate malignant_mesothelioma GAP_HIGH 0.2857 1.0 etidronic_acid 0.45 STABLE 0.85 3 0.02365 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clodronate→?; validate in malignant_mesothelioma cell model. Expected: similar to etidronic_acid (Jaccard=1.00) trandolapril barretts_esophagus GAP_LOW 0.1566 0.0 pantoprazole 0.45 STABLE 0.6 5 0.0236 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking trandolapril vs barretts_esophagus targets. Cross-check trandolapril pharmacophore against barretts_esophagus pathway. bevantolol barretts_esophagus GAP_LOW 0.1559 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02349 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking bevantolol vs barretts_esophagus targets. Cross-check bevantolol pharmacophore against barretts_esophagus pathway. midazolam barretts_esophagus GAP_LOW 0.1559 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02349 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking midazolam vs barretts_esophagus targets. Cross-check midazolam pharmacophore against barretts_esophagus pathway. vismodegib barretts_esophagus GAP_LOW 0.1559 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02349 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking vismodegib vs barretts_esophagus targets. Cross-check vismodegib pharmacophore against barretts_esophagus pathway. trandolapril coronary_artery_disease GAP_HIGH 0.1356 0.3 moexipril 0.4 STABLE 0.6 3 0.02348 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trandolapril→?; validate in coronary_artery_disease cell model. Expected: similar to moexipril (Jaccard=0.30) pralatrexate intracranial_aneurysm GAP_HIGH 0.2827 0.7142857142857143 methotrexate 0.45 STABLE 0.85 3 0.0234 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pralatrexate→?; validate in intracranial_aneurysm cell model. Expected: similar to methotrexate (Jaccard=0.71) methyldopa leprosy GAP_HIGH 0.1198 0.16666666666666666 sulfapyridine 0.45 STABLE 0.6 3 0.02333 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methyldopa→?; validate in leprosy cell model. Expected: similar to sulfapyridine (Jaccard=0.17) bevantolol epilepsy_syndrome GAP_HIGH 0.1345 0.36363636363636365 methocarbamol 0.4 STABLE 0.6 3 0.02329 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bevantolol→?; validate in epilepsy_syndrome cell model. Expected: similar to methocarbamol (Jaccard=0.36) flurandrenolide metabolic_syndrome_x GAP_HIGH 0.2292 0.6666666666666666 eplerenone 0.55 STABLE 0.85 3 0.02319 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flurandrenolide→?; validate in metabolic_syndrome_x cell model. Expected: similar to eplerenone (Jaccard=0.67) liothyronine leprosy GAP_LOW 0.1083 0.07142857142857142 menadione 0.45 STABLE 0.85 5 0.02312 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking liothyronine vs leprosy targets. Cross-check liothyronine pharmacophore against leprosy pathway. flurbiprofen barretts_esophagus GAP_LOW 0.1532 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02309 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking flurbiprofen vs barretts_esophagus targets. Cross-check flurbiprofen pharmacophore against barretts_esophagus pathway. phenacemide pagets_disease_of_bone GAP_LOW 0.1079 0.0 ibandronate 0.45 STABLE 0.85 5 0.02303 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking phenacemide vs pagets_disease_of_bone targets. Cross-check phenacemide pharmacophore against pagets_disease_of_bone pathway. methyldopa azoospermia GAP_HIGH 0.1182 0.3125 salicylate-sodium 0.45 STABLE 0.6 3 0.02302 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methyldopa→?; validate in azoospermia cell model. Expected: similar to salicylate-sodium (Jaccard=0.31) bezafibrate leprosy GAP_LOW 0.1077 0.07894736842105263 sulfapyridine 0.45 STABLE 0.85 5 0.02299 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking bezafibrate vs leprosy targets. Cross-check bezafibrate pharmacophore against leprosy pathway. probenecid atherosclerosis GAP_HIGH 0.1962 0.5555555555555556 clofibrate 0.45 STABLE 0.6 3 0.02293 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay probenecid→?; validate in atherosclerosis cell model. Expected: similar to clofibrate (Jaccard=0.56) nelarabine membranous_glomerulonephritis GAP_HIGH 0.2763 0.5 emtricitabine 0.45 STABLE 0.85 3 0.02287 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nelarabine→?; validate in membranous_glomerulonephritis cell model. Expected: similar to emtricitabine (Jaccard=0.50) mazindol barretts_esophagus GAP_LOW 0.1509 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02274 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking mazindol vs barretts_esophagus targets. Cross-check mazindol pharmacophore against barretts_esophagus pathway. phenylbutazone leprosy GAP_LOW 0.1065 0.12244897959183673 phensuximide 0.45 STABLE 0.85 5 0.02274 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking phenylbutazone vs leprosy targets. Cross-check phenylbutazone pharmacophore against leprosy pathway. mestranol crohns_disease GAP_HIGH 0.1945 0.5789473684210527 ethinyl_estradiol 0.45 STABLE 0.6 3 0.02273 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mestranol→?; validate in crohns_disease cell model. Expected: similar to ethinyl_estradiol (Jaccard=0.58) ketoprofen coronary_artery_disease GAP_HIGH 0.1311 0.3333333333333333 indomethacin 0.4 STABLE 0.6 3 0.0227 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ketoprofen→?; validate in coronary_artery_disease cell model. Expected: similar to indomethacin (Jaccard=0.33) phenylbutazone pagets_disease_of_bone GAP_LOW 0.1063 0.0 ibandronate 0.45 STABLE 0.85 5 0.02269 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking phenylbutazone vs pagets_disease_of_bone targets. Cross-check phenylbutazone pharmacophore against pagets_disease_of_bone pathway. nelarabine primary_biliary_cirrhosis GAP_HIGH 0.2737 0.5 emtricitabine 0.45 STABLE 0.85 3 0.02266 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nelarabine→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to emtricitabine (Jaccard=0.50) lidocaine rheumatoid_arthritis GAP_HIGH 0.154 0.4166666666666667 probenecid 0.4 STABLE 0.85 3 0.02266 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lidocaine→?; validate in rheumatoid_arthritis cell model. Expected: similar to probenecid (Jaccard=0.42) phenytoin barretts_esophagus GAP_LOW 0.1504 0.04 pantoprazole 0.45 STABLE 0.6 5 0.02266 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking phenytoin vs barretts_esophagus targets. Cross-check phenytoin pharmacophore against barretts_esophagus pathway. temazepam barretts_esophagus GAP_LOW 0.1504 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02266 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking temazepam vs barretts_esophagus targets. Cross-check temazepam pharmacophore against barretts_esophagus pathway. beclomethasone dilated_cardiomyopathy GAP_HIGH 0.2724 0.9166666666666666 rimexolone 0.45 STABLE 0.85 3 0.02255 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay beclomethasone→?; validate in dilated_cardiomyopathy cell model. Expected: similar to rimexolone (Jaccard=0.92) linaclotide coronary_artery_disease GAP_HIGH 0.3062 0.5 deferasirox 0.4 STABLE 0.85 3 0.02253 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay linaclotide→?; validate in coronary_artery_disease cell model. Expected: similar to deferasirox (Jaccard=0.50) oxaprozin barretts_esophagus GAP_LOW 0.1489 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02244 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking oxaprozin vs barretts_esophagus targets. Cross-check oxaprozin pharmacophore against barretts_esophagus pathway. fludrocortisone pagets_disease_of_bone GAP_LOW 0.1049 0.0 ibandronate 0.45 STABLE 0.85 5 0.02239 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking fludrocortisone vs pagets_disease_of_bone targets. Cross-check fludrocortisone pharmacophore against pagets_disease_of_bone pathway. doxepin barretts_esophagus GAP_LOW 0.148 0.0 pantoprazole 0.45 STABLE 0.6 5 0.0223 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking doxepin vs barretts_esophagus targets. Cross-check doxepin pharmacophore against barretts_esophagus pathway. calcitriol hypothyroidism GAP_LOW 0.1479 0.0 methimazole 0.45 STABLE 0.6 5 0.02229 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking calcitriol vs hypothyroidism targets. Cross-check calcitriol pharmacophore against hypothyroidism pathway. ergocalciferol hypothyroidism GAP_LOW 0.1479 0.0 methimazole 0.45 STABLE 0.6 5 0.02229 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking ergocalciferol vs hypothyroidism targets. Cross-check ergocalciferol pharmacophore against hypothyroidism pathway. telmisartan hypothyroidism GAP_LOW 0.1479 0.0 methimazole 0.45 STABLE 0.6 5 0.02229 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking telmisartan vs hypothyroidism targets. Cross-check telmisartan pharmacophore against hypothyroidism pathway. bromfenac barretts_esophagus GAP_LOW 0.1467 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02211 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking bromfenac vs barretts_esophagus targets. Cross-check bromfenac pharmacophore against barretts_esophagus pathway. paricalcitol hypothyroidism GAP_LOW 0.1466 0.0 methimazole 0.45 STABLE 0.6 5 0.02209 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking paricalcitol vs hypothyroidism targets. Cross-check paricalcitol pharmacophore against hypothyroidism pathway. entecavir vitiligo GAP_HIGH 0.2662 0.6 abacavir 0.45 STABLE 0.85 3 0.02203 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay entecavir→?; validate in vitiligo cell model. Expected: similar to abacavir (Jaccard=0.60) propranolol barretts_esophagus GAP_LOW 0.1459 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02199 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking propranolol vs barretts_esophagus targets. Cross-check propranolol pharmacophore against barretts_esophagus pathway. abacavir malignant_mesothelioma GAP_HIGH 0.2646 0.6 entecavir 0.45 STABLE 0.85 3 0.0219 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay abacavir→?; validate in malignant_mesothelioma cell model. Expected: similar to entecavir (Jaccard=0.60) alfacalcidol hypothyroidism GAP_LOW 0.1453 0.0 methimazole 0.45 STABLE 0.6 5 0.0219 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking alfacalcidol vs hypothyroidism targets. Cross-check alfacalcidol pharmacophore against hypothyroidism pathway. calcidiol hypothyroidism GAP_LOW 0.1453 0.0 methimazole 0.45 STABLE 0.6 5 0.0219 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking calcidiol vs hypothyroidism targets. Cross-check calcidiol pharmacophore against hypothyroidism pathway. calcipotriol hypothyroidism GAP_LOW 0.1453 0.0 methimazole 0.45 STABLE 0.6 5 0.0219 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking calcipotriol vs hypothyroidism targets. Cross-check calcipotriol pharmacophore against hypothyroidism pathway. chlorphenesin hypothyroidism GAP_LOW 0.1453 0.0 methimazole 0.45 STABLE 0.6 5 0.0219 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking chlorphenesin vs hypothyroidism targets. Cross-check chlorphenesin pharmacophore against hypothyroidism pathway. dihydrotachysterol hypothyroidism GAP_LOW 0.1453 0.0 methimazole 0.45 STABLE 0.6 5 0.0219 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking dihydrotachysterol vs hypothyroidism targets. Cross-check dihydrotachysterol pharmacophore against hypothyroidism pathway. fulvestrant crohns_disease GAP_HIGH 0.1873 0.5454545454545454 estradiol_valeratedienogest 0.45 STABLE 0.6 3 0.02189 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fulvestrant→?; validate in crohns_disease cell model. Expected: similar to estradiol_valeratedienogest (Jaccard=0.55) thiothixene barretts_esophagus GAP_LOW 0.1452 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02188 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking thiothixene vs barretts_esophagus targets. Cross-check thiothixene pharmacophore against barretts_esophagus pathway. phenelzine hepatitis_b GAP_HIGH 0.1779 0.5555555555555556 nateglinide 0.2 DECLINING 0.85 3 0.02182 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenelzine→?; validate in hepatitis_b cell model. Expected: similar to nateglinide (Jaccard=0.56) phenytoin alcohol_dependence GAP_HIGH 0.1118 0.19607843137254902 mazindol 0.45 STABLE 0.6 3 0.02177 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay phenytoin→?; validate in alcohol_dependence cell model. Expected: similar to mazindol (Jaccard=0.20) l-dopa barretts_esophagus GAP_LOW 0.1438 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02167 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking l-dopa vs barretts_esophagus targets. Cross-check l-dopa pharmacophore against barretts_esophagus pathway. pravastatin malaria GAP_LOW 0.1431 0.09090909090909091 caffeine 0.45 STABLE 0.6 5 0.02156 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking pravastatin vs malaria targets. Cross-check pravastatin pharmacophore against malaria pathway. dienestrol hypothyroidism GAP_LOW 0.1429 0.0 methimazole 0.45 STABLE 0.6 5 0.02153 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking dienestrol vs hypothyroidism targets. Cross-check dienestrol pharmacophore against hypothyroidism pathway. carbidopa barretts_esophagus GAP_LOW 0.1422 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02143 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking carbidopa vs barretts_esophagus targets. Cross-check carbidopa pharmacophore against barretts_esophagus pathway. fenoprofen barretts_esophagus GAP_LOW 0.1422 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02143 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking fenoprofen vs barretts_esophagus targets. Cross-check fenoprofen pharmacophore against barretts_esophagus pathway. adenosine nephrolithiasis GAP_HIGH 0.2583 0.6153846153846154 lamivudine 0.45 STABLE 0.85 3 0.02138 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay adenosine→?; validate in nephrolithiasis cell model. Expected: similar to lamivudine (Jaccard=0.62) methyldopa barretts_esophagus GAP_LOW 0.1419 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02138 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking methyldopa vs barretts_esophagus targets. Cross-check methyldopa pharmacophore against barretts_esophagus pathway. pravastatin leprosy GAP_LOW 0.1419 0.0 sulfapyridine 0.45 STABLE 0.6 5 0.02138 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking pravastatin vs leprosy targets. Cross-check pravastatin pharmacophore against leprosy pathway. droxidopa barretts_esophagus GAP_LOW 0.1417 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02135 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking droxidopa vs barretts_esophagus targets. Cross-check droxidopa pharmacophore against barretts_esophagus pathway. cabazitaxel esophageal_cancer GAP_LOW 0.1059 0.14285714285714285 pantoprazole 0.6 RISING 0.6 5 0.02128 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking cabazitaxel vs esophageal_cancer targets. Cross-check cabazitaxel pharmacophore against esophageal_cancer pathway. adenosine malignant_mesothelioma GAP_HIGH 0.2555 0.6153846153846154 lamivudine 0.45 STABLE 0.85 3 0.02115 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay adenosine→?; validate in malignant_mesothelioma cell model. Expected: similar to lamivudine (Jaccard=0.62) fentanyl barretts_esophagus GAP_LOW 0.1403 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02114 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking fentanyl vs barretts_esophagus targets. Cross-check fentanyl pharmacophore against barretts_esophagus pathway. cyproterone_acetate intracranial_aneurysm GAP_HIGH 0.255 0.7142857142857143 prednicarbate 0.45 STABLE 0.85 3 0.02111 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyproterone_acetate→?; validate in intracranial_aneurysm cell model. Expected: similar to prednicarbate (Jaccard=0.71) modafinil barretts_esophagus GAP_LOW 0.1401 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02111 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking modafinil vs barretts_esophagus targets. Cross-check modafinil pharmacophore against barretts_esophagus pathway. adenosine meningioma GAP_HIGH 0.2549 0.6153846153846154 lamivudine 0.45 STABLE 0.85 3 0.0211 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay adenosine→?; validate in meningioma cell model. Expected: similar to lamivudine (Jaccard=0.62) aciclovir metabolic_syndrome_x GAP_HIGH 0.2084 0.3333333333333333 cyclosporine 0.55 STABLE 0.85 3 0.02108 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aciclovir→?; validate in metabolic_syndrome_x cell model. Expected: similar to cyclosporine (Jaccard=0.33) clofedanol barretts_esophagus GAP_LOW 0.1399 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02108 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking clofedanol vs barretts_esophagus targets. Cross-check clofedanol pharmacophore against barretts_esophagus pathway. droxidopa schizophrenia GAP_HIGH 0.1217 0.35294117647058826 arbutamine 0.4 STABLE 0.6 3 0.02107 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay droxidopa→?; validate in schizophrenia cell model. Expected: similar to arbutamine (Jaccard=0.35) clocortolone dilated_cardiomyopathy GAP_HIGH 0.2541 0.8333333333333334 rimexolone 0.45 STABLE 0.85 3 0.02103 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clocortolone→?; validate in dilated_cardiomyopathy cell model. Expected: similar to rimexolone (Jaccard=0.83) difluprednate dilated_cardiomyopathy GAP_HIGH 0.2541 0.8333333333333334 rimexolone 0.45 STABLE 0.85 3 0.02103 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay difluprednate→?; validate in dilated_cardiomyopathy cell model. Expected: similar to rimexolone (Jaccard=0.83) toremifene barretts_esophagus GAP_LOW 0.1394 0.0 pantoprazole 0.45 STABLE 0.6 5 0.02101 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking toremifene vs barretts_esophagus targets. Cross-check toremifene pharmacophore against barretts_esophagus pathway. alendronate atherosclerosis GAP_HIGH 0.1267 0.17647058823529413 phenelzine 0.45 STABLE 0.85 3 0.02098 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alendronate→?; validate in atherosclerosis cell model. Expected: similar to phenelzine (Jaccard=0.18) cyproterone_acetate meningioma GAP_HIGH 0.2506 0.7142857142857143 prednicarbate 0.45 STABLE 0.85 3 0.02074 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cyproterone_acetate→?; validate in meningioma cell model. Expected: similar to prednicarbate (Jaccard=0.71) pamidronate atherosclerosis GAP_HIGH 0.1247 0.16666666666666666 phenelzine 0.45 STABLE 0.85 3 0.02065 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pamidronate→?; validate in atherosclerosis cell model. Expected: similar to phenelzine (Jaccard=0.17) epinephrine leprosy GAP_HIGH 0.248 0.6 pomalidomide 0.45 STABLE 0.85 3 0.02053 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay epinephrine→?; validate in leprosy cell model. Expected: similar to pomalidomide (Jaccard=0.60) ketoprofen hypothyroidism GAP_LOW 0.1361 0.0 methimazole 0.45 STABLE 0.6 5 0.02051 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking ketoprofen vs hypothyroidism targets. Cross-check ketoprofen pharmacophore against hypothyroidism pathway. ketorolac hypothyroidism GAP_LOW 0.1361 0.0 methimazole 0.45 STABLE 0.6 5 0.02051 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking ketorolac vs hypothyroidism targets. Cross-check ketorolac pharmacophore against hypothyroidism pathway. fludrocortisone alcohol_dependence SPECULATIVE 0.0959 0.1111111111111111 levorphanol 0.45 STABLE 0.85 5 0.02047 MEDIUM Full discovery pipeline needed: ~5 years Speculative: Review fludrocortisone off-target effects vs alcohol_dependence mechanism. Phenotypic screen recommended. cortisone_acetate metabolic_syndrome_x GAP_HIGH 0.2021 0.6666666666666666 eplerenone 0.55 STABLE 0.85 3 0.02045 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cortisone_acetate→?; validate in metabolic_syndrome_x cell model. Expected: similar to eplerenone (Jaccard=0.67) paricalcitol leprosy GAP_LOW 0.1357 0.07692307692307693 sulfamethizole 0.45 STABLE 0.6 5 0.02045 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking paricalcitol vs leprosy targets. Cross-check paricalcitol pharmacophore against leprosy pathway. alfacalcidol pagets_disease_of_bone GAP_LOW 0.1338 0.0 ibandronate 0.45 STABLE 0.6 5 0.02016 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking alfacalcidol vs pagets_disease_of_bone targets. Cross-check alfacalcidol pharmacophore against pagets_disease_of_bone pathway. calcidiol pagets_disease_of_bone GAP_LOW 0.1338 0.0 ibandronate 0.45 STABLE 0.6 5 0.02016 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking calcidiol vs pagets_disease_of_bone targets. Cross-check calcidiol pharmacophore against pagets_disease_of_bone pathway. calcipotriol pagets_disease_of_bone GAP_LOW 0.1338 0.0 ibandronate 0.45 STABLE 0.6 5 0.02016 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking calcipotriol vs pagets_disease_of_bone targets. Cross-check calcipotriol pharmacophore against pagets_disease_of_bone pathway. chlorphenesin pagets_disease_of_bone GAP_LOW 0.1338 0.0 ibandronate 0.45 STABLE 0.6 5 0.02016 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking chlorphenesin vs pagets_disease_of_bone targets. Cross-check chlorphenesin pharmacophore against pagets_disease_of_bone pathway. dihydrotachysterol pagets_disease_of_bone GAP_LOW 0.1338 0.0 ibandronate 0.45 STABLE 0.6 5 0.02016 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking dihydrotachysterol vs pagets_disease_of_bone targets. Cross-check dihydrotachysterol pharmacophore against pagets_disease_of_bone pathway. trandolapril hypothyroidism GAP_LOW 0.1338 0.0 methimazole 0.45 STABLE 0.6 5 0.02016 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking trandolapril vs hypothyroidism targets. Cross-check trandolapril pharmacophore against hypothyroidism pathway. dihydrotachysterol leprosy GAP_LOW 0.1333 0.07142857142857142 sulfamethizole 0.45 STABLE 0.6 5 0.02009 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking dihydrotachysterol vs leprosy targets. Cross-check dihydrotachysterol pharmacophore against leprosy pathway. bevantolol hypothyroidism GAP_LOW 0.133 0.0 methimazole 0.45 STABLE 0.6 5 0.02004 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking bevantolol vs hypothyroidism targets. Cross-check bevantolol pharmacophore against hypothyroidism pathway. estropipate hypothyroidism GAP_HIGH 0.2414 0.3333333333333333 methimazole 0.45 STABLE 0.85 3 0.01998 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estropipate→?; validate in hypothyroidism cell model. Expected: similar to methimazole (Jaccard=0.33) chlorphenesin gestational_diabetes GAP_LOW 0.1317 0.13043478260869565 bezafibrate 0.45 STABLE 0.6 5 0.01985 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking chlorphenesin vs gestational_diabetes targets. Cross-check chlorphenesin pharmacophore against gestational_diabetes pathway. fenoprofen alcohol_dependence GAP_HIGH 0.101 0.16666666666666666 mazindol 0.45 STABLE 0.6 3 0.01967 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fenoprofen→?; validate in alcohol_dependence cell model. Expected: similar to mazindol (Jaccard=0.17) fludrocortisone leprosy SPECULATIVE 0.0908 0.02702702702702703 sulfapyridine 0.45 STABLE 0.85 5 0.01938 MEDIUM Full discovery pipeline needed: ~5 years Speculative: Review fludrocortisone off-target effects vs leprosy mechanism. Phenotypic screen recommended. fluocinonide dilated_cardiomyopathy GAP_HIGH 0.2339 0.7692307692307693 rimexolone 0.45 STABLE 0.85 3 0.01936 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluocinonide→?; validate in dilated_cardiomyopathy cell model. Expected: similar to rimexolone (Jaccard=0.77) s-adenosylmethionine acquired_immunodeficiency_syndrome GAP_HIGH 0.1886 0.5428571428571428 adenosine_monophosphate 0.55 STABLE 0.85 3 0.01908 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay s-adenosylmethionine→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to adenosine_monophosphate (Jaccard=0.54) procarbazine celiac_disease GAP_HIGH 0.2288 0.6363636363636364 suprofen 0.45 STABLE 0.85 3 0.01894 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay procarbazine→?; validate in celiac_disease cell model. Expected: similar to suprofen (Jaccard=0.64) methacholine type_1_diabetes_mellitus GAP_HIGH 0.2055 0.25 homatropine_methylbromide 0.6 RISING 0.85 3 0.0189 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methacholine→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to homatropine_methylbromide (Jaccard=0.25) flavin_adenine_dinucleotide acquired_immunodeficiency_syndrome GAP_HIGH 0.1867 0.3333333333333333 entecavir 0.55 STABLE 0.85 3 0.01889 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flavin_adenine_dinucleotide→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to entecavir (Jaccard=0.33) procainamide restless_legs_syndrome GAP_HIGH 0.1863 0.7936507936507936 metoclopramide 0.55 STABLE 0.85 3 0.01885 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay procainamide→?; validate in restless_legs_syndrome cell model. Expected: similar to metoclopramide (Jaccard=0.79) procarbazine malignant_mesothelioma GAP_HIGH 0.2263 0.6363636363636364 melphalan 0.45 STABLE 0.85 3 0.01873 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay procarbazine→?; validate in malignant_mesothelioma cell model. Expected: similar to melphalan (Jaccard=0.64) thalidomide refractive_error GAP_HIGH 0.2257 0.75 epinephrine 0.45 STABLE 0.85 3 0.01868 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thalidomide→?; validate in refractive_error cell model. Expected: similar to epinephrine (Jaccard=0.75) procarbazine primary_biliary_cirrhosis GAP_HIGH 0.2248 0.6363636363636364 melphalan 0.45 STABLE 0.85 3 0.01861 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay procarbazine→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to melphalan (Jaccard=0.64) propranolol hypothyroidism GAP_LOW 0.1231 0.0 methimazole 0.45 STABLE 0.6 5 0.01855 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking propranolol vs hypothyroidism targets. Cross-check propranolol pharmacophore against hypothyroidism pathway. dipivefrin metabolic_syndrome_x GAP_HIGH 0.2589 0.75 pirbuterol 0.55 STABLE 0.6 3 0.01849 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dipivefrin→?; validate in metabolic_syndrome_x cell model. Expected: similar to pirbuterol (Jaccard=0.75) desipramine hepatitis_b GAP_HIGH 0.1508 0.42857142857142855 alvimopan 0.2 DECLINING 0.85 3 0.01849 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay desipramine→?; validate in hepatitis_b cell model. Expected: similar to alvimopan (Jaccard=0.43) fluocinonide atopic_dermatitis GAP_HIGH 0.223 0.8333333333333334 beclomethasone 0.45 STABLE 0.85 3 0.01846 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluocinonide→?; validate in atopic_dermatitis cell model. Expected: similar to beclomethasone (Jaccard=0.83) nandrolone_phenpropionate alopecia_areata GAP_HIGH 0.2229 0.5714285714285714 cyproterone_acetate 0.45 STABLE 0.85 3 0.01845 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nandrolone_phenpropionate→?; validate in alopecia_areata cell model. Expected: similar to cyproterone_acetate (Jaccard=0.57) ibuprofen type_1_diabetes_mellitus GAP_HIGH 0.1704 0.2857142857142857 glyburide 0.6 RISING 1.0 3 0.01844 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ibuprofen→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to glyburide (Jaccard=0.29) prednicarbate dilated_cardiomyopathy GAP_HIGH 0.2224 0.5454545454545454 medrysone 0.45 STABLE 0.85 3 0.01841 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prednicarbate→?; validate in dilated_cardiomyopathy cell model. Expected: similar to medrysone (Jaccard=0.55) thalidomide idiopathic_pulmonary_fibrosis GAP_HIGH 0.2218 0.75 epinephrine 0.45 STABLE 0.85 3 0.01836 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thalidomide→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to epinephrine (Jaccard=0.75) phenytoin hypothyroidism GAP_LOW 0.1213 0.0 methimazole 0.45 STABLE 0.6 5 0.01828 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking phenytoin vs hypothyroidism targets. Cross-check phenytoin pharmacophore against hypothyroidism pathway. thalidomide chronic_obstructive_pulmonary_disease GAP_HIGH 0.2194 0.75 epinephrine 0.45 STABLE 0.85 3 0.01816 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thalidomide→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to epinephrine (Jaccard=0.75) lamivudine acquired_immunodeficiency_syndrome GAP_HIGH 0.1795 0.45 regadenoson 0.55 STABLE 0.85 3 0.01816 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lamivudine→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to regadenoson (Jaccard=0.45) thalidomide atopic_dermatitis GAP_HIGH 0.2181 0.75 epinephrine 0.45 STABLE 0.85 3 0.01805 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thalidomide→?; validate in atopic_dermatitis cell model. Expected: similar to epinephrine (Jaccard=0.75) ribavirin acquired_immunodeficiency_syndrome GAP_HIGH 0.2523 0.5909090909090909 vidarabine 0.55 STABLE 0.6 3 0.01802 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ribavirin→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to vidarabine (Jaccard=0.59) doxorubicin narcolepsy GAP_HIGH 0.185 0.6363636363636364 l-arginine 0.45 STABLE 1.0 3 0.01801 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxorubicin→?; validate in narcolepsy cell model. Expected: similar to l-arginine (Jaccard=0.64) fenoprofen hypothyroidism GAP_LOW 0.1194 0.0 methimazole 0.45 STABLE 0.6 5 0.01799 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking fenoprofen vs hypothyroidism targets. Cross-check fenoprofen pharmacophore against hypothyroidism pathway. methyldopa hypothyroidism GAP_LOW 0.1191 0.0 methimazole 0.45 STABLE 0.6 5 0.01795 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking methyldopa vs hypothyroidism targets. Cross-check methyldopa pharmacophore against hypothyroidism pathway. pasireotide azoospermia GAP_HIGH 0.2159 0.3333333333333333 deferasirox 0.45 STABLE 0.85 3 0.01787 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pasireotide→?; validate in azoospermia cell model. Expected: similar to deferasirox (Jaccard=0.33) proparacaine coronary_artery_disease GAP_HIGH 0.2425 0.6875 oxybuprocaine 0.4 STABLE 0.85 3 0.01784 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay proparacaine→?; validate in coronary_artery_disease cell model. Expected: similar to oxybuprocaine (Jaccard=0.69) doxorubicin autistic_disorder GAP_HIGH 0.1824 0.6363636363636364 l-arginine 0.45 STABLE 1.0 3 0.01776 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxorubicin→?; validate in autistic_disorder cell model. Expected: similar to l-arginine (Jaccard=0.64) doxorubicin nicotine_dependence GAP_HIGH 0.1824 0.6363636363636364 l-arginine 0.45 STABLE 1.0 3 0.01776 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxorubicin→?; validate in nicotine_dependence cell model. Expected: similar to l-arginine (Jaccard=0.64) doxorubicin attention_deficit_hyperactivity_disorder GAP_HIGH 0.1822 0.6363636363636364 l-arginine 0.45 STABLE 1.0 3 0.01774 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxorubicin→?; validate in attention_deficit_hyperactivity_disorder cell model. Expected: similar to l-arginine (Jaccard=0.64) travoprost glaucoma GAP_HIGH 0.3031 0.5555555555555556 tafluprost 0.45 STABLE 0.6 3 0.01771 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay travoprost→?; validate in glaucoma cell model. Expected: similar to tafluprost (Jaccard=0.56) doxorubicin conduct_disorder GAP_HIGH 0.1819 0.6363636363636364 l-arginine 0.45 STABLE 1.0 3 0.01771 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay doxorubicin→?; validate in conduct_disorder cell model. Expected: similar to l-arginine (Jaccard=0.64) prednisolone idiopathic_pulmonary_fibrosis GAP_HIGH 0.2135 0.75 loteprednol 0.45 STABLE 0.85 3 0.01767 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prednisolone→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to loteprednol (Jaccard=0.75) nandrolone_phenpropionate ankylosing_spondylitis GAP_HIGH 0.2135 0.5714285714285714 cyproterone_acetate 0.45 STABLE 0.85 3 0.01767 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nandrolone_phenpropionate→?; validate in ankylosing_spondylitis cell model. Expected: similar to cyproterone_acetate (Jaccard=0.57) glucosamine acquired_immunodeficiency_syndrome GAP_HIGH 0.1746 0.46153846153846156 clofarabine 0.55 STABLE 0.85 3 0.01766 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glucosamine→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to clofarabine (Jaccard=0.46) prednisolone gout GAP_HIGH 0.2132 0.75 loteprednol 0.45 STABLE 0.85 3 0.01765 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prednisolone→?; validate in gout cell model. Expected: similar to loteprednol (Jaccard=0.75) pentostatin malignant_mesothelioma GAP_HIGH 0.301 0.6 telbivudine 0.45 STABLE 0.6 3 0.01759 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pentostatin→?; validate in malignant_mesothelioma cell model. Expected: similar to telbivudine (Jaccard=0.60) nandrolone_phenpropionate allergic_rhinitis GAP_HIGH 0.2119 0.5714285714285714 cyproterone_acetate 0.45 STABLE 0.85 3 0.01754 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nandrolone_phenpropionate→?; validate in allergic_rhinitis cell model. Expected: similar to cyproterone_acetate (Jaccard=0.57) prednisolone ankylosing_spondylitis GAP_HIGH 0.2113 0.75 loteprednol 0.45 STABLE 0.85 3 0.01749 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prednisolone→?; validate in ankylosing_spondylitis cell model. Expected: similar to loteprednol (Jaccard=0.75) prednisolone chronic_obstructive_pulmonary_disease GAP_HIGH 0.2112 0.75 loteprednol 0.45 STABLE 0.85 3 0.01748 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prednisolone→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to loteprednol (Jaccard=0.75) pasireotide ankylosing_spondylitis GAP_HIGH 0.2112 0.3333333333333333 deferasirox 0.45 STABLE 0.85 3 0.01748 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pasireotide→?; validate in ankylosing_spondylitis cell model. Expected: similar to deferasirox (Jaccard=0.33) adenosine_triphosphate acquired_immunodeficiency_syndrome GAP_HIGH 0.1725 0.45161290322580644 adenosine_monophosphate 0.55 STABLE 0.85 3 0.01745 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay adenosine_triphosphate→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to adenosine_monophosphate (Jaccard=0.45) floxuridine malignant_mesothelioma GAP_HIGH 0.2104 0.5714285714285714 entecavir 0.45 STABLE 0.85 3 0.01741 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay floxuridine→?; validate in malignant_mesothelioma cell model. Expected: similar to entecavir (Jaccard=0.57) nilotinib nephrolithiasis GAP_HIGH 0.2098 0.5714285714285714 sunitinib 0.45 STABLE 0.85 3 0.01737 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nilotinib→?; validate in nephrolithiasis cell model. Expected: similar to sunitinib (Jaccard=0.57) topotecan crohns_disease GAP_HIGH 0.1481 0.3333333333333333 cyclandelate 0.45 STABLE 0.6 3 0.0173 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay topotecan→?; validate in crohns_disease cell model. Expected: similar to cyclandelate (Jaccard=0.33) sunitinib polycystic_ovary_syndrome GAP_HIGH 0.1705 0.5714285714285714 crizotinib 0.55 STABLE 0.85 3 0.01725 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sunitinib→?; validate in polycystic_ovary_syndrome cell model. Expected: similar to crizotinib (Jaccard=0.57) fluorometholone dilated_cardiomyopathy GAP_HIGH 0.2072 0.5 medrysone 0.45 STABLE 0.85 3 0.01715 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluorometholone→?; validate in dilated_cardiomyopathy cell model. Expected: similar to medrysone (Jaccard=0.50) nilotinib malignant_mesothelioma GAP_HIGH 0.2071 0.5714285714285714 sunitinib 0.45 STABLE 0.85 3 0.01714 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nilotinib→?; validate in malignant_mesothelioma cell model. Expected: similar to sunitinib (Jaccard=0.57) bimatoprost idiopathic_pulmonary_fibrosis GAP_HIGH 0.293 0.6 alcaftadine 0.45 STABLE 0.6 3 0.01712 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bimatoprost→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to alcaftadine (Jaccard=0.60) dasatinib malignant_mesothelioma GAP_HIGH 0.2066 0.5833333333333334 crizotinib 0.45 STABLE 0.85 3 0.0171 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dasatinib→?; validate in malignant_mesothelioma cell model. Expected: similar to crizotinib (Jaccard=0.58) nilotinib meningioma GAP_HIGH 0.2065 0.5714285714285714 sunitinib 0.45 STABLE 0.85 3 0.01709 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nilotinib→?; validate in meningioma cell model. Expected: similar to sunitinib (Jaccard=0.57) dasatinib meningioma GAP_HIGH 0.206 0.5833333333333334 crizotinib 0.45 STABLE 0.85 3 0.01705 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dasatinib→?; validate in meningioma cell model. Expected: similar to crizotinib (Jaccard=0.58) bimatoprost creutzfeldt-jakob_disease GAP_HIGH 0.2913 0.6 cyproheptadine 0.45 STABLE 0.6 3 0.01702 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bimatoprost→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to cyproheptadine (Jaccard=0.60) bimatoprost chronic_obstructive_pulmonary_disease GAP_HIGH 0.2907 0.6 alcaftadine 0.45 STABLE 0.6 3 0.01699 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bimatoprost→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to alcaftadine (Jaccard=0.60) cytarabine membranous_glomerulonephritis GAP_HIGH 0.2051 0.4 telbivudine 0.45 STABLE 0.85 3 0.01698 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cytarabine→?; validate in membranous_glomerulonephritis cell model. Expected: similar to telbivudine (Jaccard=0.40) loteprednol crohns_disease GAP_HIGH 0.1451 0.3333333333333333 homatropine_methylbromide 0.45 STABLE 0.6 3 0.01696 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay loteprednol→?; validate in crohns_disease cell model. Expected: similar to homatropine_methylbromide (Jaccard=0.33) cytarabine malignant_mesothelioma GAP_HIGH 0.204 0.4 telbivudine 0.45 STABLE 0.85 3 0.01689 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cytarabine→?; validate in malignant_mesothelioma cell model. Expected: similar to telbivudine (Jaccard=0.40) prednisone gout GAP_HIGH 0.2032 0.8235294117647058 testolactone 0.45 STABLE 0.85 3 0.01682 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prednisone→?; validate in gout cell model. Expected: similar to testolactone (Jaccard=0.82) cytarabine primary_biliary_cirrhosis GAP_HIGH 0.2025 0.4 telbivudine 0.45 STABLE 0.85 3 0.01676 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cytarabine→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to telbivudine (Jaccard=0.40) zidovudine acquired_immunodeficiency_syndrome GAP_HIGH 0.1652 0.3333333333333333 emtricitabine 0.55 STABLE 0.85 3 0.01671 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay zidovudine→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to emtricitabine (Jaccard=0.33) flurandrenolide dilated_cardiomyopathy GAP_HIGH 0.2006 0.46153846153846156 medrysone 0.45 STABLE 0.85 3 0.01661 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flurandrenolide→?; validate in dilated_cardiomyopathy cell model. Expected: similar to medrysone (Jaccard=0.46) estradiol_valeratedienogest alcohol_dependence GAP_HIGH 0.2831 0.8333333333333334 levorphanol 0.45 STABLE 0.6 3 0.01654 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estradiol_valeratedienogest→?; validate in alcohol_dependence cell model. Expected: similar to levorphanol (Jaccard=0.83) gemcitabine membranous_glomerulonephritis GAP_HIGH 0.199 0.5714285714285714 trifluridine 0.45 STABLE 0.85 3 0.01647 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay gemcitabine→?; validate in membranous_glomerulonephritis cell model. Expected: similar to trifluridine (Jaccard=0.57) pamidronate pagets_disease_of_bone GAP_HIGH 0.1986 0.2857142857142857 clodronate 0.45 STABLE 0.85 3 0.01644 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pamidronate→?; validate in pagets_disease_of_bone cell model. Expected: similar to clodronate (Jaccard=0.29) oxybuprocaine polycystic_ovary_syndrome GAP_HIGH 0.162 0.47368421052631576 chloroprocaine 0.55 STABLE 0.85 3 0.01639 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxybuprocaine→?; validate in polycystic_ovary_syndrome cell model. Expected: similar to chloroprocaine (Jaccard=0.47) pomalidomide refractive_error GAP_HIGH 0.1977 0.6 epinephrine 0.45 STABLE 0.85 3 0.01637 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pomalidomide→?; validate in refractive_error cell model. Expected: similar to epinephrine (Jaccard=0.60) fenoprofen pagets_disease_of_bone GAP_LOW 0.1079 0.0 ibandronate 0.45 STABLE 0.6 5 0.01626 MEDIUM Full discovery pipeline needed: ~5 years Low-priority: Computational docking fenoprofen vs pagets_disease_of_bone targets. Cross-check fenoprofen pharmacophore against pagets_disease_of_bone pathway. clofarabine sclerosing_cholangitis GAP_HIGH 0.1961 0.47058823529411764 cladribine 0.45 STABLE 0.85 3 0.01623 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clofarabine→?; validate in sclerosing_cholangitis cell model. Expected: similar to cladribine (Jaccard=0.47) estropipate alopecia_areata GAP_HIGH 0.1957 0.375 estrone 0.45 STABLE 0.85 3 0.0162 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estropipate→?; validate in alopecia_areata cell model. Expected: similar to estrone (Jaccard=0.38) equilin hypothyroidism GAP_HIGH 0.2749 0.3333333333333333 methimazole 0.45 STABLE 0.6 3 0.01606 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay equilin→?; validate in hypothyroidism cell model. Expected: similar to methimazole (Jaccard=0.33) pomalidomide idiopathic_pulmonary_fibrosis GAP_HIGH 0.1937 0.6 epinephrine 0.45 STABLE 0.85 3 0.01603 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pomalidomide→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to epinephrine (Jaccard=0.60) estropipate intracranial_aneurysm GAP_HIGH 0.1934 0.375 estrone 0.45 STABLE 0.85 3 0.01601 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estropipate→?; validate in intracranial_aneurysm cell model. Expected: similar to estrone (Jaccard=0.38) clocortolone metabolic_syndrome_x GAP_HIGH 0.1583 0.5 amcinonide 0.55 STABLE 0.85 3 0.01601 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clocortolone→?; validate in metabolic_syndrome_x cell model. Expected: similar to amcinonide (Jaccard=0.50) difluprednate metabolic_syndrome_x GAP_HIGH 0.1583 0.5 amcinonide 0.55 STABLE 0.85 3 0.01601 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay difluprednate→?; validate in metabolic_syndrome_x cell model. Expected: similar to amcinonide (Jaccard=0.50) medroxyprogesterone_acetate hypothyroidism GAP_HIGH 0.1927 0.25 methimazole 0.45 STABLE 0.85 3 0.01595 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay medroxyprogesterone_acetate→?; validate in hypothyroidism cell model. Expected: similar to methimazole (Jaccard=0.25) pomalidomide chronic_obstructive_pulmonary_disease GAP_HIGH 0.1913 0.6 epinephrine 0.45 STABLE 0.85 3 0.01583 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pomalidomide→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to epinephrine (Jaccard=0.60) lapatinib nephrolithiasis GAP_HIGH 0.1902 0.5 docetaxel 0.45 STABLE 0.85 3 0.01574 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lapatinib→?; validate in nephrolithiasis cell model. Expected: similar to docetaxel (Jaccard=0.50) pomalidomide atopic_dermatitis GAP_HIGH 0.19 0.6 epinephrine 0.45 STABLE 0.85 3 0.01573 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pomalidomide→?; validate in atopic_dermatitis cell model. Expected: similar to epinephrine (Jaccard=0.60) norethindrone polycystic_ovary_syndrome GAP_HIGH 0.1555 0.5454545454545454 norelgestromin 0.55 STABLE 0.85 3 0.01573 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay norethindrone→?; validate in polycystic_ovary_syndrome cell model. Expected: similar to norelgestromin (Jaccard=0.55) quinestrol gout GAP_HIGH 0.2689 0.6923076923076923 mestranol 0.45 STABLE 0.6 3 0.01571 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay quinestrol→?; validate in gout cell model. Expected: similar to mestranol (Jaccard=0.69) methyltestosterone alopecia_areata GAP_HIGH 0.1897 0.5454545454545454 cortisone_acetate 0.45 STABLE 0.85 3 0.0157 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methyltestosterone→?; validate in alopecia_areata cell model. Expected: similar to cortisone_acetate (Jaccard=0.55) pemetrexed nephrolithiasis GAP_HIGH 0.2686 0.6666666666666666 capecitabine 0.45 STABLE 0.6 3 0.01569 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pemetrexed→?; validate in nephrolithiasis cell model. Expected: similar to capecitabine (Jaccard=0.67) dipivefrin glaucoma GAP_HIGH 0.2685 0.75 pirbuterol 0.45 STABLE 0.6 3 0.01569 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dipivefrin→?; validate in glaucoma cell model. Expected: similar to pirbuterol (Jaccard=0.75) pasireotide coronary_artery_disease GAP_HIGH 0.2129 0.3333333333333333 deferasirox 0.4 STABLE 0.85 3 0.01567 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pasireotide→?; validate in coronary_artery_disease cell model. Expected: similar to deferasirox (Jaccard=0.33) diclofenamide glaucoma GAP_HIGH 0.1891 0.3333333333333333 hydrochlorothiazide 0.45 STABLE 0.85 3 0.01565 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay diclofenamide→?; validate in glaucoma cell model. Expected: similar to hydrochlorothiazide (Jaccard=0.33) methyltestosterone dilated_cardiomyopathy GAP_HIGH 0.1888 0.47058823529411764 testosterone_propionate 0.45 STABLE 0.85 3 0.01563 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methyltestosterone→?; validate in dilated_cardiomyopathy cell model. Expected: similar to testosterone_propionate (Jaccard=0.47) medroxyprogesterone_acetate alopecia_areata GAP_HIGH 0.1881 0.5 spironolactone 0.45 STABLE 0.85 3 0.01557 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay medroxyprogesterone_acetate→?; validate in alopecia_areata cell model. Expected: similar to spironolactone (Jaccard=0.50) megestrol_acetate idiopathic_pulmonary_fibrosis GAP_HIGH 0.1879 0.625 prednicarbate 0.45 STABLE 0.85 3 0.01555 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay megestrol_acetate→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to prednicarbate (Jaccard=0.62) methyltestosterone intracranial_aneurysm GAP_HIGH 0.1875 0.5454545454545454 cortisone_acetate 0.45 STABLE 0.85 3 0.01552 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methyltestosterone→?; validate in intracranial_aneurysm cell model. Expected: similar to cortisone_acetate (Jaccard=0.55) lapatinib meningioma GAP_HIGH 0.1868 0.5 docetaxel 0.45 STABLE 0.85 3 0.01546 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lapatinib→?; validate in meningioma cell model. Expected: similar to docetaxel (Jaccard=0.50) vidarabine malignant_mesothelioma GAP_HIGH 0.1867 0.47368421052631576 entecavir 0.45 STABLE 0.85 3 0.01545 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vidarabine→?; validate in malignant_mesothelioma cell model. Expected: similar to entecavir (Jaccard=0.47) crizotinib nephrolithiasis GAP_HIGH 0.1865 0.5714285714285714 sunitinib 0.45 STABLE 0.85 3 0.01544 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay crizotinib→?; validate in nephrolithiasis cell model. Expected: similar to sunitinib (Jaccard=0.57) dinoprostone alcohol_dependence GAP_HIGH 0.1833 0.2222222222222222 naloxone 0.45 STABLE 0.85 3 0.01517 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dinoprostone→?; validate in alcohol_dependence cell model. Expected: similar to naloxone (Jaccard=0.22) estradiol_valeratedienogest pancreatitis GAP_HIGH 0.2592 0.8333333333333334 levorphanol 0.45 STABLE 0.6 3 0.01514 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estradiol_valeratedienogest→?; validate in pancreatitis cell model. Expected: similar to levorphanol (Jaccard=0.83) bimatoprost epilepsy_syndrome GAP_HIGH 0.2906 0.6 alcaftadine 0.4 STABLE 0.6 3 0.01509 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bimatoprost→?; validate in epilepsy_syndrome cell model. Expected: similar to alcaftadine (Jaccard=0.60) crizotinib primary_biliary_cirrhosis GAP_HIGH 0.1822 0.5714285714285714 sunitinib 0.45 STABLE 0.85 3 0.01508 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay crizotinib→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to sunitinib (Jaccard=0.57) cortisone_acetate dilated_cardiomyopathy GAP_HIGH 0.1818 0.46153846153846156 medrysone 0.45 STABLE 0.85 3 0.01505 MEDIUM Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cortisone_acetate→?; validate in dilated_cardiomyopathy cell model. Expected: similar to medrysone (Jaccard=0.46) crizotinib sclerosing_cholangitis GAP_HIGH 0.1808 0.5714285714285714 sunitinib 0.45 STABLE 0.85 3 0.01497 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay crizotinib→?; validate in sclerosing_cholangitis cell model. Expected: similar to sunitinib (Jaccard=0.57) prednisone coronary_artery_disease GAP_HIGH 0.203 0.8235294117647058 testolactone 0.4 STABLE 0.85 3 0.01494 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prednisone→?; validate in coronary_artery_disease cell model. Expected: similar to testolactone (Jaccard=0.82) crizotinib pancreatitis GAP_HIGH 0.1799 0.5714285714285714 sunitinib 0.45 STABLE 0.85 3 0.01489 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay crizotinib→?; validate in pancreatitis cell model. Expected: similar to sunitinib (Jaccard=0.57) fluticasone_propionate celiac_disease GAP_HIGH 0.179 0.5833333333333334 fluocinonide 0.45 STABLE 0.85 3 0.01482 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluticasone_propionate→?; validate in celiac_disease cell model. Expected: similar to fluocinonide (Jaccard=0.58) cinchocaine leprosy GAP_HIGH 0.1788 0.3 phenmetrazine 0.45 STABLE 0.85 3 0.0148 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cinchocaine→?; validate in leprosy cell model. Expected: similar to phenmetrazine (Jaccard=0.30) vitamin_c dilated_cardiomyopathy GAP_HIGH 0.2518 0.3333333333333333 ciprofloxacin 0.45 STABLE 0.6 3 0.01471 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vitamin_c→?; validate in dilated_cardiomyopathy cell model. Expected: similar to ciprofloxacin (Jaccard=0.33) vitamin_c pagets_disease_of_bone GAP_HIGH 0.2514 0.25 histamine_phosphate 0.45 STABLE 0.6 3 0.01469 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vitamin_c→?; validate in pagets_disease_of_bone cell model. Expected: similar to histamine_phosphate (Jaccard=0.25) dinoprostone leprosy GAP_HIGH 0.1766 0.15384615384615385 pomalidomide 0.45 STABLE 0.85 3 0.01462 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dinoprostone→?; validate in leprosy cell model. Expected: similar to pomalidomide (Jaccard=0.15) estriol hypothyroidism GAP_HIGH 0.2491 0.3333333333333333 methimazole 0.45 STABLE 0.6 3 0.01456 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estriol→?; validate in hypothyroidism cell model. Expected: similar to methimazole (Jaccard=0.33) dinoprost_tromethamine malignant_mesothelioma GAP_HIGH 0.1749 0.2 pemetrexed 0.45 STABLE 0.85 3 0.01448 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dinoprost_tromethamine→?; validate in malignant_mesothelioma cell model. Expected: similar to pemetrexed (Jaccard=0.20) oxybuprocaine azoospermia GAP_HIGH 0.1708 0.4782608695652174 procaine 0.45 STABLE 0.85 3 0.01414 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxybuprocaine→?; validate in azoospermia cell model. Expected: similar to procaine (Jaccard=0.48) afatinib nephrolithiasis GAP_HIGH 0.1694 0.4666666666666667 erlotinib 0.45 STABLE 0.85 3 0.01402 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay afatinib→?; validate in nephrolithiasis cell model. Expected: similar to erlotinib (Jaccard=0.47) fluoxymesterone dilated_cardiomyopathy GAP_HIGH 0.1692 0.5217391304347826 hydrocortisone 0.45 STABLE 0.85 3 0.014 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluoxymesterone→?; validate in dilated_cardiomyopathy cell model. Expected: similar to hydrocortisone (Jaccard=0.52) enalapril hepatitis_b GAP_HIGH 0.1614 0.35714285714285715 trandolapril 0.2 DECLINING 0.6 3 0.01397 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay enalapril→?; validate in hepatitis_b cell model. Expected: similar to trandolapril (Jaccard=0.36) benzocaine celiac_disease GAP_HIGH 0.1684 0.3333333333333333 cyclandelate 0.45 STABLE 0.85 3 0.01394 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzocaine→?; validate in celiac_disease cell model. Expected: similar to cyclandelate (Jaccard=0.33) lenalidomide ankylosing_spondylitis GAP_HIGH 0.1683 0.42857142857142855 menadione 0.45 STABLE 0.85 3 0.01393 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lenalidomide→?; validate in ankylosing_spondylitis cell model. Expected: similar to menadione (Jaccard=0.43) ethynodiol intracranial_aneurysm GAP_HIGH 0.2383 0.6666666666666666 megestrol_acetate 0.45 STABLE 0.6 3 0.01392 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethynodiol→?; validate in intracranial_aneurysm cell model. Expected: similar to megestrol_acetate (Jaccard=0.67) ribavirin membranous_glomerulonephritis GAP_HIGH 0.2382 0.5909090909090909 vidarabine 0.45 STABLE 0.6 3 0.01392 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ribavirin→?; validate in membranous_glomerulonephritis cell model. Expected: similar to vidarabine (Jaccard=0.59) oxybuprocaine gout GAP_HIGH 0.1679 0.4782608695652174 procaine 0.45 STABLE 0.85 3 0.0139 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxybuprocaine→?; validate in gout cell model. Expected: similar to procaine (Jaccard=0.48) ribavirin primary_biliary_cirrhosis GAP_HIGH 0.2356 0.5909090909090909 vidarabine 0.45 STABLE 0.6 3 0.01377 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ribavirin→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to vidarabine (Jaccard=0.59) equilin alcohol_dependence GAP_HIGH 0.2345 0.3333333333333333 dextromethorphan 0.45 STABLE 0.6 3 0.0137 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay equilin→?; validate in alcohol_dependence cell model. Expected: similar to dextromethorphan (Jaccard=0.33) ethynodiol meningioma GAP_HIGH 0.234 0.6666666666666666 megestrol_acetate 0.45 STABLE 0.6 3 0.01367 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethynodiol→?; validate in meningioma cell model. Expected: similar to megestrol_acetate (Jaccard=0.67) afatinib primary_biliary_cirrhosis GAP_HIGH 0.1652 0.4666666666666667 erlotinib 0.45 STABLE 0.85 3 0.01367 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay afatinib→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to erlotinib (Jaccard=0.47) benzocaine idiopathic_pulmonary_fibrosis GAP_HIGH 0.1646 0.3333333333333333 cyclandelate 0.45 STABLE 0.85 3 0.01363 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzocaine→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to cyclandelate (Jaccard=0.33) ethynodiol gout GAP_HIGH 0.233 0.6666666666666666 megestrol_acetate 0.45 STABLE 0.6 3 0.01361 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethynodiol→?; validate in gout cell model. Expected: similar to megestrol_acetate (Jaccard=0.67) hydrocortisone gout GAP_HIGH 0.1644 0.6363636363636364 testolactone 0.45 STABLE 0.85 3 0.01361 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay hydrocortisone→?; validate in gout cell model. Expected: similar to testolactone (Jaccard=0.64) estradiol_valeratedienogest coronary_artery_disease GAP_HIGH 0.2613 0.8333333333333334 levorphanol 0.4 STABLE 0.6 3 0.01357 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estradiol_valeratedienogest→?; validate in coronary_artery_disease cell model. Expected: similar to levorphanol (Jaccard=0.83) afatinib sclerosing_cholangitis GAP_HIGH 0.1637 0.4666666666666667 erlotinib 0.45 STABLE 0.85 3 0.01355 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay afatinib→?; validate in sclerosing_cholangitis cell model. Expected: similar to erlotinib (Jaccard=0.47) streptozocin hepatitis_b GAP_HIGH 0.1562 0.1875 ribavirin 0.2 DECLINING 0.6 3 0.01352 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay streptozocin→?; validate in hepatitis_b cell model. Expected: similar to ribavirin (Jaccard=0.19) aspartame hepatitis_b GAP_HIGH 0.1561 0.2857142857142857 alvimopan 0.2 DECLINING 0.6 3 0.01351 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aspartame→?; validate in hepatitis_b cell model. Expected: similar to alvimopan (Jaccard=0.29) afatinib pancreatitis GAP_HIGH 0.1629 0.4666666666666667 erlotinib 0.45 STABLE 0.85 3 0.01348 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay afatinib→?; validate in pancreatitis cell model. Expected: similar to erlotinib (Jaccard=0.47) etidronic_acid nicotine_dependence GAP_HIGH 0.162 0.25 gabapentin 0.45 STABLE 0.85 3 0.01341 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay etidronic_acid→?; validate in nicotine_dependence cell model. Expected: similar to gabapentin (Jaccard=0.25) dinoprostone idiopathic_pulmonary_fibrosis GAP_HIGH 0.1619 0.2222222222222222 epinephrine 0.45 STABLE 0.85 3 0.0134 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dinoprostone→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to epinephrine (Jaccard=0.22) etidronic_acid panic_disorder GAP_HIGH 0.1615 0.25 gabapentin 0.45 STABLE 0.85 3 0.01337 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay etidronic_acid→?; validate in panic_disorder cell model. Expected: similar to gabapentin (Jaccard=0.25) hydrocortisone atopic_dermatitis GAP_HIGH 0.161 0.6363636363636364 testolactone 0.45 STABLE 0.85 3 0.01333 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay hydrocortisone→?; validate in atopic_dermatitis cell model. Expected: similar to testolactone (Jaccard=0.64) glucosamine membranous_glomerulonephritis GAP_HIGH 0.1605 0.46153846153846156 clofarabine 0.45 STABLE 0.85 3 0.01328 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glucosamine→?; validate in membranous_glomerulonephritis cell model. Expected: similar to clofarabine (Jaccard=0.46) drostanolone alcohol_dependence GAP_HIGH 0.1599 0.3181818181818182 levorphanol 0.45 STABLE 0.85 3 0.01324 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay drostanolone→?; validate in alcohol_dependence cell model. Expected: similar to levorphanol (Jaccard=0.32) cinchocaine coronary_artery_disease GAP_HIGH 0.1785 0.4583333333333333 oxybuprocaine 0.4 STABLE 0.85 3 0.01313 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cinchocaine→?; validate in coronary_artery_disease cell model. Expected: similar to oxybuprocaine (Jaccard=0.46) imatinib barretts_esophagus GAP_LOW 0.1737 0.0 pantoprazole 0.45 STABLE 1.0 5 0.01309 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking imatinib vs barretts_esophagus targets. Cross-check imatinib pharmacophore against barretts_esophagus pathway. glucosamine primary_biliary_cirrhosis GAP_HIGH 0.1579 0.46153846153846156 clofarabine 0.45 STABLE 0.85 3 0.01307 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay glucosamine→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to clofarabine (Jaccard=0.46) stanozolol alopecia_areata GAP_HIGH 0.2236 0.5555555555555556 cortisone_acetate 0.45 STABLE 0.6 3 0.01306 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay stanozolol→?; validate in alopecia_areata cell model. Expected: similar to cortisone_acetate (Jaccard=0.56) ceruletide malignant_mesothelioma GAP_HIGH 0.1574 0.2 goserelin 0.45 STABLE 0.85 3 0.01303 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ceruletide→?; validate in malignant_mesothelioma cell model. Expected: similar to goserelin (Jaccard=0.20) allylestrenol alopecia_areata GAP_HIGH 0.2229 0.5555555555555556 ethynodiol 0.45 STABLE 0.6 3 0.01302 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay allylestrenol→?; validate in alopecia_areata cell model. Expected: similar to ethynodiol (Jaccard=0.56) riboflavin membranous_glomerulonephritis GAP_HIGH 0.2227 0.48484848484848486 adenosine_triphosphate 0.45 STABLE 0.6 3 0.01301 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay riboflavin→?; validate in membranous_glomerulonephritis cell model. Expected: similar to adenosine_triphosphate (Jaccard=0.48) betamethasone dilated_cardiomyopathy GAP_HIGH 0.1572 0.47619047619047616 fludrocortisone 0.45 STABLE 0.85 3 0.01301 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay betamethasone→?; validate in dilated_cardiomyopathy cell model. Expected: similar to fludrocortisone (Jaccard=0.48) stanozolol intracranial_aneurysm GAP_HIGH 0.2214 0.5555555555555556 cortisone_acetate 0.45 STABLE 0.6 3 0.01294 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay stanozolol→?; validate in intracranial_aneurysm cell model. Expected: similar to cortisone_acetate (Jaccard=0.56) norelgestromin alopecia_areata GAP_HIGH 0.2206 0.5555555555555556 megestrol_acetate 0.45 STABLE 0.6 3 0.01289 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay norelgestromin→?; validate in alopecia_areata cell model. Expected: similar to megestrol_acetate (Jaccard=0.56) riboflavin primary_biliary_cirrhosis GAP_HIGH 0.2201 0.48484848484848486 adenosine_triphosphate 0.45 STABLE 0.6 3 0.01286 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay riboflavin→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to adenosine_triphosphate (Jaccard=0.48) fluticasone_propionate coronary_artery_disease GAP_HIGH 0.1747 0.5833333333333334 fluocinonide 0.4 STABLE 0.85 3 0.01286 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluticasone_propionate→?; validate in coronary_artery_disease cell model. Expected: similar to fluocinonide (Jaccard=0.58) gefitinib nephrolithiasis GAP_HIGH 0.155 0.6060606060606061 vandetanib 0.45 STABLE 0.85 3 0.01283 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay gefitinib→?; validate in nephrolithiasis cell model. Expected: similar to vandetanib (Jaccard=0.61) lidocaine systemic_scleroderma GAP_HIGH 0.1547 0.4166666666666667 probenecid 0.45 STABLE 0.85 3 0.0128 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lidocaine→?; validate in systemic_scleroderma cell model. Expected: similar to probenecid (Jaccard=0.42) pazopanib celiac_disease GAP_HIGH 0.1545 0.42105263157894735 sorafenib 0.45 STABLE 0.85 3 0.01279 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pazopanib→?; validate in celiac_disease cell model. Expected: similar to sorafenib (Jaccard=0.42) telbivudine hepatitis_b GAP_HIGH 0.3474 0.6 pentostatin 0.2 DECLINING 0.85 3 0.01278 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay telbivudine→?; validate in hepatitis_b cell model. Expected: similar to pentostatin (Jaccard=0.60) norelgestromin intracranial_aneurysm GAP_HIGH 0.2184 0.5555555555555556 megestrol_acetate 0.45 STABLE 0.6 3 0.01276 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay norelgestromin→?; validate in intracranial_aneurysm cell model. Expected: similar to megestrol_acetate (Jaccard=0.56) levonorgestrel gout GAP_HIGH 0.217 0.6666666666666666 desogestrel 0.45 STABLE 0.6 3 0.01268 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levonorgestrel→?; validate in gout cell model. Expected: similar to desogestrel (Jaccard=0.67) fluoxymesterone celiac_disease GAP_HIGH 0.1526 0.5217391304347826 hydrocortisone 0.45 STABLE 0.85 3 0.01263 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluoxymesterone→?; validate in celiac_disease cell model. Expected: similar to hydrocortisone (Jaccard=0.52) probenecid leprosy GAP_HIGH 0.2157 0.5555555555555556 phenmetrazine 0.45 STABLE 0.6 3 0.0126 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay probenecid→?; validate in leprosy cell model. Expected: similar to phenmetrazine (Jaccard=0.56) allylestrenol gout GAP_HIGH 0.2154 0.5555555555555556 desogestrel 0.45 STABLE 0.6 3 0.01259 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay allylestrenol→?; validate in gout cell model. Expected: similar to desogestrel (Jaccard=0.56) drostanolone alopecia_areata GAP_HIGH 0.1521 0.35 estradiol_valeratedienogest 0.45 STABLE 0.85 3 0.01259 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay drostanolone→?; validate in alopecia_areata cell model. Expected: similar to estradiol_valeratedienogest (Jaccard=0.35) levonorgestrel ankylosing_spondylitis GAP_HIGH 0.2152 0.6666666666666666 desogestrel 0.45 STABLE 0.6 3 0.01257 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levonorgestrel→?; validate in ankylosing_spondylitis cell model. Expected: similar to desogestrel (Jaccard=0.67) lidocaine leprosy GAP_HIGH 0.1518 0.21428571428571427 phenmetrazine 0.45 STABLE 0.85 3 0.01256 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lidocaine→?; validate in leprosy cell model. Expected: similar to phenmetrazine (Jaccard=0.21) lenalidomide coronary_artery_disease GAP_HIGH 0.17 0.42857142857142855 menadione 0.4 STABLE 0.85 3 0.01251 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lenalidomide→?; validate in coronary_artery_disease cell model. Expected: similar to menadione (Jaccard=0.43) estropipate barretts_esophagus GAP_LOW 0.195 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01249 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking estropipate vs barretts_esophagus targets. Cross-check estropipate pharmacophore against barretts_esophagus pathway. flutamide barretts_esophagus GAP_LOW 0.195 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01249 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking flutamide vs barretts_esophagus targets. Cross-check flutamide pharmacophore against barretts_esophagus pathway. levonorgestrel allergic_rhinitis GAP_HIGH 0.2136 0.6666666666666666 desogestrel 0.45 STABLE 0.6 3 0.01248 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay levonorgestrel→?; validate in allergic_rhinitis cell model. Expected: similar to desogestrel (Jaccard=0.67) allylestrenol ankylosing_spondylitis GAP_HIGH 0.2135 0.5555555555555556 ethynodiol 0.45 STABLE 0.6 3 0.01247 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay allylestrenol→?; validate in ankylosing_spondylitis cell model. Expected: similar to ethynodiol (Jaccard=0.56) gefitinib primary_biliary_cirrhosis GAP_HIGH 0.1507 0.6060606060606061 vandetanib 0.45 STABLE 0.85 3 0.01247 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay gefitinib→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to vandetanib (Jaccard=0.61) pazopanib gout GAP_HIGH 0.1503 0.42105263157894735 sorafenib 0.45 STABLE 0.85 3 0.01244 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pazopanib→?; validate in gout cell model. Expected: similar to sorafenib (Jaccard=0.42) imatinib nephrolithiasis GAP_HIGH 0.1275 0.20588235294117646 sorafenib 0.45 STABLE 1.0 3 0.01242 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay imatinib→?; validate in nephrolithiasis cell model. Expected: similar to sorafenib (Jaccard=0.21) lenalidomide epilepsy_syndrome GAP_HIGH 0.1681 0.42857142857142855 menadione 0.4 STABLE 0.85 3 0.01237 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lenalidomide→?; validate in epilepsy_syndrome cell model. Expected: similar to menadione (Jaccard=0.43) gefitinib sclerosing_cholangitis GAP_HIGH 0.1493 0.6060606060606061 vandetanib 0.45 STABLE 0.85 3 0.01236 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay gefitinib→?; validate in sclerosing_cholangitis cell model. Expected: similar to vandetanib (Jaccard=0.61) vapreotide azoospermia GAP_HIGH 0.1493 0.18181818181818182 deferasirox 0.45 STABLE 0.85 3 0.01236 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vapreotide→?; validate in azoospermia cell model. Expected: similar to deferasirox (Jaccard=0.18) travoprost atherosclerosis GAP_LOW 0.1365 0.09090909090909091 salicylic_acid 0.45 STABLE 0.6 5 0.01234 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking travoprost vs atherosclerosis targets. Cross-check travoprost pharmacophore against atherosclerosis pathway. dinoprost_tromethamine barretts_esophagus GAP_LOW 0.1922 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01231 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking dinoprost_tromethamine vs barretts_esophagus targets. Cross-check dinoprost_tromethamine pharmacophore against barretts_esophagus pathway. dinoprostone barretts_esophagus GAP_LOW 0.1922 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01231 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking dinoprostone vs barretts_esophagus targets. Cross-check dinoprostone pharmacophore against barretts_esophagus pathway. pazopanib ankylosing_spondylitis GAP_HIGH 0.1485 0.42105263157894735 sorafenib 0.45 STABLE 0.85 3 0.01229 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pazopanib→?; validate in ankylosing_spondylitis cell model. Expected: similar to sorafenib (Jaccard=0.42) epoprostenol dilated_cardiomyopathy GAP_HIGH 0.2091 0.2857142857142857 acetyldigitoxin 0.45 STABLE 0.6 3 0.01222 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay epoprostenol→?; validate in dilated_cardiomyopathy cell model. Expected: similar to acetyldigitoxin (Jaccard=0.29) sunitinib celiac_disease GAP_HIGH 0.1477 0.4 sorafenib 0.45 STABLE 0.85 3 0.01222 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay sunitinib→?; validate in celiac_disease cell model. Expected: similar to sorafenib (Jaccard=0.40) etonogestrel chronic_obstructive_pulmonary_disease GAP_HIGH 0.208 0.6 medroxyprogesterone_acetate 0.45 STABLE 0.6 3 0.01215 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay etonogestrel→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to medroxyprogesterone_acetate (Jaccard=0.60) trilostane alopecia_areata GAP_HIGH 0.208 0.5555555555555556 cortisone_acetate 0.45 STABLE 0.6 3 0.01215 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trilostane→?; validate in alopecia_areata cell model. Expected: similar to cortisone_acetate (Jaccard=0.56) vorinostat autistic_disorder GAP_HIGH 0.2078 0.4 amphetamine 0.45 STABLE 0.6 3 0.01214 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vorinostat→?; validate in autistic_disorder cell model. Expected: similar to amphetamine (Jaccard=0.40) vorinostat nicotine_dependence GAP_HIGH 0.2078 0.4 amphetamine 0.45 STABLE 0.6 3 0.01214 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vorinostat→?; validate in nicotine_dependence cell model. Expected: similar to amphetamine (Jaccard=0.40) vorinostat panic_disorder GAP_HIGH 0.2073 0.4 amphetamine 0.45 STABLE 0.6 3 0.01211 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vorinostat→?; validate in panic_disorder cell model. Expected: similar to amphetamine (Jaccard=0.40) vorinostat conduct_disorder GAP_HIGH 0.2072 0.4 amphetamine 0.45 STABLE 0.6 3 0.01211 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vorinostat→?; validate in conduct_disorder cell model. Expected: similar to amphetamine (Jaccard=0.40) etonogestrel atopic_dermatitis GAP_HIGH 0.2066 0.6 medroxyprogesterone_acetate 0.45 STABLE 0.6 3 0.01207 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay etonogestrel→?; validate in atopic_dermatitis cell model. Expected: similar to medroxyprogesterone_acetate (Jaccard=0.60) trilostane intracranial_aneurysm GAP_HIGH 0.2058 0.5555555555555556 cortisone_acetate 0.45 STABLE 0.6 3 0.01202 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay trilostane→?; validate in intracranial_aneurysm cell model. Expected: similar to cortisone_acetate (Jaccard=0.56) estriol alopecia_areata GAP_HIGH 0.2043 0.375 estrone 0.45 STABLE 0.6 3 0.01194 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estriol→?; validate in alopecia_areata cell model. Expected: similar to estrone (Jaccard=0.38) norethindrone dilated_cardiomyopathy GAP_HIGH 0.1436 0.3333333333333333 dydrogesterone 0.45 STABLE 0.85 3 0.01189 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay norethindrone→?; validate in dilated_cardiomyopathy cell model. Expected: similar to dydrogesterone (Jaccard=0.33) estriol intracranial_aneurysm GAP_HIGH 0.2021 0.375 estrone 0.45 STABLE 0.6 3 0.01181 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estriol→?; validate in intracranial_aneurysm cell model. Expected: similar to estrone (Jaccard=0.38) mestranol alopecia_areata GAP_HIGH 0.2014 0.5789473684210527 ethinyl_estradiol 0.45 STABLE 0.6 3 0.01177 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mestranol→?; validate in alopecia_areata cell model. Expected: similar to ethinyl_estradiol (Jaccard=0.58) ethinyl_estradiol polycystic_ovary_syndrome GAP_HIGH 0.1633 0.5789473684210527 mestranol 0.55 STABLE 0.6 3 0.01166 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethinyl_estradiol→?; validate in polycystic_ovary_syndrome cell model. Expected: similar to mestranol (Jaccard=0.58) testosterone dilated_cardiomyopathy GAP_HIGH 0.1397 0.2222222222222222 drospirenone 0.45 STABLE 0.85 3 0.01157 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay testosterone→?; validate in dilated_cardiomyopathy cell model. Expected: similar to drospirenone (Jaccard=0.22) etonogestrel hypothyroidism GAP_HIGH 0.1974 0.25 methimazole 0.45 STABLE 0.6 3 0.01153 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay etonogestrel→?; validate in hypothyroidism cell model. Expected: similar to methimazole (Jaccard=0.25) latanoprost idiopathic_pulmonary_fibrosis GAP_HIGH 0.1962 0.3333333333333333 alcaftadine 0.45 STABLE 0.6 3 0.01146 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay latanoprost→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to alcaftadine (Jaccard=0.33) erlotinib barretts_esophagus GAP_LOW 0.152 0.0 pantoprazole 0.45 STABLE 1.0 5 0.01145 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking erlotinib vs barretts_esophagus targets. Cross-check erlotinib pharmacophore against barretts_esophagus pathway. probenecid malaria GAP_HIGH 0.1955 0.5555555555555556 tranylcypromine 0.45 STABLE 0.6 3 0.01142 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay probenecid→?; validate in malaria cell model. Expected: similar to tranylcypromine (Jaccard=0.56) imatinib hypothyroidism GAP_LOW 0.1509 0.0 methimazole 0.45 STABLE 1.0 5 0.01137 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking imatinib vs hypothyroidism targets. Cross-check imatinib pharmacophore against hypothyroidism pathway. latanoprost creutzfeldt-jakob_disease GAP_HIGH 0.1945 0.3333333333333333 cyproheptadine 0.45 STABLE 0.6 3 0.01136 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay latanoprost→?; validate in creutzfeldt-jakob_disease cell model. Expected: similar to cyproheptadine (Jaccard=0.33) voacamine systemic_scleroderma GAP_HIGH 0.1372 0.3333333333333333 vinblastine 0.45 STABLE 0.85 3 0.01136 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay voacamine→?; validate in systemic_scleroderma cell model. Expected: similar to vinblastine (Jaccard=0.33) fulvestrant alopecia_areata GAP_HIGH 0.1942 0.5454545454545454 estradiol_valeratedienogest 0.45 STABLE 0.6 3 0.01135 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fulvestrant→?; validate in alopecia_areata cell model. Expected: similar to estradiol_valeratedienogest (Jaccard=0.55) mestranol idiopathic_pulmonary_fibrosis GAP_HIGH 0.1941 0.5789473684210527 ethinyl_estradiol 0.45 STABLE 0.6 3 0.01134 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mestranol→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to ethinyl_estradiol (Jaccard=0.58) ponatinib barretts_esophagus GAP_LOW 0.1769 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01133 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking ponatinib vs barretts_esophagus targets. Cross-check ponatinib pharmacophore against barretts_esophagus pathway. vapreotide barretts_esophagus GAP_LOW 0.1769 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01133 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking vapreotide vs barretts_esophagus targets. Cross-check vapreotide pharmacophore against barretts_esophagus pathway. latanoprost chronic_obstructive_pulmonary_disease GAP_HIGH 0.1938 0.3333333333333333 alcaftadine 0.45 STABLE 0.6 3 0.01132 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay latanoprost→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to alcaftadine (Jaccard=0.33) mestranol chronic_obstructive_pulmonary_disease GAP_HIGH 0.1918 0.5789473684210527 ethinyl_estradiol 0.45 STABLE 0.6 3 0.01121 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay mestranol→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to ethinyl_estradiol (Jaccard=0.58) folic_acid acquired_immunodeficiency_syndrome GAP_HIGH 0.1103 0.16666666666666666 emtricitabine 0.55 STABLE 0.85 3 0.01116 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay folic_acid→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to emtricitabine (Jaccard=0.17) tetrahydrofolic_acid acquired_immunodeficiency_syndrome GAP_HIGH 0.1103 0.16666666666666666 emtricitabine 0.55 STABLE 0.85 3 0.01116 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tetrahydrofolic_acid→?; validate in acquired_immunodeficiency_syndrome cell model. Expected: similar to emtricitabine (Jaccard=0.17) danazol chronic_obstructive_pulmonary_disease GAP_HIGH 0.1904 0.5714285714285714 medroxyprogesterone_acetate 0.45 STABLE 0.6 3 0.01112 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay danazol→?; validate in chronic_obstructive_pulmonary_disease cell model. Expected: similar to medroxyprogesterone_acetate (Jaccard=0.57) fulvestrant alcohol_dependence GAP_HIGH 0.1904 0.46153846153846156 levorphanol 0.45 STABLE 0.6 3 0.01112 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fulvestrant→?; validate in alcohol_dependence cell model. Expected: similar to levorphanol (Jaccard=0.46) danazol atopic_dermatitis GAP_HIGH 0.1891 0.5714285714285714 medroxyprogesterone_acetate 0.45 STABLE 0.6 3 0.01105 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay danazol→?; validate in atopic_dermatitis cell model. Expected: similar to medroxyprogesterone_acetate (Jaccard=0.57) benzocaine barretts_esophagus GAP_LOW 0.1722 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01103 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking benzocaine vs barretts_esophagus targets. Cross-check benzocaine pharmacophore against barretts_esophagus pathway. lenalidomide barretts_esophagus GAP_LOW 0.1722 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01103 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking lenalidomide vs barretts_esophagus targets. Cross-check lenalidomide pharmacophore against barretts_esophagus pathway. imatinib pagets_disease_of_bone GAP_LOW 0.1455 0.037037037037037035 histamine_phosphate 0.45 STABLE 1.0 5 0.01096 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking imatinib vs pagets_disease_of_bone targets. Cross-check imatinib pharmacophore against pagets_disease_of_bone pathway. dinoprostone hypothyroidism GAP_LOW 0.1694 0.0 methimazole 0.45 STABLE 0.85 5 0.01085 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking dinoprostone vs hypothyroidism targets. Cross-check dinoprostone pharmacophore against hypothyroidism pathway. vorinostat schizophrenia GAP_HIGH 0.2073 0.4 amphetamine 0.4 STABLE 0.6 3 0.01077 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vorinostat→?; validate in schizophrenia cell model. Expected: similar to amphetamine (Jaccard=0.40) ceruletide barretts_esophagus GAP_LOW 0.1681 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01077 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking ceruletide vs barretts_esophagus targets. Cross-check ceruletide pharmacophore against barretts_esophagus pathway. diclofenamide barretts_esophagus GAP_LOW 0.1669 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01069 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking diclofenamide vs barretts_esophagus targets. Cross-check diclofenamide pharmacophore against barretts_esophagus pathway. glucosamine barretts_esophagus GAP_LOW 0.1657 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01061 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking glucosamine vs barretts_esophagus targets. Cross-check glucosamine pharmacophore against barretts_esophagus pathway. zidovudine barretts_esophagus GAP_LOW 0.1657 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01061 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking zidovudine vs barretts_esophagus targets. Cross-check zidovudine pharmacophore against barretts_esophagus pathway. testosterone alopecia_areata GAP_HIGH 0.1282 0.23076923076923078 cyproterone_acetate 0.45 STABLE 0.85 3 0.01061 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay testosterone→?; validate in alopecia_areata cell model. Expected: similar to cyproterone_acetate (Jaccard=0.23) testosterone barretts_esophagus GAP_LOW 0.1646 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01054 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking testosterone vs barretts_esophagus targets. Cross-check testosterone pharmacophore against barretts_esophagus pathway. adenosine_triphosphate barretts_esophagus GAP_LOW 0.1636 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01048 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking adenosine_triphosphate vs barretts_esophagus targets. Cross-check adenosine_triphosphate pharmacophore against barretts_esophagus pathway. lidocaine barretts_esophagus GAP_LOW 0.1636 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01048 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking lidocaine vs barretts_esophagus targets. Cross-check lidocaine pharmacophore against barretts_esophagus pathway. s-adenosylmethionine barretts_esophagus GAP_LOW 0.1636 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01048 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking s-adenosylmethionine vs barretts_esophagus targets. Cross-check s-adenosylmethionine pharmacophore against barretts_esophagus pathway. nelarabine hepatitis_b GAP_HIGH 0.283 0.5 emtricitabine 0.2 DECLINING 0.85 3 0.01041 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay nelarabine→?; validate in hepatitis_b cell model. Expected: similar to emtricitabine (Jaccard=0.50) adenosine_monophosphate barretts_esophagus GAP_LOW 0.1626 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01041 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking adenosine_monophosphate vs barretts_esophagus targets. Cross-check adenosine_monophosphate pharmacophore against barretts_esophagus pathway. alendronate chronic_kidney_failure GAP_HIGH 0.1255 0.2 mirtazapine 0.45 STABLE 0.85 3 0.01039 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay alendronate→?; validate in chronic_kidney_failure cell model. Expected: similar to mirtazapine (Jaccard=0.20) entecavir hepatitis_b GAP_HIGH 0.2806 0.6 abacavir 0.2 DECLINING 0.85 3 0.01032 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay entecavir→?; validate in hepatitis_b cell model. Expected: similar to abacavir (Jaccard=0.60) drostanolone barretts_esophagus GAP_LOW 0.1607 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01029 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking drostanolone vs barretts_esophagus targets. Cross-check drostanolone pharmacophore against barretts_esophagus pathway. clocortolone barretts_esophagus GAP_LOW 0.16 0.09090909090909091 pantoprazole 0.45 STABLE 0.85 5 0.01025 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking clocortolone vs barretts_esophagus targets. Cross-check clocortolone pharmacophore against barretts_esophagus pathway. difluprednate barretts_esophagus GAP_LOW 0.16 0.09090909090909091 pantoprazole 0.45 STABLE 0.85 5 0.01025 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking difluprednate vs barretts_esophagus targets. Cross-check difluprednate pharmacophore against barretts_esophagus pathway. testosterone hypothyroidism GAP_LOW 0.1595 0.1 methimazole 0.45 STABLE 0.85 5 0.01021 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking testosterone vs hypothyroidism targets. Cross-check testosterone pharmacophore against hypothyroidism pathway. cladribine barretts_esophagus GAP_LOW 0.1589 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01018 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking cladribine vs barretts_esophagus targets. Cross-check cladribine pharmacophore against barretts_esophagus pathway. oxybuprocaine barretts_esophagus GAP_LOW 0.1589 0.0 pantoprazole 0.45 STABLE 0.85 5 0.01018 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking oxybuprocaine vs barretts_esophagus targets. Cross-check oxybuprocaine pharmacophore against barretts_esophagus pathway. latanoprost epilepsy_syndrome GAP_HIGH 0.1938 0.3333333333333333 alcaftadine 0.4 STABLE 0.6 3 0.01007 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay latanoprost→?; validate in epilepsy_syndrome cell model. Expected: similar to alcaftadine (Jaccard=0.33) metoclopramide barretts_esophagus GAP_LOW 0.1559 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00998 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking metoclopramide vs barretts_esophagus targets. Cross-check metoclopramide pharmacophore against barretts_esophagus pathway. procainamide barretts_esophagus GAP_LOW 0.1559 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00998 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking procainamide vs barretts_esophagus targets. Cross-check procainamide pharmacophore against barretts_esophagus pathway. betamethasone barretts_esophagus GAP_LOW 0.1557 0.07142857142857142 pantoprazole 0.45 STABLE 0.85 5 0.00997 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking betamethasone vs barretts_esophagus targets. Cross-check betamethasone pharmacophore against barretts_esophagus pathway. alendronate pagets_disease_of_bone GAP_LOW 0.1552 0.14285714285714285 clodronate 0.45 STABLE 0.85 5 0.00994 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking alendronate vs pagets_disease_of_bone targets. Cross-check alendronate pharmacophore against pagets_disease_of_bone pathway. gefitinib barretts_esophagus GAP_LOW 0.1545 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00989 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking gefitinib vs barretts_esophagus targets. Cross-check gefitinib pharmacophore against barretts_esophagus pathway. ponatinib hypothyroidism GAP_LOW 0.1541 0.0 methimazole 0.45 STABLE 0.85 5 0.00987 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking ponatinib vs hypothyroidism targets. Cross-check ponatinib pharmacophore against hypothyroidism pathway. vapreotide hypothyroidism GAP_LOW 0.1541 0.0 methimazole 0.45 STABLE 0.85 5 0.00987 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking vapreotide vs hypothyroidism targets. Cross-check vapreotide pharmacophore against hypothyroidism pathway. sunitinib barretts_esophagus GAP_LOW 0.1538 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00985 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking sunitinib vs barretts_esophagus targets. Cross-check sunitinib pharmacophore against barretts_esophagus pathway. vandetanib barretts_esophagus GAP_LOW 0.1538 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00985 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking vandetanib vs barretts_esophagus targets. Cross-check vandetanib pharmacophore against barretts_esophagus pathway. probenecid coronary_artery_disease GAP_HIGH 0.1891 0.5833333333333334 chloroprocaine 0.4 STABLE 0.6 3 0.00982 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay probenecid→?; validate in coronary_artery_disease cell model. Expected: similar to chloroprocaine (Jaccard=0.58) pazopanib barretts_esophagus GAP_LOW 0.1532 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00981 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking pazopanib vs barretts_esophagus targets. Cross-check pazopanib pharmacophore against barretts_esophagus pathway. teniposide barretts_esophagus GAP_LOW 0.1532 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00981 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking teniposide vs barretts_esophagus targets. Cross-check teniposide pharmacophore against barretts_esophagus pathway. erlotinib hypothyroidism GAP_LOW 0.1292 0.0 methimazole 0.45 STABLE 1.0 5 0.00973 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking erlotinib vs hypothyroidism targets. Cross-check erlotinib pharmacophore against hypothyroidism pathway. fluoxymesterone barretts_esophagus GAP_LOW 0.1515 0.058823529411764705 pantoprazole 0.45 STABLE 0.85 5 0.0097 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking fluoxymesterone vs barretts_esophagus targets. Cross-check fluoxymesterone pharmacophore against barretts_esophagus pathway. adenine barretts_esophagus GAP_LOW 0.1509 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00966 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking adenine vs barretts_esophagus targets. Cross-check adenine pharmacophore against barretts_esophagus pathway. tioguanine barretts_esophagus GAP_LOW 0.1509 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00966 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking tioguanine vs barretts_esophagus targets. Cross-check tioguanine pharmacophore against barretts_esophagus pathway. drostanolone hypothyroidism GAP_LOW 0.1494 0.058823529411764705 methimazole 0.45 STABLE 0.85 5 0.00957 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking drostanolone vs hypothyroidism targets. Cross-check drostanolone pharmacophore against hypothyroidism pathway. gemcitabine barretts_esophagus GAP_LOW 0.1494 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00957 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking gemcitabine vs barretts_esophagus targets. Cross-check gemcitabine pharmacophore against barretts_esophagus pathway. sorafenib barretts_esophagus GAP_LOW 0.1494 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00957 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking sorafenib vs barretts_esophagus targets. Cross-check sorafenib pharmacophore against barretts_esophagus pathway. estradiol intracranial_aneurysm GAP_HIGH 0.1633 0.5384615384615384 estrone 0.45 STABLE 0.6 3 0.00954 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estradiol→?; validate in intracranial_aneurysm cell model. Expected: similar to estrone (Jaccard=0.54) norethindrone barretts_esophagus GAP_LOW 0.1489 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00954 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking norethindrone vs barretts_esophagus targets. Cross-check norethindrone pharmacophore against barretts_esophagus pathway. conjugated_estrogens alopecia_areata GAP_HIGH 0.1627 0.3333333333333333 estrone 0.45 STABLE 0.6 3 0.00951 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay conjugated_estrogens→?; validate in alopecia_areata cell model. Expected: similar to estrone (Jaccard=0.33) estradiol nephrolithiasis GAP_HIGH 0.1623 0.5384615384615384 estrone 0.45 STABLE 0.6 3 0.00948 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estradiol→?; validate in nephrolithiasis cell model. Expected: similar to estrone (Jaccard=0.54) dexamethasone barretts_esophagus GAP_LOW 0.148 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00948 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking dexamethasone vs barretts_esophagus targets. Cross-check dexamethasone pharmacophore against barretts_esophagus pathway. vinblastine barretts_esophagus GAP_LOW 0.148 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00948 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking vinblastine vs barretts_esophagus targets. Cross-check vinblastine pharmacophore against barretts_esophagus pathway. estradiol celiac_disease GAP_HIGH 0.1621 0.5384615384615384 estrone 0.45 STABLE 0.6 3 0.00947 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estradiol→?; validate in celiac_disease cell model. Expected: similar to estrone (Jaccard=0.54) adenosine_monophosphate systemic_scleroderma GAP_HIGH 0.1144 0.26229508196721313 vidarabine 0.45 STABLE 0.85 3 0.00947 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay adenosine_monophosphate→?; validate in systemic_scleroderma cell model. Expected: similar to vidarabine (Jaccard=0.26) alendronate barretts_esophagus GAP_LOW 0.1475 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00945 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking alendronate vs barretts_esophagus targets. Cross-check alendronate pharmacophore against barretts_esophagus pathway. pamidronate barretts_esophagus GAP_LOW 0.1475 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00945 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking pamidronate vs barretts_esophagus targets. Cross-check pamidronate pharmacophore against barretts_esophagus pathway. voacamine barretts_esophagus GAP_LOW 0.1471 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00942 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking voacamine vs barretts_esophagus targets. Cross-check voacamine pharmacophore against barretts_esophagus pathway. conjugated_estrogens intracranial_aneurysm GAP_HIGH 0.1605 0.3333333333333333 estrone 0.45 STABLE 0.6 3 0.00938 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay conjugated_estrogens→?; validate in intracranial_aneurysm cell model. Expected: similar to estrone (Jaccard=0.33) testosterone pagets_disease_of_bone GAP_LOW 0.1464 0.09090909090909091 histamine_phosphate 0.45 STABLE 0.85 5 0.00937 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking testosterone vs pagets_disease_of_bone targets. Cross-check testosterone pharmacophore against pagets_disease_of_bone pathway. diclofenamide hypothyroidism GAP_LOW 0.1441 0.0 methimazole 0.45 STABLE 0.85 5 0.00923 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking diclofenamide vs hypothyroidism targets. Cross-check diclofenamide pharmacophore against hypothyroidism pathway. norethindrone hypothyroidism GAP_LOW 0.1437 0.1 methimazole 0.45 STABLE 0.85 5 0.0092 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking norethindrone vs hypothyroidism targets. Cross-check norethindrone pharmacophore against hypothyroidism pathway. folic_acid barretts_esophagus GAP_LOW 0.1431 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00916 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking folic_acid vs barretts_esophagus targets. Cross-check folic_acid pharmacophore against barretts_esophagus pathway. tetrahydrofolic_acid barretts_esophagus GAP_LOW 0.1431 0.0 pantoprazole 0.45 STABLE 0.85 5 0.00916 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking tetrahydrofolic_acid vs barretts_esophagus targets. Cross-check tetrahydrofolic_acid pharmacophore against barretts_esophagus pathway. adenosine_triphosphate hypothyroidism GAP_LOW 0.1408 0.0 methimazole 0.45 STABLE 0.85 5 0.00902 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking adenosine_triphosphate vs hypothyroidism targets. Cross-check adenosine_triphosphate pharmacophore against hypothyroidism pathway. s-adenosylmethionine hypothyroidism GAP_LOW 0.1408 0.0 methimazole 0.45 STABLE 0.85 5 0.00902 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking s-adenosylmethionine vs hypothyroidism targets. Cross-check s-adenosylmethionine pharmacophore against hypothyroidism pathway. adenosine_monophosphate hypothyroidism GAP_LOW 0.1397 0.0 methimazole 0.45 STABLE 0.85 5 0.00895 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking adenosine_monophosphate vs hypothyroidism targets. Cross-check adenosine_monophosphate pharmacophore against hypothyroidism pathway. topotecan celiac_disease GAP_HIGH 0.1515 0.3333333333333333 cyclandelate 0.45 STABLE 0.6 3 0.00885 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay topotecan→?; validate in celiac_disease cell model. Expected: similar to cyclandelate (Jaccard=0.33) mannitol barretts_esophagus GAP_LOW 0.195 0.0 pantoprazole 0.45 STABLE 0.6 5 0.00881 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking mannitol vs barretts_esophagus targets. Cross-check mannitol pharmacophore against barretts_esophagus pathway. loteprednol celiac_disease GAP_HIGH 0.1485 0.3333333333333333 homatropine_methylbromide 0.45 STABLE 0.6 3 0.00868 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay loteprednol→?; validate in celiac_disease cell model. Expected: similar to homatropine_methylbromide (Jaccard=0.33) dexamethasone pagets_disease_of_bone GAP_LOW 0.1352 0.125 histamine_phosphate 0.45 STABLE 0.85 5 0.00866 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking dexamethasone vs pagets_disease_of_bone targets. Cross-check dexamethasone pharmacophore against pagets_disease_of_bone pathway. topotecan idiopathic_pulmonary_fibrosis GAP_HIGH 0.1477 0.3333333333333333 cyclandelate 0.45 STABLE 0.6 3 0.00863 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay topotecan→?; validate in idiopathic_pulmonary_fibrosis cell model. Expected: similar to cyclandelate (Jaccard=0.33) metoclopramide hypothyroidism GAP_LOW 0.133 0.0 methimazole 0.45 STABLE 0.85 5 0.00852 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking metoclopramide vs hypothyroidism targets. Cross-check metoclopramide pharmacophore against hypothyroidism pathway. procainamide hypothyroidism GAP_LOW 0.133 0.0 methimazole 0.45 STABLE 0.85 5 0.00852 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking procainamide vs hypothyroidism targets. Cross-check procainamide pharmacophore against hypothyroidism pathway. podofilox dilated_cardiomyopathy GAP_HIGH 0.1449 0.25 ciprofloxacin 0.45 STABLE 0.6 3 0.00847 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay podofilox→?; validate in dilated_cardiomyopathy cell model. Expected: similar to ciprofloxacin (Jaccard=0.25) loteprednol primary_biliary_cirrhosis GAP_HIGH 0.1444 0.3333333333333333 homatropine_methylbromide 0.45 STABLE 0.6 3 0.00844 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay loteprednol→?; validate in primary_biliary_cirrhosis cell model. Expected: similar to homatropine_methylbromide (Jaccard=0.33) teniposide hypothyroidism GAP_LOW 0.1304 0.0 methimazole 0.45 STABLE 0.85 5 0.00835 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking teniposide vs hypothyroidism targets. Cross-check teniposide pharmacophore against hypothyroidism pathway. cabazitaxel barretts_esophagus GAP_LOW 0.1841 0.14285714285714285 pantoprazole 0.45 STABLE 0.6 5 0.00832 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking cabazitaxel vs barretts_esophagus targets. Cross-check cabazitaxel pharmacophore against barretts_esophagus pathway. adenosine_triphosphate pagets_disease_of_bone GAP_LOW 0.1293 0.0 ibandronate 0.45 STABLE 0.85 5 0.00828 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking adenosine_triphosphate vs pagets_disease_of_bone targets. Cross-check adenosine_triphosphate pharmacophore against pagets_disease_of_bone pathway. s-adenosylmethionine pagets_disease_of_bone GAP_LOW 0.1293 0.0 ibandronate 0.45 STABLE 0.85 5 0.00828 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking s-adenosylmethionine vs pagets_disease_of_bone targets. Cross-check s-adenosylmethionine pharmacophore against pagets_disease_of_bone pathway. adenosine_monophosphate pagets_disease_of_bone GAP_LOW 0.1283 0.0 ibandronate 0.45 STABLE 0.85 5 0.00822 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking adenosine_monophosphate vs pagets_disease_of_bone targets. Cross-check adenosine_monophosphate pharmacophore against pagets_disease_of_bone pathway. adenine hypothyroidism GAP_LOW 0.1281 0.0 methimazole 0.45 STABLE 0.85 5 0.0082 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking adenine vs hypothyroidism targets. Cross-check adenine pharmacophore against hypothyroidism pathway. sorafenib pagets_disease_of_bone GAP_LOW 0.127 0.0625 histamine_phosphate 0.45 STABLE 0.85 5 0.00813 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking sorafenib vs pagets_disease_of_bone targets. Cross-check sorafenib pharmacophore against pagets_disease_of_bone pathway. sorafenib hypothyroidism GAP_LOW 0.1266 0.0 methimazole 0.45 STABLE 0.85 5 0.00811 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking sorafenib vs hypothyroidism targets. Cross-check sorafenib pharmacophore against hypothyroidism pathway. alendronate alcohol_dependence GAP_LOW 0.1263 0.14285714285714285 temazepam 0.45 STABLE 0.85 5 0.00809 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking alendronate vs alcohol_dependence targets. Cross-check alendronate pharmacophore against alcohol_dependence pathway. dexamethasone hypothyroidism GAP_LOW 0.1252 0.0 methimazole 0.45 STABLE 0.85 5 0.00802 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking dexamethasone vs hypothyroidism targets. Cross-check dexamethasone pharmacophore against hypothyroidism pathway. desmopressin barretts_esophagus GAP_LOW 0.1769 0.0 pantoprazole 0.45 STABLE 0.6 5 0.008 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking desmopressin vs barretts_esophagus targets. Cross-check desmopressin pharmacophore against barretts_esophagus pathway. felypressin barretts_esophagus GAP_LOW 0.1769 0.0 pantoprazole 0.45 STABLE 0.6 5 0.008 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking felypressin vs barretts_esophagus targets. Cross-check felypressin pharmacophore against barretts_esophagus pathway. terlipressin barretts_esophagus GAP_LOW 0.1769 0.0 pantoprazole 0.45 STABLE 0.6 5 0.008 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking terlipressin vs barretts_esophagus targets. Cross-check terlipressin pharmacophore against barretts_esophagus pathway. podofilox nephrolithiasis GAP_HIGH 0.1367 0.2857142857142857 epirubicin 0.45 STABLE 0.6 3 0.00799 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay podofilox→?; validate in nephrolithiasis cell model. Expected: similar to epirubicin (Jaccard=0.29) pamidronate hypothyroidism GAP_LOW 0.1247 0.0 methimazole 0.45 STABLE 0.85 5 0.00799 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking pamidronate vs hypothyroidism targets. Cross-check pamidronate pharmacophore against hypothyroidism pathway. procainamide pagets_disease_of_bone GAP_LOW 0.1243 0.017857142857142856 histamine_phosphate 0.45 STABLE 0.85 5 0.00796 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking procainamide vs pagets_disease_of_bone targets. Cross-check procainamide pharmacophore against pagets_disease_of_bone pathway. epirubicin dilated_cardiomyopathy GAP_HIGH 0.1361 0.2 ciprofloxacin 0.45 STABLE 0.6 3 0.00795 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay epirubicin→?; validate in dilated_cardiomyopathy cell model. Expected: similar to ciprofloxacin (Jaccard=0.20) travoprost barretts_esophagus GAP_LOW 0.1753 0.0 pantoprazole 0.45 STABLE 0.6 5 0.00793 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking travoprost vs barretts_esophagus targets. Cross-check travoprost pharmacophore against barretts_esophagus pathway. teniposide dilated_cardiomyopathy GAP_LOW 0.1231 0.14285714285714285 ciprofloxacin 0.45 STABLE 0.85 5 0.00788 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking teniposide vs dilated_cardiomyopathy targets. Cross-check teniposide pharmacophore against dilated_cardiomyopathy pathway. mannitol hypothyroidism GAP_LOW 0.1722 0.0 methimazole 0.45 STABLE 0.6 5 0.00779 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking mannitol vs hypothyroidism targets. Cross-check mannitol pharmacophore against hypothyroidism pathway. metoclopramide pagets_disease_of_bone GAP_LOW 0.1215 0.0 ibandronate 0.45 STABLE 0.85 5 0.00778 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking metoclopramide vs pagets_disease_of_bone targets. Cross-check metoclopramide pharmacophore against pagets_disease_of_bone pathway. danazol hypothyroidism GAP_LOW 0.1717 0.14285714285714285 methimazole 0.45 STABLE 0.6 5 0.00776 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking danazol vs hypothyroidism targets. Cross-check danazol pharmacophore against hypothyroidism pathway. conjugated_estrogens barretts_esophagus GAP_LOW 0.1708 0.0 pantoprazole 0.45 STABLE 0.6 5 0.00772 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking conjugated_estrogens vs barretts_esophagus targets. Cross-check conjugated_estrogens pharmacophore against barretts_esophagus pathway. vitamin_a barretts_esophagus GAP_LOW 0.1708 0.0 pantoprazole 0.45 STABLE 0.6 5 0.00772 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking vitamin_a vs barretts_esophagus targets. Cross-check vitamin_a pharmacophore against barretts_esophagus pathway. folic_acid hypothyroidism GAP_LOW 0.1203 0.0 methimazole 0.45 STABLE 0.85 5 0.0077 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking folic_acid vs hypothyroidism targets. Cross-check folic_acid pharmacophore against hypothyroidism pathway. tetrahydrofolic_acid hypothyroidism GAP_LOW 0.1203 0.0 methimazole 0.45 STABLE 0.85 5 0.0077 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking tetrahydrofolic_acid vs hypothyroidism targets. Cross-check tetrahydrofolic_acid pharmacophore against hypothyroidism pathway. vindesine hypertension GAP_HIGH 0.3133 0.875 voacamine 0.8 RAPID_RISE 0.85 3 0.00768 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vindesine→?; validate in hypertension cell model. Expected: similar to voacamine (Jaccard=0.88) lamivudine hepatitis_b GAP_HIGH 0.2088 0.6153846153846154 adenosine 0.2 DECLINING 0.85 3 0.00768 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lamivudine→?; validate in hepatitis_b cell model. Expected: similar to adenosine (Jaccard=0.62) vindesine obesity GAP_HIGH 0.3122 0.875 voacamine 0.8 RAPID_RISE 0.85 3 0.00766 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay vindesine→?; validate in obesity cell model. Expected: similar to voacamine (Jaccard=0.88) alitretinoin barretts_esophagus GAP_LOW 0.1669 0.0 pantoprazole 0.45 STABLE 0.6 5 0.00754 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking alitretinoin vs barretts_esophagus targets. Cross-check alitretinoin pharmacophore against barretts_esophagus pathway. danazol barretts_esophagus GAP_LOW 0.1669 0.0 pantoprazole 0.45 STABLE 0.6 5 0.00754 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking danazol vs barretts_esophagus targets. Cross-check danazol pharmacophore against barretts_esophagus pathway. tretinoin barretts_esophagus GAP_LOW 0.1669 0.0 pantoprazole 0.45 STABLE 0.6 5 0.00754 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking tretinoin vs barretts_esophagus targets. Cross-check tretinoin pharmacophore against barretts_esophagus pathway. adenosine_triphosphate leprosy GAP_LOW 0.1178 0.043478260869565216 phensuximide 0.45 STABLE 0.85 5 0.00754 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking adenosine_triphosphate vs leprosy targets. Cross-check adenosine_triphosphate pharmacophore against leprosy pathway. etoricoxib glaucoma GAP_HIGH 0.1284 0.3333333333333333 polythiazide 0.45 STABLE 0.6 3 0.0075 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay etoricoxib→?; validate in glaucoma cell model. Expected: similar to polythiazide (Jaccard=0.33) estradiol barretts_esophagus GAP_LOW 0.165 0.07692307692307693 pantoprazole 0.45 STABLE 0.6 5 0.00746 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking estradiol vs barretts_esophagus targets. Cross-check estradiol pharmacophore against barretts_esophagus pathway. etoricoxib refractive_error GAP_HIGH 0.1271 0.3333333333333333 polythiazide 0.45 STABLE 0.6 3 0.00743 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay etoricoxib→?; validate in refractive_error cell model. Expected: similar to polythiazide (Jaccard=0.33) metoclopramide leprosy GAP_LOW 0.1149 0.08333333333333333 phenmetrazine 0.45 STABLE 0.85 5 0.00736 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking metoclopramide vs leprosy targets. Cross-check metoclopramide pharmacophore against leprosy pathway. tretinoin pagets_disease_of_bone GAP_LOW 0.1624 0.125 histamine_phosphate 0.45 STABLE 0.6 5 0.00734 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking tretinoin vs pagets_disease_of_bone targets. Cross-check tretinoin pharmacophore against pagets_disease_of_bone pathway. ethinyl_estradiol barretts_esophagus GAP_LOW 0.1622 0.05555555555555555 pantoprazole 0.45 STABLE 0.6 5 0.00733 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking ethinyl_estradiol vs barretts_esophagus targets. Cross-check ethinyl_estradiol pharmacophore against barretts_esophagus pathway. mannitol pagets_disease_of_bone GAP_LOW 0.1607 0.0 ibandronate 0.45 STABLE 0.6 5 0.00727 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking mannitol vs pagets_disease_of_bone targets. Cross-check mannitol pharmacophore against pagets_disease_of_bone pathway. epinephrine hypertension GAP_HIGH 0.2921 1.0 clenbuterol 0.8 RAPID_RISE 0.85 3 0.00716 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay epinephrine→?; validate in hypertension cell model. Expected: similar to clenbuterol (Jaccard=1.00) epinephrine obesity GAP_HIGH 0.291 1.0 clenbuterol 0.8 RAPID_RISE 0.85 3 0.00714 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay epinephrine→?; validate in obesity cell model. Expected: similar to clenbuterol (Jaccard=1.00) epinephrine type_2_diabetes_mellitus GAP_HIGH 0.2905 1.0 clenbuterol 0.8 RAPID_RISE 0.85 3 0.00712 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay epinephrine→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to clenbuterol (Jaccard=1.00) goserelin barretts_esophagus GAP_LOW 0.1566 0.0 pantoprazole 0.45 STABLE 0.6 5 0.00708 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking goserelin vs barretts_esophagus targets. Cross-check goserelin pharmacophore against barretts_esophagus pathway. alitretinoin pagets_disease_of_bone GAP_LOW 0.1554 0.1 histamine_phosphate 0.45 STABLE 0.6 5 0.00703 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking alitretinoin vs pagets_disease_of_bone targets. Cross-check alitretinoin pharmacophore against pagets_disease_of_bone pathway. desmopressin hypothyroidism GAP_LOW 0.1541 0.0 methimazole 0.45 STABLE 0.6 5 0.00697 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking desmopressin vs hypothyroidism targets. Cross-check desmopressin pharmacophore against hypothyroidism pathway. felypressin hypothyroidism GAP_LOW 0.1541 0.0 methimazole 0.45 STABLE 0.6 5 0.00697 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking felypressin vs hypothyroidism targets. Cross-check felypressin pharmacophore against hypothyroidism pathway. terlipressin hypothyroidism GAP_LOW 0.1541 0.0 methimazole 0.45 STABLE 0.6 5 0.00697 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking terlipressin vs hypothyroidism targets. Cross-check terlipressin pharmacophore against hypothyroidism pathway. folic_acid pagets_disease_of_bone GAP_LOW 0.1088 0.0 ibandronate 0.45 STABLE 0.85 5 0.00697 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking folic_acid vs pagets_disease_of_bone targets. Cross-check folic_acid pharmacophore against pagets_disease_of_bone pathway. tetrahydrofolic_acid pagets_disease_of_bone GAP_LOW 0.1088 0.0 ibandronate 0.45 STABLE 0.85 5 0.00697 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking tetrahydrofolic_acid vs pagets_disease_of_bone targets. Cross-check tetrahydrofolic_acid pharmacophore against pagets_disease_of_bone pathway. travoprost hypothyroidism GAP_LOW 0.1524 0.0 methimazole 0.45 STABLE 0.6 5 0.00689 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking travoprost vs hypothyroidism targets. Cross-check travoprost pharmacophore against hypothyroidism pathway. epirubicin barretts_esophagus GAP_LOW 0.152 0.0 pantoprazole 0.45 STABLE 0.6 5 0.00687 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking epirubicin vs barretts_esophagus targets. Cross-check epirubicin pharmacophore against barretts_esophagus pathway. podofilox barretts_esophagus GAP_LOW 0.152 0.0 pantoprazole 0.45 STABLE 0.6 5 0.00687 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking podofilox vs barretts_esophagus targets. Cross-check podofilox pharmacophore against barretts_esophagus pathway. prednicarbate obesity GAP_HIGH 0.2783 0.8571428571428571 eplerenone 0.8 RAPID_RISE 0.85 3 0.00683 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prednicarbate→?; validate in obesity cell model. Expected: similar to eplerenone (Jaccard=0.86) topotecan barretts_esophagus GAP_LOW 0.1509 0.0 pantoprazole 0.45 STABLE 0.6 5 0.00682 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking topotecan vs barretts_esophagus targets. Cross-check topotecan pharmacophore against barretts_esophagus pathway. prednicarbate type_2_diabetes_mellitus GAP_HIGH 0.2778 0.8571428571428571 eplerenone 0.8 RAPID_RISE 0.85 3 0.00681 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay prednicarbate→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to eplerenone (Jaccard=0.86) procainamide leprosy GAP_LOW 0.1053 0.017543859649122806 lenalidomide 0.45 STABLE 0.85 5 0.00674 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking procainamide vs leprosy targets. Cross-check procainamide pharmacophore against leprosy pathway. flavin_adenine_dinucleotide hepatitis_b GAP_HIGH 0.1793 0.3333333333333333 adenosine 0.2 DECLINING 0.85 3 0.0066 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flavin_adenine_dinucleotide→?; validate in hepatitis_b cell model. Expected: similar to adenosine (Jaccard=0.33) etoricoxib barretts_esophagus GAP_LOW 0.1455 0.0 pantoprazole 0.45 STABLE 0.6 5 0.00658 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking etoricoxib vs barretts_esophagus targets. Cross-check etoricoxib pharmacophore against barretts_esophagus pathway. loteprednol barretts_esophagus GAP_LOW 0.1448 0.0 pantoprazole 0.45 STABLE 0.6 5 0.00655 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking loteprednol vs barretts_esophagus targets. Cross-check loteprednol pharmacophore against barretts_esophagus pathway. alitretinoin hypothyroidism GAP_LOW 0.1441 0.0 methimazole 0.45 STABLE 0.6 5 0.00651 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking alitretinoin vs hypothyroidism targets. Cross-check alitretinoin pharmacophore against hypothyroidism pathway. tretinoin hypothyroidism GAP_LOW 0.1441 0.0 methimazole 0.45 STABLE 0.6 5 0.00651 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking tretinoin vs hypothyroidism targets. Cross-check tretinoin pharmacophore against hypothyroidism pathway. etidronic_acid osteoporosis GAP_HIGH 0.4673 1.0 clodronate 0.45 STABLE 0.85 3 0.00645 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay etidronic_acid→?; validate in osteoporosis cell model. Expected: similar to clodronate (Jaccard=1.00) desmopressin pagets_disease_of_bone GAP_LOW 0.1426 0.0 ibandronate 0.45 STABLE 0.6 5 0.00645 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking desmopressin vs pagets_disease_of_bone targets. Cross-check desmopressin pharmacophore against pagets_disease_of_bone pathway. felypressin pagets_disease_of_bone GAP_LOW 0.1426 0.0 ibandronate 0.45 STABLE 0.6 5 0.00645 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking felypressin vs pagets_disease_of_bone targets. Cross-check felypressin pharmacophore against pagets_disease_of_bone pathway. terlipressin pagets_disease_of_bone GAP_LOW 0.1426 0.0 ibandronate 0.45 STABLE 0.6 5 0.00645 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking terlipressin vs pagets_disease_of_bone targets. Cross-check terlipressin pharmacophore against pagets_disease_of_bone pathway. felypressin leprosy GAP_LOW 0.1424 0.058823529411764705 sulfamethizole 0.45 STABLE 0.6 5 0.00644 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking felypressin vs leprosy targets. Cross-check felypressin pharmacophore against leprosy pathway. terlipressin leprosy GAP_LOW 0.1424 0.058823529411764705 sulfamethizole 0.45 STABLE 0.6 5 0.00644 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking terlipressin vs leprosy targets. Cross-check terlipressin pharmacophore against leprosy pathway. mannitol leprosy GAP_LOW 0.1419 0.0 sulfapyridine 0.45 STABLE 0.6 5 0.00641 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking mannitol vs leprosy targets. Cross-check mannitol pharmacophore against leprosy pathway. travoprost pagets_disease_of_bone GAP_LOW 0.141 0.0 ibandronate 0.45 STABLE 0.6 5 0.00638 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking travoprost vs pagets_disease_of_bone targets. Cross-check travoprost pharmacophore against pagets_disease_of_bone pathway. desmopressin leprosy GAP_LOW 0.1358 0.058823529411764705 sulfamethizole 0.45 STABLE 0.6 5 0.00614 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking desmopressin vs leprosy targets. Cross-check desmopressin pharmacophore against leprosy pathway. beclomethasone type_2_diabetes_mellitus GAP_HIGH 0.2467 0.9166666666666666 rimexolone 0.8 RAPID_RISE 0.85 3 0.00605 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay beclomethasone→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to rimexolone (Jaccard=0.92) goserelin hypothyroidism GAP_LOW 0.1338 0.0 methimazole 0.45 STABLE 0.6 5 0.00605 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking goserelin vs hypothyroidism targets. Cross-check goserelin pharmacophore against hypothyroidism pathway. fluorometholone obesity GAP_HIGH 0.2454 0.75 eplerenone 0.8 RAPID_RISE 0.85 3 0.00602 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluorometholone→?; validate in obesity cell model. Expected: similar to eplerenone (Jaccard=0.75) fluorometholone type_2_diabetes_mellitus GAP_HIGH 0.2449 0.75 eplerenone 0.8 RAPID_RISE 0.85 3 0.00601 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluorometholone→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to eplerenone (Jaccard=0.75) riboflavin hepatitis_b GAP_HIGH 0.2294 0.48484848484848486 adenosine_triphosphate 0.2 DECLINING 0.6 3 0.00596 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay riboflavin→?; validate in hepatitis_b cell model. Expected: similar to adenosine_triphosphate (Jaccard=0.48) etoricoxib pagets_disease_of_bone GAP_LOW 0.1281 0.09090909090909091 clodronate 0.45 STABLE 0.6 5 0.00579 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking etoricoxib vs pagets_disease_of_bone targets. Cross-check etoricoxib pharmacophore against pagets_disease_of_bone pathway. cabazitaxel hypothyroidism GAP_LOW 0.1276 0.0 methimazole 0.45 STABLE 0.6 5 0.00577 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking cabazitaxel vs hypothyroidism targets. Cross-check cabazitaxel pharmacophore against hypothyroidism pathway. terlipressin dilated_cardiomyopathy GAP_LOW 0.1254 0.04 testosterone_propionate 0.45 STABLE 0.6 5 0.00567 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking terlipressin vs dilated_cardiomyopathy targets. Cross-check terlipressin pharmacophore against dilated_cardiomyopathy pathway. flurandrenolide obesity GAP_HIGH 0.2288 0.6666666666666666 eplerenone 0.8 RAPID_RISE 0.85 3 0.00561 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flurandrenolide→?; validate in obesity cell model. Expected: similar to eplerenone (Jaccard=0.67) clocortolone type_2_diabetes_mellitus GAP_HIGH 0.2284 0.8333333333333334 rimexolone 0.8 RAPID_RISE 0.85 3 0.0056 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clocortolone→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to rimexolone (Jaccard=0.83) difluprednate type_2_diabetes_mellitus GAP_HIGH 0.2284 0.8333333333333334 rimexolone 0.8 RAPID_RISE 0.85 3 0.0056 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay difluprednate→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to rimexolone (Jaccard=0.83) flurandrenolide type_2_diabetes_mellitus GAP_HIGH 0.2283 0.6666666666666666 eplerenone 0.8 RAPID_RISE 0.85 3 0.0056 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flurandrenolide→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to eplerenone (Jaccard=0.67) etoricoxib hypothyroidism GAP_LOW 0.1227 0.0 methimazole 0.45 STABLE 0.6 5 0.00555 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking etoricoxib vs hypothyroidism targets. Cross-check etoricoxib pharmacophore against hypothyroidism pathway. goserelin pagets_disease_of_bone GAP_LOW 0.1223 0.0 ibandronate 0.45 STABLE 0.6 5 0.00553 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking goserelin vs pagets_disease_of_bone targets. Cross-check goserelin pharmacophore against pagets_disease_of_bone pathway. desmopressin dilated_cardiomyopathy GAP_LOW 0.1209 0.04 testosterone_propionate 0.45 STABLE 0.6 5 0.00547 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking desmopressin vs dilated_cardiomyopathy targets. Cross-check desmopressin pharmacophore against dilated_cardiomyopathy pathway. thalidomide hypertension GAP_HIGH 0.218 0.75 clenbuterol 0.8 RAPID_RISE 0.85 3 0.00535 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay thalidomide→?; validate in hypertension cell model. Expected: similar to clenbuterol (Jaccard=0.75) methylprednisolone asthma GAP_HIGH 0.2859 1.0 fluorometholone 0.6 RISING 0.85 3 0.00526 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay methylprednisolone→?; validate in asthma cell model. Expected: similar to fluorometholone (Jaccard=1.00) cabazitaxel pagets_disease_of_bone GAP_LOW 0.1161 0.0 ibandronate 0.45 STABLE 0.6 5 0.00525 LOW Full discovery pipeline needed: ~5 years Low-priority: Computational docking cabazitaxel vs pagets_disease_of_bone targets. Cross-check cabazitaxel pharmacophore against pagets_disease_of_bone pathway. aciclovir hypertension GAP_HIGH 0.209 0.3333333333333333 cyclosporine 0.8 RAPID_RISE 0.85 3 0.00513 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay aciclovir→?; validate in hypertension cell model. Expected: similar to cyclosporine (Jaccard=0.33) fluocinonide type_2_diabetes_mellitus GAP_HIGH 0.2083 0.7692307692307693 rimexolone 0.8 RAPID_RISE 0.85 3 0.00511 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluocinonide→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to rimexolone (Jaccard=0.77) bimatoprost alzheimers_disease GAP_HIGH 0.29 0.6 alcaftadine 0.8 RAPID_RISE 0.6 3 0.00502 LOW Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay bimatoprost→?; validate in alzheimers_disease cell model. Expected: similar to alcaftadine (Jaccard=0.60) cortisone_acetate obesity GAP_HIGH 0.2017 0.6666666666666666 eplerenone 0.8 RAPID_RISE 0.85 3 0.00495 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cortisone_acetate→?; validate in obesity cell model. Expected: similar to eplerenone (Jaccard=0.67) cortisone_acetate type_2_diabetes_mellitus GAP_HIGH 0.2011 0.6666666666666666 eplerenone 0.8 RAPID_RISE 0.85 3 0.00493 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cortisone_acetate→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to eplerenone (Jaccard=0.67) beclomethasone type_1_diabetes_mellitus GAP_HIGH 0.2577 0.9166666666666666 rimexolone 0.6 RISING 0.85 3 0.00474 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay beclomethasone→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to rimexolone (Jaccard=0.92) pomalidomide hypertension GAP_HIGH 0.19 0.6 clenbuterol 0.8 RAPID_RISE 0.85 3 0.00466 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pomalidomide→?; validate in hypertension cell model. Expected: similar to clenbuterol (Jaccard=0.60) medroxyprogesterone_acetate type_2_diabetes_mellitus GAP_HIGH 0.1897 0.5714285714285714 levonorgestrel 0.8 RAPID_RISE 0.85 3 0.00465 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay medroxyprogesterone_acetate→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to levonorgestrel (Jaccard=0.57) beclomethasone asthma GAP_HIGH 0.2484 0.9166666666666666 rimexolone 0.6 RISING 0.85 3 0.00457 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay beclomethasone→?; validate in asthma cell model. Expected: similar to rimexolone (Jaccard=0.92) dinoprost_tromethamine hypertension GAP_HIGH 0.1864 0.25 trimetrexate 0.8 RAPID_RISE 0.85 3 0.00457 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dinoprost_tromethamine→?; validate in hypertension cell model. Expected: similar to trimetrexate (Jaccard=0.25) cabazitaxel alcohol_dependence GAP_LOW 0.1011 0.058823529411764705 levorphanol 0.45 STABLE 0.6 5 0.00457 ARCHIVE Full discovery pipeline needed: ~5 years Low-priority: Computational docking cabazitaxel vs alcohol_dependence targets. Cross-check cabazitaxel pharmacophore against alcohol_dependence pathway. dipivefrin hypertension GAP_HIGH 0.2595 0.75 pirbuterol 0.8 RAPID_RISE 0.6 3 0.00449 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dipivefrin→?; validate in hypertension cell model. Expected: similar to pirbuterol (Jaccard=0.75) estradiol_valeratedienogest alzheimers_disease GAP_HIGH 0.2588 0.8333333333333334 levorphanol 0.8 RAPID_RISE 0.6 3 0.00448 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay estradiol_valeratedienogest→?; validate in alzheimers_disease cell model. Expected: similar to levorphanol (Jaccard=0.83) dipivefrin obesity GAP_HIGH 0.2585 0.75 pirbuterol 0.8 RAPID_RISE 0.6 3 0.00447 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dipivefrin→?; validate in obesity cell model. Expected: similar to pirbuterol (Jaccard=0.75) clocortolone type_1_diabetes_mellitus GAP_HIGH 0.2394 0.8333333333333334 rimexolone 0.6 RISING 0.85 3 0.0044 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clocortolone→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to rimexolone (Jaccard=0.83) difluprednate type_1_diabetes_mellitus GAP_HIGH 0.2394 0.8333333333333334 rimexolone 0.6 RISING 0.85 3 0.0044 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay difluprednate→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to rimexolone (Jaccard=0.83) fluticasone_propionate hypertension GAP_HIGH 0.1714 0.5833333333333334 fluocinonide 0.8 RAPID_RISE 0.85 3 0.0042 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluticasone_propionate→?; validate in hypertension cell model. Expected: similar to fluocinonide (Jaccard=0.58) fluocinonide type_1_diabetes_mellitus GAP_HIGH 0.2193 0.7692307692307693 rimexolone 0.6 RISING 0.85 3 0.00403 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluocinonide→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to rimexolone (Jaccard=0.77) oxybuprocaine obesity GAP_HIGH 0.1626 0.47368421052631576 chloroprocaine 0.8 RAPID_RISE 0.85 3 0.00399 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay oxybuprocaine→?; validate in obesity cell model. Expected: similar to chloroprocaine (Jaccard=0.47) proparacaine osteoporosis GAP_HIGH 0.239 0.6875 oxybuprocaine 0.45 STABLE 0.85 3 0.0033 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay proparacaine→?; validate in osteoporosis cell model. Expected: similar to oxybuprocaine (Jaccard=0.69) proparacaine migraine GAP_HIGH 0.2389 0.6875 oxybuprocaine 0.45 STABLE 0.85 3 0.0033 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay proparacaine→?; validate in migraine cell model. Expected: similar to oxybuprocaine (Jaccard=0.69) flutamide type_1_diabetes_mellitus GAP_HIGH 0.1772 0.25 glyburide 0.6 RISING 0.85 3 0.00326 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay flutamide→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to glyburide (Jaccard=0.25) fluticasone_propionate asthma GAP_HIGH 0.1715 0.5833333333333334 fluocinonide 0.6 RISING 0.85 3 0.00315 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluticasone_propionate→?; validate in asthma cell model. Expected: similar to fluocinonide (Jaccard=0.58) benzocaine type_1_diabetes_mellitus GAP_HIGH 0.1702 0.3333333333333333 cyclandelate 0.6 RISING 0.85 3 0.00313 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay benzocaine→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to cyclandelate (Jaccard=0.33) entecavir osteoporosis GAP_HIGH 0.225 0.47368421052631576 vidarabine 0.45 STABLE 0.85 3 0.0031 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay entecavir→?; validate in osteoporosis cell model. Expected: similar to vidarabine (Jaccard=0.47) hydrocortisone asthma GAP_HIGH 0.1611 0.6363636363636364 testolactone 0.6 RISING 0.85 3 0.00296 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay hydrocortisone→?; validate in asthma cell model. Expected: similar to testolactone (Jaccard=0.64) fluoxymesterone type_1_diabetes_mellitus GAP_HIGH 0.1545 0.5217391304347826 hydrocortisone 0.6 RISING 0.85 3 0.00284 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay fluoxymesterone→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to hydrocortisone (Jaccard=0.52) azacitidine osteoporosis GAP_HIGH 0.2011 0.4782608695652174 vidarabine 0.45 STABLE 0.85 3 0.00277 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay azacitidine→?; validate in osteoporosis cell model. Expected: similar to vidarabine (Jaccard=0.48) folic_acid type_2_diabetes_mellitus GAP_HIGH 0.1109 0.2727272727272727 methotrexate 0.8 RAPID_RISE 0.85 3 0.00272 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay folic_acid→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to methotrexate (Jaccard=0.27) tetrahydrofolic_acid type_2_diabetes_mellitus GAP_HIGH 0.1109 0.2727272727272727 methotrexate 0.8 RAPID_RISE 0.85 3 0.00272 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay tetrahydrofolic_acid→?; validate in type_2_diabetes_mellitus cell model. Expected: similar to methotrexate (Jaccard=0.27) clofarabine osteoporosis GAP_HIGH 0.1957 0.4782608695652174 vidarabine 0.45 STABLE 0.85 3 0.0027 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay clofarabine→?; validate in osteoporosis cell model. Expected: similar to vidarabine (Jaccard=0.48) dinoprost_tromethamine migraine GAP_HIGH 0.1861 0.25 trimetrexate 0.45 STABLE 0.85 3 0.00257 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay dinoprost_tromethamine→?; validate in migraine cell model. Expected: similar to trimetrexate (Jaccard=0.25) regadenoson osteoporosis GAP_HIGH 0.251 0.6363636363636364 vidarabine 0.45 STABLE 0.6 3 0.00244 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay regadenoson→?; validate in osteoporosis cell model. Expected: similar to vidarabine (Jaccard=0.64) cinchocaine migraine GAP_HIGH 0.175 0.4583333333333333 oxybuprocaine 0.45 STABLE 0.85 3 0.00241 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cinchocaine→?; validate in migraine cell model. Expected: similar to oxybuprocaine (Jaccard=0.46) cinchocaine osteoporosis GAP_HIGH 0.175 0.4583333333333333 oxybuprocaine 0.45 STABLE 0.85 3 0.00241 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cinchocaine→?; validate in osteoporosis cell model. Expected: similar to oxybuprocaine (Jaccard=0.46) cladribine osteoporosis GAP_HIGH 0.1515 0.32 glucosamine 0.45 STABLE 0.85 3 0.00209 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay cladribine→?; validate in osteoporosis cell model. Expected: similar to glucosamine (Jaccard=0.32) lamivudine osteoporosis GAP_HIGH 0.1501 0.4090909090909091 vidarabine 0.45 STABLE 0.85 3 0.00207 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay lamivudine→?; validate in osteoporosis cell model. Expected: similar to vidarabine (Jaccard=0.41) topotecan type_1_diabetes_mellitus GAP_HIGH 0.1534 0.3333333333333333 cyclandelate 0.6 RISING 0.6 3 0.00199 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay topotecan→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to cyclandelate (Jaccard=0.33) pamidronate osteoporosis GAP_HIGH 0.1444 0.2857142857142857 clodronate 0.45 STABLE 0.85 3 0.00199 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay pamidronate→?; validate in osteoporosis cell model. Expected: similar to clodronate (Jaccard=0.29) loteprednol type_1_diabetes_mellitus GAP_HIGH 0.1503 0.3333333333333333 homatropine_methylbromide 0.6 RISING 0.6 3 0.00195 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay loteprednol→?; validate in type_1_diabetes_mellitus cell model. Expected: similar to homatropine_methylbromide (Jaccard=0.33) ethinyl_estradiol osteoporosis GAP_HIGH 0.1646 0.5789473684210527 mestranol 0.45 STABLE 0.6 3 0.0016 ARCHIVE Phenotypic screen + target ID + clinical: ~3 years High-priority: Binding assay ethinyl_estradiol→?; validate in osteoporosis cell model. Expected: similar to mestranol (Jaccard=0.58) felypressin gestational_diabetes GAP_LOW 0.1313 0.047619047619047616 zafirlukast 0.45 STABLE 0.6 5 0.00099 ARCHIVE Full discovery pipeline needed: ~5 years Low-priority: Computational docking felypressin vs gestational_diabetes targets. Cross-check felypressin pharmacophore against gestational_diabetes pathway.